Back grey_arrow_rt.gif
 
Recent articles on HIV. Check out articles on HIV related Bone Issues and HIV and Aging.
 
null.gif
 
 
  1. Failing Fragmented HIV Care Continuum for Aging & Elderly PLWH & all PLWH - (06/13/22)
     
  2. Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States - (06/13/22)
     
  3. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19 - (06/13/22)
     
  4. Greater risk of post-vaccination breakthrough severe COVID-19 illness in people with HIV and CD4 <350 - (06/13/22)
     
  5. CROI: Clinical Pharmacology at CROI 2022 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center - (03/28/22)
     
  6. CROI: CROI 2022 and HIV prevention - NATAP Report by Renee Heffron, PhD and Connie Celum, MD, University of Washington (03/28/22)
     
  7. CROI: Summary from virtual CROI 2022 for HIV and liver disease Hepatitis elimination for 2030 on track? Is fatty liver disease a growing concern? New insights from CROI 2022. - Prof. Dr. Jurgen K. Rockstroh Department of Medicine I University Hospital Bonn Venusberg-Campus 1 53127 Bonn Germany - (03/21/22)
     
  8. CROI: HIV Prevention and Resistance on PrEP - By Christina K. Psomas MD PhD - (04/20/22)
     
  9. Health Department Launches Monkeypox Vaccine Clinic for People Who May Have Been Exposed to Monkeypox - (06/25/22)
     
  10. Lenacapavir for HIV-1 - Potential Promise of a Long-Acting Antiretroviral Drug - EDITORIAL - (06/25/22)
     
  11. Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV - (06/25/22)
     
  12. A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) - (06/21/22)
     
  13. THE EFFECT OF MENOPAUSAL STATUS, AGE, AND HIV ON NON-AIDS COMORBIDITY BURDEN AMONG U.S. WOMEN - (06/20/22)
     
  14. Disability Measured in PLWH in London: 39.5% Severe Disability; 70.5% Moderate Disability - (06/03/22)
     
  15. bNabs Combination Study new reports & antibody-resistance - (06/02/22)
     
  16. PLWH Had 3 X Worse Fatigue. Fatigue associated with Worse Cognition, Daily Functioning - (06/02/22)
     
  17. Medicines Patent Pool, ViiV Healthcare enter negotiations over voluntary licensing of cabotegravir Long-Acting for HIV pre-exposure prophylaxis - (06/01/22)
     
  18. PLWH Had 3x Worse Fatigue. Fatigue Associated with Worse Cognition (but not in HIV-neg.) & Worse Daily Function in PLWH - (06/01/22)
     
  19. COVID 5th Wave So Africa - Boosters "Stay Up-To-date" White House Briefing - (06/01/22)
     
  20. Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors - (06/01/22)
     
  21. Brain Affects by Integrase Inhibitors & ARTs - Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors - (05/31/22)
     
  22. Maraviroc-Does it Improve Cognitive Function? New Research This Week in Mice - (05/31/22)
     
  23. Interferon therapy shows striking results against COVID-19 - (05/31/22)
     
  24. Peginterferon Lambda Single Injection for Newly Diagnosed COVID - TOGETHER Phase 3 Study - (05/31/22)
     
  25. Interferon [lambda] therapy shows striking results against COVID-19 - (05/31/22)
     
  26. Biden Administration Announces Launch of First COVID Federally-Supported Test to Treat Site - (05/26/22)
     
  27. CDC 2020 HIV Surveillance report - COVID Impact, Racial Disparities in Low Viral Suppression Rates, Death Rates, Linkage to care, Care, PrEP, Geography - (05/26/22)
     
  28. Maraviroc Restores Middle Age Memory Loss in Mice, "Could Be Used To Reverse Cognitive Deficits Caused by HIV" - (05/26/22)
     
  29. CROI: Increased Physical Strength is Associated with Improved Brain Integrity in Older People Living with HIV - (05/23/22)
     
  30. Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapies - (05/24/22)
     
  31. Molnupiravir for the Treatment of COVID-19 in Immunocompromised Patients: Efficacy, Safety, and Virology Results from the Phase 3 MOVe-OUT Trial - (05/24/22)
     
  32. PrEP for Individuals who Inject Drugs - (05/18/22)
     
  33. Associations Between Central Obesity and Lifelong Antiviral Therapy in Adults Living With HIV Acquired From Early Childhood - (05/16/22)
     
  34. FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV - Press Release - (05/16/22)
     
  35. Carotid Intima-Media Thickness and Midlife Cognitive Function- - (05/16/22)
     
  36. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection - (05/13/22)
     
  37. NAFLD Is Increasingly Affecting Patients With HIV - (05/11/22)
     
  38. Duke's Klotman is under consideration as the next NIH head - (05/09/22)
     
  39. New Funding for HIV+ Women's Program: HIV Prevention & Care for Black Women - (05/05/22)
     
  40. Abnormal cognitive aging in people with HIV: Evidence from Data Integration between two countries' cohort studies - (05/03/22)
     
  41. HIV is associated with elevated FibroScan-AST (FAST) score - (05/03/22)
     
  42. TaiMed Receives from Theratechnologies Notification of Returning Commercialization Rights for Trogarzo in European Territory - (04/28/22)
     
  43. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study - (04/28/22)
     
  44. THERATECHNOLOGIES TO FOCUS ITS COMMERCIALIZATION ACTIVITIES ON THE NORTH AMERICAN TERRITORY - Trogarza - (04/27/22)
     
  45. HIV Neurocognitive Impairment Starts at 40-50 Years Old - (04/22/22)
     
  46. Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples - (04/20/22)
     
  47. Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis - (04/20/22)
     
  48. Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a European multicenter prospective study - patients with MetS had the highest prevalence of NAFLD (71%) - (04/20/22)
     
  49. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association - (04/20/22)
     
  50. Testosterone Therapy is Associated With Depression, Suicidality, and Intentional Self-Harm: Analysis of a National Federated Database - (04/18/22)
     
  51. Real-world safety of pre-exposure prophylaxis for HIV - Comment - (04/18/22)
     
  52. HIV Death Rates Almost Double in NYC Compared to General Population; Heart Disease is A Leading Increasing Cause of Death in NYC - (04/18/22)
     
  53. Overall vertical transmission of HCV, transmission net of clearance, and timing of transmission. - (04/18/22)
     
  54. "clinicians must recognize that patients with HIV have a unique CVD risk profile that may dictate different approaches" - need for tailored cardiovascular prevention strategies in patients with HIV - (04/18/22)
     
  55. Brain Decline in Frail PLH Not Detectable By Standard Neuropsych Tests - (04/18/22)
     
  56. Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples - (04/18/22)
     
  57. New York State Department of Health Announces Emergence of Recently Identified, Highly Contagious Omicron Subvariants in New York and Urges Continued Vigilance Against COVID-19 - (04/18/22)
     
  58. Reduced Cardiac Strain Among Women with HIV Relates to Inflammatory Monocyte Activation - (04/13/22)
     
  59. SUBCLINICAL ATHEROSCLEROSIS AND IMMUNE ACTIVATION AMONG US FEMALES VS MALES WITH HIV women have more immune activation - (04/13/22)
     
  60. Aging & Immune System: Women-Specific Aspects (higher inflammation; estrogen; menopause; response to HIV by women) - (04/13/22)
     
  61. CV Risk Factors Common Among 50 Yr Old PLWH - "Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial" - (04/13/22)
     
  62. Among WWH in the REPRIEVE trial, more advanced reproductive age is associated with metabolic dysregulation and region of residence - (04/13/22)
     
  63. Health systems must adapt to the special needs of ageing people with HIV and comorbid diseases to improve both patient-centred and population-centred health outcomes - (04/13/22)
     
  64. Double the Relative Risk for HIV+ Women for Heart Attacks Highest rates at 65-74 Years Old - (04/12/22)
     
  65. Arc of Aging with HIV 1996-2022: from promise to disappointment & despair: a broken HIV healthcare system. Slide talk by Jules Levin - (04/11/22)
     
  66. SAGE-718 in Parkinson's Disease Mild Cognitive Impairment: Results from the Phase 2 PARADIGM Study (Part A) - Improvements Observed in Study - (04/08/22)
     
  67. NYC DOH COVID PrEP, Treatment - Evusheld for pre-exposure prophylaxis - (04/08/22)
     
  68. Therapeutic Management of Nonhospitalized Adults With COVID-19 - (04/06/22)
     
  69. HIV Funding from Lil Was X & Elton John at Oscar Post Party
     
    Lil Nas X Teams Up with Gilead COMPASS Initiative® to Raise Nearly $500,000 for Community Organizations Addressing HIV in the Southern United States     - (04/05/22)
     
  70. SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical Center - (04/05/22)
     
  71. Cognitive Impairment at Midlife in Long-Term Cannabis Users - (04/05/22)
     
  72. Quality of Life Worse for Long-Term Survivors; Frailty/Function worse for >65 - (04/01/22)
     
  73. CROI: Oral TDF/FTC Provides Early Mucosal Protection In Both On- Demand And Daily Regimen - (04/01/22)
     
  74. CROI: Contributions to the Decline in HIV Incidence among GBM in the UK: A Modelling Study - HIV Elimination in 25 Years - (03/31/22)
     
  75. CROI: DEEPHIV: DEEP LEARNING TO PREDICT DDI RELEVANCE FOR ARVS - (03/31/22)
     
  76. CROI: Machine Learning Quantifies Accelerated White Matter Aging in Persons with HIV - (03/31/22)
     
  77. ViiV HEALTHCARE ANNOUNCES US FDA APPROVAL OF TRIUMEQ PD, THE FIRST DISPERSIBLE SINGLE TABLET REGIMEN CONTAINING DOLUTEGRAVIR, A ONCE-DAILY TREATMENT FOR CHILDREN LIVING WITH HIV - (03/29/22)
     
  78. ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg - (03/29/22)
     
  79. CROI: Long acting doravirine for treatment and prevention of vaginal HIV transmission - (03/30/22)
     
  80. CROI: CROI 2022 Key Aging & Comorbidities Highlights - (03/28/22)
     
  81. CROI: CROI 2022 Aging & HIV Symposium - (03/28/22)
     
  82. Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere - (03/28/22)
     
  83. Gilead's Aging Positively 2nd Round Grantees Announced - (03/28/22)
     
  84. Excess cancer prevalence in men with HIV: A nationwide analysis of Medicaid data - (03/28/22)
     
  85. Mortality Is Greater For Some PLWH: African-Americans, Elderly, Frail, Comorbidities, Women - (03/28/22)
     
  86. ViiV HEALTHCARE ANNOUNCES LABEL UPDATE FOR ITS LONG-ACTING HIV TREATMENT, CABENUVA (CABOTEGRAVIR, RILPIVIRINE), TO BE INITIATED WITH OR WITHOUT AN ORAL LEAD-IN PERIOD - (03/24/22)
     
  87. Senolytics for Poets - (03/24/22)
     
  88. Jak-STAT Inhibition: Therapeutic Intervention for Inflammaging and Comorbidities in PWH - (03/24/22)
     
  89. ViiV HEALTHCARE ANNOUNCES LABEL UPDATE FOR ITS LONG-ACTING HIV TREATMENT, CABENUVA (CABOTEGRAVIR, RILPIVIRINE), TO BE INITIATED WITH OR WITHOUT AN ORAL LEAD-IN PERIOD - (03/24/22)
     
  90. CROI: IMPACT OF SVR WITH DAAs IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS - (03/22/22)
     
  91. CROI: CROI Symposium: Aging & HIV "care of PLWH has NOT kept up with the reality of this aging population" - (03/23/22)
     
  92. CROI: IMPACT OF SVR WITH DAAs IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS - (03/22/22)
     
  93. CROI: ADHERENCE IN THE ACTG A5360 HCV MINIMAL MONITORING (MINMON) TRIAL - (03/22/22)
     
  94. CROI: CANNABIS USE AND HEPATIC STEATOSIS BY MRI-PDFF - (03/22/22)
     
  95. CROI: Regional Variation in HBV Prevalence in People Living with HIV in Botswana - (03/22/22)
     
  96. CROI: LOW RATES OF HEPATITIS B VACCINATION AMONG PEOPLE WITH HIV - (03/22/22)
     
  97. CROI: Randomized Trial of HBV Revaccination in MSM Born in the Neonatal Vaccination Era - (03/22/22)
     
  98. Alzheimer's disease and related dementias among older U.S. Medicare beneficiaries with and without HIV - (03/21/22)
     
  99. CROI: NEW HEPATITIS B INFECTION AMONG HIV PATIENTS: WHO IS AT RISK? - (03/21/22)
     
  100. CROI: ACTG A5324: A RANDOMIZED TRIAL OF ART INTENSIFICATION FOR COGNITIVE IMPAIRMENT IN PWH - Mark Mascolini (03/21/22)
     
  101. CROI: FEASIBILITY AND VIRAL RESPONSE TO TREATING ACUTE/EARLY HIV IN A MULTINATIONAL STUDY - (03/21/22)
     
  102. CROI: IMPACT OF SVR WITH DAAs IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS - (03/21/22)
     
  103. CROI: Integration of HIV and HCV Services with Medication for Opioid Use Disorder in the U.S. - (03/21/22)
     
  104. EACS: SOLAR 3D: A PROSPECTIVE STUDY SWITCHING TO DTG/3TC FROM 3- OR 4-DRUG ART FOR MAINTENANCE OF VIRAL SUPPRESSION WITH HISTORIC M184V/I MUTATION AND PRIOR VIROLOGICAL FAILURES: 48 WEEK PRIMARY ENDPOINT RESULTS - (03/21/21)
     
  105. CROI: Integration of HIV and HCV Services with Medication for Opioid Use Disorder in the U.S. - (03/18/22)
     
  106. CROI: A RETROSPECTIVE ANALYSIS OF BONE LOSS IN EMTRICITABINE/TENOFOVIR THERAPY FOR HIV PrEP - (03/18/22)
     
  107. Finding the 'Tipping Point' to Permanent Kidney Damage - (03/15/22)
     
  108. Long- Covid in PLWH & Immune Responses in PLWH Recovering From COVID Prior to Vaccine Availability - (03/15/22)
     
  109. CROI: SARS-CoV-2 CSF N Antigen Detection is Associated with CNS Inflammation in Neuro-COVID - (03/15/22)
     
  110. CROI: NIH Launches Clinical Trial of Three mRNA HIV Vaccines - (03/14/22)
     
  111. South Africa Approves Dapivirine Vaginal Ring for Use by Women - (03/14/22)
     
  112. CROI: HIV-1 RNA TRANSCRIPTS IN CSF CD4+ T CELLS, NOT MONOCYTES, ARE LINKED TO BRAIN INJURY - (03/14/22)
     
  113. 210,000 PLWH in USA Over >60 years Old - (03/11/22)
     
  114. CROI: Treatment with Broadly Neutralizing Antibodies in Children with HIV in Botswana (The Tatelo Study) - (03/11/22)
     
  115. CROI: NON-OBESE NAFLD IS ASSOCIATED WITH HIGHER SCD14 CONCENTRATIONS IN ADULTS WITH HIV - (03/11/22)
     
  116. CROI: 11% - HIGH INCIDENCE RATE OF CT-MEASURED NAFLD IN MACS MEN WITH AND WITHOUT HIV INFECTION - (03/11/22)
     
  117. CROI: DETERMINANTS OF LIVER STEATOSIS IN PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY - ALT matters - (03/11/22)
     
  118. CROI: IMPACT OF NASH ON THE SURVIVAL OF PEOPLE LIVING WITH HIV - (03/11/22)
     
  119. CROI: PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE VERTICALLY HIV-INFECTED YOUTHS - (03/11/22)
     
  120. CROI: Effect of Tenofovir on T-cell Maturational Subsets in Long Term Aviraemic HIV Adults - (03/11/22)
     
  121. CROI: NEUROSYMPTOMATIC HIV-1 CSF ESCAPE ASSOCIATES WITH REPLICATION IN CNS CD4+ T CELLS - (03/11/22)
     
  122. Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose - (03/08/22)
     
  123. More alcohol, less brain: Association begins with an average of just one drink a day - (03/07/22)
     
  124. CROI: Effect of Tenofovir on T-cell Maturational Subsets in Long Term Aviraemic HIV Adults - (03/08/22)
     
  125. CROI: NEUROSYMPTOMATIC HIV-1 CSF ESCAPE ASSOCIATES WITH REPLICATION IN CNS CD4+ T CELLS - (03/07/22)
     
  126. CROI: PBR28 PET IMAGING IN PEOPLE WHO STARTED ART DURING ACUTE VERSUS CHRONIC HIV INFECTION - (03/07/22)
     
  127. CROI: HPV Genotyping in a Study of Adjunctive Vaccine For Treatment of Cervical Dysplasia - (03/07/22)
     
  128. More alcohol, less brain: Association begins with an average of just one drink a day - (03/07/22)
     
  129. Evaluation of Computerized Cognitive Training and Cognitive and Daily Function in Patients Living With HIVA Meta-analysis - (03/07/22)
     
  130. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment - (03/07/22)
     
  131. More alcohol, less brain: Association begins with an average of just one drink a day - (03/07/22)
     
  132. Evaluation of Computerized Cognitive Training and Cognitive and Daily Function in Patients Living With HIVA Meta-analysis - (03/07/22)
     
  133. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment - (03/07/22)
     
  134. CROI: STATIN USE IN ART-TREATED HIV REVEALS AN ALTERED MACROPHAGE TRANSCRIPTOMIC PROFILE - (03/04/22)
     
  135. CROI: PREVALENCE OF ANEMIA AND RISK FACTORS IN PEOPLE WITH HIV IN THE MODERN ART ERA: aging, Blacks, women, Hispanics have higher risk - (03/04/22)
     
  136. CROI: Impaired response of memory Treg to HDL is associated with high cardiovascular disease risk in persons with HIV - (03/04/22)
     
  137. CROI: Carl Dieffenbach Highlights Aging & Comorbidities for PLWH, Frailty & Research & the Need for Better Care: "care of people living with HIV has NOT kept up with the reality of this aging population" - (03/04/22)
     
  138. Booster Waning Benefit vs Omicron UK Study NEJM just published - Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant - (03/04/22)
     
  139. CROI: PERINATAL HIV-1 TRANSMISSION IN FRANCE: U=U FOR MOTHERS ON ART FROM CONCEPTION....no perinatal transmission in this analysis - (03/03/22)
     
  140. CROI: LONG-ACTING INJECTABLE FOR PREVENTION OF HIV AND UNPLANNED PREGNANCY - (03/02/22)
     
  141. CROI: Phase 2b Efficacy Trial of Mosaic HIV-1 Vaccine Regimen in African Women (Imbokodo) - (03/02/22)
     
  142. CROI: PERINATAL HIV-1 TRANSMISSION IN FRANCE: U=U FOR MOTHERS ON ART FROM CONCEPTION - (03/02/22)
     
  143. CROI: ARCHIVED RESISTANCE AND RESPONSE TO <40 C/ML AND TND - DTG/3TC FDC AT WEEK 48 IN SALSA - (03/01/22)
     
  144. CROI: Estimating the Lifetime Risk of a Diagnosis of HIV Infection in the United States, Blacks have highest risk - (03/01/22)
     
  145. Risk, resiliency in aging brain focus of $33 million grant - (03/01/22)
     
  146. Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatability Issues - (03/01/22)
     
  147. CROI: Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques Ad26/MVA+PGT121+Vesatolimod - (03/01/22)
     
  148. CROI: Development of Viral Biomarkers in SHIV Infected Non-Human Primates in Reservoirs - (03/01/22)
     
  149. CROI: Adolescent and Parent Experiences with Long-acting Injectables in the MOCHA Study - (03/01/22)
     
  150. CROI: The FUNCFRAIL Score to discriminate Frailty in Older Adults with HIV - (02/28/22)
     
  151. CROI: Potent Targeted Activator of Cell Kill (TACK) Molecules Eliminate HIV Infected Cells - (02/28/22)
     
  152. CROI: 2DR vs. 3DR INTEGRASE INHIBITOR-BASED REGIMENS INITIATION AND CD4+/CD8+ RATIO RECOVERY - (02/26/22)
     
  153. CROI: CORONARY FLOW RESERVE ON DTG/ABC/3TC AT BASELINE AND AFTER SWITCH TO BIC/FTC/TAF - (02/26/22)
     
  154. CROI: EFdA OFFERS COMPLETE PROTECTION FROM REPEATED PENILE HIV CHALLENGES - (02/26/22)
     
  155. CROI: Association of Sleep Disruption with Kynurenine Pathway Activation in Women Living with HIV - (02/26/22)
     
  156. CROI: Lifetime HIV Risk 1 in 120 in US, Highest in Black and Hispanic Males - Mark Mascolini (02/26/22)
     
  157. CROI: REVERSIBILITY OF CENTRAL NERVOUS SYSTEM ADVERSE EVENTS IN COURSE OF ART - (02/25/22)
     
  158. CROI: Atrial Fibrillation Risk Factors Among Patients in HIV Care in the United States - (02/25/22)
     
  159. CROI: Sleep and Frailty Among Men with and Without HIV - poor sleep for PLWH - (02/25/22)
     
  160. CROI: POOR SLEEP IS LINKED TO CVD RISK IN PLWH IN A SOUTHWESTERN US CLINIC - 40% Have Sleeping Difficuties - (02/25/22)
     
  161. CROI: A novel comorbidity index predicts cognitive change in people with chronic HIV - (02/24/22)
     
  162. CROI: Aging Symposium 2022 - Jules Levin slides, talk - NATAP - National AIDS Treatment Advocacy Project (02/24/22)
     
  163. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants (02/24/22)
     
  164. CROI: Impact of Rheumatologic Therapies on Cardiovascular Outcomes in People with HIV (02/24/22)
     
  165. CROI: Inflammatory clusters are associated with multimorbidity and Cardiovascular disease in People with HIV on effective treatment (02/24/22)
     
  166. CROI: Effects of Air Pollutants on Neuroimaging Measures Diverge by HIV Status: poverty-neighborhood area & HIV effect brain structure (02/24/22)
     
  167. CROI: HIV-INDUCED CELLULAR SENESCENCE IN PLWH IS DECREASED EX VIVO BY D+Q SENOLYTIC DRUGS (02/24/22)
     
  168. CROI: Associations Between Plasma Biomarkers and Neurocognition in ART-Treated PWH (02/24/22)
     
  169. CROI: COUNTERFACTUAL ESTIMATION OF CAB-LA EFFICACY AGAINST PLACEBO USING EXTERNAL TRIAL DATA (02/24/22)
     
  170. CROI: INFLAMMATION AND IMMUNE ACTIVATION NOT DRIVEN BY ON-ART HIV-SPECIFIC IMMUNE RESPONSES - "Die is Cast Before ART" HIV Long-Lasting Immune Dysreguation (02/24/22)
     
  171. CROI: A RANDOMIZED TRIAL OF DTG PLUS DRV/c AS A SWITCH STRATEGY IN SUBJECTS WITH MDR HIV-1 (02/24/22)
     
  172. CROI: Associations Between Plasma Biomarkers and Neurocognition in ART-Treated PWH (02/24/22)
     
  173. CROI: PRECLINICAL STUDIES TOWARD A PHASE I/IIA TRIAL USING ANTI-HIV DUOCAR-T CELL THERAPY (02/24/22)
     
  174. CROI: Choice and Adherence to Dapivirine Ring or Oral PrEP by Young African Women in REACH (02/23/22)
     
  175. CROI: The Bi-directional Effects of Hormone Therapy and PrEP in Transgender Individuals (02/23/22)
     
  176. CROI: NEURAL TUBE DEFECTS AND PRENATAL EXPOSURE TO DOLUTEGRAVIR: UNITED STATES, 2008-2019 (02/23/22)
     
  177. CROI: No Interactions Between Hormone Therapy and PrEP in Transgender Women or Men - Mark Mascolini (02/23/22)
     
  178. CROI: IMPACT OF MATERNAL HIV/HBV CO-INFECTION ON PREGNANCY AND INFANT OUTCOMES (02/23/22)
     
  179. Young PLWH at Low-Risk for CVD: 50% have Plaque 23% Vulnerable Plaque, CAC in 35% - (02/22/22)
     
  180. CROI: IMPACT OF MATERNAL HIV/HBV CO-INFECTION ON PREGNANCY AND INFANT OUTCOMES (02/23/22)
     
  181. CROI: The role of HIV/HBV/HCV triple infection in end stage liver disease (ESLD) and all cause mortality in Europe (02/23/22)
     
  182. CROI: Growth of infants with perinatal exposure to maternal DTG vs EFV and TDF vs TAF: the randomized IMPAACT 2010 trial - (02/22/22)
     
  183. CROI: ACTG A5351s: Effect of Immune-Modulatory Interventions on CMV Replication during ART - (02/22/22)
     
  184. CROI: More Adverse Birth Outcomes With COVID Plus HIV in Botswana - Mark Mascolini (02/22/22)
     
  185. CROI: Post-COVID19 Quality of Life: Low Satisfaction With Physical and Mental Health Status - (02/22/22)
     
  186. CROI: SARS-CoV-2 Prevalence Similar in Adults and Children in 15-Site US Study - Mark Mascolini (02/22/22)
     
  187. CROI: From NAFLD to MAFLD: implications of change in terminology in PWH - (02/22/22)
     
  188. CROI: NAFLD IS COMMON AND ASSOCIATED WITH CARDIOVASCULAR RISK IN REPRIEVE PARTICIPANTS - (02/22/22)
     
  189. CROI: HBIg-Free Strategy Prevents Vertical HBV Transmission-If Mothers Start TDF Soon Enough - Mark Mascolini (02/22/22)
     
  190. CROI: Proteinuria Is Common Among People with HIV With Controlled Viremia - (02/22/22)
     
  191. CROI: MUSCLE QUALITY AND PHYSICAL FUNCTION IN MEN WITH AND WITHOUT HIV - (02/22/22)
     
  192. CROI: IS THERE A ROLE OF NOVEL ART REGIMENS IN THE DECLINING PREVALENCE OF HAND? HAND 22% Today in Italy- Asymptomatic Remains Prevalent 10%-24% - (02/22/22)
     
  193. CROI: SERUM AND CSF ULTRA-SENSITIVE DETECTION OF NFL AND ALZHEIMER'S BIOMARKERS IN PLWH - (02/22/22)
     
  194. CROI: Triple & Double bNAbs Studies - (02/21/22)
     
  195. CROI: Injectable, Biodegradable, Removable PrEP/Contraceptive Tested in Mice - Mark Mascolini (02/21/22)
     
  196. CROI: HIV-Infected Cells Recirculate Throughout Organs During Suppressive ART - Mark Mascolini (02/21/22)
     
  197. CROI: Lenacapavir Shots or Tabs Control HIV in First-Line ART Combinations - Mark Mascolini (02/21/22)
     
  198. CROI: Most Large HIV Molecular Clusters in US Primarily Involve MSM - Mark Mascolini (02/21/22)
     
  199. CROI: Dolutegravir Pharmacokinetics In People with HIV Receiving Daily 1HP for Latent TB Treatment (ACTG A5372) - (02/20/22)
     
  200. CROI: The Impact of COVID-19 on Adverse Birth Outcomes in Botswana by HIV Status - (02/20/22)
     
  201. CROI: Role of Renin-Angiotensin-Aldosterone System Activation in Arterial Inflammation in HIV - (02/20/22)
     
  202. Sex differences in type 2 diabetes mellitus prevalence among persons with HIV: women with HIV appear to have greater risk & >65 worse - (02/18/22)
     
  203. CROI: DURABILITY OF SARS-COV-2 mRNA VACCINE IMMUNE RESPONSE IN PLWH WITH ADVANCED DISEASE - (02/18/22)
     
  204. CROI: Immunogenicity and reactogenicity to COVID-19 mRNA vaccine additional dose in PLWH - (02/18/22)
     
  205. CROI: SARS-CoV-2 Vaccine Immunogenicity in PLWH in The Netherlands & age, CD4, HIV viral load effects - (02/18/22)
     
  206. CROI: Sotrovimab mAb Limits Progression to Severe COVID Regardless of Serostatus - Mark Mascolini (02/18/22)
     
  207. CROI: Intramuscular Sotrovimab Noninferior to IV for Mild/Moderate COVID - Mark Mascolini (02/18/22)
     
  208. CROI: One Quarter Ordering Free HIV Self-Tests in US Never Tested Before - Mark Mascolini (02/18/22)
     
  209. CROI: Choice and Adherence to Dapivirine Ring or Oral PrEP by Young African Women in REACH: 67% prefer ring vs 31% oral PrEP - (02/18/22)
     
  210. CROI: PHASE III TRIAL OF MOLNUPIRAVIR IN ADULTS WITH MILD SARS-COV2 INFECTION IN INDIA - (02/18/22)
     
  211. CROI: PREDICTORS OF NEURODEVELOPMENT IN HIV-EXPOSED UNINFECTED INFANTS - (02/18/22)
     
  212. CROI: Casirivimab and Imdevimab Combination Provides Long-Term Protection Against COVID-19 - phase 3 study in preventing COVID in household contacts of infected individuals - (02/18/22)
     
  213. CROI: Camostat Does Not Relieve COVID Symptoms or Clear Virus in Placebo Trial - Mark Mascolini(02/17/22)
     
  214. CROI: Dolutegravir Reversibly Induces Mitochondrial Fragmentation and Toxicity In Vitro - (02/17/22)
     
  215. CROI: IMPROVING INTESTINAL BARRIER USING GLP-2 AGONIST REDUCES ARTERIAL INFLAMMATION IN PWH - (02/16/22)
     
  216. CROI: Dual Monoclonal Antibody Cuts COVID Risk in 8-Month Placebo Trial - Mark Mascolini (02/16/22)
     
  217. CROI: COVID-19 BOOSTER VACCINE EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION - in reducing breakthrough, duration of benefit (02/16/22)
     
  218. CROI: 00136: A RANDOMIZED TRIAL OF SWITCHING TREATMENT-EXPERIENCED ADULTS FROM PI/r TO DTG - (02/17/22)
     
  219. CROI: Bolstering ART With DTG +/- MVC Does Not Help Neurocognitive Performance - Mark Mascolini (02/16/22)
     
  220. CROI: LONGITUDINAL MODELING OF EARLY HIV BURDEN IN THE CENTRAL NERVOUS SYSTEM (02/16/22)
     
  221. CROI: New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor - press release (02/16/22)
     
  222. CROI: Lenacapavir as part of a Combination Regimen in Treatment-Naï ve People with HIV: Week 54 Results (02/16/22)
     
  223. CROI: Big Drops in HIV/STI Testing (But Sometimes Not Diagnoses) When COVID Arrived - Mark Mascolini (02/16/22)
     
  224. CROI: African NADIA Trial Favors 2nd-Line TDF Over ZDV, and DRV/r Over DTG - Mark Mascolini (02/16/22)
     
  225. CROI: Switching From NNRTI to DTG-Even With Same NRTIs-Superior to PI - Mark Mascolini (02/16/22)
     
  226. CROI: Phase 1 Study of Long-Acting 3BNC117 and 10-1074 in Viremic Adults Living With HIV (02/16/22)
     
  227. CROI: Lenacapavir as part of a Combination Regimen in Treatment-Naï ve People with HIV: Week 54 Results (02/16/22)
     
  228. POST-ACUTE SEQUELAE AND ADAPTIVE IMMUNE RESPONSES IN PEOPLE LIVING WITH HIV RECOVERING FROM SARS-COV-2 INFECTION - (02/16/22)
     
  229. CROI: PHASE I PK, SAFETY, AND ACCEPTABILITY STUDY OF A 90-DAY TENOFOVIR VAGINAL RING (02/16/22)
     
  230. CROI: EFFECT OF DIRECT-ACTING ANTIVIRALS ON HCV INCIDENCE AMONG PEOPLE LIVING WITH HIV (02/16/22)
     
  231. CROI: COVID Pushes USA Farther Off Course to Meet HCV Elimination Goals - Mark Mascolini (02/16/22)
     
  232. CROI: Asymptomatic SARS-CoV-2 Infection is Extremely Common among People with HIV (02/16/22)
     
  233. CROI: Long COVID Definition - POST-ACUTE SEQUELAE OF SARS-COV-2: CLINICAL CONDITION COMPARISON IN A MATCHED COHORT (02/16/22)
     
  234. CROI: COVID Symptoms Reported Lasting Longer in US Than South Africa, Peru - Mark Mascolini (02/16/22)
     
  235. CROI: Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer (02/15/22)
     
  236. CROI: Treating Anal Lesions in HIV+ Cuts Anal Cancer Rate 57% in Randomized Trial - Mark Mascolini (02/15/22)
     
  237. CROI: Outpatient Clinics Efficient in Spotting Recent HIV in 3 African Countries - Mark Mascolini (02/15/22)
     
  238. CROI: RNA Assay Spots HIV Earlier in CAB-LA PrEP Users, May Avert Resistance - Mark Mascolini (02/15/22)
     
  239. CROI: CAB-LA PrEP Keeps Advantage Over TDF/FTC in 1-Year Unblinded Phase- Seven Breakthrough Infections Despite On-Time CAB-LA Injections - Mark Mascolini (02/15/22)
     
  240. CROI: ISLATRAVIR DISTRIBUTION IN MUCOSAL TISSUES, PBMC & PLASMA AFTER MONTHLY ORAL DOSING (02/15/22)
     
  241. CROI: PHASE IIA TRIAL OF ISLATRAVIR QM FOR HIV PrEP: WEEK 24 METABOLIC AND RENAL OUTCOMES (02/15/22)
     
  242. CROI: THE IMPACT OF 3BNC117 AND ROMIDEPSIN TREATMENT AT ART INITIATION ON HIV-1 PERSISTENCE - Mark Mascolini (02/15/22)
     
  243. CROI: Long COVID Definition - Cardiac Rhythm Upsets, Diabetes, GU Symptoms Emerge as Persistent COVID Problems (02/15/22)
     
  244. CROI: ANGIOGENIC FACTORS IN RNA-SEQ OF SKIN AND GASTROINTESTINAL KAPOSI SARCOMA LESIONS (02/15/22)
     
  245. CROI: NONSMALL CELL LUNG CARCINOMA IN PLWH HARBORS IMMUNOREGULATORY TUMOR MICROENVIRONMENT (02/15/22)
     
  246. CROI: GUT MICROBIOTA, PLASMA METABOLOMICS, AND ATHEROSCLEROSIS IN HIV INFECTION (02/15/22)
     
  247. CROI: MI Risk Not Falling in HIV Group, as It Is in non-HIV Peers - Mark Mascolini (02/15/22)
     
  248. CROI: CROI Monday Feb 14: 5 Key Aging & Metabolic Oral Presentation Studies - (02/15/22)
     
  249. CROI: TENOFOVIR ALAFENAMIDE IS ASSOCIATED WITH SHORTER TELOMERE LENGTH IN PEOPLE WITH HIV - (02/15/22)
     
  250. CROI: Macrophage-specific arterial infiltration relates to plaque type and immune activation in HIV - (02/14/22)
     
  251. CROI: PLWH Have Higher levels of Fat Tissue Fibrosis - INFLAMMATION AND KYNURENINE PATHWAY LINKED TO TYPE 2 DIABETES AND FAT FIBROSIS IN HIV - (02/14/22)
     
  252. CROI: Trends in Myocardial Infarction Risk by HIV Status in Two US Healthcare Systems - (02/14/22)
     
  253. Effect of HIV and Interpersonal Trauma on Cortical Thickness, Cognition, and Daily Functioning - (02/14/22)
     
  254. CROI: One Third on ART 48 Hours From Birth Eligible for ART Interruption - Mark Mascolini (02/14/22)
     
  255. CROI: TREATMENT WITH SOF/VEL/VOX IN HIV-HCV COINFECTED PATIENTS PREVIOUSLY EXPOSED TO DAAs - (02/14/22)
     
  256. CROI: Impact of HCV cure on depressive symptoms in the HIV-HCV co-infected population - (02/14/22)
     
  257. CROI: Two or More Anticholinergics Tied to Falls, Frailty in People With HIV - Mark Mascolini (02/14/22)
     
  258. CROI: Geographical Differences in Functional Impairment of PLWH: Over One Third in Global HIV Analysis Have Impaired Physical Function - Mark Mascolini (02/14/22)
     
  259. CROI: IV PUSH ADMINISTRATION OF IBALIZUMAB: PHARMACOKINETICS, SAFETY, AND EFFICACY - (02/14/22)
     
  260. CROI: Infant Stunting Worse With Maternal EFV Than DTG, Similar With TAF and TDF - Mark Mascolini (02/14/22)
     
  261. CROI: IMPACT OF TREATMENT INTERRUPTION ON COLONIC MUCOSA IN ACUTELY TREATED PARTICIPANTS - (02/14/22)
     
  262. CROI: COVID Vax More Likely in Older, Heavier Men (vs Women) in Global HIV Trial - Mark Mascolini (02/14/22)
     
  263. CROI: COVID mRNA Vaccines Appear to Protect Against Infection Transmission - Mark Mascolini (02/14/22)
     
  264. CROI: COVID Vax Booster Cuts Breakthrough Infections, Hospital Use, Death - Mark Mascolini (02/14/22)
     
  265. CROI: Post-Acute Long COVID: Lower Heart Rates During Exercise Point to Autonomic Dysfunction Causing Symptoms - Mark Mascolini (02/14/22)
     
  266. CROI: Impact of the COVID-19 Pandemic on HIV Outpatient Care and Viral Suppression in NYC - (02/14/22)
     
  267. CROI: PREVALENCE OF ANEMIA AND RISK FACTORS IN PEOPLE WITH HIV IN THE MODERN ART ERA - (02/14/22)
     
  268. Long-term cardiovascular outcomes of COVID-19 - (02/13/22)
     
  269. CROI: Assessing health-related quality of life in people with HIV and cognitive issues - (02/13/22)
     
  270. CROI: Impact of COVID outbreak on prevention and care for HIV and other STI's at a large hospital - (02/13/22)
     
  271. CROI: SARS-COV-2 VACCINATION: IMPACT ON HIV-1 RNA LEVELS AND ANTIBODY RESPONSE AMONG PLWH - (02/13/22)
     
  272. CROI: Impact of COVID outbreak on prevention and care for HIV and other STI's at a large hospital - (02/13/22)
     
  273. CROI: SARS-COV-2 VACCINATION: IMPACT ON HIV-1 RNA LEVELS AND ANTIBODY RESPONSE AMONG PLWH - (02/13/22)
     
  274. CROI: PETRAM RESULTS: BONE TURNOVER CHANGES ON 18F-NaF PET/CT AFTER A RANDOMISED SWITCH TO TAF - (02/13/22)
     
  275. CROI: Decreased Myelin Content and Cognitive Performance in Adults with Perinatal HIV - (02/13/22)
     
  276. CROI: SAFETY AND PK OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE IN ADOLESCENTS - (02/13/22)
     
  277. CROI: EFFECT OF L74I POLYMORPHISM ON FITNESS OF HIV-1 SUBTYPE A6 RESISTANT TO CABOTEGRAVIR - (02/13/22)
     
  278. CROI: Birth Outcomes following Prenatal Exposure to Dolutegravir: the Dolomite-EPPICC study - (02/13/22)
     
  279. CROI: IMPAACT 2019: PK & Safety of Dispersible ABC/DTG/3TC in Children with HIV 6 to <14kg - (02/13/22)
     
  280. CROI: COGNITIVE PREDICTORS OF EVERYDAY FUNCTIONING IN THE WOMEN'S INTERAGENCY HIV STUDY - (02/12/22)
     
  281. CROI: ADHERENCE TO ANTIRETROVIRAL THERAPY IN MEDICARE FEE-FOR-SERVICE BENEFICIARIES WITH HIV - (02/12/22)
     
  282. CROI: Islatravir does not prolong QTc in a thorough QT study in healthy participants - (02/12/22)
     
  283. CROI: Kinetics of Lenacapavir in Participants With Severe Renal Impairment - (02/12/22)
     
  284. CROI: Evaluation of Potential Drug-Drug Interactions Between Islatravir and Lenacapavir - (02/12/22)
     
  285. CROI: Absence of Cross-Resistance to Lenacapavir in HIV Entry Inhibitor-Resistant Isolates - (02/12/22)
     
  286. CROI: Immunogenicity and Prophylactic Efficacy of Arenavirus-Based SIV Vaccine in Macaques - (02/12/22)
     
  287. CROI: LONG ACTING LENACAPAVIR PROTECTS AGAINST INTRAVENOUS CHALLENGE WITH SIMIAN-TROPIC HIV - (02/12/22)
     
  288. CROI: WEEK 48 METABOLIC HEALTH AFTER SWITCH TO DTG/3TC VS CAR BY BASELINE REGIMEN (SALSA) - (02/12/22)
     
  289. CROI: B/F/TAF Five-Year Outcomes in Treatment-Naïve Adults - (02/12/22)
     
  290. CROI: COVID-19 and the HIV continuum in people living with HIV enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts - (02/12/22)
     
  291. CROI: Long-Acting Lenacapavir in People With Multidrug-Resistant HIV-1: Week 52 Results - (02/12/22)
     
  292. CROI: FEMINIZING HORMONAL THERAPIES WORSEN CARDIOMETABOLIC PROFILES IN TRANSGENDER WOMEN - (02/12/22)
     
  293. CROI: IMPACT OF INTEGRASE STRAND TRANSFER INHIBITORS ON COGNITION IN THE HAILO COHORT - (02/12/22)
     
  294. CROI: Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults - (02/12/22)
     
  295. CROI: Abnormal cognitive aging is detected despite clinically defined cognitive stability - (02/12/22)
     
  296. CROI: LONG-ACTING CABOTEGRAVIR+RILPIVIRINE EVERY 2 MONTHS: ATLAS-2M WEEK 152 RESULTS - (02/12/22)
     
  297. CROI: VIIV HEALTHCARE TO PRESENT NEW LONG-TERM FINDINGS FROM ITS INNOVATIVE 2-DRUG AND LONG-ACTING HIV MEDICINES PORTFOLIO AT CROI 2022 - (02/12/22)
     
  298. CDC - HIV+ Black Adults More Social Vulnerabilty; Higher Mortality; More Commorbidites - (02/10/22)
     
  299. Fatty Liver (NAFLD) in HIV+ Young, Children, Adolescents - (02/08/22)
     
  300. CROI: Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs - (02/08/22)
     
  301. Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs - (02/08/22)
     
  302. A New Class of Antiviral Therapy Could Treat COVID-19 - (02/08/22)
     
  303. PLWH in NYC-COVID Vaccinations Disparities - (02/08/22)
     
  304. Undertreated midlife symptoms for women living with HIV linked to lack of menopause discussions with providers - menopausal hormone therapy under-utilized - (02/07/22)
     
  305. Transitioning to Frailty for PLWH 2 fold higher, Risk Factors - (02/06/22)
     
  306. ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals - (02/06/22)
     
  307. PCSK9 (Repatha) in HIV+, Affect on Plaque - (02/06/22)
     
  308. Long-Haul COVID Cases Could Spike after Latest Wave - (02/05/22)
     
  309. Mortality & Elderly PLWH - (02/05/22)
     
  310. Updated cholesterol guidelines offer more personalized risk assessment, additional treatment options for people at the highest risk - risk factors - (02/05/22)
     
  311. HIV CVD Guidelines - 2019 - Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association - (02/05/22)
     
  312. FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year - (02/05/22)
     
  313. NIA: Data shows racial disparities in Alzheimer's disease diagnosis between Black and white research study participants - (02/03/22)
     
  314. Protection by 4th dose of BNT162b2 against Omicron in Israel - (02/04/22)
     
  315. Merck readies oral, macrocyclic PCSK9 inhibitor for phase II test - (02/03/22)
     
  316. NIA: Data shows racial disparities in Alzheimer's disease diagnosis between Black and white research study participants - (02/03/22)
     
  317. ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment - (02/03/22)
     
  318. Fatty Liver in HIV: higher prevalence, progresses faster, ALT/AST Predict - (02/02/22)
     
  319. Cabenuva Long-Acting New Paradigm in HIV Treatment - (02/01/22)
     
  320. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study - (02/01/22)
     
  321. Perceived Barriers to Long-Acting Cabotegravir/Rilpivirine Better Than Expected - (02/01/22)
     
  322. IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology - (01/27/22)
     
  323. Impact of long-acting therapies on the global HIV epidemic - (01/27/22)
     
  324. Evolocumab (PCSK9 Inhibitor for Heart Disease) in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study - (01/27/22)
     
  325. Peripheral artery disease and physical function in women with and without HIV - (01/27/22)
     
  326. Evolocumab (PCSK9 Inhibitor for Heart Disease) in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study - (01/27/22)
     
  327. Peripheral artery disease and physical function in women with and without HIV - (01/27/22)
     
  328. PLWH Survival Declines with Comorbidities Danish Cohort - (01/25/22)
     
  329. Mutimorbidity Increases 50% in PLWH Over Past Several Years; 76% of HIV Have Polypharmacy. - (01/25/22)
     
  330. HIV Care Fragmentation - PLWH Did Not Receive Good Specialty Care for Hypertension & Hyperlipidemia - (01/25/22)
     
  331. HIV infection is associated with an increased risk of PAD, Peripheral Artery Disease - (01/25/22)
     
  332. Telomere Length, Traditional Risk Factors, HIV-related Factors and Coronary Artery Disease Events in Swiss Persons Living with HIV - (01/25/22)
     
  333. 26%, 10x HIGHer Prevalence of Peripheral Artery Disease in African-American Women with HIV in WIHS - (01/25/22)
     
  334. What is Frailty in PLWH ? 25% of HIV+ Men in MACS >65 Were Frail in 2013; 42% of HIV+ Women >60 in WIHS in 2019 were Frail/Pre-Frail. Frailty Increases Mortality - (01/25/22)
     
  335. EHE Goals Unmet - Two-Thirds of New HIV Infections Occur Among MSM - Inequities & Disparities - (01/25/22)
     
  336. Genital Inflammation is Not Associated with Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEP - (01/20/22)
     
  337. One Alcohol Drink A Day Increases Cancers Risk - (01/20/22)
     
  338. No amount of alcohol is good for the heart, new report says, but critics disagree on science - (01/20/22)
     
  339. Deaths Attributable to Cancer in the US Human Immunodeficiency Virus Population During 2001 2015 - (01/19/22)
     
  340. Menopause Is Associated With Immune Activation in Women With HIV - (01/19/22)
     
  341. Gilead says counterfeiting network sold $250 mln worth of its HIV drugs - (01/18/22)
     
  342. NYS Guidelines COVID Oral & Monoclonal Antibodies Treatments Eligibility - (01/18/22)
     
  343. Fall & Frailty Increase Mortality in Older PLWH Frailty Assessments In Routine Care - (01/18/22)
     
  344. Doravirine/3TC/TDF In EACS Initial Combination ART Guidelines as well as Raltegravir - (01/16/22)
     
  345. Older adult opioid overdose death rates on the rise - 4 times higher for African-American Men - (01/16/22)
     
  346. San Francisco Dept of Public Health: 71% >50, 29% >65 PLWH - (01/16/22)
     
  347. HIV Capsid Lenacapavir Review Treatment & Prevention, PK, Mechanism, Resistance - (01/15/22)
     
  348. 2 Recent study publications from Kaiser on Dementia & Heart Failure in PLWH - (01/15/22)
     
  349. Long-term HIV Pre-exposure Prophylaxis Trajectories Among Racial & Ethnic Minority Patients: Short, Declining, & Sustained Adherence - (01/15/22)
     
  350. Transgender Women and PrEP Care in NYC - (01/15/22)
     
  351. Impact of Heroin and HIV on Gut Integrity and Immune Activation - (01/15/22)
     
  352. Reduced Levels of NAD in Skeletal Muscle and Increased Physiologic Frailty Are Associated With Viral Coinfection in Asymptomatic Middle-Aged Adults - (01/13/22)
     
  353. Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare System - (01/12/22)
     
  354. Life Expectancy Decreases with Comorbidities - Comorbidity-Adjusted Life Expectancy: A New Tool to Inform Recommendations for Optimal Screening Strategies - (01/12/22)
     
  355. Preeminence of Dolutegravir-Based Antiretroviral Therapy in Children and Adolescents - (01/12/22)
     
  356. Life expectancy estimates based on comorbidities and frailty to inform preventive care - (01/11/22)
     
  357. 60% in NYC >50 years old & 30% > 60 years old - (01/09/22)
     
  358. Sex Differences in People Aging With HIV - women have worse quality of life & physical function & suffer more exhaustion - (01/09/22)
     
  359. Women with HIV Have More Comorbidities, Worse Physical Function, & Inflammation - (01/07/22)
     
  360. Faces of Frailty [women] in Aging with HIV Infection - (01/07/22)
     
  361. Body Changes for Young Adults Acquiring HIV at Early Age & Perinatally - (01/06/22)
     
  362. Life Expectancy for PLWH: disparities for Blacks, Women; Frailty High Rates in MACS, Physical Impairments by Age Worsen; Cognitive Impairment in Older PLWH - (01/04/22)
     
  363. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children - (01/03/22)
     
  364. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data - (01/03/22)
     
  365. More evidence for worse COVID-19 outcomes in people with HIV - (01/03/22)
     
  366. Comparison of dementia incidence and prevalence between individuals with and without HIV infection in primary care from 2000 to 2016 - (01/03/22)
     
  367. CVD Score Predicts Frailty? - Cardiovascular risk score associations with frailty in men and women with or at risk for HIV - (01/03/22)
     
  368. Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from simian HIV acquisition by long-acting cabotegravir in macaques - (01/03/22)
     
  369. Tenofovir alafenamide plasma concentrations are reduced in pregnant women living with HIV: data from the PANNA Network - (12/30/21)
     
  370. 25% PLWH Report Discrimination Experience in Health Care Setting - (12/30/21)
     
  371. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment - (12/29/21)
     
  372. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US - (12/29/21)
     
  373. New CDC Vital Signs Report Reveals a Decade of Continuing HIV Inequities on Eve of World AIDS Day - (12/28/21)
     
  374. PLWH - Women; Life Expectancy-disparities; Social Determinants; Frailty; Physical & Cognitive Impairment - (12/28/21)
     
  375. Pfizer COVID Protease & DDIs with HIV ARTs - (12/28/21)
     
  376. FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year - (12/23/21)
     
  377. Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment - (12/23/21)
     
  378. Merck and Ridgeback's Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19 - (12/23/21)
     
  379. ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention - (12/23/21)
     
  380. PLWH who adhere to ART but smoke are substantially more likely to die from lung cancer than from AIDS-related causes - (12/23/21)
     
  381. Excess Black Deaths PLWH & Higher Morbidity - (12/23/21)
     
  382. Social Determinants of Health & African-Americans Associated with Chronic Comorbidities & Brain Aging - (12/23/21)
     
  383. The shifting age distribution of people with HIV using antiretroviral therapy in the United States, 2020 to 2030......23% >65y, 20% >70y (200,000+) and Impact - (12/23/21)
     
  384. Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns - (12/21/21)
     
  385. PrEP Barriers & Challenges - (12/21/21)
     
  386. COVID-19 Vaccination Rates in a Global HIV Cohort - (12/13/21)
     
  387. "I'm Just Forgetting and I Don't Know Why": Exploring How People Living With HIV-Associated Neurocognitive Disorder View, Manage, and Obtain Support for Their Cognitive Difficulties - study interviewing 25 PLWH average age 51 diagnosed with HAND (HIV-associated neurocognitive disorder) - (12/13/21)
     
  388. Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter? - (12/13/21)
     
  389. SARS-CoV-2 Infection Among People Living With HIV Compared With People Without HIV: Survey Results From the MACS-WIHS Combined Cohort Study - (12/10/21)
     
  390. Experimental mRNA HIV Vaccine Safe, Shows Promise in Animals NIAID Scientists Developed Vaccine Platform - (12/10/21)
     
  391. EACS: Distinct groupings of people with HIV and pain associate differently with pain-related healthcare use and health-related quality-of-life (HRQoL): findings from the Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study - (12/03/21)
     
  392. Safety & Efficacy of SARS-CoV-2 Monoclonal Neutralizing Anibodies BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients - (12/03/21)
     
  393. Remdesivir For the Treatment of High-Risk Non-Hospitalized Individuals with COVID-19: A Randomized, Double, Blind, Placebo-Controlled Trial PINETREE Study -RDV for 3 day 87% reduction in hospitalization, there were no deaths in either arm - (12/03/21)
     
  394. New Aging/HIV Language in New US AIDS Strategy 2022-2026 - (12/02/21)
     
  395. Gender Inequity-Inappropriate Prescribing for Elderly PLWH in Swiss Cohort - (11/30/21)
     
  396. Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study - (11/30/21)
     
  397. The Clinical Safety, Pharmacokinetics, and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor - (11/30/21)
     
  398. Einstein and Montefiore Researchers Awarded $7.6 Million in NIH Grants to Study Depression in People Living with HIV - (11/22/21)
     
  399. "I'm Just Forgetting and I Don't Know Why": Exploring How People Living With HIV-Associated Neurocognitive Disorder View, Manage, and Obtain Support for Their Cognitive Difficulties - (11/21/21)
     
  400. High-Dose Marine Omega-3s Raise Risk for Atrial Fibrillation - (11/19/21)
     
  401. The Esperanza Patient: More Hope for a Sterilizing HIV-1 Cure: A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation - (11/17/21)
     
  402. AASLD: INSTIs and DAAs Boost Liver Transplant Survival in HIV+ and HIV+/HCV+ in US - (11/16/21)
     
  403. AASLD: Simple Tool Tells Primary Care Docs When to Refer People With NAFLD - Mark Mascolini - (11/15/21)
     
  404. AASLD: HIV is independently associated with elevated FibroScan-AST (FAST) score, a non-invasive measurement of non-alcoholic steatohepatitis with significant activity and fibrosis - Mark Mascolini - (11/15/21)
     
  405. AASLD: Simple Tool Tells Primary Care Docs When to Refer People With NAFLD - Mark Mascolini - (11/15/21)
     
  406. AASLD: HIV is independently associated with elevated FibroScan-AST (FAST) score, a non-invasive measurement of non-alcoholic steatohepatitis with significant activity and fibrosis - Mark Mascolini - (11/15/21)
     
  407. Weight Change in NEAT-022, Switch to dolutegravir from boosted PI, 96 weeks at Glasgow 2018 - (11/11/21)
     
  408. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV - (11/10/21)
     
  409. No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naïve adults - (11/10/21)
     
  410. EACS: Efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in patients with pre-existing nrti resistances: real world data - (11/10/21)
     
  411. EACS: Integrase inhibitor drug resistance in clinical practice in the United Kingdom - (11/10/21)
     
  412. Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults - (11/08/21)
     
  413. EACS: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study - (11/06/21)
     
  414. EACS: People with HIV and suppressed viremia on ART are not at increased risk for acquiring SARS-CoV-2 infection SARS-CoV-2 Risk No Higher With Well-Controlled HIV Than in HIV-Negatives - Mark Mascolini (11/06/21)
     
  415. EACS: Tolerability and antiviral activity of bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) treatment switch in patients aged 55 years or older with HIV: the BIO study - (11/06/21)
     
  416. EACS: Gender-related differences in safety after switching to BICTEGRAVIR/TAF/FTC in "real life" - (11/06/21)
     
  417. EACS: Efficacy and safety of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically-suppressed HIV patients (EBONY Study) - (11/06/21)
     
  418. EACS: Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study - (11/06/21)
     
  419. EACS: More than half of well-treated persons living with HIV have angiography verified coronary artery disease Angiography Confirms Coronary Artery Disease in Over Half With HIV in Copenhagen - Mark Mascolini (11/06/21)
     
  420. EACS: Increased neurocognitive impairment and white matter damaged in young adults with perinatal HIV infection. A case-control study - (11/06/21)
     
  421. EACS: EACS: Long-Acting Injectable Cabotegravir + Rilpivirine. - (11/06/21)
     
  422. EACS: A fog that impacts everything: understanding quality of life in people living with HIV and cognitive impairment - poor mental & physical function - (11/06/21)
     
  423. EACS: Long-term HIV survivors and adults 65 or over with HIV: two separate profiles with different needs - (11/03/21)
     
  424. EACS: Comorbidities in women living with HIV: a systematic review - higher rates for kidney, bone, heart, neurocognitive diseases - (11/03/21)
     
  425. EACS: Themes of Aging from Older PLWH: A fog that impacts everything: understanding quality of life in people living with HIV and cognitive impairment - (11/03/21)
     
  426. EACS: Comparison of baseline characteristics and cardiovascular outcomes of a multicentre UK cohort of people living with HIV with previously reported cohorts - (11/03/21)
     
  427. EACS: Correlation between inflammatory biomarkers with four cardiovascular disease (CVD) risk models in aging patients living with HIV - (11/03/21)
     
  428. EACS: Incidence of diabetes mellitus in PLWHIV: impact of antiretroviral therapy - (11/03/21)
     
  429. EACS: Subclinical atherosclerosis burden in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors - (11/03/21)
     
  430. EACS: Liver disease in people living with HIV (PLWHIV) after the microelimination of HCV infection: non-viral hepatitis & NAFLD - (11/02/21)
     
  431. EACS: Factors associated with excess depressive disorders in women and men living with HIV in south-western France compared to the general French population - see slides below - (11/02/21)
     
  432. EACS: Faster lung function decline in well-treated people living with HIV compared with uninfected controls: a longitudinal matched cohort study - Mark Mascolini (11/02/21)
     
  433. EACS: Decreasing incidence and determinants of Bacterial Pneumonia in people with HIV: The Swiss HIV Cohort Study (SHCS) - (11/02/21)
     
  434. EACS: Stigma Drives Higher Depression Rate in HIV+ Men and Women in France - Mark Mascolini (11/02/21)
     
  435. New HRSA Funding Opportunities Focus on HIV and Aging Oct 28 published - (11/02/21)
     
  436. EACS: Bacterial Pneumonia Incidence Drops Sharply in Swiss HIV Cohort Study - Mark Mascolini (11/02/21)
     
  437. EACS: Incidence and risk factors for suicide, violent/accidental deaths, and substance abuse deaths in persons living with HIV - (11/02/21)
     
  438. EACS: Change in body mass index (BMI) and association with clinical outcomes after initiation of contemporary HIV antiretroviral (ARV) regimens in EuroSIDA - (11/02/21)
     
  439. EACS: Maraviroc or Metformin Does Not Lower Liver Fat in People With HIV and NAFLD - Mark Mascolini (11/02/21)
     
  440. EACS: Hepatitis C elimination in time of COVID-19 pandemic: the experience of University Hospital Center in Paris, France - (11/01/21)
     
  441. EACS: Maraviroc or Metformin Does Not Lower Liver Fat in People With HIV and NAFLD - Mark Mascolini (11/01/21)
     
  442. EACS: Hepatic steatosis associated with integrase strand transfer inhibitors - does the substance matter? - (11/01/21)
     
  443. EACS: Insulin resistance in PWH is associated with abdominal obesity and prior exposure to thymidine analogues and/or didanosine - (11/01/21)
     
  444. EACS: Safety Profile of Cabotegravir + Rilpivirine During Oral Lead-In and Through Long-Acting Therapy: Pooled Analysis of the Phase 3 FLAIR, ATLAS, and ATLAS-2M Studies - (11/01/21)
     
  445. EACS: UNDERSTANDING THE PERCEIVED THERAPEUTIC NEED AND VALUE ASSOCIATED WITH NOVEL LONG-ACTING ANTIRETROVIRAL REGIMENS AMONG PEOPLE LIVING WITH HIV IN 12 EUROPEAN COUNTRIES - (11/01/21)
     
  446. EACS: European Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes - (11/01/21)
     
  447. EACS: Highly Effective Two-drug Regimens of an Integrase Inhibitor and Reverse Transcriptase Inhibitor in Real-World Setting - Data from COMBINE-2 Study - (11/01/21)
     
  448. EACS: 12-month outcomes - patient satisfaction - of Dolutegravir (DTG) + Lamivudine (3TC) in ART-naïve and pre-treated PLHIV in Germany: Real-world data from the German URBAN cohort - (11/01/21)
     
  449. EACS: Evaluating the relationship between inflammation biomarker interleukin-6 (IL-6) levels and residual, low-Level viraemia in HIV-1 suppressed participants in the TANGO study at week 96 (WK96) - (11/01/21)
     
  450. EACS: The potential clinical impact of the observed differences in IL-6, a marker of inflammation, associated with some antiretroviral regimens - (11/01/21)
     
  451. EACS: Angiography Confirms Coronary Artery Disease in Over Half With HIV in Copenhagen - Mark Mascolini (11/01/21)
     
  452. EACS: PLW Presented Late To Care in WHO European Region 2019 - (11/01/21)
     
  453. EACS: Viral Suppression in 40 Countries in Europe & Central Asia 2020 - (11/01/21)
     
  454. EACS: Angiography Confirms Coronary Artery Disease in Over Half With HIV in Copenhagen - Mark Mascolini (11/01/21)
     
  455. EACS: SWITCHING TO DTG/3TC IS NON-INFERIOR TO CONTINUING CURRENT ANTIRETROVIRAL REGIMEN AT WEEK 48: SALSA SUBGROUP ANALYSES - (10/31/21)
     
  456. EACS: SWITCHING TO DTG/3TC IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN AT WEEK 144: TANGO SUBGROUP ANALYSES - (10/31/21)
     
  457. EACS: 2 year outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected PLHIV: Real-world data from the German JUNGLE cohort - (10/31/21)
     
  458. EACS: Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): Examining Healthcare Staff Attitudes During a Hybrid III Implementation-Effectiveness Trial Implementing Cabotegravir + Rilpivirine Long-Acting Injectable (CAB + RPV LA) for People Living With HIV - (10/30/21)
     
  459. EACS: Perspectives on the Acceptability, Appropriateness, Feasibility, Barriers, and Facilitators From Patients Receiving Cabotegravir + Rilpivirine Long-Acting Injectable Treatment (CAB + RPV LA): Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) - (10/30/21)
     
  460. EACS: Healthcare Staff Perspectives on the Implementation of HIV Injectable Treatment: Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) - (10/30/21)
     
  461. EACS: Characteristics, treatment patterns, and viral load for treatment-experienced people living with HIV and switching to an MTR or STR ARV after 2018 - (10/30/21)
     
  462. EACS: Long-term efficacy of bictegravir/emtricitabine/tenofovir alafenamide after switch from boosted protease inhibitor-based regimens including in those with preexisting resistance and viral blips - (10/30/21)
     
  463. EACS: Prevalence and risk factors of preexisting TAMs in clinical trial participants and sustained viral suppression after switching to bictegravir/emtricitabine/tenofovir alafenamide - (10/30/21)
     
  464. EACS: Evaluating virological outcomes in people with HIV on stable ART with reduced frequency of HIV viral load monitoring during the COVID-19 pandemic Less Viral Load Tracking During COVID Has No Immediate Ill Effects - Mark Mascolini (10/30/21)
     
  465. EACS: Domestic abuse (DA) screening in people living with HIV (PLWH) More Domestic Abuse Screening in HIV+ During COVID Discloses Spike in Reports - Mark Mascolini (10/30/21)
     
  466. EACS: Immunogenicity of mRNA vaccination against SARS-CoV-2 in persons living with HIV (PLWHs) with low CD4 count or previous AIDS Immune Response to mRNA COVID Vaccines Weaker in HIV+ With Low CD4s - Mark Mascolini (10/30/21)
     
  467. EACS: Chemsex practice in men who have sex with men: reduction or relapse during lockdown? Results of the CheRRLock study COVID Lockdown Boosts Chemsex Use, Cuts Sex Partners in Paris MSM - Mark Mascolini (10/30/21)
     
  468. EACS: New HCV Diagnoses Down by Two Thirds in HIV+ Swiss MSM 2010-2020 - Mark Mascolini (10/30/21)
     
  469. EACS: Chemsex practice in men who have sex with men: reduction or relapse during lockdown? Results of the CheRRLock study COVID Lockdown Boosts Chemsex Use, Cuts Sex Partners in Paris MSM - Mark Mascolini (10/29/21)
     
  470. EACS: Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting - (10/29/21)
     
  471. EACS: Progression to Anal Cancer Precursor 11 Per 100 Person-Years in HIV+ MSM - Mark Mascolini (10/29/21)
     
  472. EACS: Renal Safety of On-demand and Daily TDF-FTC for HIV Pre-exposure Prophylaxis in the ANRS-PREVENIR Study - (10/29/21)
     
  473. EACS: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 12-month effectiveness, persistence, and safety in a multi-country cohort study - (10/29/21)
     
  474. EACS: Patient-reported outcome (PRO) measures at 12 months in a real-world cohort of people living with HIV with a high prevalence of comorbidities receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel - (10/29/21)
     
  475. EACS: COMPARATIVE EFFICACY OF FOSTEMSAVIR VERSUS IBALIZUMAB IN HEAVILY TREATMENT-EXPERIENCED HIV PATIENTS - (10/29/21)
     
  476. EACS: LONG-TERM INFLAMMATION BIOMARKER CHANGES WITH FOSTEMSAVIR IN HEAVILY TREATMENT-EXPERIENCED ADULTS WITH HIV-1: EXPLORATORY ANALYSES OF THE PHASE 3 BRIGHTE STUDY - (10/29/21)
     
  477. EACS: IMPACT OF TREATMENT ADHERENCE ON EFFICACY OF DTG + 3TC AND DTG + TDF/FTC: POOLED WEEK 144 ANALYSIS OF THE GEMINI-1 AND GEMINI-2 CLINICAL STUDIES - (10/29/21)
     
  478. EACS: Subgroup efficacy analyses of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV (CAPELLA study) - (10/29/21)
     
  479. EACS: EMERGENT RESISTANCE TO ANTIRETROVIRAL AGENTS USED IN OPTIMIZED BACKGROUND THERAPY WITH FOSTEMSAVIR: WEEK 96 RESULTS OF THE PHASE 3 BRIGHTE STUDY IN HEAVILY TREATMENT-EXPERIENCED ADULTS LIVING WITH MULTIDRUG-RESISTANT HIV-1 - (10/29/21)
     
  480. EACS: Recent Abacavir Use and Incident Cardiovascular Disease in Contemporary Treated PLWH within the RESPOND Cohort Consortium - (10/29/21)
     
  481. EACS: Efficacy and Safety Outcomes by BMI Category Over 48 Weeks in Phase 3/3b Cabotegravir and Rilpivirine Long-Acting Trials - (10/29/21)
     
  482. EACS: Outcomes for Participants During Long-Term Follow-Up After Discontinuation of Cabotegravir + Rilpivirine Long-Acting in the Phase 3/3b Clinical Trials - (10/29/21)
     
  483. EACS: Efficacy and Safety of Islatravir in Combination With Doravirine Through 144 Weeks for Treatment-Naïve Adults With HIV-1 Infection in a Phase 2b Trial - (10/29/21)
     
  484. EACS: Resistance analysis of long-acting lenacapavir in highly treatment-experienced people with HIV after 26 weeks of treatment - (10/28/21)
     
  485. EACS: Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV (PLWH) within the RESPOND cohort consortium - Mark Mascolini - (10/28/21)
     
  486. EACS: Multiclass Resistance to Antiretrovirals Waning in Europe - Mark Mascolini - (10/28/21)
     
  487. EACS: High HIV Positivity Rate When Self-Tests Distributed by LGBT Health Center Clients - Mark Mascolini - (10/28/21)
     
  488. EACS: Kidney Toxicity Rare With Daily or On-Demand (As-Needed) PrEP - Mark Mascolini - (10/28/21)
     
  489. EACS: Safety and Efficacy of Doravirine in Treatment-Naïve Adults with HIV-1: 4 Years of Experience From the DRIVE-FORWARD and DRVIVE-AHEAD Clinical Trials - (10/28/21)
     
  490. EACS: ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be implemented successfully in a variety of European healthcare settings - (10/28/21)
     
  491. EACS: ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV - (10/28/21)
     
  492. The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries - (10/27/21)
     
  493. Trends in Cardiovascular Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status, 1999-2018 - (10/27/21)
     
  494. EACS: Evaluating the relationship between inflammation biomarker interleukin-6 (IL-6) levels and residual, low-Level viraemia in HIV-1 suppressed participants in the TANGO study at week 96 (WK96) - (10/27/21)
     
  495. EACS: Durable efficacy and safety of DTG + 3TC in treatment-naive people with HIV-1 stratified by age: 144-week results from GEMINI-1 and -2 - (10/27/21)
     
  496. EACS: Incidence of hypertension in people living with HIV receiving InSTI versus other third-drug ART regimens in the RESPOND cohort - (10/27/21)
     
  497. EACS: High incidence of subclinical peripheral artery disease in people living with HIV in Denmark: a 2-year follow-up study - (10/27/21)
     
  498. EACS: Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF - (10/27/21)
     
  499. EACS: Week 192 bone and renal markers from the ADVANCE trial - (10/27/21)
     
  500. EACS: ViiV Healthcare presents real-world evidence at EACS 2021 reinforcing the use of its 2-drug regimens Dovato (dolutegravir/lamivudine) and Juluca (dolutegravir/rilpivirine) for the treatment of people living with HIV - (10/27/21)
     
  501. EACS: Subclinical atherosclerosis burden in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors - (10/27/21)
     
  502. EACS: GENDER DIFFERENCES OF SUBCLINICAL ATHEROSCLEROSIS BURDEN IN CAROTID AND FEMORAL TERRITORIES IN PEOPLE LIVING WITH HIV: A SUBANALYSIS OF THE VASI STUDY - (10/27/21)
     
  503. EACS: Comorbidities and antiretroviral utilization among people living with HIV in the United States - (10/27/21)
     
  504. EACS: Change in body mass index (BMI) and association with clinical outcomes after initiation of contemporary HIV antiretroviral (ARV) regimens in EuroSIDA - (10/27/21)
     
  505. EACS: Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021 - (10/27/21)
     
  506. EACS: Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection - (10/25/21)
     
  507. Trends in Cardiovascular Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status, 1999-2018 - (10/27/21)
     
  508. Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults - (10/26/21)
     
  509. EACS: Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection - (10/25/21)
     
  510. U.S. Food and Drug Administration Approves Expanded Indication of Gilead's Biktarvy® for Treatment of HIV-1 in Pediatric Populations - (10/22/21)
     
  511. Less talk, more action: New report sponsored by ViiV Healthcare provides roadmap to achieve health equity by 2040 - (10/20/21)
     
  512. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data - (10/20/21)
     
  513. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study - (10/20/21)
     
  514. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization - (10/20/21)
     
  515. Focus Groups - 2015 - WIHS-Wash DC - Women want Pre-Exposure Prophylaxis but are Advised Against it by Their HIV-positive Counterparts - (10/17/21)
     
  516. Black Cisgender Women's PrEP Knowledge, Attitudes, Preferences, and Experience in Chicago - (10/17/21)
     
  517. "PrEP"ing for a PrEP demonstration project: understanding PrEP knowledge and attitudes among cisgender women - (10/17/21)
     
  518. Co-located HIV Services Can Help Women Who Inject Drugs Access PrEP, Study Shows - (10/17/21)
     
  519. Perceived HIV Acquisition Risk and Low Uptake of PrEP Among a Cohort of Transgender Women With PrEP Indication in the Eastern and Southern United States - (10/17/21)
     
  520. Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California - (10/17/21)
     
  521. IDWeek: Reasons for not using PrEP and actions that may facilitate PrEP uptake in Ontario and British Columbia, Canada - (10/17/21)
     
  522. IDWeek: Barriers to PrEP Implementation Among Patient-Facing Staff in Three Urban Clinics - (10/17/21)
     
  523. IDWeek: A Survey of HIV PrEP Prescribing Practices at an Academic Medical Center in the Pacific Northwest United States - (10/17/21)
     
  524. IDWeek: SUBOPTIMAL UPTAKE, RETENTION, AND ADHERENCE OF DAILY ORAL PREP AMONG PEOPLE WITH OUD RECEIVING HCV TREATMENT - (10/17/21)
     
  525. IDWeek: Bridging the Gap in PrEP Provider Training: An Implementation Science Study. insurance navigation for PrEP - (10/17/21)
     
  526. Renal impairment in a large-scale HIV pre-exposure prophylaxis implementation cohort - (10/14/21)
     
  527. Task Force Issues Draft Recommendation Statement on Aspirin Use to Prevent Cardiovascular Disease - (10/12/21)
     
  528. Providers PrEP: Identifying Primary Health care Providers' Biases as Barriers to Provision of Equitable PrEP Services - (10/07/21)
     
  529. IDWeek: Preliminary Findings from a HIV Self-Testing Program among People Who Use Drugs - (10/06/21)
     
  530. PLWH Have Higher COVID Testing, Diagnosis & Hospitalization at Kaiser Permanente So. Calif. - (10/07/21)
     
  531. IDWeek: Racial and Ethnic Disparities in COVID-19 Incidence among Persons with HIV in a Multisite-Cohort - (10/05/21)
     
  532. Cross-sectional study of correlates and prevalence [high rates] of functional and high-risk multimorbidity in an academic HIV practice in New York City at Cornell-Weill HIV Clinic - (10/05/21)
     
  533. Menopause Is Associated With Immune Activation in Women With HIV; mortality, heart disease, discrimination, stigma - (10/05/21)
     
  534. IDWeek: Lower SARS-CoV-2 IgG and Surrogate Virus Neutralization Titers Post-mRNA Vaccination among People Living with HIV - (10/05/21)
     
  535. IDWeek: Switch to DTG/3TC Noninferior to Maintaining TAF Regimen for 144 Weeks - Mark Mascolini (10/04/21)
     
  536. IDWeek: In Vitro Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence - (10/04/21)
     
  537. IDWeek: Increasing trends in multimorbidity and polypharmacy over a 5-year period in people living with HIV in the United States - Big US Study Confirms Ballooning Multimorbidity, Polypharmacy With HIV - (10/04/21)
     
  538. Weight Increases with Reyataz & Efavirenz in Treatment-Naives A5202 - (09/27/21)
     
  539. Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults - Results of a Controlled Trial - (09/22/21)
     
  540. CROI: Summary from virtual CROI 2021 for HIV and liver disease HIV and the liver: hot topics - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (04/10/21)
     
  541. IDWeek: EFFICACY AND SAFETY OF LONG-ACTING CABOTEGRAVIR + RILPIVIRINE IN PARTICIPANTS WITH HIV/HCV CO-INFECTION: ATLAS-2M 48-WEEK RESULTS - (10/04/21)
     
  542. IDWeek: Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1-Infected Participants - (10/03/21)
     
  543. IDWeek: Implementation of Long-acting Injectable Cabotegravir-Rilpivirine for HIV-1 treatment at a Ryan White-funded Clinic in the U.S. South - (10/03/21)
     
  544. IDWeek: Renal function, Lipid profile, and Cardiovascular Events After Switching to Abacavir-containing Regimen in Antiretroviral-therapy-experienced People Living with HIV in Northern Thailand - (10/03/21)
     
  545. IDWeek: Use of tenofovir disoproxil fumarate shows weight loss vs placebo: a meta-analysis of 7 clinical trials in 19,359 HIV-negative individuals - (10/03/21)
     
  546. IDWeek: Interim Analysis of Real-World Community-Based HIV Rapid Start Antiretroviral with BFTAF Versus Conventional HIV Antiretroviral Therapy Start The RoCHaCHa Study a Pilot Study - (10/03/21)
     
  547. IDWeek: Long-term clinical outcomes following SARS-CoV-2 infection include persistent symptoms and cardiovascular disease beyond 3 months post-infection - (10/03/21)
     
  548. IDWeek: Monoclonal Regdanvimab Cuts COVID Progression Risk in Placebo Trial - Mark Mascolini (10/03/21)
     
  549. IDWeek: CHARACTERIZATION OF HEAVILY TREATMENT-EXPERIENCED HIV-1-INFECTED CLINICAL TRIAL PARTICIPANTS INFECTED WITH SARS-COV-2 COVID-19: FOSTEMSAVIR BRIGHTE PHASE 3 CLINICAL TRIAL - (10/03/21)
     
  550. IDWeek: Improvement in Diet Attenuates Antiretroviral Therapy (ART) Associated Weight Gain in Persons with Human Immunodeficiency Virus (PWH) Improved Diet Tied to Lower ART-Related Weight Gain in 870-Person US Study - Mark Mascolini (10/02/21)
     
  551. IDWeek: EFFECTIVENESS AND TOLERABILITY OF DTG+3TC IN CLINICAL PRACTICE: EVIDENCE IN PLHIV FROM REAL-WORLD DATA - (10/02/21)
     
  552. IDWeek: COVID-19 Symptoms Persist Beyond 1 Month in 25% of US Military Group - Mark Mascolini (10/02/21)
     
  553. IDWeek: Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 weeks. Low and Similar Rates of New Metabolic Problems: 3 Years With 3 ART Regimens - Mark Mascolini (10/02/21)
     
  554. IDWeek: Sex and race disparities in premature mortality among people with HIV: a 21-year observational cohort study - Premature Mortality Higher in Women and Blacks in US HIV Group - (10/01/21)
     
  555. IDWeek: Risk of Virologic Failure Among Treatment-experienced Suppressed People with HIV (PWH) Treated with Single-Tablet 2-Drug (2DR) vs 3-Drug (3DR) Regimens - Mark Mascolini (10/01/21)
     
  556. IDWeek: EFFECTS OF THE "UNDETECTABLE = UNTRANSMITTABLE" ("U=U") EDUCATIONAL CAMPAIGN ON TREATMENT OUTCOMES AND PERCEPTIONS AMONG PEOPLE LIVING WITH HIV IN NORTH AMERICAN COUNTRIES - (10/01/21)
     
  557. IDWeek: Strong HIV Control for 72 Weeks With B/F/TAF in US Blacks - Mark Mascolini (10/01/21)
     
  558. IDWeek: North American Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes - (10/01/21)
     
  559. IDWeek: REAL-WORLD PERSISTENCY OF PATIENTS RECEIVING TENOFOVIR-BASED PRE-EXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE US - (10/01/21)
     
  560. IDWeek: Adherence to F/TDF for PrEP in Dried Blood Spots and HIV Infection Rates: A Pooled Analysis of Global PrEP Studies - (10/01/21)
     
  561. IDWeek: Pre-exposure prophylaxis (PrEP) prescriptions among individuals at high risk for HIV in the United States, 2012-2018 - (10/01/21)
     
  562. IDWeek: Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis (PrEP): A Real-World Evidence Analysis in the United States - (10/01/21)
     
  563. IDWeek: Offering Drug Injectors PrEP While ID Inpatients Not Successful - Mark Mascolini (10/01/21)
     
  564. IDWeek: Lower CD4s and Higher Viral Load-Not Antiretrovirals-Tied to Excessive Weight Gain - Mark Mascolini (10/01/21)
     
  565. IDWeek: COVID Brings Drops in HIV Care Visits, Viral Load Measures, and ART Stops - Mark Mascolini (09/30/21)
     
  566. IDWeek: Remdesivir Linked to Viral Clearance Only in Certain Subsets - Mark Mascolini (09/30/21)
     
  567. IDWeek: Treatment with molnupiravir in the MOVe-In and MOVe-Out clinical trials results in an increase in transition mutations across the SARS-CoV-2 genome - (09/30/21)
     
  568. IDWeek: Use of immune-viral dynamics modeling to understand molnupiravir drug effect for COVID-19 - (09/30/21)
     
  569. IDWeek: Clinical Characteristics of Patients Living with HIV Hospitalized for COVID-19 - PLWH have Higher Mortality Rate - (09/30/21)
     
  570. IDWeek: Molnupiravir maintains antiviral activity against SARS-CoV-2 variants in vitro and in early clinical studies - (09/30/21)
     
  571. IDWeek: Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021 - (09/30/21)
     
  572. IDWeek: CHARACTERISTICS, COMORBIDITIES, AND MEDICATION BURDEN AMONG PEOPLE LIVING WITH HIV IN THE US MEDICARE PROGRAM - (09/30/21)
     
  573. IDWeek: Increasing trends in multimorbidity and polypharmacy over a 5-year period in people living with HIV in the United States - (09/30/21)
     
  574. IDWeek: The Efficacy and Safety of Maintenance With Doravirine Plus Two NRTIs After Initial Suppression in Adults With HIV-1 in the DRIVE-FORWARD Clinical Trial: Results From the Study Extension Through 192 Weeks - (09/30/21)
     
  575. IDWeek: High Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide in African-American Adults With HIV Including Those with Preexisting Resistance, Viral Blips, and Suboptimal Adherence - (09/30/21)
     
  576. IDWeek: QUALITATIVE PATIENT-PARTICIPANT PERSPECTIVES ON IMPLEMENTATION OF MONTHLY CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING (CAB+RPV LA) INJECTABLE IN THE UNITED STATES (CUSTOMIZE) - (09/30/21)
     
  577. IDWeek: Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living With HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials - (09/30/21)
     
  578. IDWeek: MATERNAL DOLUTEGRAVIR (DTG) USE, AND PREGNANCY AND BIRTH OUTCOMES: THE ANTIRETROVIRAL PREGNANCY REGISTRY (APR) - (09/29/21)
     
  579. IDWeek: HIGH RATES OF VIROLOGIC SUPPRESSION WITH DTG/3TC IN NEWLY DIAGNOSED ADULTS WITH HIV-1 INFECTION AND BASELINE VIRAL LOAD ≥500,000 C/ML: 48-WEEK SUBGROUP ANALYSIS OF THE STAT STUDY - (09/29/21)
     
  580. IDWeek: Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks (CALIBRATE) - (09/29/21)
     
  581. IDWeek: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 144 WEEKS (TANGO STUDY) - (09/29/21)
     
  582. IDWeek: Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial - (09/29/21)
     
  583. IDWeek: Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 weeks. Low and Similar Rates of New Metabolic Problems: 3 Years With 3 ART Regimens - Mark Mascolini (09/29/21)
     
  584. IDWeek: Monoclonal Lenzilumab Cuts Need for Ventilation in Phase 3 COVID Trial - Mark Mascolini (09/29/21)
     
  585. IDWeek: Invasive Pneumococcal Disease Rate 17-Fold Higher With HIV in US - Mark Mascolini - (09/29/21)
     
  586. IDWeek: ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021 - (09/29/21)
     
  587. PWH -Higher Rates of Frailty Transitioning & Deaths - (09/28/21)
     
  588. ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals - (09/28/21)
     
  589. FDA grants Priority Review to ViiV Healthcare's New Drug Application for cabotegravir long-acting for prevention of HIV - (09/28/21)
     
  590. AGE: Factors influencing psychological distress during the COVID-19 pandemic in people aging with HIV - (09/28/21)
     
  591. AGE: Rapid Aging of HIV Immune System Reported in 2011 and Earlier by Rita Effros & UCLA Researchers. - (09/28/21)
     
  592. AGE: Frailty and resilience in people living with HIV during the COVID era: two complementary constructs? Sarcopenia, frailty & % of adipose tissue worsened. 37% were Frail & Non-Resilient - (09/28/21)
     
  593. AGE: Factors influencing psychological distress during the COVID-19 pandemic in people aging with HIV - (09/27/21)
     
  594. Pharm: Tenofovir alafenamide concentrations are reduced by half in pregnant women living with HIV: data from the PANNA Network. - By Mark Mascolini - (09/27/21)
     
  595. AGE: Pain Linked to Depression, Worse Physical Function, Falls, Frailty and Inflammation in Older People With HIV - By Mark Mascolini - (09/27/21)
     
  596. AGE: Burden of age-associated chronic comorbidities among people living with and without HIV: Years of life lost to premature mortality in British Columbia, Canada - (09/27/21)
     
  597. AGE: COVID Vaccine Effectivity in Aging & HIV Populations - (09/27/21)
     
  598. AGE: NYC Ryan White Part A: Program Model of Care for HIV and Aging - (09/25/21)
     
  599. AGE: Black and Hispanic women in the United States are disproportionally affected by the HIV infection - (09/25/21)
     
  600. AGE: Preliminary Hearing Data in Older Adults Living with 1HIV from 2the DETECT Study - (09/25/21)
     
  601. AGE: Survey of Consumers, Clinicians and Service Providers about Needs of Long-Term Survivors and People Aging with HIV in New York State - (09/25/21)
     
  602. AGE: Cognitive Impairment in Aging PLWH - Bruce Brew, MD lecture - (09/25/21)
     
  603. AGE: NAFLD Independently Tied to Worse Physical Quality of Life With HIV - By Mark Mascolini - (09/25/21)
     
  604. AGE: NAFLD Independently Tied to Worse Physical Quality of Life With HIV - (09/24/21)
     
  605. AGE: Polypharmacy Halves Odds of Nonadherence to ART-Frailty Boosts Odds - (09/24/21)
     
  606. AGE: Life Years Lost Due to Comorbidities 2.5 Time Greater With HIV - (09/24/21)
     
  607. AGE: Less Healthy Response to Skeletal Muscle Damage in Older Men With HIV - Mark Mascolini (09/23/21)
     
  608. AGE: Higher Viral Load Predicts Thromboembolism in People With HIV - Mark Mascolini (09/23/21)
     
  609. AGE: Rare Menopausal Hormone Therapy in HIV+ Women Tied to Lack of Clinician Discussion - Mark Mascolini (09/23/21)
     
  610. Intl Wrkshp Clin Pharm: Clinical Application for Coadministration of FTR and HCV medications - (09/22/21)
     
  611. Intl Wrkshp Clin Pharm: Special Populations Including End Organ Failure: Focus on Long-Acting Cabotegravir and Rilpivirine - (09/22/21)
     
  612. Intl Wrkshp Clin Pharm: Prevalence of clinically significant drug-drug interactions with antiretrovirals against HIV over time: a systematic review of the literature - (09/21/21)
     
  613. Intl Wrkshp Clin Pharm: Risk of Low-Level HIV Rises With Each Worse TDF Adherence Level - Mark Mascolini - (09/21/21)
     
  614. Intl Wrkshp Clin Pharm: Proposed Fostemsavir Precautions With HCV Meds - Mark Mascolini - (09/21/21)
     
  615. Intl Wrkshp Clin Pharm: Dolutegravir Troughs Higher With 3TC, Lower With TAF - Mark Mascolini - (09/21/21)
     
  616. Intl Wrkshp Clin Pharm: First 2 Reports of Bictegravir in Pregnancy Suggest Efficacy - Mark Mascolini - (09/21/21)
     
  617. Intl Wrkshp Clin Pharm: No Drop in Rate of Drug-Drug & Interactions With HIV Drugs Since 1985 - Mark Mascolini - (09/21/21)
     
  618. Congresswoman Barbara Lee and Jenniffer González continue to fight for those living with HIV Congressional HIV/AIDS Caucus Co-chairs introduce bipartisan bill (supporting aging/HIV & goals of HIV Awareness Ageing Day) - (09/21/21)
     
  619. IAS: COMORBIDITIES AND AGEING; IMMUNOMETABOLISM AND HIV PATHOGENESIS; TB & HIV; HIV Natural Controllers - Christina K. Psomas, MD (09/20/21)
     
  620. Intl Wrkshp Clin Pharm: Drug-Drug Interaction Risk High With COVID Meds in Hospital - Mark Mascolini - (09/20/21)
     
    621. Intl Wrkshp Clin Pharm: New Oral Ribonucleoside Optimal at 800 mg Twice Daily vs SARS-CoV-2 - Mark Mascolini - (09/20/21)
     
    Intl Wrkshp Clin Pharm: Phase 1 Trial Suggests Antidiarrheal Nitazoxanide Dose for COVID - Mark Mascolini - (09/20/21)
     
  621. COVID-19 Disease Severity among People with HIV Infection or Solid Organ Transplant in the United States: A Nationally-representative, Multicenter, Observational Cohort Study - (09/20/21)
     
  622. Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial - (09/20/21)
     
  623. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz - (09/17/21)
     
  624. Life-long Antiretroviral Therapy: Playing the Long Game (weight gain) - (09/17/21)
     
  625. Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults - (09/16/21)
     
  626. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial - (09/16/21)
     
  627. Behavioral and Clinical Characteristics of Persons Living with Diagnosed HIV Infection-Medical Monitoring Project, United States, 2019 Cycle - (09/15/21)
     
  628. Behavioral and Clinical Characteristics of Persons Living with Diagnosed HIV Infection-Medical Monitoring Project, United States, 2019 Cycle - (09/15/21)
     
  629. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study - (09/14/21)
     
  630. Ultra-long-acting removable drug delivery system for HIV treatment and prevention - (09/14/21)
     
  631. Long-acting implants to treat and prevent HIV infection - (09/14/21)
     
  632. IL-6 BLOCKADE DECREASES INFLAMMATION AND INCREASES CD127 EXPRESSION IN HIV INFECTION - (09/10/21)
     
  633. HIV and antiretroviral therapy-related fat alterations - (09/02/21)
     
  634. Fat & ART Effects in HIV, Comorbidities: Initiating ART Is Associated With Decreased Fat Density in People Living With HIV - (09/02/21)
     
  635. Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials - (09/02/21)
     
  636. IAS: Anxiety and Alcohol Consumption in the Miami Adult Studies on HIV (MASH) Cohort During the COVID-19 Pandemic - (09/01/21)
     
  637. Food Insecurity Affects HIV+ Minorities & Associated with Comorbidities & Mortality - (09/01/21)
     
  638. Managing frailty in people living with HIV: establishing and reviewing a new clinical service at Royal Free HIV Clinic London UK - (09/01/21)
     
  639. Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV - (09/01/21)
     
  640. IAS: Long-Acting Treatment: Cabotegravir/rilpivirine; Long-Acting Injectable PrEP HPTN 083, 084 - (08/31/21)
     
  641. Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa - (08/31/21)
     
  642. Heart Disease & HIV: statement from American Heart Association Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association - (08/31/21)
     
  643. The challenge of HIV treatment in an era of polypharmacy - (08/31/21)
     
  644. Aging, Comorbidities Screening Tests PWH Should Be Doing - (08/31/21)
     
  645. IAS: DECLINE IN HIV TESTING AND CHANGES IN POSITIVITY RATES DURING THE COVID-19 PANDEMIC - (08/30/21)
     
  646. IAS: Lenacapavir; Islatravir, Doravirine at IAS 2021 - (08/30/21)
     
  647. IAS: Co-morbidity and HIV: What Matters to Patients ? - IAS Symposium - Growing old with HIV: Co-morbidities and ageing (CME) - (08/25/21)
     
  648. Immunogenicity and safety of the BNT162b2 mRNA Covid-19 vaccine in people living with HIV-1 - (08/24/21)
     
  649. Switch to Doravirine 2 Studies, DRIVE-SHIFT Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV - (08/24/21)
     
  650. Cerebrovascular Contributions to Neurocognitive Disorders in People Living With HIV - (08/24/21)
     
  651. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine - FDA Grants Full Approval - (08/24/21)
     
  652. IAS: HIV Immune Response to COVID - 2 studies: 1- Robust SARS-CoV-2-specific serological and functional t-cell immunity in PLWHIV, 2 - SARS-Cov-2 immunity in COVID-19 convalescent individuals living with HIV: bulk immune profiling and SARS-CoV-2 specific humoral and cellular immune responses - (08/24/21)
     
  653. IAS: Virological suppression in people living with HIV infection is not protective of subclinical atherosclerosis - (08/24/21)
     
  654. IAS: Low rates of testing for sexually transmitted infections in an insured cohort of men and women living with HIV - (08/24/21)
     
  655. IAS: Chronic morphine administration alters gut-brain homeostasis in SHIV infected rhesus macaques - (08/24/21)
     
  656. IAS: Food insecurity is associated with increased immune activation in people living with HIV - (08/24/21)
     
  657. European Medicines Agency Validates Gilead's Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options - (08/23/21)
     
  658. NYC Forum on Older People with HIV: Developing a Service Model for PWH Over 50 in NYC - (08/23/21)
     
  659. IAS: Changes in Inflammation Scores Among People Living with HIV (PLWH) Under Different Antiretroviral Treatment (ART) Regimes - (08/23/21)
     
  660. IAS: Baricitinib reduces macrophage-mediated inflammation in HIV infection - (08/23/21)
     
  661. IAS: Ageing and renal insufficiency in persons living with and without HIV in AFRICOS - (08/23/21)
     
  662. IAS: Daily Variations- HIV & Immunity, T-Cell Exhaustion in Vertically Acquired HIV-children/adolescents/adults - (08/23/21)
     
  663. IAS: Circulating GDF15 levels [cellular stress] are associated with aging, risk of non-AIDS comorbidities and integrated HIV DNA in ART-treated people living with HIV - (08/23/21)
     
  664. IAS: Stress & Aging, Sleep & Brain - (08/23/21)
     
  665. IAS: Prioritizing the evaluation of HIV prevention interventions in pregnancy: Interim results from a randomized, open¬ label safety trial of dapivirine vaginal ring and oral tenofovir disoproxil fumarate/emtricitabine use in late pregnancy - (08/23/21)
     
  666. IAS: Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention Among Women Who Engaged in Transactional Sex - (08/23/21)
     
  667. Working HAND in HAND: Central nervous system complications in people with HIV - (08/21/21)
     
  668. IAS: Dolutegravir + 3TC at IAS 2021 - (08/19/21)
     
  669. IAS: Metabolics, Comorbidities & Aging at IAS 2021 - (08/15/21)
     
  670. ACIP Aug 13 slides Immunocompromsed: Evidence to Recommendation Framework: An Additional Dose of mRNA COVID-19 Vaccine Following a Primary Series in Immunocompromised People - (08/13/21)
     
  671. IAS: PSYCHOLOGICAL STRESS IS ASSOCIATED WITH CAROTID INFLAMMATION IN PERSONS WITH TREATED HIV INFECTION - (08/13/21)
     
  672. IAS: Proteomic evidence of vesatolimod-induced enhancement of 'cross-talk' • between innate and adaptive immune cells in HIV controllers on ART - (08/11/21)
     
  673. IAS: GS-9822, a preclinical LEDGIN, displays a block-and-lock phenotype in cell culture - (08/11/21)
     
  674. IAS: LOWER HIV RESERVOIR SIZE IN INDIVIDUALS WHO MAINTAIN HIGHER CD4+ T CELL COUNTS PRIOR TO ANTIRETROVIRAL THERAPY INITIATION: THE STRATEGIC TIMING OF ANTIRETROVIRAL TREATMENT (START} HIV RESERVOIR STUDY. - (08/11/21)
     
  675. IAS: Early treated individuals had lower reservoir size, lower viral diversity and higher susceptibility to bNAbs
    Evaluation of HIV-1 reservoir size and broadly neutralizing antibody (bNAb) susceptibility in individuals who initiated ART during acute and chronic infection     - (08/11/21)
     
  676. Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States - (08/09/21)
     
  677. Weight Change - Dolutegravir - Children, Adolescents - Intl Workshop on Pediatrics, HIV - (08/09/21)
     
  678. HIV-1 PERSISTENCE IN THE CNS: MECHANISMS OF LATENCY, PATHOGENESIS AND AN UPDATE ON ERADICATION STRATEGIES - (08/09/21)
     
  679. IAS: Switch to INSTI more than offset negative effects of weight gain on incidence of insulin resistance in people living with HIV - (08/09/21)
     
  680. IAS: Combination of high liver and visceral fat predict diabetes in people living with HIV - (08/09/21)
     
  681. B/F/TAF In Virologically Suppressed Adolescents and Children: Two-year Outcomes in 6 to <18 Year Olds and Six-month Outcomes in Toddlers - (08/06/21)
     
  682. Long-term Safety & Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide Single-Tablet Regimen in Children and Adolescents Living With HIV - (08/06/21)
     
  683. IAS: The association of coronary calcification with visceral adiposity in people living with HIV. Results from the Liverpool multiparametric imaging collaboration - (08/06/21)
     
  684. IAS: Prevalence and predictors of elevated arterial blood pressure in ageing people living with HIV attending care in Zambia - (08/06/21)
     
  685. IAS: Sexual Minority Stress and Accelerated Cellular aging in Treated HIV Infection - (08/06/21)
     
  686. Weight Change - Dolutegravir - Children, Adolescents - Intl Workshop on Pediatrics, HIV - (08/05/21)
     
  687. HIV-1 PERSISTENCE IN THE CNS: MECHANISMS OF LATENCY, PATHOGENESIS AND AN UPDATE ON ERADICATION STRATEGIES - (08/05/21)
     
  688. IAS: Long-Acting Treatment & PrEP Key Studies at IAS 2021 - (08/04/21)
     
  689. ACTG Starts New weight Gain, HIV Study Including Switch to Doravirine - (07/30/21)
     
  690. Exposure to dolutegravir from two formulations in children in the ODYSSEY trial - Intl Pediatrics Workshop - (07/26/21)
     
  691. Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial - Intl Pediatrics Workshop - (07/26/21)
     
  692. Efficacy, Safety and Tolerability of Guideline-Recommended ARVs from Pediatric Clinical Trials: A Systematic Review - Intl Pediatrics Workshop - (07/26/21)
     
  693. Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial - Intl Pediatics Workshop - (07/26/21)
     
  694. DOLUTEGRAVIR-BASED ART IS SUPERIOR TO STANDARD OF CARE IN YOUNG CHILDREN LIVING WITH HIV - Intl Pediatrics Workshop - (07/26/21)
     
  695. ART & Cervical Cancer Women with HIV Risk - (07/26/21)
     
  696. IAS: Immunoscenescence and HIV: mutual interactions? - (07/26/21)
     
  697. IAS: Poor sleep quality in people with HIV linked to lower CSF amyloid beta 42 - (07/26/21)
     
  698. IAS: HCV Reinfection Rate Almost 4% in Global Analysis of People With HIV - Mark Mascolini (07/26/21)
     
  699. IAS: Drug Injecting Remains Barrier to HCV Elimination in Netherlands - Mark Mascolini (07/26/21)
     
  700. IAS: HCV Cure Rate 92% in Hard-to-Reach Vietnam Drug-Injecting Group - Mark Mascolini (07/26/21)
     
  701. Coronavirus Disease 2019 (COVID-19) Infection Among People With Human Immunodeficiency Virus in New York City: A Population-Level Analysis of Linked Surveillance Data - Commentary & paper 50% Higher COVID Deaths, hospitalizations & ICU due to COVID for PLWH vs HIV-Neg in NYC - (07/22/21)
     
  702. IAS: Aging PLWH & Higher Readmission Hospital Rates than the General Population Hospital Readmissions Fall in Big HIV Group But Still High vs Non-HIV Patients - Mark Mascolini (07/23/21)
     
  703. IAS: Good Adherence to Vaginal Ring and Daily PrEP in Half of Young African Women - Mark Mascolini (07/23/21)
     
  704. IAS: Improving Hormone Levels in Transgenders Receiving Hormone Therapy - Mark Mascolini (07/23/21)
     
  705. IAS: Fostemsavir Serious Adverse Events More Frequent in People Over 50, Men, North Americans - Mark Mascolini (07/23/21)
     
  706. IAS: Integrase strand transfer inhibitor (INSTI) use and cancer incidence - Mark Mascolini (07/23/21)
     
  707. IAS: Trichloroacetic Acid an Alternative to Electrocautery for Anal Cancer Precursor? - Mark Mascolini (07/23/21)
     
  708. IAS: US MSM Seem Eager for Injectable PrEP-Side Effects, Cost Biggest Concerns - Mark Mascolini (07/23/21)
     
  709. IAS: Achievement of Undetectable HIV-1 RNA in the B/F/TAF Treatment-Naïve Clinical Trials - (07/22/21)
     
  710. IAS: Long-acting Capsid Inhibitor Effective as PrEP Against Vaginal SHIV Transmission in Macaques - (07/22/21)
     
  711. IAS: Barriers to Expanding PrEP Uptake among cis-gender African American Women in the US South - (07/22/21)
     
  712. IAS: Understanding participant experiences and preferences in an injectable PrEP trial: A qualitative substudy of barriers, facilitators, and preferences for PrEP use among MSM and TGW - (07/22/21)
     
  713. IAS: CLINICAL IMPACT OF ANTIRETROVIRAL AGENTS USED IN OPTIMIZED BACKGROUND THERAPY WITH FOSTEMSAVIR IN HEAVILY TREATMENT-EXPERIENCED ADULTS WITH HIV-1: EXPLORATORY ANALYSES OF THE PHASE 3 BRIGHTE STUDY - (07/22/21)
     
  714. IAS: LONG-TERM (96-WEEK) SAFETY OF FOSTEMSAVIR (FTR) IN HEAVILY TREATMENT-EXPERIENCED (HTE) ADULTS INFECTED WITH MULTIDRUG-RESISTANT (MDR) HIV-1 (BRIGHTE PHASE 3 STUDY) - (07/22/21)
     
  715. IAS: Safety Analysis of Islatravir in Combination With Doravirine in Treatment-Naïve Adults With HIV-1 Infection Through 96 Weeks Islatravir/Doravirine Adverse Events Less Frequent in Second Half of 96-Week Trial - Mark Mascolini (07/22/21)
     
  716. IAS: High interest in long-acting injectable HIV pre-exposure prophylaxis among nationwide online sample of United States men who have sex with men, 2019 - (07/22/21)
     
  717. IAS: Variation in preferences for long-acting injectable PrEP among US men who have sex with men: a latent class analysis - (07/22/21)
     
  718. IAS: Preferences for implementing long-acting injectable pre-exposure prophylaxis among cisgender men who have sex with men in the US - Online Survey - (07/22/21)
     
  719. IAS: Safety Analysis of Islatravir in Combination With Doravirine in Treatment-Naïve Adults With HIV-1 Infection Through 96 Weeks - (07/22/21)
     
  720. IAS: Safety and Pharmacokinetics of Oral Islatravir Once Monthly for HIV Pre-exposure Prophylaxis (PrEP): Week 24 Analysis of a Phase 2a Trial - (07/22/21)
     
  721. IAS: Clinical characteristics and prognostic factors in people living with HIV hospitalized with COVID-19: findings from the WHO Global Clinical Platform - (07/22/21)
     
  722. IAS: Unsuppressed plasma HIV-RNA is associated with worse COVID-19 outcomes among people living with HIV. - (07/22/21)
     
  723. IAS: The association of cardiovascular risk factors and disease in people living with HIV in the UK: a retrospective matched cohort study - (07/21/21)
     
  724. IAS: The association of cardiovascular risk factors and disease in people living with HIV in the UK: a retrospective matched cohort study Higher CVD Risk With HIV, Especially in People Younger Than 40 - Mark Mascolini - (07/21/21)
     
  725. IAS: Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV - (07/21/21)
     
  726. IAS: Higher comorbidity and comedication burden in women and young people living with HIV More Comorbidities, Polypharmacy With HIV-But Subgroup Differences Abound - (07/21/21)
     
  727. IAS: Mitochondrial disorders in activated memory CD4+ T cells derived from HIV-infected immunological non-responders - (07/21/21)
     
  728. IAS: Higher CVD Risk With HIV, Especially in People Younger Than 40 - Mark Mascolini - (07/21/21)
     
  729. IAS: Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019-June 2020. - (07/21/21)
     
  730. IAS: Outcomes of Participants Switching from F/TDF to F/TAF for PrEP: Week 48 Results from the DISCOVER Open Label Phase - (07/21/21)
     
  731. IAS: Long-term Analysis of B/F/TAF in Treatment-Naïve Adults Living With HIV Through Four Years of Follow-up - (07/21/21)
     
  732. IAS: Sub-40-Copy Virologic Hints May Favor DTG/3TC Over Multidrug Combos in TANGO - Mark Mascolini (07/21/21)
     
  733. IAS: Only 1 More Virologic Failure on CAB + RPV in Weeks 96 to 124 of FLAIR - Mark Mascolini - (07/21/21)
     
  734. IAS: CAB + RPV Failure Risk Factor in 10% of Large French Cohort - Mark Mascolini - (07/21/21)
     
  735. IAS: Higher CVD Risk With HIV, Especially in People Younger Than 40 - Mark Mascolini - (07/21/21)
     
  736. IAS: Impact of HIV on COVID-19 Outcomes among Hospitalized Adults in the U.S. - (07/21/21)
     
  737. IAS: Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084 - (07/21/21)
     
  738. IAS: WEEK 124 OF THE RANDOMIZED, OPEN-LABEL, PHASE 3 FLAIR STUDY EVALUATING LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR TREATMENT IN ADULTS WITH HIV-1 INFECTION - (07/21/21)
     
  739. IAS: Low Proportion of Individuals Develop Metabolic Syndrome (MetS) or Hepatic Fibrosis After Switch to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed Patients: A Post Hoc Metabolic Analysis - (07/21/21)
     
  740. IAS: Prevalence of genotypic baseline risk factors of Cabotegravir + Rilpivirine failure among ARV-naïve patients - (07/21/21)
     
  741. IAS: Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study) - (07/20/21)
     
  742. IAS: CLINICAL OUTCOMES DURING CUSTOMIZE: A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY FOCUSED ON IMPLEMENTATION OF CABOTEGRAVIR PLUS RILPIVIRINE (CAB + RPV) LA IN US HEALTHCARE SETTINGS - (07/20/21)
     
  743. IAS: CUSTOMIZE: OVERALL RESULTS FROM A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY EXAMINING IMPLEMENTATION OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING INJECTABLE FOR HIV TREATMENT IN US HEALTHCARE SETTINGS; FINAL PATIENT AND PROVIDER DATA - (07/20/21)
     
  744. IAS: CAB + RPV LA IMPLEMENTATION OUTCOMES AND ACCEPTABILITY OF MONTHLY CLINIC VISITS IMPROVED DURING COVID-19 PANDEMIC ACROSS US HEALTHCARE CLINICS (CUSTOMIZE: HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY) - (07/20/21)
     
  745. IAS: Every-6-Month Lenacapavir With F/TAF Controls HIV Through 28 Weeks - Mark Mascolini (07/20/21)
     
  746. IAS: Single-Pill DTG/3TC Effective in Suppressed People for 48 Weeks: SALSA - Mark Mascolini (07/20/21)
     
  747. IAS: Long-acting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen in treatment-naïve people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE) - (07/20/21)
     
  748. IAS: lntegrase strand transfer inhibitor (INSTI) use and cancer incidence - (07/20/21)
     
  749. IAS: FEASIBILITY, EFFICACY, AND SAFETY OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING FOR NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLWH): 48-WEEK RESULTS OF THE STAT STUDY - (07/20/21)
     
  750. IAS: SWITCHING TO THE 2-DRUG REGIMEN OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) FIXED-DOSE COMBINATION IS NON-INFERIOR TO CONTINUING A 3-DRUG REGIMEN THROUGH 48 WEEKS IN A RANDOMIZED CLINICAL TRIAL (SALSA) - (07/20/21)
     
  751. IAS: COMPARISON OF VIRAL REPLICATION FOR THE 2-DRUG REGIMEN (2DR) OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) VERSUS A 3/4-DRUG TENOFOVIR ALAFENAMIDE-BASED REGIMEN (TBR) IN THE TANGO STUDY THROUGH WEEK 96 - (07/20/21)
     
  752. IAS: Comparing adherence to HIV Pre-Exposure Prophylaxis (PrEP) among new, male PrEP users initiating F/TAF vs. F/TDF - (07/20/21)
     
  753. IAS: Long-term Efficacy Among Participants Switched to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) with Preexisting Resistance and Viral Blips - (07/20/21)
     
  754. IAS: Week 72 Outcomes and COVID-19 Impact From the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in Black American Adults With HIV - (07/20/21)
     
  755. IAS: Higher comorbidity and co-medication burden in women and young people living with HIV - (07/20/21)
     
  756. IAS: Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019-June 2020 - Mark Mascolini (07/20/21)
     
  757. IAS: METABOLIC HEALTH OUTCOMES AT WEEK 144 IN THE TANGO STUDY, COMPARING A SWITCH TO DTG/3TC VERSUS MAINTENANCE OF TAF-BASED REGIMENS - (07/20/21)
     
  758. IAS: DTG + 3TC IN GEMINI-1 & -2: HIV-1 REPLICATION AT <50 C/ML AND VL 'BLIPS' THROUGH 144 WEEKS - (07/20/21)
     
  759. IAS: Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged 65 years or older: week 96 results from an international, Phase 3b, open-label trial - (07/19/21)
     
  760. IAS: The safety and efficacy of maintenance with doravirine/lamivudine/tenofovir through 192 weeks in adults with HIV-1: Results from the DRIVE-AHEAD clinical trial - (07/19/21)
     
  761. IAS: Week 96 Metabolic and Bone Outcomes of a Phase 2b Trial of Islatravir and Doravirine - (07/19/21)
     
  762. IAS: SARS-CoV-2 Rate Similar in TDF PrEP Users and Matched No-TDF Controls - Mark Mascolini (07/19/21)
     
  763. IAS: ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19 - (07/19/21)
     
  764. IAS: ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs - (07/19/21)
     
  765. IAS: ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021 - (07/19/21)
     
  766. IAS: Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults - (07/19/21)
     
  767. IAS: New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor - (07/19/21)
     
  768. IAS: Gilead to Present New Data at IAS 2021 Demonstrating the Company's Commitment to Advancing Innovation in HIV Research - (07/19/21)
     
  769. WHO warns that HIV infection increases risk of severe and critical COVID-19 - (07/15/21)
     
  770. ART & Cervical Cancer Women with HIV Risk - (07/14/21)
     
  771. An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging - (07/14/21)
     
  772. IAS: Gilead to Present New Data at IAS 2021 Demonstrating the Company's Commitment to Advancing Innovation in HIV Research - (07/12/21)
     
  773. IAS: Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021 - (07/12/21)
     
  774. 2 New studies: Diabetes-Depression-Women & High Suicide Rates PLWH - (07/09/21)
     
  775. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) - (07/09/21)
     
  776. Moving on From HAND: Why We Need New Criteria for Cognitive Impairment in Persons Living With HIV and a Proposed Way Forward - (07/09/21)
     
  777. EASL: Mortality risk following HCV cure among people with HCV/HIV co-infection (07/06/21)
     
  778. ACTG Reports REPRIEVE Study HIV+ Heart Disease Risk with CT Angiography - (07/05/21)
     
  779. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options - (07/02/21)
     
  780. ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV - (06/22/21)
     
  781. Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial - (06/29/21)
     
  782. Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir - (06/22/21)
     
  783. Sudden Cardiac Death and Myocardial Fibrosis, Determined by Autopsy, in Persons with HIV - (06/21/21)
     
  784. NYC Planning Council talk by Jules: Aging with HIV in the US & NYC-clinical & community care & services needs, unmet needs - (06/14/21)
     
  785. Medicare PLWH: Blacks & Latinos 4-Fold Greater Risk - (06/14/21)
     
  786. HHS-Older PLWH Reduced Survival by 3.6 times & More Comorbidities - (06/14/21)
     
  787. Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005-2015 - (06/09/21)
     
  788. Redistribution of brain glucose metabolism in people with HIV after antiretroviral therapy initiation - (06/09/21)
     
  789. Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers - (06/09/21)
     
  790. Assessing the health status and mortality of older people over 65 with HIV - greater mortality, more comorbidities - (06/07/21)
     
  791. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study - (06/05/21)
     
  792. Clinical features and outcomes of COVID-19 among people living with HIV in the United States: A multicenter study from a large global health research network (TriNetX) - PWH had higher rates of poor COVID outcomes - (06/05/21)
     
  793. Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus - (06/05/21)
     
  794. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial - (06/05/21)
     
  795. HIV/AIDS at 40: COVID Could Increase by 10% Rates in HIV-related Deaths; PLWH with HIV & Undetectable HIV RNA may Experience 13 years Accelerated Aging, Fauci - (06/05/21)
     
  796. HIV and Hepatitis C Linkage-to-Care Initiative for New Orleans Residents Experiencing Homelessness During the COVID-19 Pandemic - (06/01/21)
     
  797. With No End in Sight on Omega-3 Debate, Nissen Calls for More Trials - Fish Oils/New Study "No strong evidence they prevent CVD events" - (05/18/21)
     
  798. Organ Reserve, Excess Metabolic Capacity, and Aging - (05/18/21)
     
  799. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir - (05/16/21)
     
  800. HIV disease duration, but not active brain infection, predicts cortical amyloid beta deposition - (05/11/21)
     
  801. New Data on Colchicine Bring Conflicting Results - (05/10/21)
     
  802. Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity - (05/10/21)
     
  803. Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus - undetectable HIV viral load reduced risk - (05/10/21)
     
  804. Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis - (05/10/21)
     
  805. Changes in Glomerular Kidney Function Among HIV-1 Uninfected Men and Women Receiving Emtricitabine Tenofovir Disoproxil Fumarate Preexposure Prophylaxis -A Randomized Clinical Trial - (05/10/21)
     
  806. HPV vaccination to prevent recurrence of Anal Intraepithelial Neoplasia in HIV+ MSM - a randomised, placebo-controlled multicentre trial - (05/10/21)
     
  807. Changes in Fat Mitochondrial DNA and Function in Subjects Randomized to Abacavir-Lamivudine or Tenofovir DF-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s, Substudy of A5202 - (05/10/21)
     
  808. Cabotegravir for PrEP -083, 084 recent data - (05/04/21)
     
  809. ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV - (05/04/21)
     
  810. Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus Coinfected Persons in North America - (05/03/21)
     
  811. Accelerated Brain Aging and Cerebral Blood Flow Reduction in Persons With Human Immunodeficiency Virus - (04/29/21)
     
  812. Genital Inflammation & HIV Acqusition Associated in Women.....STIs also associated with Inflammation & HIV Acquisition - new study - (06/26/15)
     
  813. LATEST UPDATE ON HIV LIPODYSTROPHY: Interview with Dr Grace McComsey - (04/17/17)
     
  814. 75-85% in SF-NY-Florida-Boston with HIV Are Over 40 Years Old....25% over 60 in SF-Florida-NY - (09/04/19)
     
  815. CROI: COVID & HIV - Antiviral Molnupiravir, monoclonal antibody combinations, Convalesecent Plasma - (03/19/21)
     
  816. CROI: CANNABIS USE ASSOCIATED WITH DECREASED ART ADHERENCE IN AGING PEOPLE WITH HIV - (05/10/21)
     
  817. CROI: FEMINIZING THERAPY DECREASES D-DIMER BUT WORSENS INSULIN SENSITIVITY IN TRANS WOMEN - (05/08/21)
     
  818. CROI: 28th Virtual Conference on Retroviruses and Opportunistic Infection March 7-10, 2021 Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center - (04/27/21)
     
  819. CROI: CROI 2021 Highlights
    By Christina K. Psomas
    European Hospital Marseille, Marseille, France - (04/26/21)
     
  820. CROI: Clinical Pharmacology at CROI 2021. New Drugs & Formulations; PrEP; HIV Treatment - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center 986000 Nebraska Medical Center - (04/21/21)
     
  821. CROI: LOWER UPTAKE OF DOLUTEGRAVIR AMONG WOMEN OF REPRODUCTIVE POTENTIAL VS MEN-KENYA - (04/14/21)
     
  822. CROI: DRAMATIC DECLINE IN PUBLIC SECTOR HIV/STI TESTING DURING SARS-CoV-2 PANDEMIC, OREGON - (04/13/21)
     
  823. CROI: HIV Prevention at CROI 2021. NATAP Report by Renee Heffron, PhD and Connie Celum, MD, University of Washington - (04/13/21)
     
  824. CROI: Summary from virtual CROI 2021 for HIV and liver disease HIV and the liver: hot topics - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (04/10/21)
     
  825. CROI: SERUM BIOMARKERS IDENTIFY CARDIAC DYSFUNCTION IN (perinatally infected) YOUTH LIVING WITH HIV - (04/06/21)
     
  826. CROI: QUINOLINIC ACID IS ASSOCIATED WITH CAROTID INTIMA-MEDIA THICKNESS IN HIV - (04/06/21)
     
  827. CROI: DORAVIRINE CONCENTRATIONS AND HIV-1 RNA SUPPRESSION IN MALE AND FEMALE GENITAL FLUIDS - (04/06/21)
     
  828. CROI: TRENDS IN TRUVADA AND DESCOVY PRESCRIPTIONS FOR PrEP IN THE UNITED STATES, 2014-2020 - (04/05/21)
     
  829. CROI: TOTAL AND UNBOUND DORAVIRINE CONCENTRATIONS AND VIRAL SUPPRESSION IN CSF OF HIV+ PTS - (04/05/21)
     
  830. CROI: VIRUS REMISSION WITH AN OPTIMIZED EARLY ART REGIMEN IN MACAQUES - (04/05/21)
     
  831. CROI: IMPAACT 2014 24-WEEK PK AND SAFETY OF DORAVIRINE/3TC/TDF IN ADOLESCENTS WITH HIV-1 - (04/05/21)
     
  832. CROI: REMDESIVIR VERSUS STANDARD OF CARE FOR SEVERE COVID-19 - (04/05/21)
     
  833. CROI: ACUTE KIDNEY INJURY IN PATIENTS WITH MODERATE COVID-19 TREATED WITH RDV VERSUS SoC - (04/05/21)
     
  834. CROI: TREATMENT AND OUTCOMES OF COVID-19 IN THE US: ARE THEY DIFFERENT ACCORDING TO RACE? - (04/05/21)
     
  835. CROI: SAFETY AND EFFICACY OF REMDESIVIR IN A PEDIATRIC COVID-19 POPULATION - (04/05/21)
     
  836. CROI: VASCULAR INJURY MARKERS ASSOCIATED WITH COGNITIVE IMPAIRMENT IN HIV PATIENTS ON ART - (03/30/21)
     
  837. CROI: SEX DIFFERENCES IN WHITE-MATTER LOSS AND ASSOCIATED AXONAL INJURY IN PLWH - (03/30/21)
     
  838. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV - A Cohort Study - (03/28/21)
     
  839. CROI: RELATIONSHIP OF T-CELL MITOCHONDRIAL GENE EXPRESSION AND DIABETES IN PERSONS WITH HIV - (03/28/21)
     
  840. CROI: ELUCIDATING THE ORIGINS OF HIV-1 IN THE CEREBROSPINAL FLUID - (03/28/21)
     
  841. CROI: CORONARY ARTERY DISEASE, TRADITIONAL RISK, AND INFLAMMATION AMONG PWH IN REPRIEVE - (03/28/21)
     
  842. CROI: Women & HIV at CROI - (03/28/21)
     
  843. CROI: Neurocognition & PLWH - CROI 2021 - (03/28/21)
     
  844. CROI: Laboratory Analysis of HIV Infections in HPTN 083: Injectable CAB for PrEP - (03/26/21)
     
  845. CROI: HIV AMBULATORY CARE DURING COVID-19 PANDEMIC IN US: VISITS AND VIRAL LOAD TESTING - "dropped precipitously" - (03/20/21)
     
  846. CROI: IMPACT OF COVID-19 ON COMMERCIAL LABORATORY TESTING FOR HIV IN THE UNITED STATES - (03/22/21)
     
  847. CROI: COVID & HIV - Antiviral Molnupiravir, monoclonal antibody combinations, Convalesecent Plasma - (03/19/21)
     
  848. CROI: Weight Gain / Loss - (03/19/21)
     
  849. CROI: New PrEP at CROI 2021 - (03/19/21)
     
  850. CROI: CROI 2021 - Complications: HIV, COVID - (03/19/21)
     
  851. CROI: CROI 2021 - New HIV Drugs - (03/19/21)
     
  852. CROI: Aging & HIV Highlights at CROI 2021 - (03/25/21)
     
  853. CROI: STATIN USE AND COGNITIVE PERFORMANCE IN THE MULTICENTER AIDS COHORT STUDY - (03/26/21)
     
  854. CROI: DECREASED HIV DIAGNOSES AMONG MSM OF COLOR IN THRIVE-FUNDED JURISDICTIONS, 2014-2018 - (03/25/21)
     
  855. CROI: GENDER-AFFIRMING SURGERY ASSOCIATED WITH HIGH VIRAL SUPPRESSION AMONG TRANSGENDER PWH - (03/25/21)
     
  856. CROI: IMPACT OF COMMON SIDE EFFECTS ON PrEP PERSISTENCE DURING PREGNANCY IN SOUTH AFRICA - (03/25/21)
     
  857. CROI: COST-EFFECTIVENESS OF LONG-ACTING PrEP AMONG MSM/TGW IN THE US - (03/25/21)
     
  858. CROI: EPIGENETIC AGING ASSOCIATED WITH COGNITIVE IMPAIRMENT IN OLDER BLACK ADULTS WITH HIV - (03/24/21)
     
  859. CROI: DEMENTIA INCIDENCE AMONG ART-TREATED PEOPLE WITH HIV IN A PRIMARY CARE SETTING - (03/24/21)
     
  860. CROI: NEUROCOGNITIVE DYSFUNCTION, INFLAMMATION, AND ADIPOSITY IN TREATED HIV PATIENTS - (03/24/21)
     
  861. CROI: PWH AND ALZHEIMER'S DISEASE RISK: CLARIFYING THE HAND PHENOTYPE OVER TIME - (03/24/21)
     
  862. CROI: HEPATITIS B SEROPROTECTION AMONG YOUNG ADULTS LIVING WITH PERINATALLY ACQUIRED HIV - (03/23/21)
     
  863. CROI: BARRIERS IMPACTING TELEHEALTH MEDICAL-APPOINTMENT ADHERENCE AMONG PLWHA - (03/23/21)
     
  864. CROI: PrEP USE AND REFERRAL: BLACK PARTNERS OF PEOPLE WITH HIV IN PARTNER SERVICES, 2019 - (03/22/21)
     
  865. CROI: A SURVEY-BASED PILOT STUDY TO ASSESS THE EFFECTS OF COVID-19 ISOLATION ON OLDER PLWH - (03/22/21)
     
  866. CROI: LOW PROPORTIONS OF LINKAGE & PRESCRIPTIONS OF PrEP IN BLACK WOMEN (THRIVE, 2015-2020) - (03/22/21)
     
  867. CROI: CHANGES IN ACCESS TO CARE FOR WOMEN LIVING WITH HIV DURING THE COVID-19 PANDEMIC - (03/22/21)
     
  868. CROI: PLWH AND CANCER EXHIBIT UNIQUE PATTERN OF ACTIVATED AND EXHAUSTED CD8+ T CELLS - (03/22/21)
     
  869. CROI: RANDOMIZED CONTROLLED TRIAL OF MARAVIROC FOR HIV-ASSOCIATED NEUROCOGNITIVE IMPAIRMENT - (03/22/21)
     
  870. CROI: THE USE OF LESS NEUROTOXIC ANTIRETROVIRALS: SECONDARY ENDPOINTS OF THE MARAND-X STUDY - (03/22/21)
     
  871. CROI: IMMUNE MARKERS AND TO TIME TO REBOUND DURING HIV TREATMENT INTERRUPTION IN ACTG A5345 - (03/22/21)
     
  872. CROI: PHARMACY REVERSALS: A NOVEL INDICATOR OF GAPS IN THE HIV PrEP CARE CASCADE - (03/21/21)
     
  873. CROI: A NOVEL APPROACH TO MEASURE PrEP UPTAKE AMONG POPULATIONS WITH PERSISTENT HIV RISK - (03/21/21)
     
  874. CROI: IMMUNE MARKERS AND TO TIME TO REBOUND DURING HIV TREATMENT INTERRUPTION IN ACTG A5345 - (03/21/21)
     
  875. CROI: PREDICTORS OF PrEP UPTAKE IN A SEXUAL HEALTH CLINIC WITH IMMEDIATE PrEP INITIATION - (03/20/21)
     
  876. CROI: RISK OF CANCER BY HIV STATUS AND BIRTH REGION: A NATIONWIDE REGISTER-BASED STUDY - (03/20/21)
     
  877. CROI: ACTIVATING PKC-ε INDUCES HIV EXPRESSION WITH IMPROVED TOLERABILITY - (03/19/21)
     
  878. CROI: HIV REBOUND IN CONTROLLERS IS ASSOCIATED WITH SPECIFIC FECAL MICROBIOME PROFILE - (03/19/21)
     
  879. CROI: MATHEMATICAL MODELING OF PREDICTORS OF POSTTREATMENT CONTROL IN HIV CURE TRIALS - (03/19/21)
     
  880. CROI: EVALUATION OF bNAb SENSITIVITY BY GENOTYPING AND PHENOTYPING FOR HIV CLINICAL TRIALS - (03/19/21)
     
  881. CROI: ULTRASENSITIVE HIV-1 DRUG-RESISTANCE ANALYSIS IN THE DISCOVER PrEP TRIAL - (03/19/21)
     
  882. CROI: THE ANTIRETOVIRAL PREGNANCY REGISTRY: 30 YEARS OF MONITORING FOR CONGENITAL ANOMALIES - (03/19/21)
     
  883. CROI: SEX DIFFERENCES IN DIABETES PREVELANCE AMONG PERSONS WITH HIV IN THE UNITED STATES...40% of HIV+ Women >65 have diabetes. - (03/19/21)
     
  884. CROI: IMPACT OF REPRODUCTIVE AGING ON HIV PERSISTENCE IN CISGENDER MEN AND WOMEN WITH HIV - (03/19/21)
     
  885. CROI: ACCELERATED CEREBRAL BLOOD-FLOW REDUCTION AND BRAIN AGING IN PEOPLE LIVING WITH HIV PLWH associated with accelerated brain age - (03/18/21)
     
  886. CROI: INCIDENT DIABETES ASSOCIATED WITH INTEGRASE STRAND TRANSFER INHIBITOR INITIATION - (03/18/21)
     
  887. CROI: CSF MARKERS OF AD-RELATED PATHOLOGY AND MEMORY DEFICITS IN OLDER PEOPLE WITH HIV - (03/18/21)
     
  888. CROI: Incidence of HIV infection with daily or on-demand oral PrEP with TDF/FTC in France - (03/18/21)
     
  889. Burden of Hypertension, Diabetes, Cardiovascular Disease, and Lung Disease Among Women Living With Human Immunodeficiency Virus (HIV) in the United States - (03/18/21)
     
  890. Global data shows increasing PrEP use and widespread adoption of WHO PrEP recommendations - (03/18/21)
     
  891. CROI: Incidence of HIV infection with daily or on-demand oral PrEP with TDF/FTC in France - (03/17/21)
     
  892. CROI: NEURON DAMAGE AND RESERVOIR ARE SECONDARY TO HIV TRANSCRIPTS DESPITE SUPPRESSIVE ART - (03/17/21)
     
  893. CROI: DRUG-USE STIGMA AND HEPATITIS C VIRUS INFECTION AMONG PWID IN INDIA - (03/17/21)
     
  894. CROI: ACCESS TO HCV CARE AMONG HIV/HCV-COINFECTED PEOPLE WHO INJECT DRUGS ACROSS CANADA - (03/16/21)
     
  895. CROI: HIV/HCV COINFECTION TRENDS IN SPAIN (2015-2019) - (03/16/21)
     
  896. CROI: NO CHANGE IN INCIDENCE OF RECENTLY ACQUIRED HCV IN HIV+ MSM IN GERMANY (NOCO COHORT) - (03/16/21)
     
  897. CROI: HEPATITIS C CASCADE OF CARE IN HIV/HCV-COINFECTED PERSONS IN EUROPE IN THE DAA ERA - (03/16/21)
     
  898. CROI: SELF-TESTING FOR HCV: MULTICOUNTRY EVIDENCE ON USABILITY AND ACCEPTABILITY - (03/16/21)
     
  899. CROI: COST-EFFECTIVENESS OF HCV TESTING STRATEGIES FOR HCV ELIMINATION AMONG MSM IN THE US - (03/16/21)
     
  900. CROI: REINFECTION WITH THE HEPATITIS C VIRUS IN MEN WHO HAVE SEX WITH MEN - (03/16/21)
     
  901. CROI: PREVALENCE AND FACTORS ASSOCIATED WITH SARS-CoV-2 ANTIBODIES IN A SPANISH HIV COHORT - (03/16/21)
     
  902. CROI: COVID-19 IN HOSPITALIZED HIV-POSITIVE AND HIV-NEGATIVE PATIENTS: A MATCHED STUDY - (03/16/21)
     
  903. Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV - (03/15/21)
     
  904. CROI: SECOND ANTIRETROVIRAL THERAPY REGIMEN IN VIREMIC PEOPLE WITH HIV IN THE US, 2008-2018 - (03/15/21)
     
  905. CROI: CHARACTERIZING FIRST VIRAL FAILURES AMONG ANTIRETROVIRAL THERAPY INITIATORS IN THE US - (03/15/21)
     
  906. CROI: Dual mAb Prevents Symptomatic COVID-19 in Household-Exposed Group: Interim Results of Placebo-Controlled Trial - Mark Mascolini (03/15/21)
     
  907. CROI: RISK FACTORS FOR HOSPITALIZATION IN PEOPLE WITH HIV AND COVID-19 - (03/15/21)
     
  908. CROI: T-CELL IMMUNE DYSREGULATION AND MORTALITY IN WOMEN WITH HIV - (03/15/21)
     
  909. CROI: Risk factors for progression from prediabetes to diabetes in persons with HIV - Integrase Inhibitors Tied to Lower Risk of Progression from Prediabetes to Diabetes - HAILO - Mark Mascolini - (03/15/21)
     
  910. CROI: PREDICTED 10-YEAR RISKS OF CARDIOVASCULAR DISEASE AND DIABETES IN THE ADVANCE TRIAL - (03/15/21)
     
  911. CROI: CARDIOMETABOLIC HEALTH IN HIV+ AND HIV- PREGNANT SOUTH AFRICAN WOMEN - (03/15/21)
     
  912. CROI: CASIRIVIMAB WITH IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 PREVENTION: INTERIM RESULTS - (03/15/21)
     
  913. CROI: PREDICTED LONG-TERM ADVERSE BIRTH AND CHILD HEALTH OUTCOMES IN THE ADVANCE TRIAL - (03/15/21)
     
  914. CROI: In US Groups COVID Testing More Likely With HIV, But Positivity Similar With/Without HIV - Mark Mascolini (03/15/21)
     
  915. CROI: HIV-1 DNA GENOTYPING IS OFTEN VARIABLE IN REPEAT TESTING FROM SINGLE BLOOD DRAWS - (03/15/21)
     
  916. CROI: URINE MITOCHONDRIAL DNA, WEIGHT LOSS, AND BODY COMPOSITION IN OLDER ADULTS WITH HIV - (03/14/21)
     
  917. CROI: COMORBIDITY BURDEN IS ASSOCIATED WITH HOSPITALIZATION FOR COVID-19 AMONG PWH - (03/14/21)
     
  918. CROI: CHARACTERIZING COVID-19 PRESENTATION AND CLINICAL OUTCOMES IN HIV PATIENTS IN THE US - (03/14/21)
     
  919. CROI: Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir - (03/14/21)
     
  920. CROI: Online Mindfulness Lessons Ease Depression, Anxiety in Older HIV+ During COVID - Mark Mascolini (03/14/21)
     
  921. CROI: IN VITRO MODEL TO ASSESS ANTIRETROVIRAL THERAPY ON ADIPOCYTE BIOLOGY - (03/14/21)
     
  922. CROI: BEYOND PAIN: PRESCRIPTION OPIOID USE IN THE WOMEN'S INTERAGENCY HIV STUDY - (03/14/21)
     
  923. CROI: ASSOCIATION BETWEEN INTEGRASE INHIBITORS (InSTIs) AND CARDIOVASCULAR DISEASE (CVD) - (03/14/21)
     
  924. CROI: INFLAMMATORY AND ATHEROGENESIS MARKERS 148 WEEKS POSTSWITCH TO DTG+RPV IN SWORD-1/ -2 - (03/14/21)
     
  925. CROI: RENAL/BONE OUTCOMES AFTER LONG-ACTING CABOTEGRAVIR + RILPIVIRINE IN ATLAS + ATLAS-2M - (03/14/21)
     
  926. CROI: WEIGHT GAIN POST-ART IN HIV+ LATINOS/AS DIFFERS IN THE US, CANADA, AND LATIN AMERICA - (03/14/21)
     
  927. CROI: CHARACTERISTICS OF HIV+ AND HIV- PATIENTS UNDERGOING BARIATRIC SURGERY: OBEVIH STUDY - (03/14/21)
     
  928. CROI: HEROIN USE IS ASSOCIATED WITH HIGH-AORTIC BUT LOW-SPLEEN/ MARROW UPTAKE BY PET IN HIV - (03/14/21)
     
  929. CROI: HIV Linked to 4.5-Fold Higher Risk of Aortic Aneurysm - Mark Mascolini (03/14/21)
     
  930. CROI: BEYOND PAIN: PRESCRIPTION OPIOID USE IN THE WOMEN'S INTERAGENCY HIV STUDY - (03/12/21)
     
  931. CROI: Acute Kidney Injury Less Frequent With Remdesivir Than Standard of Care - Mark Mascolini (03/12/21)
     
  932. CROI: HIV REPLICATION IN THE CNS IS ASSOCIATED WITH NEUROCOGNITION AND DEPRESSION PRE-ART - (03/12/21)
     
  933. CROI: FACTORS ASSOCIATED WITH SYSTEMIC IMMUNE ACTIVATION IN A GLOBAL HIV COHORT - (03/12/21)
     
  934. CROI: INTRANASAL INSULIN IMPROVES ATTENTION AND MEMORY IN PEOPLE WITH HIV - (03/12/21)
     
  935. CROI: HIV-1, INSUFFICIENT SLEEP, AND ENDOTHELIAL VASODILATOR FUNCTION - (03/12/21)
     
  936. CROI: FTC-TP in Dried Blood Spots Predicts Future Detectable Viral Load in US Study - Mark Mascolini (03/12/21)
     
  937. CROI: Resistance and Response in Phase 2a Study of HIV Maturation Inhibitor - Mark Mascolini (03/12/21)
     
  938. CROI: Favipiravir Has Clinical Pluses vs Standard Care for In-Hospital COVID-19 - Mark Mascolini (03/12/21)
     
  939. CROI: A PLACEBO-CONTROLLED ATI TRIAL OF HTI VACCINES IN EARLY TREATED HIV INFECTION - (03/12/21)
     
  940. CROI: DIET QUALITY BY GLOBAL BURDEN OF DISEASE REGION IN PWH IN THE REPRIEVE TRIAL - (03/12/21)
     
  941. CROI: MATERNAL WEIGHT AND ADVERSE PREGNANCY OUTCOMES AMONG WOMEN ON ART AT CONCEPTION - (03/11/21)
     
  942. CROI: ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES IN IMPAACT 2010 - (03/11/21)
     
  943. CROI: SAFETY/EFFICACY OF DTG VS EFV, TDF VS TAF IN PREGNANCY/POSTPARTUM: IMPAACT 2010 TRIAL - (03/11/21)
     
  944. CROI: Complex Vaccine-Escape Mutation Profiles in 947 People With HBV - Mark Mascolini - (03/11/21)
     
  945. CROI: PHASE 1 PK, SAFETY, AND ACCEPTABILITY STUDY OF 3-MONTH DAPIVIRINE VAGINAL RINGS - (03/11/21)
     
  946. CROI: RCT OF AN ONLINE MENTAL HEALTH INTERVENTION AMONG OLDER PLWH DURING COVID-19 PANDEMIC - Improved Depression, Anxiety & Loneliness - (03/11/21)
     
  947. CROI: HIGHER COMORBIDITY BURDEN PREDICTS WORSENING NEUROCOGNITION IN PEOPLE WITH HIV - (03/11/21)
     
  948. CROI: New PrEP at CROI 2021 - (03/11/21)
     
  949. CROI: WEEK 96 EFFICACY AND SAFETY OF CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS: ATLAS-2M - (03/11/21)
     
  950. CROI: Three-Month Vaginal Ring Yields Higher Dapivirine Levels in US Study - Mark Mascolini (03/10/21)
     
  951. CROI: Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021 - (03/10/21)
     
  952. CROI: ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV - (03/10/21)
     
  953. CROI: DOLUTEGRAVIR-BASED ART IS SUPERIOR TO NNRTI/PI-BASED ART IN CHILDREN AND ADOLESCENTS - (03/10/21)
     
  954. CROI: BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN HIGH- RISK AMBULATORY PATIENTS - (03/10/21)
     
  955. CROI: Convalescent Plasma Has No Effect on Survival or Disease Course With Severe COVID-19 - Mark Mascolini (03/10/21)
     
  956. CROI: mAb Bamlanivimab Lowers Odds of SARS-CoV-2 and Symptomatic COVID-19 in Nursing Facilities - Mark Mascolini - (03/10/21)
     
  957. CROI: BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING - (03/10/21)
     
  958. CROI: REDUCTION IN INFECTIOUS SARS-CoV-2 IN TREATMENT STUDY OF COVID-19 WITH MOLNUPIRAVIR - (03/10/21)
     
  959. CROI: DoLPHIN2 FINAL RESULTS DOLUTEGRAVIR VS EFAVIRENZ IN LATE PREGNANCY TO 72W POSTPARTUM - (03/10/21)
     
  960. CROI: COVID Virus Can Linger in Gut a Half-Year After Symptoms Clear - Mark Mascolini - (03/10/21)
     
  961. CROI: Disrupted Gut Integrity, Other Gut Factors, Tied to COVID-19 Severity - Mark Mascolini - (03/10/21)
     
  962. CROI: Low New-HIV Rate With Both Daily and On-Demand PrEP in Paris MSM - Mark Mascolini - (03/10/21)
     
  963. CROI: Resistance and Response in Phase 2a Study of HIV Maturation Inhibitor - Mark Mascolini - (03/10/21)
     
  964. CROI: Gilead's Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI - (03/10/21)
     
  965. CROI: Racial/Ethnic Minorities With HIV More Likely to Get COVID-19 in US - Mark Mascolini (03/09/21)
     
  966. CROI: NNRTI MK-8507 Selects V106 Mutations, Active Against Common NNRTI Mutations - Mark Mascolini (03/09/21)
     
  967. CROI: PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254 - (03/09/21)
     
  968. CROI: HIV AND COVID-19 INPATIENT OUTCOMES: A MATCHED RETROSPECTIVE MULTICENTRE ANALYSIS - (03/09/21)
     
  969. CROI: In-Hospital COVID-19 Outcomes Not Worse With HIV in 6-Center UK Analysis - Mark Mascolini (03/09/21)
     
  970. CROI: ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR - (03/09/21)
     
  971. CROI: POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH - (03/09/21)
     
  972. CROI: RESISTANCE PROFILE OF MK-8507, A NOVEL NNRTI SUITABLE FOR WEEKLY ORAL HIV TREATMENT - (03/09/21)
     
  973. CROI: ASSESSMENT OF OBESITY AND METABOLIC PROFILE BY INTEGRASE INHIBITOR USE IN REPRIEVE - (03/09/21)
     
  974. CROI: Resistance Testing Did Not Boost HIV Control Rates in Randomized African Trial - Mark Mascolini - (03/09/21)
     
  975. CROI: DISPARITIES IN TIMELY RECEIPT OF ART PRESCRIPTION IN HIV CARE IN THE US, 2012-2018 - (03/09/21)
     
  976. CROI: Faster Time to Viral Suppression in US South, But Suppression Rates Still Modest - Mark Mascolini (03/09/21)
     
  977. CROI: Time to ART Improves for Blacks, Southerners in US, But Still Lags for Drug Users - Mark Mascolini (03/09/21)
     
  978. CROI: Second-Line DTG Noninferior to DRV/r in African NADIA Trial - Mark Mascolini (03/09/21)
     
  979. CROI: COVID-19 HOSPITALIZATION AMONG PEOPLE WITH HIV OR SOLID ORGAN TRANSPLANT IN THE US - (03/09/21)
     
  980. CROI: REDUCED SUSCEPTIBILITY TO TEMSAVIR IS NOT LINKED TO IBA OR MVC RESISTANCE - (03/09/21)
     
  981. CROI: GSK3640254 IS A NOVEL MATURATION INHIBITOR WITH AN OPTIMIZED VIROLOGY PROFILE - (03/09/21)
     
  982. CROI: ISLATRAVIR PK THRESHOLD & DOSE SELECTION FOR MONTHLY ORAL HIV-1 PrEP - (03/08/21)
     
  983. CROI: NEXT-GENERATION ISLATRAVIR IMPLANTS PROJECTED TO PROVIDE YEARLY HIV PROPHYLAXIS - (03/08/21)
     
  984. CROI: IDENTIFICATION OF UNIQUE PROTEINS PREDICTIVE OF MORTALITY AND MECHANISMS IN HIV - (03/08/21)
     
  985. CROI: BIOLOGICAL PROFILES PREDICT CORONARY ARTERY DISEASE IN PWH AND RISK-MATCHED CONTROLS - (03/08/21)
     
  986. CROI: Short-course alendronate for the prevention of art-associated bone loss Alendronate for 14 Weeks Before and During First ART Wards Off 48-Week Bone Loss - Mark Mascolini (03/08/21)
     
  987. CROI: PREVENTION OF CARDIOVASCULAR DISEASE IN PERSONS WITH AND WITHOUT HIV - (03/08/21)
     
  988. CROI: Control of Lipids and Diabetes-But Not BP-Cuts Cardio Risk With HIV - Mark Mascolini (03/08/21)
     
  989. CROI: 12-Year Cognitive Decline is Associated with Lung Disease, Diabetes, and Depression - (03/08/21)
     
  990. CROI: Diabetes, Lung Disease, Depression, Cannabis Tied to 12-Year Cognitive Drop With HIV - (03/08/21)
     
  991. CROI: Avoid CYP, P-gp, UGT Inducers With HIV Capsid Inhibitor Lenacapavir - Mark Mascolini (03/08/21)
     
  992. CROI: CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS - (03/08/21)
     
  993. CROI: Multimorbidity in people with HIV using ART in the US: Projections to 2030 - (03/08/21)
     
  994. CROI: Female Sex Modifies Link Between Inflammation and Non-AIDS Vascular Events - Mark Mascolini (03/08/21)
     
  995. CROI: SEX MODIFIES THE ASSOCIATION BETWEEN INFLAMMATION AND VASCULAR EVENTS IN TREATED HIV - (03/08/21)
     
  996. CROI: INTEGRASE INHIBITORS TARGET MITOCHONDRIA IN BROWN ADIPOCYTES DISRUPTING THERMOGENESIS - (03/08/21)
     
  997. CROI: WEIGHT GAIN AMONG PWH WHO SWITCH TO ART-CONTAINING InSTIs OR TAF - (03/08/21)
     
  998. CROI: HIV WITH TRANSMITTED DRUG RESISTANCE IS DURABLY SUPPRESSED BY B/F/TAF AT WEEK 144 - (03/08/21)
     
  999. CROI: ASSESSMENT OF OBESITY AND METABOLIC PROFILE BY INTEGRASE INHIBITOR USE IN REPRIEVE - (03/07/21)
     
  1000. CROI: WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS - (03/07/21)
     
  1001. CROI: IMPACT OF REPRODUCTIVE AGING ON IMMUNE FUNCTION IN CISGENDER MEN AND WOMEN WITH HIV - (03/07/21)
     
  1002. CROI: WEIGHT GAIN AFTER SWITCHING DIFFERENT INTEGRASE STRAND TRANSFER INHIBITORS (InSTIs) - (03/07/21)
     
  1003. CROI: ASSOCIATION BETWEEN NEWER ANTIRETROVIRALS AND INCREASE IN BODY MASS INDEX IN RESPOND - (03/07/21)
     
  1004. CROI: COMORBIDITY BURDEN IN PEOPLE LIVING WITH HIV IN THE UNITED STATES - (03/06/21)
     
  1005. CROI: HIV DIFFERENTIALLY IMPACTS AGE-RELATED COMORBIDITY BURDEN AMONG US WOMEN AND MEN - (03/06/21)
     
  1006. CROI: MODEL-INFORMED DOSE SELECTION FOR ISLATRAVIR/MK-8507 ORAL ONCE-WEEKLY PHASE 2B STUDY - (03/06/21)
     
  1007. CROI: WEEK 96 ANALYSIS OF VIRAL BLIPS FROM A PHASE 2B TRIAL OF ISLATRAVIR AND DORAVIRINE - (03/06/21)
     
  1008. CROI: 4-YEAR OUTCOMES OF B/F/TAF IN TREATMENT-NAIVE ADULTS - (03/06/21)
     
  1009. CROI: SWITCHING TO DTG/3TC FDC IS NONINFERIOR TO TBR FOR 96 WEEKS: TANGO SUBGROUP ANALYSES - (03/06/21)
     
  1010. CROI: DURABLE EFFICACY OF DTG+3TC IN GEMINI-1&2: YEAR 3 SUBGROUP ANALYSES - (03/06/21)
     
  1011. CROI: WEEKLY ORAL TENOFOVIR ALAFENAMIDE PROTECTS MACAQUES FROM VAGINAL SHIV INFECTION - (03/06/21)
     
  1012. CROI: LONG-ACTING HIV CAPSID INHIBITOR EFFECTIVE AS PrEP IN A SHIV RHESUS MACAQUE MODEL - (03/06/21)
     
  1013. CROI: LONG-ACTING CABOTEGRAVIR+RILPIVIRINE IN OLDER ADULTS: POOLED PHASE 3 WEEK-48 RESULTS - (03/06/21)
     
  1014. CROI: CABOTEGRAVIR PPK SIMULATION TO INFORM Q2M STRATEGIES FOLLOWING DOSING INTERRUPTIONS - (03/06/21)
     
  1015. CROI: POPPK MODELING OF Q2M IM RPV LA FOR MANAGING DOSING INTERRUPTIONS IN HIV-1 PATIENTS - (03/06/21)
     
  1016. CROI: ViiV Healthcare presents data for long-acting cabotegravir and rilpivirine for the treatment of HIV showing continued virologic suppression to 96 weeks - (03/06/21)
     
  1017. HIV PrEP Poor Persistence - (03/04/21)
     
  1018. Non-Viral Liver Disease in HIV+ - Increased Prevalence of Liver Fibrosis in PLWH Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls - (03/02/21)
     
  1019. HIV+ Women Have Higher Burden of Comorbidities vs HIV- Women / Accelerated-Earlier by 10 Years - (03/02/21)
     
  1020. CROI: ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021 - (03/02/21)
     
  1021. ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months - (02/26/21)
     
  1022. Cognitive ageing is premature among a community sample of optimally treated people living with HIV - (02/26/21)
     
  1023. Motor function declines over time in human immunodeficiency virus and is associated with cerebrovascular disease, while HIV-associated neurocognitive disorder remains stable - (02/26/21)
     
  1024. HIV+ Women & MSM: aging & other issues - (02/22/21)
     
  1025. Loss of viral suppression by 31% in SF is deleterious to the individual and hinders treatment-as-prevention: the COVID-19 pandemic is threatening the goals of the US EHE initiative. - (02/22/21)
     
  1026. Indirect HIV morbidity and mortality due to COVID-19- PLWH presenting with more advanced HIV - (02/22/21)
     
  1027. Aging Guidelines Called For by HIV Researchers /Women with HIV... "What It Means to Age With HIV Infection, Years Gained Are Not Comorbidity Free" - (02/13/21)
     
  1028. Incident Non-AIDS Comorbidity Burden among Women with or at-risk for HIV in the U.S - suggest high susceptibility to -premature aging - (02/13/21)
     
  1029. New PrEP Long-Acting Lenacapavir Trials - (02/13/21)
     
  1030. COVID Impact on Older HIV+ / Quality of Life NOT Viral suppression Is Endpoint !!!! - (02/11/21)
     
  1031. Impact of COVID on HIV & Aging in Era of ART - (02/11/21)
     
  1032. New PrEP Studies: Long-Acting HIV-1 Capsid Inhibitor Lenacapavir Every 6 Months - (02/10/21)
     
  1033. Resilience and frailty in people living with HIV during the COVID era: two complementary constructs? - (02/09/21)
     
  1034. Immunodeficiency and Cancer in 3.5 Million People Living with Human Immunodeficiency Virus: the South African HIV Cancer Match Study - (02/08/21)
     
  1035. Accelerated Aging, Senesence & New Senolytic Therapeutic drugs - (02/08/21)
     
  1036. New HIV "Cure" Strategy - (02/08/21)
     
  1037. GLS1 inhibitor selectively eliminates senescent cells, ameliorates age-associated disorders
  1038. HIVR4P: The AMP Studies: Phase 2b Proof-of-Concept Trials Designed to Test the Efficacy of VRC01 Antibody to Prevent HIV Acquisition - (02/05/21)
     
  1039. HIVR4P: Social, economic, mental health, and medical care impacts of COVID-19 in a US cohort of sexual and gender minority adolescents and young adults (SGM AYA) at-risk for HIV - (02/05/21)
     
  1040. HIVR4P: US COVID-19 Prevention Network Outlines Goals, Shows Moderna Trial Impact - Mark Mascolini - (02/04/21)
     
  1041. HIVR4P: With COVID Here, Mental Health, Money Woes Grow in US Sex- and Gender-Minority Youth - Mark Mascolini - (02/04/21)
     
  1042. HIVR4P: Low and Transient Rectal Dapivirine Levels in 7-Day Rectal Gel Trial - Mark Mascolini - (02/04/21)
     
  1043. HIVR4P: Higher Rectal Penetration Needed With PC-1005 Microbicide Gel - Mark Mascolini - (02/04/21)
     
  1044. HIVR4P: Climbing Rectal Gonorrhea Rate But Falling HIV Rate in British MSM - Mark Mascolini - (02/04/21)
     
  1045. HIVR4P: Bottoms are up at the HIV Research for Prevention Virtual Conference - (02/04/21)
     
  1046. HIVR4P: Only Half in Representative US Sample Intends to Get COVID Vaccine - Mark Mascolini - (02/03/21)
     
  1047. HIVR4P: More Than One Quarter of People Feel No COVID Symptoms Before Shedding Virus - Mark Mascolini - (02/03/21)
     
  1048. COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States - (02/01/21)
     
  1049. HIVR4P: Most US MSM Unaware of-and Not Interested in-As-Needed PrEP - Mark Mascolini - (01/29/21)
     
  1050. HIVR4P: COVID Restraints Followed by More Condom-Free Sex, Less PrEP, in Amsterdam MSM - Mark Mascolini (01/29/21)
     
  1051. HIVR4P: Steep Dapivirine Drops in Vaginal Fluid With Cyclic Use of DPV/LNG Vaginal Ring - Mark Mascolini- (01/29/21)
     
  1052. HIVR4P: PK Goals Met With 90-Day TFV/LNG Vaginal Ring in 47-Woman Randomized Trial - Mark Mascolini - (01/29/21)
     
  1053. HIVR4P: Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021 - (01/29/21)
     
  1054. HIVR4P: Early Data Hint Once-Monthly Oral PrEP Feasible With Novel Antiretroviral - Mark Mascolini - (01/29/21)
     
  1055. HIVR4P: VARIABLE HIV SEROINCIDENCE RATES IN A COHORT OF HIGH-RISK MEN WHO HAVE SEX WITH MEN AND TRANSGENDER WOMEN IN CHINA - (01/29/21)
     
  1056. HIVR4P: Impact of UGT Induction by Rifampin and Rifabutin on Cabotegravir Long-Acting Pharmacokinetics for HIV Pre-exposure Prophylaxis (PrEP) using Population Pharmacokinetic Modeling and Simulation - (01/29/21)
     
  1057. HIVR4P: MRI EXAMINATION OF CABOTEGRAVIR LONG-ACTING FORMULATION DEPOT KINETICS IN HEALTHY ADULT VOLUNTEERS - (01/29/21)
     
  1058. HIVR4P: DISTRIBUTION OF LONG-ACTING (LA) CABOTEGRAVIR (CAB) IN PLASMA, MUCOSAL TISSUES, AND ASSOCIATED FLUIDS AFTER A SINGLE ULTRASOUND-GUIDED INTRAMUSCULAR (IM) INJECTION IN HEALTHY ADULT PARTICIPANTS - (01/29/21)
     
  1059. HIVR4P: Utilization Patterns and HIV Incidence Within the First Year of Initiation of TDF/FTC for HIV Pre-exposure Prophylaxis (PrEP) Among Insured Individuals in the US - (01/28/21)
     
  1060. HIVR4P: Biodegradable TAF Implants Protect 6 of 6 Macaques From Vaginal SHIV - Mark Mascolini - (01/28/21)
     
  1061. HIVR4P: Trial design, enrollment status, demographics, and pharmacokinetic (PK) data from a blinded interim analysis from a phase 2a trial of islatravir once monthly (QM) for HIV pre-exposure prophylaxis (PrEP) - (01/28/21)
     
  1062. HIVR4P: Over One Third of New HIV Diagnoses in North Carolina Involve Recent Infection - Mark Mascolini - (01/28/21)
     
  1063. HIVR4P: Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: results from HPTN 084 - (01/28/21)
     
  1064. HIVR4P: Design and testing of a cabotegravir reservoir implant for HIV prevention - (01/28/21)
     
  1065. HIVR4P: User Wish List for Microarray Patch to Prevent HIV and Pregnancy: Small, Discreet, Easy to Use, Long-Acting - Mark Mascolini - (01/28/21)
     
  1066. HIVR4P: High protection against vaginal SHIV infection in macaques by a biodegradable implant releasing tenofovir alafenamide - (01/27/21)
     
  1067. HIVR4P: Understanding HIV prevention from the perspective of adolescent girls and young women at high risk of HIV infection - (01/26/21)
     
  1068. HIVR4P: Sex work in the wake of SARSCoV2 in Zimbabwe: A qualitative study - (01/26/21)
     
  1069. HIVR4P: Shelter-in-place but at what cost? Barriers to healthcare and other social determinants of health among young women under South Africa's COVID-19 lockdown - (01/26/21)
     
  1070. HIVR4P: High resolution and 3D ultrasound imaging of implant and intravaginal ring drug delivery devices during HIV pre-exposure prophylaxis (PrEP) preclinical and clinical studies - (01/26/21)
     
  1071. HIVR4P: Switching from F/TDF to F/TAF for HIV Pre-exposure Prophylaxis: An Analysis of the Real-World Data - (01/26/21)
     
  1072. HIVR4P: Long-Acting CAB Superior to Daily Oral TDF/FTC in Preventing HIV in Women - Mark Mascolini - (01/26/21)
     
  1073. HIVR4P: Antibody Infusions Prevent Acquisition of Some HIV Strains, NIH Studies Find - (01/26/21)
     
  1074. Optimal Allocation of Societal HIV Prevention Resources to Reduce HIV Incidence in the United States - (01/25/21)
     
  1075. Prevalence and Incidence of Human Papillomavirus Infection in Men Having Sex With Men Enrolled in a Pre-exposure Prophylaxis Study: A Sub-study of the Agence Nationale de Recherches sur le SIDA et les Hepatites Virales "Intervention Preventive de l'Exposition aux Risques avec et pour les hommes Gays" Trial - (01/25/21)
     
  1076. J&J COVID Vaccine- Interim Results of a Phase 1 2a Trial of Ad26.COV2.S Covid-19 Vaccine - (01/15/21)
     
  1077. ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe - (01/14/21)
     
  1078. Five Year Lower Extremity Function is Associated with White Matter Abnormality in Older Adults - (01/14/21)
     
  1079. COVID-19 death in people with HIV: interpret cautiously - Comment - (01/12/21)
     
  1080. A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use - (01/11/21)
     
  1081. AASLD: Efficacy and safety of subcutaneous semaglutide once-daily versus placebo in patients with nonalcoholic steatohepatitis
    Semaglutide Resolves NASH in Big Placebo-Controlled Trial     - (01/07/21)
     
  1082. IAC 2020 Virtual: 2 HIV Vaccine Studies/Functional Cure & mRNA Vaccine for HIV
    Functional HIV Cure in Monkey with 3 Monoconal antibodies     - (01/06/21)
     
  1083. Blunted muscle mitochondrial responses to exercise training in older adults with HIV - (01/05/21)
     
  1084. COVID/Long-Acting 2-Antibody Combination for prevention/Treatment by AstraZeneca - (01/05/21)
     
  1085. Discovery of Virus Variant in Colorado and California Alarms Scientists - (01/05/21)
     
  1086. How HIV Research Laid the Foundation for Covid Vaccines - (01/05/21)
     
  1087. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol - (01/05/21)
     
  1088. Viral suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19 - (01/05/21)
     
  1089. HPTN 078: High Prevalence of HCV Antibodies Among Urban U.S. Men Who Have Sex with Men (MSM) Independent of HIV Status - (01/05/21)
     
  1090. Disparities in HIV Viral Suppression in the USA - (01/05/21)
     
  1091. CROI: Summary from virtual CROI 2020 for HIV and liver disease HIV and the liver: what is new? - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (03/25/20)
     
  1092. COVID-19 Susceptibility and Outcomes Among People Living With HIV in San Francisco - (12/21/20)
     
  1093. AASLD: HIGH PREVALENCE OF FATTY LIVER DISEASE [FLD] AND ADVANCED FIBROSIS IN AN URBAN MULTIETHNIC US COHORT OF PERSONS WITH HIV - (12/21/20)
     
  1094. AASLD: PREVALENCE AND RISK FACTORS OF HEPATIC STEATOSIS AND FIBROSIS IN AMERICAN ADULTS: A POPULATION-BASED STUDY - (12/21/20)
     
  1095. AASLD: GLOBAL PREVALENCE OF HEPATITIS C VIRUS IN WOMEN OF CHILDBEARING AGE IN 2019: A MODELING STUDY - (12/21/20)
     
  1096. AASLD: AUTOMATED VIRAL HEPATITIS (HCV AND HBV) SCREENING: LESSONS ON EXPANSION & SUSTAINABILITY AMIDST THE COVID-19 PANDEMIC - (12/21/20)
     
  1097. ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe - (12/21/20)
     
  1098. NIH Workshop on HIV-Associated Comorbidities, Coinfections, and Complications: Summary and Recommendation for Future Research - (12/21/20)
     
  1099. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study - (12/21/20)
     
  1100. Using health technology to capture digital phenotyping data in HIV-associated neurocognitive disorders - (12/21/20)
     
  1101. AASLD: AUTOMATED VIRAL HEPATITIS (HCV AND HBV) SCREENING: LESSONS ON EXPANSION & SUSTAINABILITY AMIDST THE COVID-19 PANDEMIC - (01/08/21)
     
  1102. AASLD: Distinct lipidomic signatures between persons living with HIV and seronegative persons: combined analysis of the ACTG 5260s and the MACS/WIHS Combined Cohort Study - (12/18/20)
     
  1103. AdverseReactComor: Distinct lipidomic signatures between persons living with HIV and seronegative persons: combined analysis of the ACTG 5260s and the MACS/WIHS Combined Cohort Study - (12/17/20)
     
  1104. Lenacapavir (GS-6207): A First-in-Class Long Acting HIV Capsid Inhibitor - (12/15/20)
     
  1105. Progress in long-acting Agents for HIV Treatment & PrEP: ViiV healthcare program: Focus on Cabotegravir Long-Acting Injection; Future ViiV LA programs at HIV-DART - (12/15/20)
     
  1106. AdverseReactComor: Non-alcoholic fatty liver disease (NAFLD) in HIV-monoinfected patients: results from the European ECHAM study - (12/14/20)
     
  1107. Islatravir Long-Acting Implant: RECENT PROGRESS IN DEVELOPMENT OF LONG-ACTING INJECTABLES FOR HIV TREATMENT at HIV DART - (12/14/20)
     
  1108. Life expectancy in HIV-positive persons in Switzerland - (12/14/20)
     
  1109. Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV - (12/14/20)
     
  1110. Pregnant Women/Poor outcomes & Neighborhood/Crime/violence/education - Association of Adverse Neighborhood Exposures With HIV Viral Load in Pregnant Women at Delivery - (12/14/20)
     
  1111. ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available - (12/11/20)
     
  1112. An Approach to Improve Diversity and Inclusion in Clinical Trials: The DEFINE Trial (D/C/F/TAF Evaluated As a Fixed-dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain) - (12/10/20)
     
  1113. HIV Infection, Cancer Treatment Regimens, and Cancer Outcomes Among Elderly Adults in the United States......HIV+ Elevated Cancer Mortality-BREAST/PROSTATE/Colorectal - (12/09/20)
     
  1114. AdverseReactComor: The Impact of Covid-19 and Its Response on the Psychosocial Wellbeing and Medical Care among Persons Living with HIV and COPD - (12/08/20)
     
  1115. AdverseReactComor: Attitudes Toward COVID-19 Among People Living with HIV Attending a Multiethnic Outpatient Center in Houston, Texas - (12/08/20)
     
  1116. Are LDL as Important in CVD ? Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk - (12/08/20)
     
  1117. AdverseReactComor: Greater Incident Proteinuria in Pre-Diabetic Men with HIV than Without HIV: The Multicenter AIDS Cohort Study - (12/07/20)
     
  1118. AdverseReactComor: Greater Increases Over Time in BMI, Waist Circumference and Subcutaneous and Visceral Fat Area Among Men with HIV - (12/07/20)
     
  1119. AdverseReactComor: Prevalence of Silent Atherosclerosis and Other Comorbidities in an Outpatient Cohort of Adults Living with HIV - (12/07/20)
     
  1120. AdverseReactComor: Faster decline in lung function in treated HIV-positive vs. HIV negative AGEhIVcohort participants independent of smoking behavior - (12/07/20)
     
  1121. AdverseReactComor: Effect of tesamorelin on risk of development or progression of diabetic retinopathy and glycemic control in HIV-infected subjects with diabetes and central adiposity - (12/07/20)
     
  1122. AdverseReactComor: Vitamin D & Muscoskeletal Health Among Youth with HIV presented today at Comorbidities Workshop - (12/07/20)
     
  1123. AdverseReactComor: Hypertension Prevalence Higher in US vs Global reported today at Comorbidities Workshop - (12/07/20)
     
  1124. AdverseReactComor: Carotid Artherosclerosis in Suppressed HIV+ at Comorbidties Workshop - (12/07/20)
     
  1125. AdverseReactComor: NAFLD in HIV+ today at Comorbidities Workshop - (12/07/20)
     
  1126. AdverseReactComor: COVID Affect on HIV+ reported at Comorbidities Workshop - (12/07/20)
     
  1127. AdverseReactComor: Sleep & HIV - Presented Today at Comorbidities Workshop - (12/04/20)
     
  1128. AdverseReactComor: PrEP - FTC, TDF - Changes Mitochondria & Cardiovascular Function presented at Comorbidities Workshop - (12/04/20)
     
  1129. AdverseReactComor: Proteinuria 3 x Higher in HIV+ in MACS just presented at Comorbidities Workshop - (12/04/20)
     
  1130. AdverseReactComor: In vitro exposure of leukocytes to HIV pre-exposure prophylaxis (PrEP) decreases mitochondrial function and alters gene expression profiles. - (12/04/20)
     
  1131. AdverseReactComor: Mitochondria & Accelerated Aging in HIV - presented at the Comorbidities Workshop - (12/04/20)
     
  1132. IPM's Dapivirine Ring for Women's HIV Prevention Receives WHO Prequalification - (12/02/20)
     
  1133. A High Percentage of People with HIV on Antiretroviral Therapy Experience Detectable Low-Level Plasma HIV-1 RNA Following COVID-19 - (11/28/20)
     
  1134. AASLD: Can low liver fat be bad for your heart? Visceral Fat & Heart Disease - (11/24/20)
     
  1135. AASLD: Breastfeeding Linked to Lower Chance of Severe Fibrosis in US Women With NAFLD - Mark Mascolini - (11/24/20)
     
  1136. ViiV Healthcare announces results of the PROgress study demonstrating that the inclusion of patient reported outcomes into clinical practice can improve HIV care - (11/18/20)
     
  1137. ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention - (11/18/20)
     
  1138. Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1 - (11/18/20)
     
  1139. AASLD: Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis - (11/17/20)
     
  1140. AASLD: Sugary Drinks, High Trans Fats Lead Dietary Risks for Death With NAFLD - Mark Mascolini (11/17/20)
     
  1141. AASLD: The Lipidomics of HIV-related NAFLD - (11/17/20)
     
  1142. AASLD: Dietary Risks for Liver Related Morality Among Nonalcoholic Fatty Liver Disease (NAFLD) - (11/17/20)
     
  1143. AASLD: Treatment with Growth Hormone-Releasing Hormone Analog ReducesVEGFA, TGFβ1, and CSF1: Mechanisms of Tesamorelin Effect in Nonalcoholic Fatty Liver Disease - (11/17/20)
     
  1144. AASLD: Country and WHO Regional Trends for Hepatitis C Virus (HCV) Mortality, 1990-2019: An Analysis of the Global Burden of Disease (GBD) Study - (11/17/20)
     
  1145. AASLD: Statins Tied to Lower HCC Risk in HBV Group Without Cirrhosis - Mark Mascolini (11/17/20)
     
  1146. ViiV Healthcare announces CHMP positive opinion for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe - (11/13/20)
     
  1147. Treatment Is More Than Prevention: Perceived Personal and Social Benefits of Undetectable = Untransmittable Messaging Among Sexual Minority Men Living with HIV - (11/12/20)
     
  1148. Statement-NIH Study Finds Long-Acting Injectable Drug Prevents HIV Acquisition in Cisgender Women - (11/09/20)
     
  1149. ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women - (11/09/20)
     
  1150. Recent Weight Changes Studies - (11/05/20)
     
  1151. Antiretroviral Therapy-Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial - (11/04/20)
     
  1152. Additive effects of green tea and coffee on all-cause mortality in patients with type 2 diabetes mellitus: the Fukuoka Diabetes Registry - (11/04/20)
     
  1153. GLASGOW: Fat distribution and density in PLWH with ≥5% weight gain - (11/03/20)
     
  1154. Inflammation Marker D-Dimer Associated with cell-associated HIV RNA in Virally Suppressed HIV+..... Aging is associated with inflammation and non-significantly higher ca-HIV RNA levels - (11/03/20)
     
  1155. New NYC Funding for Care & Services for Black & Latino Older PLWH - Geriatric Clinic - Men & & Women, Transgender, Young - 5 Service Categories, including Hepatitis C - (11/03/20)
     
  1156. CDC: HIV Mortality - HIV+ Dying Increasingly Consist of Women, Blacks/African-Americans, South residents, older HIV+ - cancer, heart disease, suicide among leading causes of death - (11/03/20)
     
  1157. ID Week: Gilead Sciences' Commitment to the COVID-19 Pandemic - (11/03/20)
     
  1158. ID Week: Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients - (11/03/20)
     
  1159. ID Week: Safety of Remdesivir vs Standard of Care in Patients With Moderate COVID-19 - (11/03/20)
     
  1160. ID Week: Baseline Characteristics Associated With Clinical Improvement in Hospitalized Patients With Moderate COVID-19 - (11/03/20)
     
  1161. ID Week: Remdesivir vs Standard Care in Patients With Moderate COVID-19 - (11/03/20)
     
  1162. ID Week: Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated With Remdesivir - (11/03/20)
     
  1163. ID Week: Rates of COVID Testing, Diagnosis, and Hospital Admission Higher With HIV - Mark Mascolini (11/02/20)
     
  1164. ID Week: COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States - increased risk of COVID & had worse outcomes, heroin the worst - (11/02/20)
     
  1165. ID Week: HCV Treatment Less Likely for Women, Current Drug Users, Detectable HIV Load - Mark Mascolini (11/02/20)
     
  1166. ID Week: Opioid Clinic Use Doubles After COVID Arrives at Alabama HIV Center - Mark Mascolini (11/02/20)
     
  1167. ID Week: HAVES VS HAVE-NOTS IN HEALTHCARE COMMUNICATION: EXAMINING THE PARADOX WHERE PLHIV WHO NEED QUALITY DISCUSSIONS WITH THEIR PROVIDERS THE MOST, ACCESS IT THE LEAST - (11/02/20)
     
  1168. ID Week: Health Technology Assessment of New Long-Acting, Directly-Observed HIV Treatments in Canada: Impact of Real-World Adherence to Daily Oral Therapy on Treatment, Transmission and Cost-Effectiveness - (11/02/20)
     
  1169. ID Week: Forgiveness of BIC/FTC/TAF: In Vitro Simulations of Intermittent Poor Adherence Find Limited HIV-1 Breakthrough and High Barrier to Resistance - (11/02/20)
     
  1170. ID Week: Bone mineral density screening in veterans living with HIV : Only One Quarter of US HIV+ Veterans Group Screened for Low BMD - Mark Mascolini (11/02/20)
     
  1171. ID Week: IMPACT OF TREATMENT ADHERENCE ON EFFICACY OF DTG + 3TC AND DTG + TDF/FTC: POOLED ANALYSIS OF THE GEMINI-1 AND -2 CLINICAL STUDIES - (11/02/20)
     
  1172. ID Week: SAFETY, EFFICACY, AND DURABILITY OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE AS MAINTENANCE THERAPY FOR HIV-1 INFECTION: LATTE-2 WEEK 256 RESULTS - (11/02/20)
     
  1173. ID Week: HIV-1 RNA BLIPS AND LOW-LEVEL REPLICATION DURING PHASE III/IIIB CABOTEGRAVIR + RILPIVIRINE LONG-ACTING STUDIES ARE SIMILAR TO ORAL 3-DRUG THERAPY AND NOT ASSOCIATED WITH WEEK 48 VIROLOGIC OUTCOME - (11/02/20)
     
  1174. ID Week: LONG-TERM PATIENT ADHERENCE AND MANAGEMENT OF TREATMENT INTERRUPTIONS WITH LONG-ACTING INJECTABLE CABOTEGRAVIR + RILPIVIRINE FOR MAINTENANCE THERAPY IN PHASE 2B/3 STUDIES - (11/02/20)
     
  1175. ID Week: Association of Aging, Frailty and Place of Residence with Skin, Oral and Gut Microbiome Characteristics and Pathogenicity Reservoirs - (11/02/20)
     
  1176. ID Week: TREATMENT-RELATED PHYSICAL, EMOTIONAL, AND PSYCHOSOCIAL CHALLENGES AND THEIR IMPACT ON INDICATORS OF QUALITY OF LIFE - (10/30/20)
     
  1177. ID Week: NO DOSE ADJUSTMENT OF METFORMIN WITH FOSTEMSAVIR COADMINISTRATION BASED ON MECHANISTIC STATIC AND PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS - (10/30/20)
     
  1178. ID Week: HEALTH CARE RESOURCE UTILIZATION AND COST OF PEOPLE LIVING WITH HIV (PLWH) IN US COMMERCIAL AND MEDICARE ADVANTAGE HEALTH PLANS - (10/30/20)
     
  1179. ID Week: Regional and Racial Disparities in Response to Antiretroviral Therapy (ART) Among People Living with Human Immunodeficiency Virus (PLWH) - (10/30/20)
     
  1180. ID Week: Real World Community-Based HIV Rapid Start Antiretroviral with BFTAF Versus Conventional HIV Antiretroviral Therapy Start - The RoCHaCHa Study, a Pilot Study - (10/30/20)
     
  1181. ID Week: Increasing incidence of obstructive sleep apnea in patients with HIV: A nationwide database analysis - (10/30/20)
     
  1182. ID Week: PATIENT-REPORTED OUTCOMES ON LONG-ACTING CABOTEGRAVIR + RILPIVIRINE AS MAINTENANCE THERAPY: FLAIR 96-WEEK RESULTS - (10/30/20)
     
  1183. ID Week: Older Age, Comorbidities Predict Hospital Trip for COVID-19 in HIV Group - Mark Mascolini - (10/30/20)
     
  1184. ID Week: Four in 5 on ART Resume Therapy in Hospital, One Third Change ARVs - Impact of hospitalization on antiretroviral therapy for people living with HIV - Mark Mascolini - (10/30/20)
     
  1185. ID Week: B/F/TAF Controls HIV in 10 of 10 on Hemodialysis for Kidney Disease - (10/28/20)
     
  1186. ID Week: SUMMARY OF COVID-RELATED IMPACT ON CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING (CAB + RPV LA) DOSING ACROSS THE SIX ONGOING GLOBAL PHASE IIB and III CLINICAL TRIALS - (10/28/20)
     
  1187. ID Week: Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF) - (10/28/20)
     
  1188. ID Week: Increased Diagnosis Acute HIV Through Routine ED Screening & Rapid Linkage to Care & Initiation of HAARTDuring the COVID-19 Pandemic - (10/28/20)
     
  1189. ID Week: Using the F/TDF Adherence-Efficacy Relationship to Calculate Background HIV Incidence: Results From the DISCOVER Trial - (10/28/20)
     
  1190. ID Week: ViiV Healthcare presents positive new findings from two studies of its investigational, long-acting regimen of cabotegravir and rilpivirine, including five-year data showing long-term durability, efficacy, safety, and tolerability - (10/28/20)
     
  1191. ID Week: Database Links Bictegravir and Dolutegravir to Metabolic Problems - Mark Mascolini (10/28/20)
     
  1192. ID Week: ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19 across its clinical development programme for investigational, long-acting cabotegravir and rilpivirine - (10/28/20)
     
  1193. ID Week: ViiV Healthcare presents continued positive findings from first-ever implementation science study on integrating an investigational once-monthly injectable HIV treatment into US healthcare practices - (10/28/20)
     
  1194. ID Week: Database Links Bictegravir and Dolutegravir to Metabolic Problems - Mark Mascolini (10/28/20)
     
  1195. ID Week: PATIENT PERSPECTIVES ON IMPLEMENTATION OF A LONG-ACTING INJECTABLE ANTIRETROVIRAL THERAPY REGIMEN IN HIV US HEALTHCARE SETTINGS: INTERIM RESULTS FROM THE CUSTOMIZE STUDY - (10/28/20)
     
  1196. ID Week: Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline - (10/28/20)
     
  1197. ID Week: Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine - (10/28/20)
     
  1198. ID Week: Gastrointestinal (GI) Adverse Events With Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Through Week 96: An AMBER Post Hoc Analysis - (10/26/20)
     
  1199. ID Week: Who does not show up for followup in an HIV PrEP clinic? More Education Favors Steady PrEP-Bisexuals, Heterosexuals Need More Support - Mark Mascolini (10/26/20)
     
  1200. ID Week: Week-48 Outcomes From the BRAAVE 2020 Study: a Randomized Switch to B/F/TAF in African-American Adults With HIV - (10/26/20)
     
  1201. ID Week: Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline - (10/26/20)
     
  1202. ID Week: Efficacy and Safety of Doravirine in Treatment-Naïve Adults ≥50 Years Old With HIV-1 - (10/26/20)
     
  1203. ID Week: IMPACT OF TREATMENT ADHERENCE ON EFFICACY OF DTG + 3TC AND DTG + TDF/FTC: POOLED ANALYSIS OF THE GEMINI-1 AND -2 CLINICAL STUDIES - (10/26/20)
     
  1204. ID Week: Preexisting resistance and week 48 virologic outcomes after switching to B/F/TAF in African American adults with HIV - Frequent Resistance Before B/F/TAF Does Not Dim Week-48 Viral Response - Mark Mascolini (10/26/20)
     
  1205. ID Week: Empiric Antibiotics Frequent-But Usually Not Needed-for COVID-19 - Mark Mascolini (10/26/20)
     
  1206. ID Week: Pain in Two Thirds of Older US HIV Group Tied to Comorbidities - Mark Mascolini (10/26/20)
     
  1207. ID Week: Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with Severe COVID-19 Pneumonia Early Steroids Cut Need for Ventilation, Shorten ICU Stay, With COVID - Mark Mascolini (10/26/20)
     
  1208. ID Week: Increasing incidence of obstructive sleep apnea in patients with HIV: A nationwide database analysis- Sleep Apnea Rate Rises 5-Fold Among Hospital Inpatients With HIV - (10/26/20)
     
  1209. ID Week: One Quarter of 65+ Group With HIV and Polypharmacy Fall, 10% Seek Emergency Care - (10/26/20)
     
  1210. ID Week: One Quarter of 65+ Group With HIV and Polypharmacy Fall, 10% Seek Emergency Care - (10/23/20)
     
  1211. ID Week: Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence - (10/23/20)
     
  1212. ID Week: Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study - (10/23/20)
     
  1213. ID Week: Impact of Age and Medical Comorbidities on Renal Outcomes in the DISCOVER Trial - (10/23/20)
     
  1214. ID Week: QUALITATIVE FINDINGS FROM A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY TO EXPLORE PERSPECTIVES OF HEALTHCARE STAFF ON EARLY IMPLEMENTATION OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING INJECTABLE IN THE UNITED STATES (CUSTOMIZE) - (10/22/20)
     
  1215. ID Week: Weight change associated with switching to bictegravir/emtricitabine/tenofovir alafenamide in virally suppressed people with HIV Weight Climbs With Switch to Bictegravir Across Baseline Regimens - Mark Mascolini - (10/22/20)
     
  1216. ID Week: Congestive heart failure in persons living with HIV: are we providing standard of care? Most People With HIV and CHF Get Correct CHF Care-With Notable Exceptions - Mark Mascolini - (10/22/20)
     
  1217. ID Week: Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence - (10/22/20)
     
  1218. ID Week: HIV Control With Ibalizumab for 7.8 to 9.5 Years With Few Regimen Tweaks - Mark Mascolini - (10/22/20)
     
  1219. ID Week: Increasing incidence of obstructive sleep apnea in patients with HIV: A nationwide database analysis Sleep Apnea Rate Rises 5-Fold Among Hospital Inpatients With HIV - Mark Mascolini - (10/22/20)
     
  1220. ID Week: Risk Factors and Metabolic Implications of Integrase Inhibitor Associated Weight Gain - Mark Mascolini - (10/22/20)
     
  1221. ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV - (10/20/20)
     
  1222. Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine - (10/20/20)
     
  1223. HRSA New Resources Available on HIV and Aging: Care, Screening Tools & Staff Training - (10/20/20)
     
  1224. GLASGOW: Cancer, transplantation, and other immunocompromising conditions were not significantly associated with severe COVID-19 or death in hospitalized COVID-19 patients in Chicago - (10/20/20)
     
  1225. GLASGOW: Integrase based first-line HIV antiretroviral treatment in the Mediterranean Resistance (MeditRes) HIV collaboration - (10/20/20)
     
  1226. GLASGOW: FOSTEMSAVIR AND ETHINYL ESTRADIOL DRUG INTERACTION: CLINICAL APPLICATION FOR CO-ADMINISTRATION - (10/20/20)
     
  1227. GLASGOW: MODEL-BASED APPROACH OF DOSE SELECTION AND OPTIMAL PK SAMPLING OF FOSTEMSAVIR FOR PEDIATRIC PATIENTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION - (10/20/20)
     
  1228. GLASGOW: EVALUATION AND CLINICAL APPLICATION OF FOSTEMSAVIR CO-ADMINISTRATION WITH TUBERCULOSIS MEDICATIONS - (10/20/20)
     
  1229. GLASGOW: FOSTEMSAVIR EXPOSURE-RESPONSE RELATIONSHIPS IN TREATMENT EXPERIENCED HIV PATIENTS - (10/20/20)
     
  1230. GLASGOW: CLINICAL SIGNIFICANCE OF GP120 POLYMORPHISMS, TMR IC50 FC, AND HIV-1 SUBTYPE IN BRIGHTE - (10/20/20)
     
  1231. GLASGOW: Starting or switching to bictegravir/ emtricitabine/ tenofovir alafenamide (B/F/TAF) in clinical practice: Pooled 12-month results from the global BICSTaR study - (10/20/20)
     
  1232. GLASGOW: Long-Term Follow-Up After a Switch to Bictegravir, Emtricitabine, Tenofovir Alafenamide (B/F/TAF) from a Boosted Protease Inhibitor-Based Regimen - (10/20/20)
     
  1233. GLASGOW: The clinical relevance of potential drug-drug interactions (DDIs) with bictegravir/ emtricitabine/ tenofovir alafenamide (B/F/TAF) -Real-world data from the German IQVIA prescription database - (10/20/20)
     
  1234. GLASGOW: FACTORS ASSOCIATED WITH INTEREST IN A LONG-ACTING HIV REGIMEN: PERSPECTIVES OF PEOPLE LIVING WITH HIV, AND PHYSICIANS IN WESTERN EUROPE - (10/15/20)
     
  1235. GLASGOW: Bictegravir/ emtricitabine/ tenofovir alafenamide (B/F/TAF)shows high efficacy in clinical study participants infected with HIV-1 subtype F - (10/15/20)
     
  1236. GLASGOW: CABOTEGRAVIR + RILPIVIRINE LONG-ACTING AS HIV-1 MAINTENANCE THERAPY: ATLAS WEEK 96 RESULTS - (10/15/20)
     
  1237. GLASGOW: Rapid DTG/3TC Safe and Usually Effective in US Test-and-Treat Trial - Mark Mascolini (10/15/20)
     
  1238. GLASGOW: Lenacapavir resistance analysis in a phase Ib clinical proof of-concept study: Resistance to HIV Capsid Inhibitor Rare and Linked to Single Mutation - Mark Mascolini (10/15/20)
     
  1239. GLASGOW: Islatravir in Combination With Doravirine Maintains HIV-1 Viral Suppression Through 96 Weeks - (10/15/20)
     
  1240. GLASGOW: Associations with weight change and patient reported outcomes after switching from efavirenz/ emtricitabine/ tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/ emtricitabine/ tenofovir alafenamide (BIC/FTC/TAF) - (10/15/20)
     
  1241. GLASGOW: Unmet Needs PLWH, ViiV Positive Perspectives Global Study - (10/15/20)
     
  1242. GLASGOW: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN (TBR) IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 96 WEEKS (TANGO STUDY) - (10/15/20)
     
  1243. GLASGOW: A COMBINATION OF VIRAL AND PARTICIPANT FACTORS INFLUENCE VIROLOGIC OUTCOME TO LONG-ACTING CABOTEGRAVIR + RILPIVIRINE: MULTIVARIABLE AND BASELINE FACTOR ANALYSES ACROSS ATLAS, FLAIR AND ATLAS-2M PHASE 3 STUDIES - (10/15/20)
     
  1244. GLASGOW: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN (TBR) IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 96 WEEKS (TANGO STUDY) - (10/15/20)
     
  1245. GLASGOW: Increased levels of immune activation and exhaustion in vertically HIV-1 infected young adults - (10/12/20)
     
  1246. GLASGOW: SAFETY AND EFFICACY OF CABOTEGRAVIR + RILPIVIRINE LONG-ACTING WITH AND WITHOUT ORAL LEAD-IN: FLAIR WEEK 124 RESULTS - (10/12/20)
     
  1247. GLASGOW: Frailty of Greek PLWHIV in association with clinical markers and psychological factors; Preliminary results of a nationwide study. - (10/12/20)
     
  1248. GLASGOW: Multidrug Resistance Still Boosts Death Risk in 31,000-Person Italian Study - Mark Mascolini (10/12/20)
     
  1249. GLASGOW: Clinically Relevant Transmitted Integrase Resistance Low in Mediterranean Countries - Mark Mascolini - (10/12/20)
     
  1250. GLASGOW: Lenacapavir Resistance Analysis in a Phase 1b Proof-of-Concept Clinical Study - (10/12/20)
     
  1251. GLASGOW: The clinical relevance of potential drug-drug interactions (DDIs) with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) - Real-world data from the German IQVIA prescription database - (10/12/20)
     
  1252. GLASGOW: Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol (UK): a prospective observational study - (10/12/20)
     
  1253. GLASGOW: Safety, Tolerability and Pharmacokinetics Following Single- and Multiple-Dose Administration of the Novel NNRTI MK-8507 With a Midazolam Interaction Arm - (10/12/20)
     
  1254. GLASGOW: Lenacapavir Resistance Analysis in a Phase 1b Clinical Proof-Of-Concept Study - (10/12/20)
     
  1255. GLASGOW: SINGLE DOSES OF MK-8507, A NOVEL HIV-1 NNRTI, REDUCED HIV VIRAL LOAD FOR AT LEAST A WEEK - (10/09/20)
     
  1256. GLASGOW: Islatravir Plus Doravirine Maintains HIV Control Through 96 Weeks - Mark Mascolini - (10/09/20)
     
  1257. GLASGOW: Patient-reported outcomes (PROs) after 1 year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): The BICSTaR cohort - (10/09/20)
     
  1258. GLASGOW: Starting or switching to bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) in clinical practice: Pooled 12-month results from the global BICSTaR study - (10/09/20)
     
  1259. GLASGOW: Switching to Bictegravir/Emtricitabine/TenofovirAlafenamide(B/F/TAF) in Adults Aged ≥ 65 Years: Week 72 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449) - (10/09/20)
     
  1260. GLASGOW: Sustained Viral Suppression After Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Among Clinical Trial Participants With Preexisting M184V/I - (10/09/20)
     
  1261. GLASGOW: 12-month outcome of Dolutegravir/Rilpivirine in virologically suppressed HIV-infected patients: Real-world data from the German JUNGLE cohort - (10/09/20)
     
  1262. GLASGOW: Real-world data from the prospective URBAN cohort study on the use of Dolutegravir (DTG) + Lamivudine (3TC) in ART-naïve and pre-treated people living with HIV in Germany - (10/08/20)
     
  1263. GLASGOW: FEASIBILITY, EFFICACY, AND SAFETY OF USING DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING FOR NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLWH): THE STAT STUDY - (10/08/20)
     
  1264. GLASGOW: EFFICACY AND SAFETY OF DOLUTEGRAVIR IN TREATMENT-NAIVE PEOPLE LIVING WITH HIV-1 STRATIFIED BY AGE (>50): META-ANALYSIS OF 48-WEEK RESULTS FROM ARIA, FLAMINGO, SINGLE, AND SPRING-2 - (10/08/20)
     
  1265. GLASGOW: Persistence of antiretroviral therapy regimens among veterans with HIV newly initiating treatment in the US - Mark Mascolini (10/08/20)
     
  1266. GLASGOW: DURABLE EFFICACY OF DOLUTEGRAVIR (DTG) PLUS LAMIVUDINE (3TC) IN ANTIRETROVIRAL TREATMENT-NAIVE ADULTS WITH HIV-1 INFECTION- 3-YEAR RESULTS FROM THE GEMINI STUDIES - (10/08/20)
     
  1267. GLASGOW: Real-word characterization of the Portuguese population living with HIV who initiated Raltegravir based-regimen between 2015 and 2017 -REALITY Study - RAL Persistence 49 Yr Olds with Comorbidities - (10/08/20)
     
  1268. GLASGOW: Islatravir Selects for HIV-1 Variants in MT4-GFP Cells That Profoundly Reduce Replicative Capacity in Peripheral Blood Mononuclear Cells - (10/08/20)
     
  1269. GLASGOW: Analysis of Protocol-Defined Virologic Failure Through Week 96 From a Phase 2 Trial (P011) of Islatravir and Doravirine in Treatment-Naïve Adults WithHIV-1 Infection - (10/08/20)
     
  1270. GLASGOW: Long-term Treatment Efficacy and Safety Following Switch to Doravirine/ Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF): Week 144 Results of the DRIVE-SHIFT Trial - (10/08/20)
     
  1271. GLASGOW: Comorbidity Rate Does Not Affect F/TAF Persistence Through 24 Months - Mark Mascolini - (10/06/20)
     
  1272. GLASGOW: The relationship between smoking, current CD4, viral load and cancer in PLWH - (10/06/20)
     
  1273. GLASGOW: "WHAT ABOUT ME?" THE UNMET NEEDS OF MEN WHO HAVE SEX WITH WOMEN AND DIFFERENCES IN HIV TREATMENT EXPERIENCES, PERCEPTIONS, AND BEHAVIORS BY GENDER AND SEXUAL ORIENTATION IN 25 COUNTRIES - (10/06/20)
     
  1274. GLASGOW: Prevalence of pain in women living with HIV aged 45-60: associated factors and impact on patient-reported outcomes - (10/06/20)
     
  1275. GLASGOW: Impact of adherence on viral suppression with bictegravir and dolutegravir (DTG) containing triple therapy in clinical practice - Mark Mascolini (10/06/20)
     
  1276. GLASGOW: Merck to Present New Data from the Company's Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020 - (10/06/20)
     
  1277. GLASGOW: OUTCOMES FOR WOMEN RECEIVING LONG-ACTING CABOTEGRAVIR + RILPIVIRINE MONTHLY AND EVERY 2 MONTHS: ATLAS-2M STUDY WEEK 48 RESULTS - (10/05/20)
     
  1278. GLASGOW: Highest Cancer Risk in HIV+ Current Smokers and Those With Poor HIV Control - Mark Mascolini - (10/05/20)
     
  1279. GLASGOW: SUBGROUP ANALYSIS OF PATIENT-REPORTED OUTCOMES AMONG PARTICIPANTS IN 2 PHASE III CLINICAL TRIALS OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE (ATLAS AND FLAIR) - (10/05/20)
     
  1280. GLASGOW: Fat Distribution and density in PLWH with ≥ 5% weight gain - (10/05/20)
     
  1281. GLASGOW: Renal Safety Through 96 Weeks in a Phase 2 Trial (P011) of Islatravir and Doravirine in Treatment-Naïve Adults With HIV-1 - (10/05/20)
     
  1282. GLASGOW: COMPARABILITY OF 48-WEEK EFFICACY AND SAFETY OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING EVERY 8 WEEKS TO STANDARD OF CARE IN SUPPRESSED PEOPLE LIVING WITH HIV-1 - (10/05/20)
     
  1283. GLASGOW: Virologic and CD4 Responses to DTG Generally Steady With Advancing Age - Mark Mascolini (10/05/20)
     
  1284. GLASGOW: GILEAD SCIENCES PRESENTS DATA FROM HIV RESEARCH AND DEVELOPMENT PROGRAMS AT HIV GLASGOW 2020 - (10/05/20)
     
  1285. GLASGOW: Gilead Presents Biktarvy® Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020 - (10/05/20)
     
  1286. GLASGOW: ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1 - (10/05/20)
     
  1287. GLASGOW: Over Half in UK HIV Women's Study Report Moderate or Severe Pain - Mark Mascolini - (10/05/20)
     
  1288. GLASGOW: Switch to Integrase Drug Incites BMI Gain But Perhaps Improved "Fat Quality" - Mark Mascolini (10/05/20)
     
  1289. GLASGOW: ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress - (09/28/20)
     
  1290. AGE Wrkshp: Dozing or Napping Has Bigger Cognitive Impact in People With HIV - By Mark Mascolini - (10/05/20)
     
  1291. AGE Wrkshp: A Study of Neurocognitive Performance in Women Living With and Without HIV in South Africa - (10/05/20)
     
  1292. AGE Wrkshp: Polypharmacy in 94% of Older HIV Group, Inappropriate Meds Frequent - By Mark Mascolini - (10/05/20)
     
  1293. AGE Wrkshp: Aging with HIV in Latin America and The Caribbean: a systematic review - (10/05/20)
     
  1294. AGE Wrkshp: Urine mtDNA Signals Lower Muscle, Fat Mass, Weight in Older Group With HIV - By Mark Mascolini - (10/05/20)
     
  1295. AGE Wrkshp: Effects of HIV and Aging on the brain - (10/05/20)
     
  1296. AGE Wrkshp: Age-Related Trajectories of C-Reactive Protein Among Men With and Without HIV Infection in the Multicenter AIDS Cohort Study - (10/05/20)
     
  1297. AGE Wrkshp: Bictegravir/FTC/TAF Effective at 48 Weeks in Elderly: 4-Trial Analysis - By Mark Mascolini (10/02/20)
     
  1298. AGE Wrkshp: HIV & Aging Geriatric Clinics - (10/02/20)
     
  1299. AGE Wrkshp: Increased Neuropathy in Older PLWH - (10/02/20)
     
  1300. AGE Wrkshp: Should we still care about bone? Screening, treatment, TDF vs TAF - (10/02/20)
     
  1301. AGE Wrkshp: Sex Hormone-Binding Globulin Tied to Frailty, Low BMD in Women, Not Men - By Mark Mascolini (10/02/20)
     
  1302. AGE Wrkshp: Frailty Common in HIV+ Middle-Aged: Tied to Depression, HCV, Substance Use - By Mark Mascolini (10/02/20)
     
  1303. ViiV Healthcare presents a new podcast about the Power of Being Seen - (10/01/20)
     
  1304. AGE Wrkshp: Latent Class Analysis--Unique Predictor of Hospitalization, Death in Older HIV+ - (10/01/20)
     
  1305. AGE Wrkshp: Getting HIV Infection Speeds Up Epigenetic Clock (and Biologic Aging) Right Away - By Mark Mascolini - (10/01/20)
     
  1306. AGE Wrkshp: Heart Failure Diagnosed 6 to 16 Years Earlier in Veterans With vs Without HIV - By Mark Mascolini - (10/01/20)
     
  1307. AGE Wrkshp: A Multidisciplinary Approach (Exercise Program) to Chronic Pain and Frailty Among Those Aging with HIV: Lessons Learned - (10/01/20)
     
  1308. AGE Wrkshp: ART-Associated Issues, Fat & Muscle Density, The Significance of ART-associated Weight Gain in HIV - (10/01/20)
     
  1309. AGE Wrkshp: Associations between Frailty and Clinical Characteristics, Comorbidities, and Substance Abuse Among PLWH.....12% frailty in CNICS Cohort (CAR).....past drug use associated with frailty....average age only 47 - (10/01/20)
     
  1310. AGE Wrkshp: Lack of Transportation Tied to Array of Health Measures in Aging US HIV Group - By Mark Mascolini - (10/01/20)
     
  1311. Clin Pharm: Ledipasvir Exposure Linked to SVR, But Overall Response Rate High - By Mark Mascolini (10/01/20)
     
  1312. Clin Pharm: Neonatal Liquid Dolutegravir Comparable to Pediatric Dispersible Tablets - By Mark Mascolini (10/01/20)
     
  1313. Clin Pharm: Comparison of Relative Bioavailability of TIVICAY Neonatal Liquid Formulations to Pediatric Dispersible Tablets - (10/01/20)
     
  1314. Clin Pharm: Population pharmacokinetic (PopPK) modeling and simulation of monthly intramuscular (IM) long-acting rilpivirine (RPV LA) to inform strategies following dosing interruptions in HIV-1 infected subjects - (10/01/20)
     
  1315. GLASGOW: ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress - (09/28/20)
     
  1316. Clin Pharm: No Interactions Between HIV-1 Maturation Inhibitor and TAF/FTC - By Mark Mascolini (09/30/20)
     
  1317. Clin Pharm: Levels of Long-Acting Anti-HIV bNAb High in Infants After 1 or 2 Doses--But Not High Enough - By Mark Mascolini (09/30/20)
     
  1318. Clin Pharm: Model Predicts Long-Acting IM Rilpivirine Safe With Liver Impairment - By Mark Mascolini (09/30/20)
     
  1319. Clin Pharm: Antiretroviral Drug-Drug Interaction Profile of Long-Acting Cabotegravir and Rilpivirine - (09/30/20)
     
  1320. Clin Pharm: Three Phase I Drug Interaction Studies Investigating the Next-Generation Maturation Inhibitor GSK3640254 With Oral Contraceptive Ethinyl Estradiol/Levonorgestrel, Dolutegravir, and Tenofovir Alafenamide/Emtricitabine - (09/30/20)
     
  1321. Clin Pharm: Dolutegravir (DTG) plasma concentrations under different combinations regimens for ART-pre-treated adults living with HIV - (09/30/20)
     
  1322. Clin Pharm: FOSTEMSAVIR DRUG-DRUG INTERACTION PROFILE, AN ATTACHMENT INHIBITOR AND ORAL PRODRUG OF TEMSAVIR, FOR PATIENTS WITH MULTIDRUG-RESISTANT HIV-1 INFECTION - (09/30/20)
     
  1323. Clin Pharm: No Adverse Pregnancy Outcome Patterns With Common Antiretrovirals - By Mark Mascolini (09/30/20)
     
  1324. Clin Pharm: PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF DOLUTEGRAVIR/RILPIVIRINE (JULUCA) IN HEALTHY JAPANESE ADULTS - (09/28/20)
     
  1325. Clin Pharm: THE PHARMACOKINETICS (PK) OF DOVATO (50 MG DOLUTEGRAVIR [DTG]/ 300 MG LAMIVUDINE [3TC]) FIXED-DOSE COMBINATION IN HIV-INFECTED PATIENTS - (09/28/20)
     
  1326. Clin Pharm: TFV Levels Far Lower in Milk Than Plasma With Dried Milk and Blood Spots - Mark Mascolini - (09/28/20)
     
  1327. Clin Pharm: FTC Exposure Higher in Young Transgender Men Than Cisgender Controls - Mark Mascolini - (09/28/20)
     
  1328. ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices press release - (09/28/20)
     
  1329. Rates of Detectable Viral Load & condomless Sex Among HIV+ MSM, Discordant Couples - (09/25/20)
     
  1330. Cost of Comorbidities/HIV: Mean costs of care increased from $30,312 for those without an identified comorbidity to over $46,000 for those with 2 comorbidities, and up to $219,000 for people with 11 or more. - (09/25/20)
     
  1331. TAF vs TDF in DISCOVER PrEP Trial - Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial - (09/24/20)
     
  1332. Cost Analysis Questions Value of F/TAF vs Generic F/TDF for PrEP - Mark Mascolini (09/25/20)
     
  1333. TAF vs TDF in DISCOVER PrEP Trial - Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial - (09/24/20)
     
  1334. Quantifying the reduction in sexual transmission of HIV-1 among MSM by early initiation of ART: A mathematical model. - (09/23/20)
     
  1335. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016 - Updated HIV Life Expectancy Study: 9 yrs difference; 6.8 for HIV+ >500 CD4 at ART start - (09/23/20)
     
  1336. Cost of Comorbidities/HIV: Mean costs of care increased from $30,312 for those without an identified comorbidity to over $46,000 for those with 2 comorbidities, and up to $219,000 for people with 11 or more. - (09/21/20)
     
  1337. Gaps in Monitoring Older HIV+ in UK - (09/21/20)
     
  1338. Structural and functional brain abnormalities in HIV disease revealed by multimodal MRI fusion: association with cognitive function - (09/21/20)
     
  1339. Aging HIV+ in SF & NYC: 58% in NYC & 69% in SF >50 - A tale of 2 different epidemics - (09/21/20)
     
  1340. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016 - Updated HIV Life Expectancy Study: 9 yrs difference; 6.8 for HIV+ >500 CD4 at ART start - (09/18/20)
     
  1341. Rapid ART - (09/17/20)
     
  1342. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials - (09/16/20)
     
  1343. EDITORIAL: Is Modern Antiretroviral Therapy Causing Weight Gain? - (09/16/20)
     
  1344. (Vascepa) Final EVAPORATE Results for Vascepa Raise Eyebrows - (09/16/20)
     
  1345. ADHOC Aging-HIV Database Community Call Today Sept 3 2020 - (09/16/20)
     
  1346. Sexual transmission of an extensively drug-resistant HIV-1 strain - (09/16/20)
     
  1347. Cardiovascular disease risk among transgender women living with HIV in the United States - (09/16/20)
     
  1348. EASL THERATECHNOLOGIES TO DEVELOP TESAMORELIN FOR THE TREATMENT OF NASH IN THE GENERAL POPULATION - (09/15/20)
     
  1349. Risk of Cataract Surgery in HIV-Infected Individuals: A Danish Nationwide Population-Based Cohort Study - (08/25/20)
     
  1350. New HIV ART & Long-Acting Drugs - (08/25/20)
     
  1351. CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS IS NONINFERIOR TO MONTHLY: ATLAS-2M STUDY - (08/25/20)
     
  1352. ViiV Healthcare announces data demonstrating the feasibility of Dovato (dolutegravir/lamivudine) as a treatment option for rapid initiation after diagnosis in adults with HIV-1 - PRESS RELEASE - (08/25/20)
     
  1353. FEASIBILITY, EFFICACY, AND SAFETY OF USING DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING FOR NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLWH): THE STAT STUDY - (08/25/20)
     
  1354. IAC 2020 Virtual: The first long-term remission of chronic HIV-1 infection without myeloablation? (nicotinemide + maraviroc) - (08/24/20)
     
  1355. IAC 2020 Virtual: IAC 2020: Aging, Comorbidities, weight changes, HCV-MSM, NAFLD, Challenges-Unmet Needs of elderly PLWH - (08/24/20)
     
  1356. IAC 2020 Virtual: Characteristics and Predictors of Death among Hospitalized Patients with COVID-19 in Spain - (08/14/20)
     
  1357. Cabenva (cabotegravir/rilpivirine Resubmitted for FDA Approval - (08/10/20)
     
  1358. Lower CD4 Increased Risk: Frailty and HIV Disease Severity Synergistically Increase Risk of HIV-Associated Neurocognitive Disorders - (08/10/20)
     
  1359. Sociodemographic, ecological, and spatiotemporal factors associated with HIV drug resistance in Florida: a retrospective analysis implications for 'End AIDS' - (08/10/20)
     
  1360. IAC 2020 Virtual: Is NAFLD the same disease in HIV infected patients? - (08/10/20)
     
  1361. IAC 2020 Virtual: Early weight changes associated with bictegravir-based regimens compared to other integrase inhibitors following ART-initiation in ART-naïve people living with HIV - (08/10/20)
     
  1362. ViiV Healthcare announces FDA approval of an expanded indication for Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1 - (08/07/20)
     
  1363. APLA Health Announces Statewide Strategic Planning Meeting to Address Urgent Needs of People Aging with HIV - (08/05/20)
     
  1364. IAC 2020 Virtual: Patterns of Antiretroviral Use and Immunologic Correlates at Study Entry in the REPRIEVE Trial - (08/04/20)
     
  1365. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy - (08/03/20)
     
  1366. IAC 2020 Virtual: Illicit Opioid Use After Changes in Opioids Prescribed for Chronic Pain Among People Living With and Without HIV - (08/01/20)
     
  1367. IAC 2020 Virtual: Plenary: Casualties on the road to ending HIV: Context matters in addressing HIV disparities. From the very beginning of the 40-year HIV pandemic until today, HIV disparities have remained an intractable issue. - (08/01/20)
     
  1368. IAC 2020 Virtual: Cabotegravir+Rilpivirine Long-Acting Injectable Treatment and Cabotegravir for PrEP study HPTN 083 at IAC 2020 - (08/01/20)
     
  1369. Aging/HIV AIDS United Policy/Advocacy Paper - (07/31/20)
     
  1370. Worse Short-Term Memory Predicts Poor COVID Distancing in US - Mark Mascolini (07/27/20)
     
  1371. The changing HIV epidemic: a view from the front line in the United States -holistic care needed - (07/29/20)
     
  1372. Black Cisgender Women's PrEP Knowledge, Attitudes, Preferences, and Experience in Chicago - (07/29/20)
     
  1373. Ending Epidemic??? - HIV+ MSM Condomless Sex/Detectable Viral Load Behavior USA - Blind Spot ? For Ending the Epidemic....efforts not good enough - (07/29/20)
     
  1374. Antiretroviral drug concentrations in brain tissue of adult decedents - (07/29/20)
     
  1375. High Stigma Towards Those Living with HIV Remains, GLAAD Survey: State of HIV Stigma Survey - stigma persists - GLAAD survey - (07/29/20)
     
  1376. High Stigma Towards Those Living with HIV Remains, GLAAD Survey: State of HIV Stigma Survey - stigma persists - GLAAD survey - (07/28/20)
     
  1377. from the NIH Comorbidities Workshop held Sept 2019 at NIH - Report Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop - (07/27/20)
     
  1378. IAC 2020 Virtual: Persons Living With HIV (PLWH) in Japan on 2-Drug Regimen Reveal More Complex Patient Profiles Than That of 3-Drug Regimen Cohort - (07/27/20)
     
  1379. IAC 2020 Virtual: Cardiovascular and metabolic comorbidities in HIV-infected patients in Colombia: A multicenter study - (07/27/20)
     
  1380. IAC 2020 Virtual: Vesatolimod induces dose-dependent immune responses in HIV controllers - (07/27/20)
     
  1381. IAC 2020 Virtual: Changes in Body Mass Index Over Time in Persons With and Without HIV - Kaiser - (07/27/20)
     
  1382. IAC 2020 Virtual: COVID-19 in the Largest US HIV Cohort - (07/19/20)
     
  1383. IAC 2020 Virtual: To Dose-Adjust or Not to Dose-Adjust: 3TC Dose in Renal Impairment - (07/19/20)
     
  1384. ViiV Healthcare announces new strategic alliance to enable greater access to antiretroviral medicines in Brazil - PRESS RELEASE - (07/17/20)
     
  1385. Moderna's Covid-19 Vaccine Moves to Bigger Study - (07/17/20)
     
  1386. IAC 2020 Virtual: PUTTING THE HEART BACK INTO HAART: GREATER HCP-PATIENT ENGAGEMENT IS ASSOCIATED WITH BETTER HEALTH OUTCOMES AMONG PERSONS LIVING WITH HIV (PLHIV) ON TREATMENT - (07/17/20)
     
  1387. IAC 2020 Virtual: Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana - (07/16/20)
     
  1388. IAC 2020 Virtual: Overdose Deaths Cut 10 Years Off HIV Life Expectancy: British Columbia - Mark Mascolini (07/16/20)
     
  1389. IAC 2020 Virtual: Characteristics of Patients Living with HIV (PLWH) and HIV Treatment Outcomes in Community Practices in Southern vs Non-Southern US Regions - (07/16/20)
     
  1390. IAC 2020 Virtual: FACTORS ASSOCIATED WITH RESILIENCE AMONG OLDER PEOPLE LIVING WITH HIV - (07/16/20)
     
  1391. IAC 2020 Virtual: HIV-1 DNA Testing in Viremic Patients Demonstrates a Greater Ability to Detect Drug Resistance Compared to Plasma Virus Testing - (07/16/20)
     
  1392. IAC 2020 Virtual: MODEL-BASED APPROACH OF DOSE SELECTION AND OPTIMAL PK SAMPLING OF FOSTEMSAVIR FOR PEDIATRIC PATIENTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION - (07/16/20)
     
  1393. IAC 2020 Virtual: COVID-19 Rate No Higher With HIV in Largest US HIV+/HIV- Cohort - Mark Mascolini (07/16/20)
     
  1394. Cognitive disorders in people living with HIV - (07/16/20)
     
  1395. Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV (cure) - (07/16/20)
     
  1396. PrEP in YBMSM Atlanta -. high rates of discontinuation - (07/16/20)
     
  1397. COVID Congress: Baseline Characteristics Associated With Clinical Improvement and Mortality in Hospitalized Patients With Severe COVID-19 Treated With Remdesivir - (07/16/20)
     
  1398. COVID Congress: Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care - (07/16/20)
     
  1399. GILEAD SCIENCES STATEMENT ON THE INITIATION OF CLINICAL TESTING OF AN INHALED SOLUTION OF REMDESIVIR FOR POTENTIAL OUTPATIENT TREATMENT OF COVID-19 - (07/16/20)
     
  1400. European Commission Grants Conditional Marketing Authorization for Gilead's Veklury® (remdesivir) for the Treatment of COVID-19 - (07/16/20)
     
  1401. IAC 2020 Virtual: Population pharmacokinetic (PopPK) modeling and simulation of monthly intramuscular (IM) long-acting rilpivirine (RPV LA) to inform strategies following dosing interruptions in HIV-1 infected subjects - (07/16/20)
     
  1402. IAC 2020 Virtual: ADEQUATE PLASMA LEVELS OF DOLUTEGRAVIR IN COMBINATION WITH RITONAVIR-BOOSTED DARUNAVIR: A PHARMACOKINETIC SUBGROUP-ANALYSIS OF THE DUALIS STUDY - (07/16/20)
     
  1403. IAC 2020 Virtual: The BICSTaR prospective cohort: Real-world effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice in people living with HIV (PLWH) - (07/15/20)
     
  1404. IAC 2020 Virtual: Global Positive Perspectives Study, Wave 2: Understanding the Unmet Needs of People Living with HIV - (07/15/20)
     
  1405. IAC 2020 Virtual: Cardiovascular Risk Estimation is Sub-optimal Across Two HIV Cohort - (07/15/20)
     
  1406. IAC 2020 Virtual: COMPARATIVE EFFICACY AND SAFETY OF A COMBINATION THERAPY OF DOLUTEGRAVIR AND LAMIVUDINE VS 3-DRUG ANTIRETROVIRAL REGIMENS IN TREATMENT-NAIVE HIV-1 INFECTED PATIENTS AT 96 WEEKS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS - (07/15/20)
     
  1407. IAC 2020 Virtual: Dolutegravir With TAF or TDF Could Increase Adverse Pregnancy Outcomes - Mark Mascolini (07/15/20)
     
  1408. IAC 2020 Virtual: COVID-19 Rate No Higher With HIV in Largest US HIV+/HIV- Cohort - Mark Mascolini (07/15/20)
     
  1409. IAC 2020 Virtual: The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection. - Mark Mascolini (07/15/20)
     
  1410. IAC 2020 Virtual: COVID-19 Disrupts PrEP Starts, Refills, HIV/STI Testing in Boston Clinic - Mark Mascolini (07/15/20)
     
  1411. IAC 2020 Virtual: With COVID Here, 90% of Australian MSM Have Less Sex, 40% Stop PrEP - Mark Mascolini (07/15/20)
     
  1412. IAC 2020 Virtual: High HCV Rate in Both Young and Older Drug Injectors--HIV Ups HCV Risk - Mark Mascolini (07/15/20)
     
  1413. IAC 2020 Virtual: FEASIBILITY OF IMPLEMENTING LONG-ACTING INJECTABLE ANTI-RETROVIRAL THERAPY TO TREAT HIV: A SURVEY OF HEALTH PROVIDERS FROM THE 13 COUNTRIES PARTICIPATING IN THE ATLAS-2M TRIAL - (07/15/20)
     
  1414. IAC 2020 Virtual: PrEP Halves New HIV Rate When Offered in Contraceptive Trial - Mark Mascolini - (07/15/20)
     
  1415. IAC 2020 Virtual: Doravirine Resistance Profile in Clinical Isolates and Impact of Baseline NNRTI Resistance-Associated Mutations Observed in Treatment-Naïve Participants from Phase 2 and 3 Clinical Trials - (07/15/20)
     
  1416. IAC 2020 Virtual: IS DTG+3TC EFFECTIVE AND SAFE IN CLINICAL PRACTICE? EVIDENCE FROM REAL WORLD DATA - (07/15/20)
     
  1417. IAC 2020 Virtual: COMPARISON OF VIRAL REPLICATION AT <40 C/ML FOR 2-DRUG REGIMEN (2DR) OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC FDC) VERSUS 3-DRUG REGIMEN (3DR) BASED ON TENOFOVIR ALAFENAMIDE (TAF) (TBR) IN THE TANGO STUDY - (07/15/20)
     
  1418. IAC 2020 Virtual: Is DTG+3TC effective and safe in clinical practice? Evidence from real world data - (07/15/20)
     
  1419. IAC 2020 Virtual: Almost Half of Older HIV+ Adults Report Poor Overall Health in 25-Country Survey - (07/15/20)
     
  1420. IAC 2020 Virtual: HCV Drugs for COVID-19? Three Small Studies Have Positive Hints - Mark Mascolini (07/15/20)
     
  1421. IAC 2020 Virtual: The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection - More Weight, Trunk Fat, Metabolic Syndrome With DTG+TAF/FTC in South African Trial - Mark Mascolini (07/15/20)
     
  1422. IAC 2020 Virtual: Faster virological suppression with dolutegravir versus efavirenz in pregnancy does not lower the risk of HIV mother-to-child-transmission: A meta-analysis of 5 clinical trials in 1074 pregnant women - Mark Mascolini (07/15/20)
     
  1423. IAC 2020 Virtual: The predicted risk of adverse pregnancy outcomes from treatment-induced obesity in the ADVANCE trial. - Dolutegravir With TAF or TDF Could Increase Adverse Pregnancy Outcomes - Mark Mascolini (07/15/20)
     
  1424. IAC 2020 Virtual: Racial Disparities, Communal Living in Boston COVID-19 Patients With HIV - Mark Mascolini (07/15/20)
     
  1425. IAC 2020 Virtual: Prevalence and Incidence of Hepatitis C Virus Infection in Men Who Have Sex With Men: A Global Systematic Review - (07/13/20)
     
  1426. IAC 2020 Virtual: Incidence of HCV reinfection among HIV-positive MSM and its association with sexual risk behavior: A longitudinal analysis - (07/13/20)
     
  1427. IAC 2020 Virtual: HCV Reinfection Rate 40% in Netherlands HIV+ MSM 5 Years After Clearance - Mark Mascolini (07/13/20)
     
  1428. IAC 2020 Virtual: Global HCV Burden Greater in MSM, Especially HIV+ Men: Meta-Analysis - Mark Mascolini (07/13/20)
     
  1429. IAC 2020 Virtual: Impact of COVID-19 on HIV preexposure prophylaxis care at a Boston community health center - (07/13/20)
     
  1430. IAC 2020 Virtual: Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders - (07/11/20)
     
  1431. IAC 2020 Virtual: Rapid Initiation of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Acute and Early Human Immunodeficiency Virus (HIV)-1 Infection: A DIAMOND Subgroup Analysis - (07/11/20)
     
  1432. IAC 2020 Virtual: Switching to dolutegravir plus lamivudine (DTG+3TC) is non-inferior to and as safe as continuing standard triple antiretroviral therapy (TAR) - (07/11/20)
     
  1433. IAC 2020 Virtual: Weight change among treatment naive women initiating dolutegravir in the ARIA study - (07/11/20)
     
  1434. IAC 2020 Virtual: COMPASSIONATE USE OF LONG-ACTING (LA) CABOTEGRAVIR (CAB) AND RILPIVIRINE (RPV) FOR PATIENTS IN NEED OF PARENTERAL ANTIRETROVIRAL THERAPY - (07/11/20)
     
  1435. IAC 2020 Virtual: PATIENT-REPORTED OUTCOMES THROUGH WEEK 48 OF ATLAS-2M: A STUDY OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE ADMINISTERED EVERY FOUR OR EIGHT WEEKS - (07/11/20)
     
  1436. IAC 2020 Virtual: Same COVID Mortality With/Without HIV at NY Center--More Intubations With HIV - Mark Mascolini (07/11/20)
     
  1437. IAC 2020 Virtual: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Treatment-naïve (AMBER) and Virologically Suppressed (EMERALD) Patients With Neurologic and/or Psychiatric Comorbidities: Week 96 Subgroup Analysis - (07/11/20)
     
  1438. IAC 2020 Virtual: Perceived Implementation Barriers Decrease During Initial Stages of an Implementation Science Hybrid III Study (CUSTOMIZE) of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in US Healthcare Settings: Healthcare Team Perspective - (07/10/20)
     
  1439. IAC 2020 Virtual: WEIGHT CHANGE AMONG TREATMENT-NAIVE WOMEN INITIATING DOLUTEGRAVIR IN THE ARIA STUDY - (07/10/20)
     
  1440. IAC 2020 Virtual: Double Drug Use, Double No-Condom Sex Boost HIV Risk With Already-Positive Partner - Mark Mascolini (07/10/20)
     
  1441. IAC 2020 Virtual: MSM Testing Drive Works Well in Australia-Except for One Thing - Mark Mascolini (07/10/20)
     
  1442. IAC 2020 Virtual: Prescribed Opioid Dose Increase Tied to Future Heroin Use in HIV+ People - Mark Mascolini - (07/10/20)
     
  1443. IAC 2020 Virtual: Perceived Implementation Barriers Decrease During Initial Stages of an Implementation Science Hybrid III Study (CUSTOMIZE) of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in US Healthcare Settings: Healthcare Team Perspective - (07/10/20)
     
  1444. IAC 2020 Virtual: HIV Risk and Treatment Disparities Persist in US Hispanic vs White MSM - Mark Mascolini (07/10/20)
     
  1445. IAC 2020 Virtual: Neuropathy and Neuropathic Pain Still on Rise in HIV+, But No Clear Links to ART - Mark Mascolini (07/10/20)
     
  1446. IAC 2020 Virtual: Quarter Million More With HIV in US-Mostly Women-Should Get Hep A Vaccine: CDC Now Recommends HAV Vax for Everyone With HIV at Least 1 Year Old - Mark Mascolini (07/10/20)
     
  1447. IAC 2020 Virtual: Deep Sequencing With Unique Molecular Identifiers for Evaluation of HIV-1 Drug Resistance in the DISCOVER Pre-Exposure Prophylaxis Trial - (07/10/20)
     
  1448. IAC 2020 Virtual: Prevalence and Risk Factors of Preexisting NNRTI Resistance Among Suppressed PLWH in B/F/TAF Switch Studies - (07/10/20)
     
  1449. IAC 2020 Virtual: Clinical and sociodemographic characteristics associated with poor self-rated health across multiple domains among older adults living with HIV - (07/10/20)
     
  1450. IAC 2020 Virtual: Weight gain and hyperglycemia during the dolutegravir transition in Africa - (07/10/20)
     
  1451. IAC 2020 Virtual: Prevalence and risk factors of pre-existing NNRTI resistance among suppressed PLWH in B/F/TAF switch studies - (07/10/20)
     
  1452. IAC 2020 Virtual: Baseline NRTI resistance in suppressed participants did not lead to viral blips on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+F/TAF through week 48 in study 380-4030 - (07/10/20)
     
  1453. IAC 2020 Virtual: Lenacapavir Sustained Delivery Formulation Supports 6-Month Dosing Interval - (07/10/20)
     
  1454. IAC 2020 Virtual: Improved metabolic parameters after switching from TAF-based 3- or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): The TANGO study - (07/10/20)
     
  1455. IAC 2020 Virtual: HPTN 083: Efficacy of Pre-exposure Prophylaxis (PrEP) containing Long-acting injectable cabotegravir (CAB-LA) is maintained across regions and key populations - (07/10/20)
     
  1456. IAC 2020 Virtual: Projecting the burden of multimorbidity among men who have sex with men living with HIV in the US - (07/09/20)
     
  1457. IAC 2020 Virtual: Lenacapavir (GS-6207) Sustained Delivery Formulation Supports 6-Month Dosing Interval - (07/09/20)
     
  1458. IAC 2020 Virtual: Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection - (07/09/20)
     
  1459. IAC 2020 Virtual: Islatravir Safety Through 48 Weeks With Doravirine in Phase 2 Trial - Mark Mascolini (07/09/20)
     
  1460. IAC 2020 Virtual: Almost Half in US Women's Group Make PrEP Visit--But Only 10% Start PrEP - Mark Mascolini - (07/09/20)
     
  1461. IAC 2020 Virtual: UNDERSTANDING THE CHANGING TREATMENT CONCERNS OF OLDER PEOPLE LIVING WITH HIV (PLHIV) AND DIFFICULTIES WITH PATIENT-PROVIDER COMMUNICATION - (07/09/20)
     
  1462. IAC 2020 Virtual: Pooled Analysis of 4 International Trials of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Adults Aged ≥ 65 Years Demonstrating Safety and Efficacy: Week 48 Results - (07/09/20)
     
  1463. IAC 2020 Virtual: Doravirine, Islatravir at AIDS2020 IAC - (07/09/20)
     
  1464. IAC 2020 Virtual: DISCOVER Study for HIV Pre-exposure Prophylaxis: No Evidence of Risk Compensation in Participants Taking F/TDF or F/TAF for PrEP Through 96 Weeks - (07/09/20)
     
  1465. IAC 2020 Virtual: Weight/Body Mass Index Gains Following Initiation of Integrase Strand Transfer Inhibitor Versus Protease Inhibitor Among People Living With Human Immunodeficiency Virus in the United States - (07/09/20)
     
  1466. IAC 2020 Virtual: Weight/Body Mass Index Gains Following Initiation of Integrase Strand Transfer Inhibitor Versus Protease Inhibitor Among People Living With Human Immunodeficiency Virus in the United States - (07/09/20)
     
  1467. IAC 2020 Virtual: Lenacapavir (GS-6207) Sustained Delivery Formulation Supports 6-Month Dosing Interval - (07/09/20)
     
  1468. IAC 2020 Virtual: One Third in US Stopped PrEP During COVID Shutdown, 90% Trimmed HIV Risk - Mark Mascolini (07/09/20)
     
  1469. ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available - PRESS RELEASE - (07/08/20)
     
  1470. IAC 2020 Virtual: Baseline NRTI Resistance in Suppressed Participants Did Not Lead to Viral Blips on Bictegravir/Emtricitabine/Tenofovir Alafenamide B/F/TAF or Dolutegravir DTG + F/TAF Through Week 48 in Study 380-4030 - (07/08/20)
     
  1471. IAC 2020 Virtual: The BICSTaR prospective cohort: Real-world effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice in people living with HIV (PLWH) - (07/08/20)
     
  1472. IAC 2020 Virtual: Comparative efficacy and safety of a combination therapy of dolutegravir and lamivudine vs 3-drug antiretroviral regimens in treatment-naïve HIV-1 infected patients at 96 weeks: A systematic review and network meta-analysis. - (07/08/20)
     
  1473. IAC 2020 Virtual: Sexually Transmitted Infections in the DISCOVER HIV PrEP Trial - (07/08/20)
     
  1474. IAC 2020 Virtual: IMPROVED METABOLIC PARAMETERS AFTER SWITCHING FROM TAF-BASED 3- OR 4-DRUG REGIMEN TO THE 2-DRUG REGIMEN OF DTG/3TC (DOLUTEGRAVIR/LAMIVUDINE): THE TANGO STUDY - (07/08/20)
     
  1475. IAC 2020 Virtual: Prevalence and Risk Factors of Preexisting NNRTI Resistance Among Suppressed PLWH in B/F/TAF Switch Studies - (07/08/20)
     
  1476. IAC 2020 Virtual: HPTN 083 FINAL RESULTS: Pre-exposure Prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men - (07/08/20)
     
  1477. IAC 2020 Virtual: Doravirine resistance profile in clinical isolates and impact of baseline NNRTI resistance-associated mutations observed in treatment-naïve participants from phase 3 clinical trials - (07/08/20)
     
  1478. IAC 2020 Virtual: ANALYSIS OF PROTOCOL DEFINED VIROLOGIC FAILURE THROUGH WEEK 48 FROM A PHASE 2 TRIAL (P011) OF ISLATRAVIR AND DORAVIRINE IN TREATMENT-NAÏVE ADULTS WITH HIV-1 INFECTION - (07/08/20)
     
  1479. IAC 2020 Virtual: Challenges faced by a population aging with HIV: Baseline data from the CORE healthy aging initiative (CHAI) - (07/07/20)
     
  1480. IAC 2020 Virtual: Pooled analysis of 4 international trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older demonstrating safety and efficacy: Week 48 results - (07/07/20)
     
  1481. IAC 2020 Virtual: WEIGHT CHANGES AFTER SWITCH TO DORAVIRINE/LAMIVUDINE/TDF IN THE DRIVE-SHIFT TRIAL - (07/07/20)
     
  1482. IAC 2020 Virtual: Reducing ART to less than 3-ARV regimen linked to increased systemic inflammation - (07/07/20)
     
  1483. IAC 2020 Virtual: ANALYSIS OF PROTOCOL DEFINED VIROLOGIC FAILURE THROUGH WEEK 48 FROM A PHASE 2 TRIAL (P011) OF ISLATRAVIR AND DORAVIRINE IN TREATMENT-NAïVE ADULTS WITH HIV-1 INFECTION - (07/07/20)
     
  1484. IAC 2020 Virtual: Weight gain before and after switch from TDF to TAF - (07/07/20)
     
  1485. IAC 2020 Virtual: New Findings on Gilead's Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults (and pre-existing resistance) - (07/06/20)
     
  1486. IAC 2020 Virtual: Early Weight Gain Up to 4.5 Kg/Year With Switch From TDF to TAF: Data Suggest Independent Effect of TAF on Weight - Mark Mascolini (07/06/20)
     
  1487. IAC 2020 Virtual: ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate an investigational once-monthly injectable HIV treatment in US healthcare practices - (07/06/20)
     
  1488. IAC 2020 Virtual: Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207) - (07/06/20)
     
  1489. IAC 2020 Virtual: Heavily Pretreated US HIV Patients Face Clinical Hurdles, Higher Death Risk - Mark Mascolini (07/06/20)
     
  1490. IAC 2020 Virtual: No HIV Infections in PrEP Adherers, But Only 56% Continue PrEP 5 Years - Mark Mascolini (07/06/20)
     
  1491. IAC 2020 Virtual: High STI Rate in IPERGAY PrEP Study, But Concentrated in Subgroup - Mark Mascolini (07/06/20)
     
  1492. IAC 2020 Virtual: Viral Rebound No Slower When Stopping Modern ART Combinations - Mark Mascolini (07/06/20)
     
  1493. IAC 2020 Virtual: People With HIV Gaining Weight 3 Times Faster Than HIV-Negatives in US - Mark Mascolini (07/06/20)
     
  1494. IAC 2020 Virtual: Time to HIV Diagnosis Falling in US, But Half With HIV Undiagnosed After 3 Years - (07/06/20)
     
  1495. IAC 2020 Virtual: Time to HIV Diagnosis Falling in US, But Half With HIV Undiagnosed After 3 Years - Mark Mascolini (07/06/20)
     
  1496. IAC 2020 Virtual: Only Small Weight Gains After Trial Switch to Doravirine/3TC/TDF - Mark Mascolini (07/06/20)
     
  1497. IAC 2020 Virtual: ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life - (07/06/20)
     
  1498. IAC 2020 Virtual: Kidney Disease, Diabetes Could Jump in US MSM With HIV - But Not High Lipids - Mark Mascolini (07/06/20)
     
  1499. IAC 2020 Virtual: Cigarette Smoking and Substance Use Each Independently Cuts Chances of HIV Control - Mark Mascolini (07/06/20)
     
  1500. IAC 2020 Virtual: ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual) - PRESS RELEASE - (07/06/20)
     
  1501. IAC 2020 Virtual: Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual - press release - (07/06/20)
     
  1502. IAC 2020 Virtual: Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual - (07/06/20)
     
  1503. IAC 2020 Virtual: ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual) - PRESS RELEASE - (07/02/20)
     
  1504. IAC 2020 Virtual: Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual - press release - (07/02/20)
     
  1505. Hypertension/79% in >65 HIV+ Causes-Risk Factors - (07/01/20)
     
  1506. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients - (07/01/20)
     
  1507. Disparate Impact of HIV/Aging on women - (06/30/20)
     
  1508. HIV Neuropathy: Women & Men/Prevalence-Risk Factors - (06/30/20)
     
  1509. ViiV Healthcare announces grantees selected as part of 3 million Fund dedicated to HIV research and community-based programmes during COVID-19 pandemic - PRESS RELEASE - (06/30/20)
     
  1510. Remdesivir Pricing - - An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences - press release - (06/30/20)
     
  1511. Combination of healthy lifestyle traits may substantially reduce Alzheimer's disease risk & Dietary flavonols too - (06/29/20)
     
  1512. Pericardial Adipose Tissue Volume Is Independently Associated With Human Immunodeficiency Virus Status and Prior Use of Stavudine, Didanosine, or Indinavir - (06/29/20)
     
  1513. HIV-Aging/Senescence/CAR-T-Cells. Senolytic Agents or Senolytic Therapeutics - (06/25/20)
     
  1514. Senolytic drugs reverse damage caused by senescent cells in mice - (06/25/20)
     
  1515. Urine Tenofovir Levels Measured by a Novel Immunoassay Predict HIV Protection - (06/25/20)
     
  1516. IAC: Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual - (06/24/20)
     
  1517. CROI: GUT INTEGRITY MARKERS AND ASSOCIATIONS WITH ADIPOSITY IN PEOPLE WITH AND WITHOUT HIV - (06/24/20)
     
  1518. Risk of Increased Physical Inactivity During COVID 19 Outbreak in Older People: A Call for Actions - Editorial - (06/22/20)
     
  1519. Burden of Aging with HIV: "better Care Systems Needed" UCSF - (06/22/20)
     
  1520. Fatty Liver in HIV: what the HIV Clinician Needs to Know - (06/19/20)
     
  1521. Lean NAFLD in HIV+ 14% - Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus - (06/19/20)
     
  1522. HCV Testing for HIV+ - Only 50% Are Tested - (06/18/20)
     
  1523. Older Adults on ART Have Double the Mortality Risk of Their HIV-Negative Counterparts.....Survival of people aged 50 years and older by HIV and HIV treatment status: findings from three waves of the SAGE-Wellbeing of Older People Study (SAGE-WOPS) in Uganda - (06/18/20)
     
  1524. Senolytics improve physical function and increase lifespan in old age - (06/17/20)
     
  1525. Senescent cells: an emerging target for diseases of ageing - Senotherapeutics for healthy ageing - (06/17/20)
     
  1526. senolytics might become an entirely new path for alleviating currently untreatable chronic diseases and enhancing human health span. - (06/17/20)
     
  1527. HIV and cardiovascular disease - Review - (06/16/20)
     
  1528. ART Reduced HPV Prevalence - Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis - (06/16/20)
     
  1529. FDA Approves Merck's GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers - (06/16/20)
     
  1530. HIV & Neurocognitive Impairment - 2 recent studies - (06/15/20)
     
  1531. On-demand HIV prevention pills worked well for San Francisco patients, Kaiser - (06/15/20)
     
  1532. Early Adopters of Event-driven Human Immunodeficiency Virus Pre-exposure Prophylaxis in a Large Healthcare System in San Francisco - (06/15/20)
     
  1533. Questioning statin therapy for older patients - (06/12/20)
     
  1534. ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV - (06/12/20)
     
  1535. HIV infects astrocytes in vivo and egresses from the brain to the periphery - After ATI - (06/12/20)
     
  1536. Metabolic Syndrome and Neurocognitive Deficits in HIV Infection - 'Metabolic syndrome most strongly associated with neurocognitive impairment......' - (06/11/20)
     
  1537. Senotherapeutics and HIV-1 Persistence & Aging/Senescence - (06/09/20)
     
  1538. Metabolic Syndrome and Neurocognitive Deficits in HIV Infection - (06/09/20)
     
  1539. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO) - (06/09/20)
     
  1540. Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy - (06/09/20)
     
  1541. Statin use is associated with insulin resistance in participants of the Canadian Multicentre Osteoporosis Study - (06/08/20)
     
  1542. Frailty in People Living with HIV - new review following several CROI reports on frailty, mitochondrial damage & brain function & frailty - (06/01/20)
     
  1543. Letter from Gilead: Update on HIV PrEP Research Among Cisgender Women - (05/28/20)
     
  1544. Fatty Liver in HIV - (05/28/20)
     
  1545. New Merck COVID Efforts-2 Vaccines+Antiviral Drug EIDD-2801; Acquisition & Collaborations - (05/26/20)
     
  1546. Long-acting drug acts like a short-term AIDS vaccine (Cabotegravir injectable long-acting HPTN-083 study) - (05/22/20)
     
  1547. Cabotegravir Injectable Long Acting PrEP Study HPTN-083 Stopped Due To Higher Efficacy - (05/22/20)
     
  1548. Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial - (05/21/20)
     
  1549. CROI: Creation of Long - Acting Nanoformulated Tenofovir Prodrugs - (05/21/20)
     
  1550. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection FLAIR - (05/21/20)
     
  1551. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression ATLAS - (05/21/20)
     
  1552. CROI: Study Suggests PrEP Access Issue: Disparity in Prior Authorizations Across US Regions - (05/20/20)
     
  1553. CROI: INFILTRATION OF VRC01 INTO THE CEREBROSPINAL FLUID IN HUMANS IN THE RV397 STUDY - (05/20/20)
     
  1554. CROI: Tenofovir Diphosphate in Dried Blood Spots Predicts Virologic Failure and Resistance - (05/20/20)
     
  1555. CROI: REAL-LIFE MANAGEMENT OF DRUG-DRUG INTERACTIONS BETWEEN ANTIRETROVIRALS AND STATINS - (05/20/20)
     
  1556. Reported preexposure prophylaxis use among male sex partners of HIV-positive men 2016-2018 - (05/19/20)
     
  1557. COVID & Genetics - CCR5 Leronlimab therapy checked COVID-19 inflammation - (05/19/20)
     
  1558. CROI: Use of an HIV Prediction Model to Evaluate PrEP Coverage in a Large Healthcare System - (05/19/20)
     
  1559. CROI: Implementation of On-Demand PrEP in a Large Integrated Healthcare System - (05/19/20)
     
  1560. CROI: Non-Daily Use of HIV Preexposure Prophylaxis in a Large Online Sample in the U.S. - (05/19/20)
     
  1561. CROI: Clinical Pharmacology at CROI 2020 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (05/19/20)
     
  1562. CROI: Biodegradable Implant for Sustained Delivery of Antiretroviral (ARV) - (05/18/20)
     
  1563. Leaning on Community-Based Participatory Research to Respond During COVID-19 - Aging HIV+ - (05/18/20)
     
  1564. CROI: Bictegravir/FTC/TAF CSF Diffusion in HIV-Infected Patients with CNS Impairment - (05/18/20)
     
  1565. CROI: Safety and Tolerability of Once Daily BIC/FTC/TAF for Post-Exposure Prophylaxis - (05/18/20)
     
  1566. CROI: There is a long Long History of Sexual Transmission of HCV in MSM, Heterosexual Men, Women, IDUs & Reinfection too - (05/18/20)
     
  1567. CROI: TFV-DP in DBS for pregnant/postpartum adolescent and young women on PrEP in Africa - (05/18/20)
     
  1568. Long-acting injectable drug prevents HIV infections - (05/18/20)
     
  1569. Global HIV prevention study to stop early after ViiV Healthcare's long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP - (05/18/20)
     
  1570. Long-acting injectable cabotegravir is highly effective for the prevention of HIV infection in cisgender men and transgender women who have sex with men - (05/18/20)
     
  1571. CROI: TFV-DP in DBS for pregnant/postpartum adolescent and young women on PrEP in Africa - (05/18/20)
     
  1572. Low-Level Viremia Increased Mortality & Comorbidities - (05/15/20)
     
  1573. Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10-13 December 2019, Miami, USA - ATI Risks, Functional Not Sterilizing Cure the Goal - (05/15/20)
     
  1574. NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19 - (05/15/20)
     
  1575. New HCV Infections Tripled: 4 times Higher than in 2009 - (05/14/20)
     
  1576. COBRA/Europe-Aging Epidemic/ Increased Brain Aging in HIV+ - (05/13/20)
     
  1577. Older HIV+ Women Have Worse Increasing Comorbidities / HOPS 95% >50 Years Old Have Increasing Numbers of Comorbidities - (05/13/20)
     
  1578. High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis - (05/13/20)
     
  1579. HIV Preexposure Prophylaxis Among Adolescents in the USA Review - (05/12/20)
     
  1580. Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated NAFLD - (05/12/20)
     
  1581. Cognitive Impairment among HIV-Infected Men with Longitudinal Follow-ups - (05/11/20)
     
  1582. Heart Disease in HIV - (05/11/20)
     
  1583. CROI: Effect of Integrase Inhibitors on Weight Gain in Children and Adolescents with HIV - (05/11/20)
     
  1584. CROI: Fat & HIV was a big part of CROI 2020 - (05/11/20)
     
  1585. CROI: Body Composition Changes Over The Menopausal Transition In Women With and At Risk For HIV - (05/11/20)
     
  1586. Hepatic Fibrosis Determined with MRE Significantly Predicts Cognitive Impairment - (05/08/20)
     
  1587. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen - (05/08/20)
     
  1588. HIV health system in South Africa is ill-equipped to handle the rising tide of HTN , CVD, Aging, Comorbities - Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa - (05/08/20)
     
  1589. PrEP & Lipids, Weight Gain - (05/08/20)
     
  1590. CROI: TELMISARTAN DECREASES MONOCYTE CX3CR1 EXPRESSION IN TREATED HIV - (05/07/20)
     
  1591. CROI: Cognitive Impairment among HIV-Infected Men with Longitudinal Follow-ups - (05/07/20)
     
  1592. CROI: RESISTIN GENE POLYMORPHISM RELATED TO WEIGHT GAIN AND PSYCHIATRIC SYMPTOMS ON InSTI - (05/07/20)
     
  1593. CROI: MEASURES OF ADIPOSE TISSUE REDISTRIBUTION AND ATHEROSCLEROTIC CORONARY PLAQUE IN HIV - (05/06/20)
     
  1594. CROI: Fat/Weight Gain/Aging Faster-mitochondria/Fat Tissue/Genetics/Metabolic Rate-Calorie Intake - (05/06/20)
     
  1595. CROI: INCREASED INFLAMMATORY CX3CR1+GPR56+CD57+ CD4+ T CELLS IN FAT FROM HIV+ DIABETICS - (05/06/20)
     
  1596. CROI: FAT GAINS OCCUR AFTER ART WITHOUT CHANGES IN METABOLIC RATE OR CALORIC INTAKE - (05/06/20)
     
  1597. CROI: Cardiac Events in HIV-infected Patients Who Use Tenofovir-Alafenamide - (05/06/20)
     
  1598. CROI: CYP2B6 GENOTYPE AND WEIGHT-GAIN DIFFERENCES BETWEEN DOLUTEGRAVIR AND EFAVIRENZ - (05/06/20)
     
  1599. CROI: Pharmacogenetics of Weight Gain after Switch from Efavirenz to Integrase Inhibitors - (05/06/20)
     
  1600. CROI: ViiV COVID-19 Community Response Fund - May 15 Deadline for Research & Community Organizations - (05/05/20)
     
  1601. Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection - (05/05/20)
     
  1602. Heart Disease in HIV - (05/05/20)
     
  1603. CROI: Kidney Disease Rates in DAD & West Africa at Young Ages: VALIDATION OF THE D:A:D CHRONIC KIDNEY DISEASE (CKD) RISK SCORE IN A LARGE AFRICAN COHORT - (05/05/20)
     
  1604. CROI: Unexpectedly High Rate of Intolerance for Dolutegravir in Real Life Setting - (05/05/20)
     
  1605. CROI: HIV Prevention at CROI 2020 - Written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (05/05/20)
     
  1606. IAS AIDS 2020 Virtual - (05/01/20)
     
  1607. New York City by Far has the Highest Rates of PLWH >55 in the USA, SF 2nd Rates by City - (04/29/20)
     
  1608. Rates HIV+ Over 55/60 Mapped, NYC, USA, by County - (04/29/20)
     
  1609. Rates by Race/Aging: Over 55 HIV+ - (04/29/20)
     
  1610. Accelerated Aging - HIV+ Appear to be 5-17 Years Older Chronologic Age - (04/28/20)
     
  1611. Depressive Disorders in HIV/AIDS:....older PLWH, social isolation, stigma, survivor guilt, shame & guilt, existential issues - (04/28/20)
     
  1612. Rates HIV+ Over 55/60 Mapped - (04/28/20)
     
  1613. NATAP: Rates by Race/Aging: Over 55 HIV+ - (04/28/20)
     
  1614. CROI: HIV Stigma Predicts Retention in Care Among US Patients in Care - (04/27/20)
     
  1615. CROI: Postpartum weight changes in women initiating DTG vs EFV in pregnancy: DolPHIN-2 - (04/27/20)
     
  1616. CROI: Dolutegravir+3TC - 2 Drug ART at CROI 2020 - (04/27/20)
     
  1617. A RANDOMIZED TRIAL OF THE IMPACT OF 3BNC117 AND ROMIDEPSIN ON THE HIV-1 RESERVOIR - (04/24/20)
     
  1618. PrEP at CROI / AIDSVu Releases Landmark County-Level Data and Interactive Maps on PrEP Use Across the U.S. - (04/22/20)
     
  1619. HIV-Experienced Clinician Workforce Capacity: Urban-Rural Disparities in the US South - (04/22/20)
     
  1620. New Long-Acting PrEP: MK-8591 - (04/22/20)
     
  1621. Theratechnologies responses to current COVID-19 pandemic - (04/22/20)
     
  1622. CROI: Cardiovascular Risk Profile: A Clinic-Based Sample of Youth Living with HIV in the US - (04/20/20)
     
  1623. CROI: Low Bone Mineral Density in Older People Living with HIV: the Renal-Bone Axis and ART - (04/20/20)
     
  1624. CROI: Comorbidities at CROI - mortality, aging..... - (04/20/20)
     
  1625. CROI: PrEP at CROI 2020 - (04/20/20)
     
  1626. CROI: INTACT PROVIRAL DNA LEVELS DECLINE IN PEOPLE WITH HIV ON ANTIRETROVIRAL THERAPY - new intact proviral DNA assay - (04/20/20)
     
  1627. Company Statements Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials - (04/16/20)
     
  1628. WHO Report: HIV+ COVID Responses - (04/16/20)
     
  1629. WHO Report: HIV+ COVID Responses - (04/14/20)
     
  1630. CROI: THE LONG AND THE SHORT OF IT: WHAT'S NEXT FOR LONG-ACTING DRUGS (04/13/20)
     
  1631. CROI: Trends in Marijuana, Alcohol, and Opioid Use in Pregnant and Postpartum Women with HIV (04/13/20)
     
  1632. CROI: MK-8504 and MK-8583 (Tenofovir Prodrugs) Single-Dose PK and Antiviral Activity in HIV Infection (04/13/20)
     
  1633. CROI: Barriers To Direct-Acting Antiviral Therapy Among HIV/HCV-Coinfected Adults (04/10/20)
     
  1634. CROI: COMPARABLE EFFICACY OF IBALIZUMAB IN COMBINATION WITH ONE OR TWO FULLY ACTIVE AGENTS (04/10/20)
     
  1635. CROI: HIV VIRAL BLIPS IN ADULTS TREATED WITH InSTI-BASED REGIMENS THROUGH 144 WEEKS........no real difference in blips between arms, non-adherence found to cause blips. (04/10/20)
     
  1636. CROI: CLINICAL AND LABORATORY OUTCOMES 24 WEEKS AFTER STARTING DTG VERSUS EFV IN ACUTE HIV (04/10/20)
     
  1637. CROI: NOD2 and TLR8 Agonists Enhance IL-15 Mediated Activation of HIV Expression (04/10/20)
     
  1638. CROI: SAFETY AND EFFICACY OF DTG VS EFV AND TDF VS TAF IN PREGNANCY: IMPAACT 2010 TRIAL (04/10/20)
     
  1639. CROI: RENAL IMPAIRMENT IN A PREEXPOSURE PROPHYLAXIS IMPLEMENTATION COHORT IN AUSTRALIA (04/10/20)
     
  1640. CROI: SUSTAINED HIV REMISSION IN THE LONDON PATIENT: THE CASE FOR HIV CURE (04/09/20)
     
  1641. CROI: PGT121 AND VESATOLIMOD IN CHRONICALLY TREATED SHIV-INFECTED RHESUS MONKEYS (04/09/20)
     
  1642. CROI: Post-Discharge Outcomes Following Acute Coronary Syndrome in HIV [ Disparities for PLWH ] (04/09/20)
     
  1643. CROI: HIV-1 Drug Resistance in the DISCOVER Pre-exposure Prophylaxis Trial (04/09/20)
     
  1644. CROI: COMBINED ACTIVE AND PASSIVE IMMUNIZATION IN SHIV-INFECTED RHESUS MONKEYS (04/09/20)
     
  1645. CROI: PREVALENCE OF RESISTANCE AND LIMITED THERAPEUTIC OPTIONS IN PATIENTS VIREMIC ON ART (04/09/20)
     
  1646. CROI: Drug Resistance is USA & Europe: 2 studies at CROI 2020 (04/09/20)
     
  1647. CROI: MK-8591/Islatravir vs ART Resistance / Metabolics (04/09/20)
     
  1648. CROI: PRO 140 IN VITRO ACTIVITY IN HTE SUBJECTS WITH A 4-CLASS DRUG-RESISTANT HIV-1 VIRUS (04/08/20)
     
  1649. CROI: CLEARANCE OF HPV ANAL HIGH-GRADE INTRAEPITHELIAL LESIONS WITH LOW-DOSE POMALIDOMIDE (04/08/20)
     
  1650. CROI: ON-DEMAND HIV POSTEXPOSURE PROPHYLAXIS BY TAF/EVG VAGINAL INSERTS IN MACAQUES (04/08/20)
     
  1651. CROI: CROI ART/HIV Drug Studies (04/08/20)
     
  1652. CROI: BRAIN AGE BASED ON SLEEP ENCEPHALOGRAPHY IS ELEVATED IN HIV+ ADULTS ON ART (04/08/20)
     
  1653. CROI: Dolutegravir in Malawai (04/08/20)
     
  1654. CROI: HIV TRANSCRIPTION PROFILE IN BLOOD, GUT, LIVER, AND GENITAL TRACT IN SUPPRESSED WOMEN (04/08/20)
     
  1655. CROI: Need for optimization of screening methods for anal intraepithelial neoplasia in people living with HIV (04/08/20)
     
  1656. CROI: High Resolution Anoscopy (HRA) in the Real World: Predictors of Guideline-Based Follow Up at a Large Academic Medical Center (04/08/20)
     
  1657. CROI: ANAL PRECANCER SCREENING AMONG MSM: WHAT IS THE BEST STRATEGY? (04/08/20)
     
  1658. CROI: START OR SWITCH OF INTEGRASE INHIBITORS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV (04/08/20)
     
  1659. CROI: CLINICAL SIGNIFICANCE OF gp120 POLYMORPHISMS, TMR IC50FC AND HIV-1 SUBTYPE IN BRIGHTE (04/08/20)
     
  1660. CROI: 2-Drug Regimen Comparable to 3-Drug Regimens up to 18 Months in a Real-World Setting (04/07/20)
     
  1661. CROI: INTEGRASE INHIBITOR START OR SWITCH IMPACTS LEARNING IN WOMEN WITH HIV (04/07/20)
     
  1662. CROI: Anal Cancer Screening: Is it Time for Cytology and High-risk HPV Co-testing? (04/07/20)
     
  1663. CROI: IN VITRO IMPACT OF TAF ON MITOCHONDRIAL FUNCTION IN IMMUNE CELLS (04/07/20)
     
  1664. CROI: TRICARBOXYLIC ACID METABOLITES PREDICT METABOLIC COMORBIDITIES AND DEATH IN AGING PWH (04/07/20)
     
  1665. CROI: TRICARBOXYLIC ACID METABOLITES PREDICT METABOLIC COMORBIDITIES AND DEATH IN AGING PWH (04/07/20)
     
  1666. CROI: Baseline and Acquired Comorbidities in Patients Initiating ART in the HOPS, 2008-2018 (04/07/20)
     
  1667. CROI: Race Impact on Dolutegravir-Associated Weight Gain Among Previously ART-Naïve People Living with HIV (04/07/20)
     
  1668. CROI: MORTALITY AMONG PEOPLE WITH HIV WITH A HISTORY OF INJECTION DRUG USE, NEW YORK CITY, 2008-2017 (04/07/20)
     
  1669. CROI: Results from a PrEP Demonstration Project for At-Risk Cisgender Women in the US - PrEP/PEP at CROI (04/06/20)
     
  1670. CROI: IMPACT OF ANTIRETROVIRAL THERAPY INITIATION ON EPIGENETIC AGING AND TELOMERE LENGTH (04/06/20)
     
  1671. CROI: VIROLOGIC FAILURE AND RESISTANCE IN DOLUTEGRAVIR-BASED MAINTENANCE DUAL REGIMENS (04/06/20)
     
  1672. CROI: Dolutegravir+3TC - 2 Drug ART at CROI (04/06/20)
     
  1673. J&J COVID Vaccine: "We are counting on a 10 euro vaccine against coronavirus" - (04/06/20)
     
  1674. Letter from Gilead: Message from Amy Flood: Supporting our friends and partners - (04/06/20)
     
  1675. COVID & HIV+ China Report Preliminary Data, How do PLWH Fare? - (04/06/20)
     
  1676. CROI: Results from a PrEP Demonstration Project for At-Risk Cisgender Women in the US - PrEP/PEP at CROI (04/04/20)
     
  1677. CROI: DOLUTEGRAVIR USE IS ASSOCIATED WITH HIGHER POSTPARTUM WEIGHT COMPARED TO EFAVIRENZ (04/04/20)
     
  1678. CROI: GREATER INCIDENCE OF DIABETES OVER 10 YEARS AMONG DEPRESSED US VETERANS WITH HIV (04/04/20)
     
  1679. CROI: Diabetes, Weight Gain, & Integrase Inhibitor Use in North American HIV+ Persons (04/04/20)
     
  1680. CROI: Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Disease "LIFE HIV Study" (04/04/20)
     
  1681. CROI: Low-level viremia during ART and the risk of death, AIDS, and serious non-AIDS events (04/04/20)
     
  1682. CROI: EFFECTS OF VIRAL LOAD ON NEUROIMAGING AND NEUROPSYCHOLOGICAL PERFORMANCE (04/04/20)
     
  1683. CROI: EXPLAINING RACIAL DISPARITIES IN VIRAL SUPPRESSION AMONG MSM LIVING WITH HIV (04/04/20)
     
  1684. CROI: EXPLOSIVE HIV AND HCV EPIDEMICS DRIVEN BY NETWORK VIREMIA (04/04/20)
     
  1685. CROI: Long Island has 6,649 cases with both counties combined. (04/04/20)
     
  1686. CROI: HCV INCIDENCE AMONG HIV-INFECTED MSM IN FRANCE: RESULTS FROM THE FHDH-ANRS CO4 COHORT (04/04/20)
     
  1687. CROI: Clinical Features and Outcomes of Patients Stopping DTG for Neuropsychiatric Symptoms (04/04/20)
     
  1688. CROI: INVESTIGATION OF CLASSIC AND HIV-RELATED FACTORS FOR HEPATIC STEATOSIS AMONG PWID - 20% ALIVE Cohort (04/02/20)
     
  1689. CROI: NAFLD AND LIVER FIBROSIS PREDICT HIGH CARDIOVASCULAR RISK IN HIV-MONOINFECTED PATIENT (04/02/20)
     
  1690. Letter from Gilead: Message from Amy Flood: Supporting our friends and partners - (04/02/20)
     
  1691. CROI: EFFECTS OF VIRAL LOAD ON NEUROIMAGING AND NEUROPSYCHOLOGICAL PERFORMANCE (04/01/20)
     
  1692. CROI: Understanding Who Does and Does Not Gain Weight with Integrase Inhibitors (INSTI) (04/01/20)
     
  1693. CROI: Adipocyte Dysfunction Despite Reduced Adipose Inflammation in Diabetics with HIV (04/01/20)
     
  1694. CROI: Once-daily etravirine/raltegravir (400/800 mg) as maintenance regimen (04/01/20)
     
  1695. CROI: Losartan does not improve lymphatic tissue fibrosis or T-cell recovery in HIV infection (04/01/20)
     
  1696. CROI: EFFECTS OF HIV, AGE, AND SEX ON SKELETAL MUSCLE MASS AND DENSITY (04/01/20)
     
  1697. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? - (04/01/20)
     
  1698. Dysregulation of immune response in patients with COVID-19 in Wuhan, China - (04/01/20)
     
  1699. ViiV Healthcare Announces First Global Regulatory Approval of CABENUVA; the First Complete, Long-acting, Regimen for the Treatment of HIV - (04/01/20)
     
  1700. CROI: EXPLOSIVE HIV AND HCV EPIDEMICS DRIVEN BY NETWORK VIREMIA AMONG PWID (03/31/20)
     
  1701. CROI: EFFECTS OF VIRAL LOAD ON NEUROIMAGING AND NEUROPSYCHOLOGICAL PERFORMANCE (03/31/20)
     
  1702. CROI: IMPACT OF ANTIRETROVIRAL THERAPY INITIATION ON EPIGENETIC AGING AND TELOMERE LENGTH (03/31/20)
     
  1703. CROI: Women with HIV Have High Overall Burden and Early Accrual of Non-AIDS Comorbidities (03/31/20)
     
  1704. CROI: VIROLOGIC FAILURE AND RESISTANCE IN
    DOLUTEGRAVIR-BASED MAINTENANCE DUAL REGIMENS     (03/31/20)
     
  1705. CROI: VIROLOGIC OUTCOMES BY RESISTANCE CATEGORY AND PRE-TREATMENT IN THE DUALIS STUDY (dolutegravir+bDarunavir) (03/31/20)
     
  1706. CROI: DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 (03/31/20)
     
  1707. CROI: Low-level viremia during ART and the risk of death, AIDS, and serious non-AIDS events (03/31/20)
     
  1708. CROI: (03/31/20)
     
  1709. ViiV Healthcare Announces First Global Regulatory Approval of CABENUVA; the First Complete, Long-acting, Regimen for the Treatment of HIV - (03/31/20)
     
  1710. CROI: Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Disease "LIFE HIV Study" (03/30/20)
     
  1711. CROI: EFFICACY AND DURABILITY OF 2-DRUG VS 3-DRUG INSTI-BASED REGIMENS: DATA FROM REAL-LIFE (03/30/20)
     
  1712. CROI: SHALL WE DANCE? EXTENDING TANGO'S RESULTS TO CLINICAL PRACTICE (03/30/20)
     
  1713. CROI: EFFECT OF PAST VIROLOGICAL FAILURE ON DOLUTEGRAVIR + LAMIVUDINE AS MAINTENANCE REGIMEN (03/30/20)
     
  1714. CROI: VIROLOGIC OUTCOMES BY RESISTANCE CATEGORY AND PRE-TREATMENT IN THE DUALIS STUDY (03/30/20)
     
  1715. CROI: LONG-TERM DTG+3TC SWITCH EFFICACY IN PATIENTS WITH ARCHIVED 3TC RESISTANCE (03/30/20)
     
  1716. CROI: Rising BMI Tied to Risk of Diabetes But Not CVD in D:A:D Analysis - Mark Mascolini (03/30/20)
     
  1717. CROI: Retinal Thinning in Well-Controlled HIV-infected Patients (03/30/20)
     
  1718. CROI: Retinal Thinning in Well-Controlled HIV-infected Patients (03/30/20)
     
  1719. CROI: EFFECTS OF HIV INFECTION AND IMMUNE REGULATION ON LONGITUDINAL LUNG FUNCTION DECLINE (03/30/20)
     
  1720. CROI: Modifiable Risk Factors for Kidney and Heart Disease Have Less Impact in HIV+ Than HIV- - Mark Mascolini (03/30/20)
     
  1721. CROI: Increased overall life expectancy but not comorbidity-free years for people with HIV - Mark Mascolini (03/27/20)
     
  1722. CROI: HIV DNA DETECTED IN IMMUNE CELL SUBSETS IN CSF DURING ART (03/27/20)
     
  1723. CROI: 50% PREVALENCE OF PHYSICAL FUNCTION IMPAIRMENT AND FRAILTY IN MIDDLE-AGED PWH - age 46-55 (03/27/20)
     
  1724. CROI: Effects of HIV on Myelin Maps (03/27/20)
     
  1725. CROI: NOVEL ANTIRETROVIRAL AGENTS: TRANSFORMING THE CARE OF PEOPLE WITH HIV (03/27/20)
     
  1726. CROI: EFFECTS OF HIV INFECTION AND IMMUNE REGULATION ON LONGITUDINAL LUNG FUNCTION DECLINE (03/27/20)
     
  1727. CROI: RAPID START LEADS TO SUSTAINED VIRAL SUPPRESSION IN YOUNG PEOPLE IN THE SOUTH (03/26/20)
     
  1728. CROI: Assessment of Immediate Initiation of Antiretroviral Therapy (ART) in New York City (03/26/20)
     
  1729. CROI: ASSESSMENT OF IMMEDIATE INITIATION OF ANTIRETROVIAL THERAPY IN NYC (03/26/20)
     
  1730. CROI: Summary from virtual CROI 2020 for HIV and liver disease HIV and the liver: what is new? - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (03/25/20)
     
  1731. CROI: TRENDS AND CHARACTERISTICS OF HIV-1 DRUG RESISTANCE IN THE UNITED STATES (2012-2018) (03/25/20)
     
  1732. CROI: Retinal Thinning in Well-Controlled HIV-infected Patients (03/23/20)
     
  1733. CROI: EFFECT OF ANTICHOLINERGIC MEDICATIONS ON BRAIN INTEGRITY IN OLDER HIV-POSITIVE ADULTS (03/23/20)
     
  1734. CROI: BENEFITS OF RILPIVIRINE FOR LIVER FIBROSIS IN HIV/HCV COINFECTED SUBJECTS (03/23/20)
     
  1735. CROI: Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated Nonalcoholic Fatty Liver Disease (03/23/20)
     
  1736. CROI: Fibrosis Progression Over 6-Fold Higher in NAFLD With vs Without HIV - Mark Mascolini (03/23/20)
     
  1737. CROI: VISCERAL FAT IS A PREDICTOR OF LIVER FIBROSIS AND FIBROSIS PROGRESSION IN PEOPLE LIVING WITH HIV (03/23/20)
     
  1738. RAPID START LEADS TO SUSTAINED VIRAL SUPPRESSION IN YOUNG PEOPLE IN THE SOUTH (03/26/20)
     
  1739. CROI: CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD (03/23/20)
     
  1740. CROI: Bictegravir/Emtricitabine/Tenofovir Alafenamide Low-Dose Tablet Relative Bioavailability in Healthy Volunteers and PK in Children With HIV (03/20/20)
     
  1741. CROI: Much Higher Death Rate After Cancer Diagnosis in People With HIV - Mark Mascolini (03/20/20)
     
  1742. CROI: HIV DNA DETECTED IN IMMUNE CELL SUBSETS IN CSF DURING ART (03/20/20)
     
  1743. CROI: CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS IS NONINFERIOR TO MONTHLY DOSING: WEEK 48 RESULTS FROM THE ATLAS-2M STUDY (03/20/20)
     
  1744. CROI: CROI ART/HIV Drug Studies (03/20/20)
     
  1745. CROI: PET IMAGING OF SYNAPTIC DENSITY IN HIV: PRELIMINARY FINDINGS FROM A PILOT STUDY (03/20/20)
     
  1746. CROI: 50% PREVALENCE OF PHYSICAL FUNCTION IMPAIRMENT AND FRAILTY IN MIDDLE-AGED PWH - age 46-55 (03/20/20)
     
  1747. CROI: PWH had a greater burden (5x) of primarily eccentric arterial wall enhancement compared with persons without HIV (03/20/20)
     
  1748. CROI: HIV DNA DETECTED IN IMMUNE CELL SUBSETS IN CSF DURING ART (03/27/20)
     
  1749. CROI: PWH had a greater burden (5x) of primarily eccentric arterial wall enhancement compared with persons without HIV (03/27/20)
     
  1750. CROI: PET IMAGING OF SYNAPTIC DENSITY IN HIV: PRELIMINARY FINDINGS FROM A PILOT STUDY (03/27/20)
     
  1751. CROI: SINGLE-CELL GENOMIC ANALYSIS OF BLOOD AND CSF T CELLS IN HIV+ AND HIV- ADULTS......T Cell Exhaustion in CNS HIV (03/17/20)
     
  1752. CROI: HIV-1 REPLICATION AT <50 C/ML TO 148 WEEKS FOR SWORD 1 TO 148 WEEKS FOR SWORD-1/SWORD-2 Studies with DTG+RPV (03/17/20)
     
  1753. CROI: MITOCHONDRIAL DNA, COGNITIVE FUNCTION, AND FRAILTY IN OLDER ADULTS WITH HIV (03/17/20)
     
  1754. CROI: CABOTEGRAVIR PHARMACOKINETIC TAIL IN PREGNANCY AND NEONATAL OUTCOMES (03/17/20)
     
  1755. CROI: BICTEGRAVIR DISTRIBUTION AND BICTEGRAVIR/FTC/TAF ACTIVITY IN GENITAL TRACT AND RECTUM (03/17/20)
     
  1756. CROI: Bictegravir/Emtricitabine/Tenofovir Alafenamide Low-Dose Tablet Relative Bioavailability in Healthy Volunteers and PK in Children With HIV (03/17/20)
     
  1757. CROI: Less Coronary Intervention, Higher Mortality in HIV+ People With Acute Coronary Syndrome - Mark Mascolini (03/17/20)
     
  1758. CROI: Starting ART With a PI or an InSTI (Mainly Raltegravir) May Heighten Risk of Diabetes - Mark Mascolini (03/17/20)
     
  1759. CROI: METABOLIC COMPLICATIONS OF HIV AND ITS THERAPIES (03/17/20)
     
  1760. CROI: Rising BMI Tied to Risk of Diabetes But Not CVD in D:A:D Analysis - Mark Mascolini (03/17/20)
     
  1761. CROI: Predicted 10-year risks of diabetes and cardiovascular disease in the ADVANCE trial (03/17/20)
     
  1762. CROI: Testosterone Use Tied to Signals of Atherosclerosis Progression in Men With HIV (03/17/20)
     
  1763. CROI: VISCERAL FAT IS A PREDICTOR OF LIVER FIBROSIS AND FIBROSIS PROGRESSION IN PEOPLE LIVING WITH HIV (03/17/20)
     
  1764. CROI: Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated Nonalcoholic Fatty Liver Disease (03/17/20)
     
  1765. CROI: BICTEGRAVIR DISTRIBUTION AND BICTEGRAVIR/FTC/TAF ACTIVITY IN GENITAL TRACT AND RECTUM (03/16/20)
     
  1766. CROI: Safety, PK, and Efficacy of Low-Dose B/F/TAF in Children ≥2 Years Old Living With HIV (03/16/20)
     
  1767. CROI: Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in vivo: The AMC-095 Study (03/16/20)
     
  1768. CROI: Use of D/C/F/TAF With Neurologic/Psychiatric Comorbidities: AMBER Subgroup Analysis (03/16/20)
     
  1769. CROI: DISCOVER: NO EFFECT OF HORMONES ON F/TAF OR F/TDF PK, EFFICACY & SAFETY IN TRANSWOMEN (03/16/20)
     
  1770. CROI: IMPLEMENTATION OF MOBILE PrEP, STI, AND HIV PREVENTION SERVICES IN SOUTH FLORIDA (03/16/20)
     
  1771. CROI: PK, Food Effect, and Safety of Oral GS-6207, a Novel HIV-1 Capsid Inhibitor (03/16/20)
     
  1772. CROI: Cabotegravir + Rilpivirine PK Following Long-Acting HIV Treatment Discontinuation (03/16/20)
     
  1773. CROI: Preexisting Resistance and B/F/TAF Switch Efficacy in African Americans (03/16/20)
     
  1774. CROI: ABSENCE OF GS-6207 PHENOTYPIC RESISTANCE IN HIV Gag CLEAVAGE SITE AND OTHER MUTANTS (03/16/20)
     
  1775. CROI: DOSE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS LONG-ACTING HIV CAPSID INHIBITOR GS-6207 (03/16/20)
     
  1776. CROI: CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION (03/16/20)
     
  1777. CROI: FOSTEMSAVIR EXPOSURE-RESPONSE RELATIONSHIPS IN TREATMENT EXPERIENCED HIV PATIENTS (03/16/20)
     
  1778. CROI: DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 (03/16/20)
     
  1779. CROI: IMPACT OF PrEP AND TasP ON INCIDENCE OF HIV DIAGNOSES IN 48 HIGHEST-BURDEN US AREAS (03/16/20)
     
  1780. CROI: Preexisting Resistance and B/F/TAF Switch Efficacy in African Americans (03/13/20)
     
  1781. CROI: ASSESSING THE VIROLOGIC IMPACT OF ARCHIVED RESISTANCE IN AN HIV-1 Switch Study TANGO Through Week 48 (03/13/20)
     
  1782. CROI: INSOMNIA AND RISK OF INCIDENT MYOCARDIAL INFARCTION AMONG PEOPLE LIVING WITH HIV (03/13/20)
     
  1783. CROI: DRUG LEVELS, ADHERENCE, AND RISKS FOR LOW ADHERENCE IN THE DISCOVER PrEP STUDY (03/13/20)
     
  1784. NYS & NYC COVID-19 Announcements - Prescriptions for Uninsured & More - (03/13/20)
     
  1785. CROI: Predicted Rise in Diabetes Risk With TAF/FTC+DTG Versus TDF/FTC+DTG - Mark Mascolini (03/12/20)
     
  1786. Phase 3 Doravirine/Islatravir - (03/12/20)
     
  1787. CROI: Modeling-Supported Islatravir Dose Selection for Phase 3 - (03/12/20)
     
  1788. CROI: CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD - (03/12/20)
     
  1789. CROI: 144-Week Efficacy and Safety of B/F/TAF in Treatment-Naive Adults Age ≥50 Years - (03/12/20)
     
  1790. CROI: NOVEL ANTIRETROVIRAL AGENTS: TRANSFORMING THE CARE OF PEOPLE WITH HIV - (03/11/20)
     
  1791. CROI: HORMONE USE AND HIV ALTER CARDIOVASCULAR BIOMARKER PROFILES IN TRANSGENDER WOMEN - (03/11/20)
     
  1792. CROI: Testosterone Use Tied to Signals of Atherosclerosis Progression in Men With HIV - Mark Mascolini (03/11/20)
     
  1793. CROI: DISCOVER: 96-Week Follow-up of Black and Hispanic/Latinx Study Participants - (03/11/20)
     
  1794. CROI: Themed Discussion FAT IN FOCUS - (03/11/20)
     
  1795. CROI: Pre-ART CD4% and HIV Load Tied to Reservoir Size in Early-Treated Infants - Mark Mascolini (03/11/20)
     
  1796. CROI: GREATER WEIGHT GAIN AFTER SWITCH TO INSTI-BASED REGIMEN FROM NNRTI VS. PI REGIMENS - (03/11/20)
     
  1797. CROI: Life Expectancy With HIV Improving--But Added Years Often Not Healthy - Mark Mascolini (03/11/20)
     
  1798. CROI: Community- Versus Clinic-Based ART Boosts HIV Control in African Study - Mark Mascolini (03/11/20)
     
  1799. CROI: Low Adherence to Treatment and Follow-up of Anal Cancer Precursor - Mark Mascolini (03/11/20)
     
  1800. CROI: Doubled Risk of non-HIV Mortality in US People at Risk for HIV - Mark Mascolini (03/11/20)
     
  1801. CROI: Intact Proviral HIV DNA Drops During Long-Term Suppressive ART - Mark Mascolini (03/11/20)
     
  1802. CROI: Weekly Islatravir Protects Monkeys Against IV Challenge With SIV - Mark Mascolini (03/11/20)
     
  1803. CROI: Losartan Does Not Improve Inflammation or Fibrosis Markers in Older People on ART - Mark Mascolini (03/11/20)
     
  1804. CROI: Pomalidomide Clears Anal Cancer Precursor in High Proportion With or Without HIV - Mark Mascolini (03/11/20)
     
  1805. CROI: Lower CD4/CD8 Ratio Boosts Cancer Risk in US/Canada HIV Group - Mark Mascolini (03/11/20)
     
  1806. CROI: F/TAF and F/TDF Efficacy and Safety as PrEP for 96 Weeks - Mark Mascolini (03/11/20)
     
  1807. CROI: Initial Weight, Low CD4/CD8, Low Activity Drive Weight Gains After InSTI Switch - Mark Mascolini (03/11/20)
     
  1808. CROI: DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 - (03/11/20)
     
  1809. CROI: WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251 - (03/11/20)
     
  1810. CROI: FTC/TAF + BIC Postexposure Prophylaxis Protects Macaques Against Rectal SHIV Infection - (03/11/20)
     
  1811. CROI: Longer Term Efficacy and Safety of F/TAF and F/TDF For HIV PrEP: DISCOVER Trial Week 96 Results - (03/11/20)
     
  1812. CROI: ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership - (03/11/20)
     
  1813. CROI: ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting injectable treatment regimen in adults living with HIV-1 - (03/11/20)
     
  1814. CROI: Glucose Upsets Tied to Worse Physical Function in Men With or Without HIV - Mark Mascolini (03/11/20)
     
  1815. CROI: LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS - (03/11/20)
     
  1816. CROI: STRUCTURAL ANALYSES OF A BOUND ANTI-CD4 ADNECTIN INHIBITOR OF HIV-1 [Combinectin GSK3732394] - (03/11/20)
     
  1817. CROI: Mortality 4-Fold Higher With HIV in Canadian Group--in Sync With Comorbidity Tally - Mark Mascolini (03/11/20)
     
  1818. CROI: Safety & Analytic Treatment Interruption Outcomes of Vesatolimod in HIV Controllers - (03/11/20)
     
  1819. CROI: HIV Severity and Incident Heart Failure Among Adults in a Large Healthcare System - (03/11/20)
     
  1820. CROI: WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251 - (03/11/20)
     
  1821. CROI: ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing - (03/11/20)
     
  1822. CROI: New Data on Gilead's Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults - (03/11/20)
     
  1823. CROI: HIV cure from bench to bedside.....and to community - (03/11/20)
     
  1824. Could Colchicine Be the New Aspirin? - (03/09/20)
     
  1825. HIV Itself Ages PLWH - Immunosenescence - (03/09/20)
     
  1826. HIV Causes Aging In HIV & Contributes to the Onset Prematurelly & in Greater Rates of Comorbidities - (03/09/20)
     
  1827. Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate? - (03/09/20)
     
  1828. CROI: Islatravir Metabolic Outcomes in a Phase 2b Trial of Treatment-Naïve Adults with HIV-1 - (03/09/20)
     
  1829. CROI: SAFETY & PHARMACOKINETICS OF GS-9722 IN HIV-NEGATIVE PARTICIPANTS AND PEOPLE WITH HIV - (03/09/20)
     
  1830. CROI: A RANDOMIZED TRIAL OF THE IMPACT OF 3BNC117 AND ROMIDEPSIN ON THE HIV-1 RESERVOIR - (03/09/20)
     
  1831. CROI: Greater Population-Level Viral Control Tied to Lower HIV Incidence in 4 Large Trials - Mark Mascolini - (03/09/20)
     
  1832. CROI: Every-2-Month Maintenance CAB + RPV Noninferior to Monthly Dosing for 48 Weeks. ATLAS-2M study - Mark Mascolini (03/09/20)
     
  1833. CROI: ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing - press release - (03/09/20)
     
  1834. CROI: Merck Announces New Data from Broad HIV Program at CROI 2020 - (03/02/20)
     
  1835. Geriatric model & screening assessments ALL HIV clinics should have - (02/28/20)
     
  1836. Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study - (02/27/20)
     
  1837. FDA approves drug that lowers cholesterol in a new way
    Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance     - (02/24/20)
     
  1838. CROI: Changes in markers of T-cell Senescence and Exhaustion With HIV Therapy - (02/21/20)
     
  1839. Aging of HIV+ in US.....an epidemic coming - (02/21/20)
     
  1840. Multiple roles for HIV broadly neutralizing antibodies - (02/21/20)
     
  1841. Understanding The Relationship Between HPV and Anal Cancer - (02/14/20)
     
  1842. Loss of Preexisting Immunological Memory Among Human Immunodeficiency Virus-Infected Women Despite Immune Reconstitution With Antiretroviral Therapy - (02/14/20)
     
  1843. Novel Antiretroviral Agents - (02/14/20)
     
  1844. Increased Healthcare Costs for Older HIV+ - (02/10/20)
     
  1845. The HIV Continuum of Care for Adolescents and Young Adults Attending 13 Urban US HIV Care Centers of the NICHD-ATN-CDC-HRSA SMILE Collaborative..... - (02/10/20)
     
  1846. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV - (02/10/20)
     
  1847. Preexposure Prophylaxis Indication Criteria Underidentify Black and Latinx Persons and Require Revision - (02/07/20)
     
  1848. Functional Interval Training for Veterans Exercising Through Telehealth. (FIT-VET) - (02/06/20)
     
  1849. Antiretroviral therapy in older people with HIV - HIV AND AGING: Edited by Kristine M. Erlandson - (02/04/20)
     
  1850. Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV - (02/04/20)
     
  1851. Regional brain volumetric changes despite 2 years of treatment initiated during acute HIV infection - (02/03/20)
     
  1852. New End AIDS CDC Funding for Health Departments - (02/03/20)
     
  1853. HIV postexposure prophylaxis-in-pocket "PIP" - (02/03/20)
     
  1854. Weight Gain in HIV+ - (01/29/20)
     
  1855. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV - (01/29/20)
     
  1856. Weight GAIN - ARTs, Integrase - (01/29/20)
     
  1857. Harvard HIV and Aging Workshop: Perspectives and Priorities from Claude D. Pepper Centers and Centers for AIDS Research - (01/28/20)
     
  1858. Gender & Racial Aging/HIV Disparities - (01/28/20)
     
  1859. AGE: Food Insecurity and Frailty among Women Living with or At-risk for HIV in the U.S. - (01/24/20)
     
  1860. NIAID Launches First Clinical Trial to Test Antibody-Drug Combination for Long-Acting HIV Treatment - (01/27/20)
     
  1861. AGE: Can Frailty Be Prevented or Reversed???? - (01/24/20)
     
  1862. Epidemiological studies have identified a potential temporal link between marijuana use and myocardial infarction - (01/24/20)
     
  1863. Frailty & 5x Higher Mortality in HIV+ Women (WIHS) & Men (MACS) with HIV; frailty doubles fracture rate in older women with HIV; Ever opiate or cocaine use was also associated with increased risk - (01/24/20)
     
  1864. A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1 A Multicenter Trial of the AIDS Clinical Trials Group (ACTG) - A5357 - (01/24/20)
     
  1865. CROI: Longitudinal Phenotyping of Declarative Memory Among Women Living with HIV - (01/24/20)
     
  1866. Aging in NYC: Black/Latino 25% >60 Yrs Old; 75% >40. 23,000 >60 - (01/23/20)
     
  1867. HIV/Aging in NYC 80%+ over 40 Yrs Old/IDUs 95%/HIGH Death Rates for Older HIV - (01/23/20)
     
  1868. AGE: Frailty and Aging (worse mortality): The last 10 years of aging research, and next steps. - (01/23/20)
     
  1869. EACS: Aging with HIV (01/22/20)
     
  1870. AGE: Loneliness & Social Isolation in HIV: Reduces Mental & Physical Health. The "Village Model in HIV study: pilot in San Diego, app" - (01/22/20)
     
  1871. Despite ART/Faster Immune Aging in HIV+ - (01/17/19)
     
  1872. New MK-8591 Publication - (01/17/19)
     
  1873. Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017 - (01/17/19)
     
  1874. Aging Successfully in WIHS...BUT. Prevalence and Correlates of Self-Rated Successful Aging Among Older Women Living With HIV - (01/17/19)
     
  1875. Alzheimers & Amyloid, Mild Cognitive Impairment in HIV - (01/17/19)
     
  1876. Dovato (dolutegravir/lamivudine), the once-daily, single-pill, 2-drug regimen for the treatment of HIV-1 infection, granted marketing approval by Japan Ministry of Health, Labour and Welfare - (01/16/19)
     
  1877. Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV - (01/13/19)
     
  1878. 9th HIV Persistance During Therapy Workshop; Reservoirs & Eradication Strategies Workshop - (01/13/19)
     
  1879. Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University - (01/13/19)
     
  1880. Long-Term Impact of Calcium and Vitamin D Supplementation on Bone Density in HIV+ Patients with Documented Deficiencies - (01/06/19)
     
  1881. Prescribing in Elderly PLWH - Top Ten Drug Classes to Avoid in Elderly PLWH - (01/06/19)
     
  1882. Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017..... three times higher than in the general population - (12/20/19)
     
  1883. Doravrine - a relatively New ART [NNRTI] - (12/20/19)
     
  1884. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV [London]....'although there appear to be outliers' - (12/18/19)
     
  1885. HIV drug resistance in a cohort of HIV-infected MSM in the United States - (12/18/19)
     
  1886. HIV and African American Gay and Bisexual Men: HV incidence 8 Times Higher for African-Americans & 3 times Higher for Hispanics than whites. - (12/18/19)
     
  1887. Fauci: Comorbidities in Persons With HIV - The Lingering Challenge - (12/18/19)
     
  1888. The elusive end to HIV in the USA - Editorial - (12/16/19)
     
  1889. ViiV Healthcare files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV - (12/16/19)
     
  1890. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back - (12/16/19)
     
  1891. HIV and the Aging Brain - Miami CFAR Aging Conference - (12/12/19)
     
  1892. Multimorbidity in Elderly Subjects according to the year of diagnosis of HIV-Infection - A Cross-Sectional DATAIDS Cohort Study....'40% diabetes, 10% cancers, 80% elevated cholesterol, 30% low kidney function eGFR <60, 20% osteoporosis, 80% high blood pressure - (12/12/19)
     
  1893. Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study; Commentary: Thinking About Getting Older With Human Immunodeficiency Virus "HIV Clinics Need To Expand Services" - (12/12/19)
     
  1894. Ruth M. Rothstein CORE Center and Cook County Health HIV Integrated Program launch 'CORE Healthy Aging Initiative 2.0' - (12/12/19)
     
  1895. EACS: Integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in adipose tissue and adipocytes (12/12/19)
     
  1896. EACS: Comparable effectiveness of Raltegravir-based dual therapy versus other regimes in patients switched for maintenance (12/09/19)
     
  1897. EACS: Real World Utilisation of Raltegravir 1200mg Once Daily (The RETRO Study) (12/09/19)
     
  1898. Prevalence and 1-year incidence of frailty among women with and without HIV in the Women's Interagency HIV Study - (12/09/19)
     
  1899. Inflammaging: Discover the Fountain of Youth CFAR Miami Conference - (12/09/19)
     
  1900. ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available - (12/05/19)
     
  1901. People ageing with HIV face an uncertain future - (12/05/19)
     
  1902. HIV Outcomes Beyond Viral Suppression - Series Lancet HIV, - (12/05/19)
     
  1903. New Survey of Young Adults Uncovers Low Levels of Accurate Knowledge About HIV Transmission Coupled with High-Risk Sexual Behaviors - (12/05/19)
     
  1904. CT Fat Density Accurately Reflects Histologic Fat Quality in Adults With HIV On and Off Antiretroviral Therapy - Adipose/Fat Density & Quality - (12/05/19)
     
  1905. EACS: Depression and kynurenine/tryptophan ratio in people living with HIV (12/04/19)
     
  1906. EACS: Restless legs syndrome and health-related quality of life in HIV: results from the POPPY sleep substudy (12/04/19)
     
  1907. EACS: AIDS DEFINING AND NON-DEFINING CANCERS IN PERSONS LIVING WITH HIV IN A SINGLE CENTER COHORT FOLLOWED SINCE 1986 (12/04/19)
     
  1908. EACS: Non-Alcoholic Fatty Liver Disease is a significant predictor of cardiovascular risk in HIV-mono-infected patients (12/04/19)
     
  1909. EACS: Long-acting antiretroviral drugs / Marta Boffito MD (12/04/19)
     
  1910. Bisphosphonates and lower mortality risk, Heart Disease & Bone Disease Associated in HIV+ - (12/04/19)
     
  1911. Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults - (12/04/19)
     
  1912. EACS: Pharmacokinetics of Cabotegravir and Rilpivirine Long-Acting Injectables in HIV-Infected Individuals Through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies (12/02/19)
     
  1913. EACS: Prevalence of InSTI resistance and effectiveness of InSTI-based regimens in HIV-infected patients: results from a European cohort study (12/02/19)
     
  1914. EACS: HIV infection in individuals seeking post-exposure prophylaxis (PEP): a retrospective data linkage study (12/02/19)
     
  1915. EACS: Injectable Long Acting Antiretroviral for HIV Treatment or Prevention: The ANRS CLAPT Study (12/02/19)
     
  1916. EACS: Will HIV-infected patients Taking Oral ARV Switch to Long-Acting Injectable ART when It Becomes Available? (12/02/19)
     
  1917. IDWeek: Population Pharmacokinetic (PPK) Modeling and Simulation of Long-Acting (LA) Cabotegravir (CAB) to Inform Strategies Following Dosing Interruptions in HIV-1 Infected Subjects - (12/02/19)
     
  1918. EACS: POPULATION PHARMACOKINETIC ANALYSIS OF DOLUTEGRAVIR IN HIV/TB COINFECTED PEOPLE WITH AND WITHOUT RIFAMPICIN (11/26/19)
     
  1919. EACS: Dolutegravir-based regimens are associated with weight gain over two years following ART-initiation in ART-naïve people living with HIV (PLWH) (11/26/19)
     
  1920. EACS: POPULATION PHARMACOKINETIC ANALYSIS OF DOLUTEGRAVIR IN HIV/TB COINFECTED PEOPLE WITH AND WITHOUT RIFAMPICIN (11/26/19)
     
  1921. EACS: Characterizations of weight gain following antiretroviral regimen initiation in treatment-naïve individuals living with HIV (11/26/19)
     
  1922. EACS: Comparison of a Two-Drug Regimen (Dolutegravir/Rilpivirine) to Standard Three-Drug Regimens in Virologically Suppressed, Treatment Experienced Individuals in the Real World (11/26/19)
     
  1923. EACS: COPEDOL: a two-year French multicentric, observational, longitudinal retro-prospective study in pretreated HIV-1-infected patients starting dolutegravir based regimen due to treatment failure (11/26/19)
     
  1924. EACS: Baseline characteristics in JUNGLE, a German observational cohort study of Juluca as 2-Drug Regimen in virologically suppressed patients, compared to the phase-3 SWORD 1 & 2 study populations (11/26/19)
     
  1925. EACS: SWORD-1&-2: MAINTENANCE OR IMPROVEMENT IN RENAL FUNCTION IN PLWH THROUGH 148 WEEKS AFTER SWITCH TO THE DOLUTEGRAVIR + RILPIVIRINE 2-DRUG REGIMEN (11/26/19)
     
  1926. IWCADRH: Targeting Liver Fibrosis in Chronic Treated HIV with MitoQ - (11/26/19)
     
  1927. IWCADRH: Integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in adipose tissue and adipocytes - (11/26/19)
     
  1928. IWCADRH: Colonic microbiota exhibits disparate associations with HIV infection and sexual practices - (11/26/19)
     
  1929. IWCADRH: BESIDE - Age- and sex-related differences in concomitant diseases and use of co-medication in patients with treated HIV-infection in Germany - (11/26/19)
     
  1930. IWCADRH: Correlation between cerebrospinal fluid and plasma NfL in treated HIV infection in the COBRA study - (11/25/19)
     
  1931. EACS: A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V/I (GS-US-292-1824): Week 24 Results (11/25/19)
     
  1932. EACS: Changes in LDL After Switch from TDF to TAF in the U.S. (11/25/19)
     
  1933. EACS: Biologic Sex Is Not the Only Difference Between Men and Women: Data From the Doravirine Phase 2/3 Clinical Trials (11/25/19)
     
  1934. EACS: Islatravir Efficacy and Safety for Selected Demographic and Baseline Subgroups From a Phase 2 Trial In Treatment-naïve Adults With HIV-1 Infection (11/25/19)
     
  1935. EACS: Subclinical atherosclerosis burden by ultrasound in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors (11/22/19)
     
  1936. EACS: Retrospective analysis of co-medication patterns among patients treated for HIV, and potential interactions with antiviral treatment, in Norway during 2012-2018 using the Norwegian population-based prescription database (11/22/19)
     
  1937. EACS: Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies (11/22/19)
     
  1938. EACS: Unsupressed HIV in USA: 40% >55 Years Old Unsuppressed - CDC Reports (11/22/19)
     
  1939. EACS: Comparison of changes in bone microarchitecture with abacavir-lamivudine versus tenofovir disoproxil fumarate-emtricitabine in adults living with HIV Greater BMD Decline With TDF Than ABC, But Similar Drop in Trabecular Bone Score - Mark Mascolini (11/21/19)
     
  1940. EACS: The ADVANCE trial: the impact of DXA-assessed bone mineral density of TDF/FTC/EFV and TDF/FTC+DTG versus TAF/FTC+DTG South Africa - Mark Mascolini (11/21/19)
     
  1941. EACS: More Antimicrobial Prescriptions May Be Clue to Undiagnosed HIV - Mark Mascolini- (11/21/19)
     
  1942. EACS: Only 1% HIV Diagnosis Rate More Than 6 Months After PEP in 975 People - Mark Mascolini (11/21/19)
     
  1943. EACS: Incidence of CKD With TDF and Non-TDF Containing Antiretroviral Regimens by Baseline D:A:D CKD Risk In People Living With HIV - (11/20/19)
     
  1944. EACS: Outcomes of antiretrovirals used as the third drug in subgroups of treatment naïve individuals living with HIV - (11/18/19)
     
  1945. EACS: Baseline and Emergent Genotypic and Phenotypic Results in HIV-1-Infected, Heavily Treatment-Experienced (HTE) Participants Meeting Protocol-Defined Virologic Failure (PDVF) Criteria Through Week 96 in the Fostemsavir (FTR) Phase 3 BRIGHTE Study - (11/18/19)
     
  1946. EACS: Impact of Susceptibility Scoring on Virologic Response in Heavily Treatment-Experienced Participants with HIV-1 Receiving a Fostemsavir-Based Antiretroviral Regimen: Week 96 Results from the Randomized Cohort of the Phase 3 BRIGHTE Study - (11/18/19)
     
  1947. EACS: Absence of Naturally Existing Resistance Against The HIV-1 Capsid Inhibitor GS-6207 in HIV-1 Primary Isolates - (11/18/19)
     
  1948. EACS: Impact of Susceptibility Scoring on Virologic Response in Heavily Treatment-Experienced Participants with HIV-1 Receiving a Fostemsavir-Based Antiretroviral Regimen: Week 96 Results from the Randomized Cohort of the Phase 3 BRIGHTE Study - (11/18/19)
     
  1949. EACS: Absence of Naturally Existing Resistance Against The HIV-1 Capsid Inhibitor GS-6207 in HIV-1 Primary Isolates - (11/18/19)
     
  1950. EACS: HIV-1 from antiretroviral-naïve and experienced patients lack capsid substitutions associated with GS-6207 in vitro resistance - (11/18/19)
     
  1951. EACS: Phase 3 Randomized, Controlled DISCOVER Study of Daily F/TAF or F/TDF for HIV Pre-exposure Prophylaxis: Week 96 Results - (11/14/19)
     
  1952. EACS: Longer ART Linked to Clearance of High-Risk HPV in MSM With HIV - Mark Mascolini - (11/14/19)
     
  1953. EACS: Rapid Initiation of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Patients With Human Immunodeficiency Virus (HIV)-1 Infection: Age, Race/Ethnicity, and Gender Subgroup Analyses From the DIAMOND Study - (11/14/19)
     
  1954. EACS: Prevalence of Archived HIV-1 DNA Resistance-associated Mutations and their Lack of Effect on Virologic Outcome at Week 96 in Antiretroviral Treatment-experienced, Virologically Suppressed Patients Receiving the Once-daily, Single-tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in the EMERALD Phase III Trial - (11/14/19)
     
  1955. EACS: Short-term Neuropsychiatric Tolerability of Bictegravir Combined with FTC/TAF in Clinical Practice - (11/14/19)
     
  1956. EACS: EACS New Aging/Screening Guidelines / HIV+ Case 69 Year Old Aging in Spain - Brighton UK Geriatric HV Clinic - (11/14/19)
     
  1957. EACS: Maintenance DTG/3TC Controls HIV in People With Historical 3TC Resistance "Dolutegravir and lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a pilot clinical trial (ART-PRO)" - Mark Mascolini - (11/14/19)
     
  1958. EACS: More Than Half of Adult Group With Perinatal HIV Have Neurocognitive Impairment - Mark Mascolini - (11/13/19)
     
  1959. EACS: Fibrosis, Steatosis, and NAFLD Boost Odds of Frailty in HIV Group - Mark Mascolini (11/13/19)
     
  1960. EACS: Short-term Neuropsychiatric Tolerability of Bictegravir Combined with FTC/TAF in Clinical Practice - (11/13/19)
     
  1961. EACS: Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in routine clinical practice - (11/13/19)
     
  1962. EACS: Dolutegravir (DTG) Use During Pregnancy and Birth Outcomes: Data from the Antiretroviral Pregnancy Registry (APR) - (11/13/19)
     
  1963. EACS: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN THROUGH 48 WEEKS: SUBGROUP ANALYSES FROM THE TANGO STUDY - (11/13/19)
     
  1964. EACS: Precancer Anal Lesion Arises in 10% of Australian MSM--But Clearance Common - Mark Mascolini - (11/13/19)
     
  1965. EACS: Phase 3 Randomized, Controlled DISCOVER Study of Daily F/TAF or F/TDF for HIV Pre-exposure Prophylaxis: Week 96 Results - (11/13/19)
     
  1966. EACS: Safety and Efficacy of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People With HIV Aged 50 Years and Older - (11/12/19)
     
  1967. EACS: DISCOVER in Europe: a Subanalysis of the Phase 3, Randomized, Controlled Trial of Daily Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-exposure Prophylaxis - (11/12/19)
     
  1968. EACS: Long-term Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in ART-Naïve Adults - (11/12/19)
     
  1969. EACS: Switching to Bictegravir/Emtricitabine/TenofovirAlafenamide(B/F/TAF) in Adults Aged ≥ 65 Years: Week 48 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449) - (11/12/19)
     
  1970. EACS: Sustained Viral Suppression among Participants with Pre-existing M184V/I Who Switched to Bictegravir/Emtricitabine/TenofovirAlafenamide - (11/12/19)
     
  1971. EACS: Risk Score Predicts Diabetes Better Than HOMA-IR and Other Equations "Comparing a risk score against physiological markers for predicting diabetes incidence in HIV+ individuals" - (11/12/19)
     
  1972. EACS: New HIV Comorbidity Index Linked to Mortality, Can Outperform Other Tools - (11/12/19)
     
  1973. EACS: One Third of MSM PrEP Users in French Analysis Quit in 30 Months - Mark Mascolini - (11/12/19)
     
  1974. EACS: Switch From TDF to TAF in HIV/HBV+ Maintains Viral Control, Helps Kidneys - Mark Mascolini (11/12/19)
     
  1975. EACS: INI Resistance Remains Rare in INI-Naive--Initial CD4, Viral Load Predict Failure - Mark Mascolini - (11/12/19)
     
  1976. EACS: Integrase Inhibitors Tied to Weight Gain, Hepatic Steatosis in Longitudinal Cohort - Mark Mascolini - (11/12/19)
     
  1977. EACS: Is modern antiretroviral therapy causing weight gain? - (11/12/19)
     
  1978. EACS: Prevalence of and risk factors for low Bone Mineral Density assessed by Quantitative Computed Tomography in people living with HIV and uninfected controls Very Low BMD More Frequent With HIV--But Not After Statistical Adjustment - Mark Mascolini - (11/12/19)
     
  1979. EACS: Single Doses of Long-Acting Capsid Inhibitor GS-6207 Administered by Subcutaneous Injection Are Safe and Efficacious in People Living With HIV - (11/12/19)
     
  1980. EACS: GS-6207 Long Acting Capsid Inhibitor Safety & PK Subcutaneous - (11/12/19)
     
  1981. EACS: Safety and Efficacy of Triple Therapy with Dolutegravir plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Patients - 48 weeks results from a Phase II Study in Portugal - (11/12/19)
     
  1982. EACS: Non inferiority of dolutegravir+emtricitabine dual therapy to standard combination antiretroviral therapy in maintaining HIV suppression throughout 48 weeks: The SIMPL'HIV study - (11/12/19)
     
  1983. EACS: The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC+DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV Weight Keeps Rising Through 96 Weeks With TAF/FTC+DTG in Black Africans - (11/12/19)
     
  1984. EACS: ASSESSMENTS OF VERY-LOW-LEVEL HIV REPLICATION FOR DOLUTEGRAVIR + LAMIVUDINE (DTG + 3TC) VS DOLUTEGRAVIR + TENOFOVIR DISOPROXIL/EMTRICITABINE (DTG + TDF/FTC) IN THE GEMINI-1&-2 STUDIES THROUGH WEEK 96 - (11/08/19)
     
  1985. EACS: Uptake and discontinuation of Integrase Inhibitors (INSTIs) in a large cohort setting (DTG, EVG, RAL) DTG Easily Most Popular INI Across Europe, With Lowest Quitting Rate - Mark Mascolini (11/08/19)
     
  1986. EACS: Changes in bone mineral density in men who have sex with men on tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis: longitudinal cohort data - (11/08/19)
     
  1987. EACS: BMD Drops More Than 3% in up to One Third of MSM Using TDF PrEP for 2 Years - Mark Mascolini - (11/08/19)
     
  1988. EACS: Maintenance DTG/3TC Controls HIV in People With Historical 3TC Resistance "Dolutegravir and lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a pilot clinical trial (ART-PRO)" - Mark Mascolini - (11/08/19)
     
  1989. EACS: Changes in weight after switching to dolutegravir containing antiretroviral therapy in the Swiss HIV Cohort Study - (11/08/19)
     
  1990. EACS: Shorter time to treatment failure in PLHIV switched to dolutegravir plus either rilpivirine or lamivudine compared to integrase inhibitor-based triple therapy in a large Spanish cohort - VACH Doubled Failure Risk After Switch to DTG/RPV or DTG/3TC Versus Triple-INI Regimen - Mark Mascolini - (11/08/19)
     
  1991. EACS: Menopause Does Not Affect HIV or CD4 Response in Multicenter Spanish Group - Mark Mascolini - (11/08/19)
     
  1992. EACS: Pregnancies and Live Births Stable/Rising Since 2002 in European Women With HIV - Mark Mascolini - (11/08/19)
     
  1993. EACS: Outcomes for Women in Phase 3 Trials of Long-Acting Cabotegravir + Rilpivirine: Pooled ATLAS and FLAIR Week 48 Results - (11/08/19)
     
  1994. EACS: Are new antiretroviral treatments increasing the risks of obesity? - (11/08/19)
     
  1995. EACS: Long-term Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in ART-Naïve Adults - (11/08/19)
     
  1996. EACS: Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide vs comparators in cis-women and girls (living with HIV): an analysis of 5 clinical trials - Mark Mascolini - (11/07/19)
     
  1997. EACS: Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen Through 48 Weeks: Subgroup Analyses From the TANGO Study - (11/07/19)
     
  1998. EACS: Once-a-Month CAB/RPV Effective in Women--Fewer Adverse Events Than Men - Mark Mascolini - (11/07/19)
     
  1999. EACS: Incidence of CKD with TDF and non-TDF containing antiretroviral regimens by baseline D:A:D CKD risk in people living with HIV (PLWH) - Mark Mascolini - (11/07/19)
     
  2000. EACS: Modest 96-Week Weight Gain in Trials of Doravirine, Darunavir, Efavirenz "EFFECT OF DORAVIRINE ON BODY WEIGHT AND BODY MASS INDEX IN TREATMENT NAïVE ADULTS WITH HIV-1" - Mark Mascolini - (11/07/19)
     
  2001. EACS: Weight Keeps Rising Through 96 Weeks With TAF/FTC+DTG in Black Africans - ADVANCE Study - Mark Mascolini - (11/07/19)
     
  2002. EACS: Delayed Weight Gain in Immediate Versus Deferred ART Arm in START - "Antiretroviral therapy and body weight in the START (Strategic Timing of Antiretroviral Treatment) trial" - Mark Mascolini - (11/07/19)
     
  2003. EACS: Switch to INI Does Not Affect Average Weight Gain in Middle-Aged/Older Group - Mark Mascolini - (11/07/19)
     
  2004. EACS: Will HIV-infected patients Taking Oral ARV Switch to Long-Acting Injectable ART when It Becomes Available? - (11/06/19)
     
  2005. EACS: Outcomes of antiretrovirals used as the third drug in subgroups of treatment naïve individuals living with HIV - (11/06/19)
     
  2006. EACS: Gilead's Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials - (11/06/19)
     
  2007. EACS: Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP® - (11/06/19)
     
  2008. EACS: EACS 2019: ViiV Healthcare to present 17 abstracts from its portfolio addressing the diverse needs of people living with HIV - PRESS RELEASE - (11/06/19)
     
  2009. EACS: Screening Program Cuts Anal Cancer Precursor Rate in 405 MSM With HIV - Mark Mascolini (11/06/19)
     
  2010. EACS: Long-term Antilipid Therapy Tied to 70% Lower Death Risk in VA Cohort - Mark Mascolini (11/06/19)
     
  2011. EACS: French Studies Find Eagerness for Long-Term Injectables--With Key Cautions - Mark Mascolini (11/06/19)
     
  2012. EACS: No Change in Kidney Function, Cholesterol Ratio, or Weight When 60+ Group Switches to TAF - Mark Mascolini (11/06/19)
     
  2013. EACS: Response Differences Between First-Line Regimens in Large European Group - Mark Mascolini (11/06/19)
     
  2014. Letter from Gilead to Community: Facts About Gilead's PrEP Medications Donation to Help Support Ending the HIV Epidemic Efforts - (11/04/19)
     
  2015. Screening for Anal Cancer in the Population Living With Human Immunodeficiency Virus: A Step Closer? - EDITORIAL - (11/04/19)
     
  2016. Adjudicated Heart Failure in HIV-Infected and Uninfected Men and Women - (11/04/19)
     
  2017. Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive Considerations - (11/04/19)
     
  2018. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era - Results From the Veterans Aging Cohort Study - (11/04/19)
     
  2019. AGE: Aging Workshop Report : DNA Methylation : Heart Disease ; Kidney Disease - Christina K. Psomas MD - (11/01/19)
     
  2020. AGE: The Utility of Olfactory Function in Distinguishing Early Stage Alzheimer's Disease from HIV-associated Neurocognitive Disorder: A Pilot Study - (11/01/19)
     
  2021. AGE: Lipidome abnormalities and altered macrophage phenotype may contribute to cardiovascular disease risk in the aging HIV population - (11/01/19)
     
  2022. AGE: FRAILTY PHENOTYPE IN OLDER VIROLOGICALLY SUPPRESSED PLWH IS STRONGLY CORRELATED WITH SPECIFIC COMORBIDITIES AND TOBACCO USE - (11/01/19)
     
  2023. Bictegravir with Pre-Existing NRTI Resistance - (10/29/19)
     
  2024. Time to change cardiovascular prevention in people with HIV - A more pragmatic approach is the direct measurement of cIMT to construct cIMT-based monitoring and prevention guidelines for HIV-positive people - comment - (10/25/19)
     
  2025. Editorial - Antiretroviral Monotherapy for HIV: Game Over or Future Perspectives? - (10/25/19)
     
  2026. Brain Dysfunction/HIV-Neurologic Decline Shifting - (10/25/19)
     
  2027. Tesamorelin, liver fat, and NAFLD in the setting of HIV - Comment / Tesamorelin Prevented Progression to Liver Fibrosis in NIH Study - (10/25/19)
     
  2028. AGE: Pharmacokinetics of Cabotegravir and Rilpivirine Long-Acting Injectables in HIV-Infected Individuals Through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies - (10/24/19)
     
  2029. AGE: Frailty, Physical Function Impairment, Comorbidity Burden, and Falls are Predictive of Mortality Among Middle-Aged Adults with HIV - (10/24/19)
     
  2030. AGE: Slide Presentations - 10th HIV & Aging 2019 - (10/24/19)
     
  2031. AGE: Senescence-Associated β-Galactosidase Activity and Other Markers of Senescence in Human Peripheral Blood Immune Cells During Healthy Aging and HIV-Infection - (10/24/19)
     
  2032. IDWeek 2019: Diabetes/Weight Gain; NASH, Ethnicity in HIV+ at IDWeek 2019 Oct 2-6 Wash DC (10/24/19)
     
  2033. IDWeek 2019: Experiences and Emotional Challenges of Antiretroviral Treatment - Findings from the Positive Perspectives Study (10/24/19)
     
  2034. IDWeek 2019: "I feel empowered": Women's perspectives on and experiences with long-acting injectable anti-retroviral therapy in the United States and Spain (10/24/19)
     
  2035. IDWeek 2019: Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment Among People Living With HIV (10/24/19)
     
  2036. IDWeek 2019: PERCEPTIONS OF AND PREFERENCES FOR ORAL OR LONG-ACTING INJECTABLE ANTIRETROVIRAL TREATMENT REGIMENS IN THE UNITED STATES AND CANADA (10/24/19)
     
  2037. AGE: LONG-TERM PRE-HAART SURVIVORS OF HIV: A SPECIFIC GROUP WITH SPECIFIC NEEDS - 'high rates of mental & physical impairments' - (10/23/19)
     
  2038. AGE: Food Insecurity and Frailty among Women Living with or At-risk for HIV in the U.S. - 40% WIHS Women Have Food Insecurity - where us Ryan White Care Act? - No Safety Net - (10/23/19)
     
  2039. AGE: What is the lived experience of loneliness in older men living with HIV? A qualitative analysis to guide service development - (10/23/19)
     
  2040. AGE: Magnetic Resonance Spectroscopy Evidence of Accelerated Aging in Virally-Suppressed HIV - (10/23/19)
     
  2041. AGE: Poorer Muscle Quality and Quantity with ART Initiation is Associated with Greater Inflammation and Immune Activation - (10/21/19)
     
  2042. AGE: Blunted Increase in Muscle Mass After Exercise Training in People Aging with HIV - (10/21/19)
     
  2043. AGE: Frailty But Not HIV Tied to Falls in Large Group of Older US Women - Mark Mascolini (10/21/19)
     
  2044. IDWeek 2019: Grindr™ Use Correlates with HIV Risk & PrEP Use in Men who Have Sex with Men, San Diego (10/21/19)
     
  2045. IDWeek 2019: Clinical outcomes of patients treated with Dolutegravir functional monotherapy or Dolutegravir plus an active non-cytosine nucleoside analog: a retrospective observational cohort study of treatment-experienced patients (10/21/19)
     
  2046. IDWeek 2019: Pooled Resistance Analyses of Darunavir (DRV) Once-daily (QD) Regimens and Formulations Across 10 Clinical Studies of Treatment-naïve (TN) and Treatment-experienced (TE) Patients With Human Immunodeficiency Virus (HIV)-1 Infection (10/21/19)
     
  2047. IDWeek 2019: Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance associated mutations through 48 weeks of treatment (10/21/19)
     
  2048. IDWeek 2019: Epigenetic Age Acceleration and Non-AIDS Defining Cancers Among HIV Infected Adults (10/21/19)
     
  2049. IDWeek 2019: The Utility of Olfactory Function in Distinguishing Early Stage Alzheimer's Disease from HIV-associated Neurocognitive Disorder: A Pilot Study........"supports that these PLWH may be on an AD-like cognitive trajectory" (10/21/19)
     
  2050. ViiV HEALTHCARE SUBMITS NEW DRUG APPLICATION TO US FDA FOR THE FIRST MONTHLY, INJECTABLE, TWO-DRUG REGIMEN OF CABOTEGRAVIR AND RILPIVIRINE FOR TREATMENT OF HIV - (10/18/19)
     
  2051. Diabetes/Weight Gain; NASH, Ethnicity in HIV+ at IDWeek 2019 Oct 2-6 Wash DC - (10/18/19)
     
  2052. Injectable Cabotegravir/Rilpivirine, Oral - FDA, EMA - (10/18/19)
     
  2053. Letter from Gilead - PrEP Study in Cisgender Women and Adolescent Females - (10/18/19)
     
  2054. FDA NEWS RELEASE - FDA approves second drug (TAF) to prevent HIV infection as part of ongoing efforts to end the HIV epidemic - (10/18/19)
     
  2055. Ageing with and without HIV: will advanced age bring equity or greater disparity? Perspective by Amy Justice - (10/18/19)
     
  2056. AGE: Blunted Increase in Muscle Mass After Exercise Training in People Aging with HIV - (10/17/19)
     
  2057. AGE: Frailty phenotype is associated with antiretroviral exposure among older persons living with HIV. - (10/17/19)
     
  2058. AGE: Comorbidities Are Key Frailty Risk Factors in Older French Group With HIV - Mark Mascolini (10/17/19)
     
  2059. AGE: Real-World Use of Ibalizumab in Physician Office infusion Centers (POICs) - (10/17/19)
     
  2060. AGE: The association between mitochondrial DNA copy number and longitudinal lung function decline among people with or at risk of HIV - Mark Mascolini (10/17/19)
     
  2061. AGE: Supplemental Testosterone Contributes to Strength Differences in Men With vs Without HIV - Mark Mascolini (10/17/19)
     
  2062. AGE: Characteristics Associated with Exercise Adherence in the Setting of a Supervised Intervention - (10/17/19)
     
  2063. AGE: HIV+ People Who Need Exercise More Are Less Likely to Adhere to Program - Mark Mascolini (10/17/19)
     
  2064. AGE: Physical Function, Falls, Comorbidity > Predict Death in Middle-Aged With HIV - Mark Mascolini (10/17/19)
     
  2065. AGE: Elevated Cardiac Risk Score by ASCVD Calculation is Associated with Albuminuria in Older People Living with HIV - (10/17/19)
     
  2066. AGE: Elevated Cardiac Risk Score by ASCVD Calculation is Associated with Albuminuria in Older People Living with HIV - (10/17/19)
     
  2067. AGE: Elevated Albuminuria Tied to ASCVD Risk in Older People With HIV - (10/17/19)
     
  2068. IDWeek 2019: FRAILTY PHENOTYPE IN OLDER VIROLOGICALLY SUPPRESSED PLWH IS STRONGLY CORRELATED WITH SPECIFIC COMORBIDITIES AND TOBACCO USE (10/17/19)
     
  2069. IDWeek 2019: Real-World Use of Ibalizumab in Physician Office infusion Centers (POICs) (10/17/19)
     
  2070. IDWeek 2019: Do People With HIV Have to Exercise Harder to Get Same Muscle Benefit? - Mark Mascolini (10/17/19)
     
  2071. IDWeek 2019: Implementation of an HIV and Aging Clinical Program / A Geriatrician's Approach To Aging With HIV (10/16/19)
     
  2072. IDWeek 2019: Iceland Making Progress Toward Eliminating HCV--But Challenges Remain - Mark Mascolini (10/16/19)
     
  2073. IDWeek 2019: Attaining SVR Drives Lower Liver Mortality With Treatment of HCV - Mark Mascolini (10/16/19)
     
  2074. IDWeek 2019: BMI Jumps Slightly With Major Maintenance Regimens, Not Just Integrase Drugs - Mark Mascolini (10/16/19)
     
  2075. IDWeek 2019: Hepatic Steatosis in People Living with HIV - Effect of Sex and Race/Ethnicity - (10/16/19)
     
  2076. IDWeek 2019: T Cell Subsets Associated with Diabetes in Veterans With and Without HIV - (10/16/19)
     
  2077. IDWeek 2019: Online US/Canada Survey Finds Preference for Long-Acting Injectable ART - Mark Mascolini (10/16/19)
     
  2078. IDWeek 2019: Gilead Presents New Data From the Company's HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019 - (10/16/19)
     
  2079. IDWeek 2019: The Effect of Initiating INSTI-based vs. NNRTI-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care - (10/16/19)
     
  2080. AGE: Physical Function, Falls, Comorbidity Predict Death in Middle-Aged With HIV - Mark Mascolini - (10/15/19)
     
  2081. IDWeek 2019: Household Income and its Relationship with Patient-reported Outcomes among Older People Living with HIV - (10/15/19)
     
  2082. IDWeek 2019: Characteristics Associated with Pre-Frailty in Older People Living with HIV (47% Pre-Frailty) - (10/15/19)
     
  2083. IDWeek 2019: Poor Mental Health & Quality of Life in Virally Suppressed HIV+ - (10/15/19)
     
  2084. IDWeek 2019: Durable Efficacy of Two-Drug Regimen of DTG + 3TC in Antiretroviral Treatment-Naive Adults With HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies - (10/15/19)
     
  2085. IDWeek 2019: Long-Term Efficacy, Safety and Durability of CAB and RPV as Two-Drug Oral Maintenance Therapy - LATTE Week 312 Results - (10/15/19)
     
  2086. IDWeek 2019: Antiretroviral Therapy Anchor-based Trends in Body Mass Index following Treatment Initiation among Military Personnel with HIV - (10/11/19)
     
  2087. IDWeek 2019: Weight Change Associated with Switching to Integrase Strand Transfer Inhibitor-based Antiretroviral Regimens in HIV-positive Subjects - (10/11/19)
     
  2088. IDWeek 2019: Real world utilization of ibalizumab (IBA) without an optimized background regimen (OBT) - (10/11/19)
     
  2089. IDWeek 2019: IBALIZUMAB EFFICACY AND SAFETY THROUGH 48 WEEKS OF TREATMENT: RESULTS OF AN EXPANDED ACCESS PROTOCOL (TMB-311) - (10/11/19)
     
  2090. IDWeek 2019: Drug Injectors Accept and Use Naloxone Offered at HCV Visits - Mark Mascolini (10/11/19)
     
  2091. IDWeek 2019: BMI and ASCVD Risk Score Changes in Virologically Suppressed Patients with HIV Infection Switching from TDF to TAF Containing ART - (10/11/19)
     
  2092. IDWeek 2019: PrEP Linked to Lower HIV Incidence in US, Independent of TasP - Mark Mascolini (10/11/19)
     
  2093. IDWeek 2019: Long-Term Efficacy, Safety and Durability of CAB and RPV as Two-Drug Oral Maintenance Therapy - LATTE Week 312 Results - (10/8/19)
     
  2094. IDWeek 2019: Effects of Integrase Strand-Transfer Inhibitor Use on Lipids, Glycemic Control, and Insulin Resistance in the Women's Interagency HIV Study (WIHS) - (10/8/19)
     
  2095. IDWeek 2019: A Geriatrician's Approach to People Aging with HIV - Co-Morbidities and Aging - (10/8/19)
     
  2096. IDWeek 2019: The prevalence and burden of non-aids comorbidities in women with or at-risk for hiv infection in the united states - (10/8/19)
     
  2097. IDWeek 2019: Risk of type-2 diabetes mellitus after initiating integrase and protease inhibitors in individuals living with HIV in the United States - (10/8/19)
     
  2098. IDWeek 2019: Changes in BMI associated with antiretroviral regimens in treatment-experienced, virologically suppressed individuals living with HIV - (10/8/19)
     
  2099. IDWeek 2019: Renal Outcomes for Participants Taking F/TAF versus F/TDF for HIV PrEP in the DISCOVER Trial - (10/8/19)
     
  2100. IDWeek 2019: Longer-Term Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically-Suppressed Adults Living With HIV and End Stage Renal Disease on Chronic Hemodialysis - (10/8/19)
     
  2101. IDWeek 2019: Oral Cabotegravir and Rilpivirine Durable for 5.5 Years in LATTE Trial - Mark Mascolini (10/8/19)
     
  2102. IDWeek 2019: PrEP Significantly Reduces the Rate of New HIV Diagnoses in US Metropolitan Statistical Areas independent of Treatment as Prevention (2012-2017) - (10/8/19)
     
  2103. IDWeek 2019: A Comparison Study of Prevalence and Risk Factors for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) by Transient Elastography (TE) in HIV Infected Patients - (10/8/19)
     
  2104. IDWeek 2019: Initial DTG+3TC Noninferior to DTG+TDF/FTC - Mark Mascolini (10/8/19)
     
  2105. IDWeek 2019: Pregnancy outcomes following raltegravir exposure - Mark Mascolini (10/8/19)
     
  2106. IDWeek 2019: Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies - (10/8/19)
     
  2107. IDWeek 2019: Experiences and Emotional Challenges of Antiretroviral Treatment - Findings from the Positive Perspectives Study - (10/8/19)
     
  2108. IDWeek 2019: Fostemsavir Interaction Study Flags Strong CYP3A Inducers, Statins, Oral Contraceptives - Mark Mascolini (10/8/19)
     
  2109. IDWeek 2019: Older and Transgender People Less Likely to Get Integrase Drugs in Big DC Cohort - Mark Mascolini (10/8/19)
     
  2110. IDWeek 2019: HIV Care Continuum Outcomes among newly diagnosed PLWH in Washington, DC - (10/7/19)
     
  2111. IDWeek 2019: ART Adherence Falls Over 4 Years in 15,000 Insured People in US - Mark Mascolini (10/7/19)
     
  2112. IDWeek 2019: Bone Safety Outcomes With F/TAF vs F/TDF for PrEP in the DISCOVER Trial - (10/7/19)
     
  2113. IDWeek 2019: Durable Efficacy of Two-Drug Regimen of DTG + 3TC in Antiretroviral Treatment-Naive Adults With HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies - (10/7/19)
     
  2114. IDWeek 2019: Weight Rises--But Lipids and HbA1c Don't--After Switch to Integrase Drugs - Mark Mascolini (10/7/19)
     
  2115. IDWeek 2019: High PrEP Uptake, Good Follow-up, With Mobile Screening in Florida - Mark Mascolini (10/7/19)
     
  2116. IDWeek 2019: Mental Health, Quality of Life, and Accessibility to Care Among Virally-Suppressed People Living With HIV in the United States - (10/7/19)
     
  2117. IDWeek 2019: High Rates of Virologic Suppression Achieved in HIV-1-infected Adults Rapidly Starting Antiretroviral Therapy (ART) With the Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial - (10/7/19)
     
  2118. IDWeek 2019: The Effect of Initiating INSTI-based vs. NNRTI-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care - (10/7/19)
     
  2119. IDWeek 2019: Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate in Hispanic/Latinx and Black Participants: Efficacy, Bone and Renal Safety Results From a Pooled Analysis of 7 Clinical Trials - (10/7/19)
     
  2120. IDWeek 2019: Bone Safety Outcomes With F/TAF vs F/TDF for PrEP in the DISCOVER Trial - (10/7/19)
     
  2121. IDWeek 2019: Switching From TDF to TAF Tied to Higher BMI and Cardio Risk - Mark Mascolini (10/7/19)
     
  2122. IDWeek 2019: Online US/Canada Survey Finds Preference for Long-Acting Injectable ART - Mark Mascolini (10/4/19)
     
  2123. IDWeek 2019: Community Clinics Control HIV as Well as Hospital Clinic in Chicago MSM - Mark Mascolini (10/4/19)
     
  2124. IDWeek 2019: Possible Higher Diabetes Risk With INSTIs or PIs Than NNRTIs - Mark Mascolini (10/4/19)
     
  2125. IDWeek 2019: AIDS Mortality Does Not Differ by Race in US Group--But "Room for Improvement" - Mark Mascolini (10/4/19)
     
  2126. IDWeek 2019: MSM Grindr Users Take More Sex Risks But Seem More Open to PrEP - Mark Mascolini (10/4/19)
     
  2127. IDWeek 2019: Over Half of Mostly Black US HIV Group Has NAFLD--and Many Have NASH - Mark Mascolini (10/4/19)
     
  2128. IDWeek 2019: High HIV Control Rate With Rapid D/C/F/TAF in Newly Diagnosed - Mark Mascolini (10/4/19)
     
  2129. IDWeek 2019: HIV Suppression and Safety With Ibalizumab at 48 Weeks in Expanded Access - Mark Mascolini (10/4/19)
     
  2130. IDWeek 2019: Women With HIV and Prolonged Amenorrhea Run Higher Risk of Hip Bone Loss - Mark Mascolini (10/4/19)
     
  2131. IDWeek 2019: Lower Statin Prescription Rate for Blacks, Hispanics With HIV in US Military - Mark Mascolini (10/4/19)
     
  2132. IDWeek 2019: Syphilis, Gonorrhea Tied to HCV in MSM and Trans Women With HIV - Mark Mascolini (10/4/19)
     
  2133. IDWeek 2019: Higher Steatosis Risk in HIV+ Hispanics, But No Link to Integrase Inhibitors - Mark Mascolini (10/4/19)
     
  2134. IDWeek 2019: Lower Screening Rates for Breast and Cervical Cancer in Women With HIV - Mark Mascolini (10/4/19)
     
  2135. IDWeek 2019: High HIV Control Rate With Rapid D/C/F/TAF in Newly Diagnosed - Mark Mascolini (10/4/19)
     
  2136. IDWeek 2019: IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV - (10/03/19)
     
  2137. IDWeek 2019: IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV - (10/03/19)
     
  2138. Ageing with and without HIV: will advanced age bring equity or greater disparity? Perspective by Amy Justice - (10/03/19)
     
  2139. Reversal of epigenetic aging and immunosenescent trends in humans - (09/25/19)
     
  2140. HIV and Aging - Primary and secondary prevention of coronary artery disease among People living with HIV - HIV+ higher death risk after stroke or MI - (09/25/19)
     
  2141. Coronary atherosclerosis characteristics in HIV-infected patients on long-term antiretroviral therapy insights from coronary computed tomography-angiography - (09/24/19)
     
  2142. Excess heart age in adult outpatients in routine HIV care (HOPS) - excess heart age by 10-13 Years in HIV+ - (09/24/19)
     
  2143. Merck's PIFELTRO (doravirine) and DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed - (09/23/19)
     
  2144. Aging with HIV in the US / Proposed Research Implementation Study: clinical & community care & services needs, unmet needs - Jules Levin (09/23/19)
     
  2145. Two Thirds Higher Risk of Death After MI or Stroke With HIV in Sweden - Mark Mascolini (09/19/19)
     
  2146. New Analysis Challenges FRAX Use to Predict Osteoporosis in 40-to-49 HIV Group - Mark Mascolini (09/19/19)
     
  2147. Rates and Drivers of Quality of Life With HIV Differ in Netherlands and UK - Mark Mascolini (09/19/19)
     
  2148. Quality of Life in HIV+ in US & Globally: most unhappy - (09/13/19)
     
  2149. NEF, HIV Protein Causes CVD, Metabolic Abnormalities, Brain Disease - found in Reservoir - (09/13/19)
     
  2150. Inflammation in HIV+ Causes Mood Emotions Changes & Alters Social Interaction - (09/09/19)
     
  2151. Doxycycline prophylaxis for bacterial sexually transmitted infections - Review - (09/09/19)
     
  2152. Stigma and mental health challenges remain barriers to good quality of life for people living with HIV in urban settings - (09/09/19)
     
  2153. Mental health and HIV/AIDS the need for an integrated response. Depression Doubles Mortality in WIHS Women - (09/09/19)
     
  2154. Impact of inclisiran on LDL-C over 18 months in patients with ASCVD or risk-equivalent - Results of the Phase 3 ORION-11 trial - (09/09/19)
     
  2155. siRNA drug safely halved LDL cholesterol in phase 3 ORION-11 - (09/09/19)
     
  2156. (Phase 2 ) Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol (single dosing) - (09/09/19)
     
  2157. Treating Disease at the RNA Level with Oligonucleotides (siRNA) - Review - (09/09/19)
     
  2158. In People Living with HIV (PLWH), Menopause (natural or surgical) Contributes to the Greater Symptom Burden in Women: results from an online US survey - (09/06/19)
     
  2159. 9th Annual International Workshop on HIV & Aging 2018 Summary / Review
    Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and Aging     - (09/06/19)
     
  2160. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV - (09/05/19)
     
  2161. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV - (09/05/19)
     
  2162. ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months - (09/05/19)
     
  2163. Cannabis Anti-Inflammatory/Reservoir Reduction(Cure)? - (09/05/19)
     
  2164. New ways of developing treatment of chronic inflammation - (09/04/19)
     
  2165. People Living With HIV in New York City Still Dying From Infections, Not Just Old Age - (09/04/19)
     
  2166. What is Frailty ? Burden of frailty in the elderly population: perspectives for a public health challenge - (09/04/19)
     
  2167. HIV+ 70-74 Have Same # of Comorbidities as HIV-Neg >85, Similarly for polypharmacy. Medicare study Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis - (09/04/19)
     
  2168. HIV in Atlanta/Georgia-Aging - (09/04/19)
     
  2169. 75-85% in SF-NY-Florida-Boston with HIV Are Over 40 Years Old....25% over 60 in SF-Florida-NY - (09/04/19)
     
  2170. Cardiovascular risk of smoking may last up to 25 years, new study - (09/04/19)
     
  2171. Neurpoathy Predictors in HIV in CHARTER Group - (09/04/19)
     
  2172. IAS: Hormonal control of HIV-1 latency by estrogen imparts gender-specific restrictions on the latent reservoir - (09/03/19)
     
  2173. IAS: Symptom Burden and Inflammatory Cytokines in PLWH in the US: an analysis by sex, menopause stage and menstrual cycle phase - (09/03/19)
     
  2174. IAS: Smoking and High HIV Viremia Damage Mitochondrial DNA and May Accelerate mtDNA Aging - (09/03/19)
     
  2175. IAS: 10th International AIDS Society Conference on HIV Science - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA (09/03/19)
     
  2176. IAS: TDF/FTC Pre-Exposure Prophylaxis (PrEP) from 2012 to 2018 in the OPERA Cohort - (08/16/19)
     
  2177. IAS: Cost-effectiveness of Dolutegravir in HIV-1 Treatment-Naive Patients in Mexico - (08/16/19)
     
  2178. IAS: Changing Rates of Heavily Treatment Experienced Persons with HIV in the United States, 2000-2017 - (08/16/19)
     
  2179. IAS: Is DTG+3TC and DTG+RPV Effective and Safe in Clinical Practice? Evidence From Real World Data - (08/16/19)
     
  2180. IAS: High HIV incidence among young women in South Africa: data from the ECHO trial - (08/14/19)
     
  2181. A Novel Therapeutic (NTRX-07) Targeting Neuroinflammation in Alzheimer's disease is Undergoing Phase I trials - (08/14/19)
     
  2182. Dementia/Sleep Aids-Drugs/Women HIV+ More Vulnerable - "Sleep aids and dementia: Studies find both risks and benefits" - (08/14/19)
     
  2183. Increased Risk of Subjective Cognitive Decline in the LGBT Community - (08/14/19)
     
  2184. 18-Month Results (Open Label Extension) of a Phase 2/3 Trial of Inhaled Insulin in People With MCI or Mild Alzheimer's - (08/14/19)
     
  2185. IAS: Shorter CD8 T Cell Subset Telomeres and Lower Proliferative:Senescent CD8 Ratio in People with Chronic/Latent Viral Coinfections - (08/13/19)
     
  2186. IAS: PrEP use in young African women in HPTN 082: Effect of drug level feedback - (08/13/19)
     
  2187. IAS: HIV Prevention at IAS 2019 10th IAS Conference on HIV Science, Mexico City, Mexico 21-24 July 2019 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington (08/12/19)
     
  2188. HIV Prevention Trials Network (HPTN) Announces Initiation of HPTN 084: First Large-Scale Study in Women of a Long-Acting Injectable to Prevent HIV - (08/09/19)
     
  2189. HIV Prevention Trials Network Launches HPTN 083 - (08/09/19)
     
  2190. Gilead $17 Million RFP & ViiV Aging Projects - (08/09/19)
     
  2191. FDA Hearing Ongoing Wed Aug 7 2019 on Descovy for PrEP Vote - (08/08/19)
     
  2192. IAS: Substance Use--Especially Meth--Tied to Depression in Young HIV+/HIV- MSM - Mark Mascolini (08/06/19)
     
  2193. What Aging With HIV Means in the Year 2019 - (08/06/19)
     
  2194. IAS: "Dual epidemics: the impact of HIV and obesity on pregnancy outcomes among women in South Africa"
    'The impact of HIV and obesity on pregnancy outcomes among women in South Africa'
    Obesity in 36% of Pregnant HIV+ South African Women--But No Impact on Outcomes     - (08/05/19)
     
  2195. IAS: Adverse pregnancy outcomes among HIV-positive women in the era of universal antiretroviral therapy (ART) remain elevated compared with HIV-negative women in Lesotho - (08/05/19)
     
  2196. IAS: Higher Immune Activation With Methadone Than Naltrexone in Opioid Users With HIV - Mark Mascolini (08/05/19)
     
  2197. IAS: Inflammatory Marker and Immune Upsets After Single Forced Vaginal Penetration - Mark Mascolini (08/05/19)
     
  2198. IAS: DMPA May Have STI Advantage Over Copper IUD and Levonorgestrel Implant - Mark Mascolini (08/05/19)
     
  2199. IAS: Comorbidities Canadians: >70 HIGH Rates - (08/05/19)
     
  2200. IAS: Perspectives from the Front Lines: Encouraging Community Engagement in the Performance of Research at the Intersection of HIV and Aging - (08/05/19)
     
  2201. High CNS Penetration Increased HIV Dementia - (08/02/19)
     
  2202. CROI: CEREBRAL FUNCTION PARAMETERS IN PEOPLE LIVING WITH HIV SWITCHING INTEGRASE INHIBITOR - (08/02/19)
     
  2203. IAS: A SWITCH TO DOLUTEGRAVIR IN COMBINATION WITH BOOSTED DARUNAVIR IS SAFE AND EFFECTIVE IN SUPPRESSED PATIENTS WITH HIV - A SUBANALYSIS OF THE DUALIS STUDY - (08/02/19)
     
  2204. IAS: Five Times Higher Risk of ART Nonadherence on Days of Heavy Drinking - Mark Mascolini (08/02/19)
     
  2205. IAS: Dolutegravir use at conception: Additional surveillance data from Botswana (smaller signal) - (08/02/19)
     
  2206. IAS: No occurrences of neural tube defects among 382 women on Dolutegravir at pregnancy conception in Brazil - (08/02/19)
     
  2207. IAS: Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana - (08/02/19)
     
  2208. Treatment Adherence and Virologic Response Over 48 Weeks Among Patients Rapidly Initiating Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in the DIAMOND Study - (08/02/19)
     
  2209. IAS: A SWITCH TO DOLUTEGRAVIR IN COMBINATION WITH BOOSTED DARUNAVIR IS SAFE AND EFFECTIVE IN SUPPRESSED PATIENTS WITH HIV - A SUBANALYSIS OF THE DUALIS STUDY - (08/01/19)
     
  2210. IAS: HCV Reinfection Rate in People With HCV/HIV 13% Across Europe - Mark Mascolini - (08/01/19)
     
  2211. IAS: Inconsistent Testing in HIV+ for Top Liver Cancer Risk Factors: HBV, HCV, Alcohol - Mark Mascolini (08/01/19)
     
  2212. IAS: Biomarkers Good at Predicting NAFLD or Excluding Advanced Fibrosis With HIV (FibroScan, CAP Score) - Mark Mascolini (08/01/19)
     
  2213. IAS: Virologic Failure In ART-Naive HIV Patients With High Pre-Therapy Viral Load Burden Initiating On Common Core Agents - (08/01/19)
     
  2214. IAS: Biomarkers Good at Predicting NAFLD or Excluding Advanced Fibrosis With HIV (FibroScan, CAP Score) - Mark Mascolini (07/31/19)
     
  2215. IAS: Collaborative Care Improves HIV Provider Confidence in Managing Chronic Opioid Therapy - Mark Mascolini (07/31/19)
     
  2216. IAS: Preventive HIV vaccine Enters Phase 3 Global Study - (07/30/19)
     
  2217. IAS: More Acute HIV Diagnoses, Shorter Time to Undetectable HIV, in Amsterdam MSM Program - Mark Mascolini (07/30/19)
     
  2218. IAS: Substance Use--Especially Meth--Tied to Depression in Young HIV+/HIV- MSM - Mark Mascolini (07/30/19)
     
  2219. IAS: HIV Control Rate Lower in Women Than Men in Inner-City Vancouver - Mark Mascolini (07/30/19)
     
  2220. IAS: Meta-Analysis Confirms Aerobic Exercise Benefit on Depression With HIV - Mark Mascolini (07/30/19)
     
  2221. IAS: Week 96 Resistance and Adherence Analyses of the Once-daily, Single-tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in the AMBER and EMERALD Phase III Trials - (07/30/19)
     
  2222. IAS: Change in Kidney Function After TDF-to-TAF Switch: Who Benefits Most? - Mark Mascolini (07/30/19)
     
  2223. IAS: In Vitro Resistance Profile of GS-6207, a First-in-Class Picomolar HIV Capsid Inhibitor in Clinical Development as a Novel Long-Acting Antiretroviral Agent - (07/30/19)
     
  2224. IAS: Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen - (07/30/19)
     
  2225. IAS: Johnson & Johnson Announces New Public-Private Partnership to Support First Phase 3 Efficacy Study of Janssen's Investigational Prophylactic HIV Vaccine - (07/30/19)
     
  2226. IAS: Long-Acting MK-8591 at IAS 2019, , New ART for Treatment, PrEP - (07/30/19)
     
  2227. IAS: Prevalence and Outcomes for Heavily Treatment-Experienced (HTE) Individuals Living with HIV in a European Cohort EuroSIDA - (07/28/19)
     
  2228. IAS: WHO recommends dolutegravir as preferred HIV treatment option in all populations - (07/28/19)
     
  2229. IAS: HPTN 078: Primary results of a randomized study to engage men who have sex with men (MSM) living with HIV who are virally unsuppressed in the USA - (07/28/19)
     
  2230. IAS: ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly, injectable treatment for HIV - (07/28/19)
     
  2231. IAS: Efficacy of on-demand PrEP or PEP with single oral doses of combination tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat in macaques - (07/28/19)
     
  2232. IAS: Polypharmacy in Nearly All of 65+ HIV Group Tied to Inappropriate Prescribing - (07/28/19)
     
  2233. IAS: Loneliness Among Older People (44%) Living with HIV: Why the ''Older Old'' are Less Lonely Than the ''Younger Old'' (53%) - (07/28/19)
     
  2234. IAS: "There's no retirement plans for us": Re-analysis from a qualitative study of HIV-positive MSM who use substances - (07/27/19)
     
  2235. IAS: The ADVANCE trial: Phase 3, randomized comparison of TAF/FTC/DTG, TDF/FTC/DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection - (07/27/19)
     
  2236. IAS: Dolutegravir (DTG) Plus Lamivudine (3TC) Versus DTG Plus Tenofovir/Emtricitabine (TDF/FTC) Fixed-Dose Combination in the GEMINI Studies -Viral Load Rebound Including 'Blips' Through 48 Weeks - (07/27/19)
     
  2237. IAS: ARTS 4 Days A Week Instead of 7, not good, Jules. - "ANRS 170 QUATUOR 4/7 days maintenance strategy in antiretroviral treated adults with HIV-1 infection: an open randomised parallel non-inferiority phase III trial" - (07/27/19)
     
  2238. IAS: Twice-Daily 400-mg Raltegravir Not Noninferior to Efavirenz for HIV With TB - "Virologic efficacy of raltegravir vs. efavirenz-based antiretroviral treatment in HIV1-infected adults with tuberculosis: W48 results of the ANRS 12300 REFLATE TB2 trial" - (07/27/19)
     
  2239. IAS: Twice-Daily 400-mg Raltegravir Not Noninferior to Efavirenz for HIV With TB - "Virologic efficacy of raltegravir vs. efavirenz-based antiretroviral treatment in HIV1-infected adults with tuberculosis: W48 results of the ANRS 12300 REFLATE TB2 trial" - (07/27/19)
     
  2240. IAS: Rosuvastatin Does Not Slow Atherosclerosis in HIV+ With Moderate Risk - (07/27/19)
     
  2241. IAS: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 48 WEEKS (TANGO STUDY) - (07/26/19)
     
  2242. IAS: Out-of-Care HIV+ US MSM Will Resume Treatment, But Only Half Control HIV in 12 Months - Mark Mascolini - (07/26/19)
     
  2243. IAS: A Pooled Analysis of the Effect of Adherence on the Renal Safety of FTC/TDF (Truvada) for Prep: 7 International Demonstration Projects - (07/26/19)
     
  2244. IAS: ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance - PRESS RELEASE - (07/26/19)
     
  2245. IAS: Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019 - (07/26/19)
     
  2246. IAS: ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection - PRESS RELEASE - (07/26/19)
     
  2247. IAS: Vesatolimod (GS-9620) Is Safe and Pharmacodynamically Active in HIV-Infected Individuals - (07/26/19)
     
  2248. IAS: ISLATRAVIR (ISL, MK-8591) at doses of 0.25 to 2.25 mg QD in combination with doravirine maintains viral suppression through 48 weeks in adults with HIV-1 infection - (07/26/19)
     
  2249. IAS: Gilead Announces Latest Data in Ongoing HIV Cure Research Program - (07/25/19)
     
  2250. IAS: Gilead Presents New Findings on Profile of Descovy for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada - (07/25/19)
     
  2251. IAS: Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV - (07/25/19)
     
  2252. IAS: Incidence of HIV-Infection with Daily or On Demand PrEP with TDF/FTC in the Paris Area: An Update of the Prevenir Study - (07/25/19)
     
  2253. IAS: Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials - (07/25/19)
     
  2254. IAS: Oral TLR7 Agonist Administration Induces an Immunostimulatory Response in SIV-Infected ART-Suppressed Infant Rhesus Macaques - (07/25/19)
     
  2255. IAS: Out-of-Care HIV+ US MSM Will Resume Treatment, But Only Half Control HIV in 12 Months - Mark Mascolini - (07/25/19)
     
  2256. IAS: Vision Impairment More Frequent in Older HIV+ Men--With Functional Consequences - Mark Mascolini - (07/25/19)
     
  2257. IAS: Lower HIV Rate With F/TAF Than F/TDF in Double-Blind Noninferiority Trial - Mark Mascolini - (07/25/19)
     
  2258. IAS: Neural Tube Defect Rate 0.40% With Dolutegravir in Pregnancy--But Data Still Slim - Mark Mascolini - (07/25/19)
     
  2259. IAS: High STI Prevalence in German MSM, But Low Rates of HIV, HCV, HBV - Mark Mascolini - (07/25/19)
     
  2260. IAS: About 10% With HIV in Europe Have Heavy Treatment Experience, Few Options - "Prevalence and outcomes for heavily treatment-experienced (HTE) individuals living with HIV in a European cohort" - Mark Mascolini - (07/25/19)
     
  2261. IAS: Almost No New HIV Infections in Paris Comparison of Daily vs As-Needed PrEP - Mark Mascolini - (07/25/19)
     
  2262. IAS: Higher GI Disorder Risk When Switching to RAL or DRV Versus DTG - Mark Mascolini - (07/25/19)
     
  2263. IAS: Young Men Driving Expanding HIV Epidemic in Latin America - Mark Mascolini - (07/25/19)
     
  2264. IAS: Better Predictive Power When Combining Traditional and HIV-Specific Cardio Risk Factors - "Impact of HIV specific and traditional risk factors on the incidence of cardiovascular events in HIV-positive males over time" - Mark Mascolini - (07/25/19)
     
  2265. IAS: Viral Suppression in 60% for 96 Weeks With Fostemsavir Salvage in BRIGHTE - Mark Mascolini - (07/25/19)
     
  2266. IAS: Week-96 Potency of Dolutegravir/3TC in GEMINI Trials of First-Line ART - "Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection--96-week results from the GEMINI studies" - Mark Mascolini - (07/25/19)
     
  2267. IAS: Sharp Drops in HIV Load After 10 Days of Capsid Inhibitor Monotherapy - Mark Mascolini - (07/25/19)
     
  2268. IAS: Simulated Driving Worse in Pro Drivers With Than Without HIV - "Cognitive functioning and driving ability in HIV-infected professional drivers" - Mark Mascolini - (07/25/19)
     
  2269. IAS: HIV Infection Rate Jumps 7.5-fold When US PrEP Users Stop - Mark Mascolini - (07/25/19)
     
  2270. IAS: Differential Detection of M184V/I Between Plasma Historical HIV Genotypes and Proviral DNA from PBMCs - (07/25/19)
     
  2271. IAS: Switching to a Single-tablet Regimen of Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) from Dolutegravir plus Either F/TAF or F/TDF - (07/25/19)
     
  2272. IAS: A Subgroup Analysis of the Week 96 Efficacy and Safety Results Evaluating Fostemsavir in Heavily Treatment-Experienced HIV-1 Infected Participants in the Phase 3 BRIGHTE Study: Results From The Randomized Cohort - (07/25/19)
     
  2273. IAS: First-in-Human Trial of MK-8591-Eluting Implants Demonstrates Concentrations Suitable for HIV Prophylaxis for at Least One Year - (07/25/19)
     
  2274. IAS: Keeping the Pressure on Archived NRTI Resistance: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Triple Therapy in Study 4030 - (07/25/19)
     
  2275. IAS: Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug-resistant HIV-1 (BRIGHTE Study) - (07/25/19)
     
  2276. IAS: Previously Undocumented Pre-existing Resistance and Maintenance of Virologic Suppression in HIV-1 RNA-Suppressed Patients Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) - (07/25/19)
     
  2277. IAS: Tolerability, Safety, and Efficacy of Islatravir (MK-8591) at Doses of 0.25 to 2.25 mg QD, in Combination With Doravirine and Lamivudine Through 24 Weeks in Treatment-Naïve AdultsWith HIV-1 Infection - (07/25/19)
     
  2278. IAS: Longer-term (96-week) Efficacy and Safety of Switching to Bictegravir, Emtricitabine and Tenofovir Alafenamide (B/F/TAF) in Women - (07/25/19)
     
  2279. IAS: Utilization of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States by Age, Gender and Race/Ethnicity (2014 - 2017) - (07/25/19)
     
  2280. IAS: Long-Acting Cabotegravir and Rilpivirine is Noninferior to Oral ART as Maintenance Therapy for HIV-1 Infection: Week 48 Pooled Analysis From the Phase 3 ATLAS and FLAIR Studies - (07/25/19)
     
  2281. IAS: Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 48-Week Results - (07/25/19)
     
  2282. IAS: Patient Views on Long-Acting HIV Treatment: Cabotegravir + Rilpivirine as Maintenance Therapy (ATLAS 48-Week Results) - (07/25/19)
     
  2283. IAS: DISCOVER STUDY for HIV Pre-Exposure Prophylaxis: F/TAF has a more Rapid Onset and Longer Sustained Duration of HIV Protection Compared with F/TDF - (07/25/19)
     
  2284. IAS: Forgiveness of Antiretroviral Regimens: In Vitro HIV-1 Viral Breakthrough with 2-Drug versus 3-Drug Regimens Simulating Variable Adherence to Treatment - (07/23/19)
     
  2285. IAS: Viral Suppression in 60% for 96 Weeks With Fostemsavir Salvage in BRIGHTE - Mark Mascolini - (07/23/19)
     
  2286. IAS: ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV - (07/23/19)
     
  2287. IAS: Gilead Presents New Data on Biktarvy for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance - (07/23/19)
     
  2288. IAS: Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV - (07/23/19)
     
  2289. Scales Tip Toward 'Fish Oil' PUFA Intake for Heart Failure Prevention Predicting Risk for Incident Heart Failure With Omega-3 Fatty Acids From MESA - 1 - (07/17/19)
     
  2290. Elderly HIV+ Physiologic Changes, Polypharmacy, Prescribing Issues - (07/17/19)
     
  2291. IAS: Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019 - (07/18/19)
     
  2292. Elderly HIV+ Physiologic Changes, Polypharmacy, Prescribing Issues Prescribing issues in elderly individuals living with HIV REVIEW - (07/17/19)
     
  2293. 2-3 Times Greater MI & Heart Failure Risk in HIV+ / "rates of CVD hospitalization were double in HIV infected" - "HIV Infection and Incidence of Cardiovascular Diseases: An Analysis of a Large Healthcare Database" - (07/16/19)
     
  2294. Persistent HIV in central nervous system linked to cognitive impairment - (07/16/19)
     
  2295. IAS: IAS 2019: ViiV Healthcare showcasing innovation in HIV science - PRESS RELEASE - (07/16/19)
     
  2296. ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen - (07/11/19)
     
  2297. ViiV Healthcare begins study on implementation of once-monthly injectable HIV treatment - (07/10/19)
     
  2298. 2 News Reports on this story - Researchers have eliminated HIV in mice for the first time. Is a cure for humans next? - (07/10/19)
     
  2299. Acceptability and Preferences for Long-Acting Antiretroviral Formulations Among People Living with HIV infection - (07/10/19)
     
  2300. Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019 - (07/10/19)
     
  2301. 20th Intnl Wrkshp Clin Pharm: Tenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy - (07/10/19)
     
  2302. CROI: TOCILIZUMAB (monoclonal antibody) ALTERS LIPIDS IN HIV+ INDIVIDUALS IN A RANDOMIZED, DOUBLE-BLIND STUDY - (07/10/19)
     
  2303. Calcium Supplements May Damage the Heart - (07/09/19)
     
  2304. Most dietary supplements do not protect against heart attack and stroke - (07/09/19)
     
  2305. Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes: An Umbrella Review and Evidence Map - (07/09/19)
     
  2306. Dispense With Supplements for Improving Heart Outcomes - Editorials - (07/09/19)
     
  2307. HIV eliminated from the genomes of living animals - "Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice" - (07/09/19)
     
  2308. Aging/HIV & Senescence; NASH - (07/08/19)
     
  2309. Doubling of Rates of HIV in Nursing Homes - Nursing Home Residents by Human Immunodeficiency Virus Status: Characteristics, Dementia Diagnoses, and Antipsychotic Use - (07/08/19)
     
  2310. Fast Forward to Viral Suppression: Immediate Initiation of ARVs Following Reactive HIV+ Test Result or Engagement in HIV Care for the First Time at a Community Health Center in Washington, DC - (07/08/19)
     
  2311. Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection - (07/02/19)
     
  2312. Women - greater weight gain than men associated with integrase inhibitors - all future ART studies should include looks at weight gain. - (07/02/19)
     
  2313. CROI: Cardiovascular Update from CROI 2019 - by Priscilla Hsue MD Professor of Medicine, UCSF (07/01/19)
     
  2314. Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV...33% hepatic steatosis >/= grade 1 vs 10% controls - > grade 2 28% vs 5% controls - belly, metabolics - (06/28/19)
     
  2315. 20th Intnl Wrkshp Clin Pharm: The 20th International Workshop on Clinical Pharmacology of Antiviral Therapy - Courtney V. Fletcher, Pharm.D. Professor and Director, Antiviral Pharmacology Laboratory UNMC Center for Drug Discovery University of Nebraska Medical Center - (05/26/19)
     
  2316. Effect of HIV infection and antiretroviral therapy on immune cellular functions - integrase, mitochondria - (06/25/19)
     
  2317. When to use CT Angiography - Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups: meta-analysis of individual patient data - (06/25/19)
     
  2318. Kidney Disease "Risk Factor for CVD" - (06/19/19)
     
  2319. Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base - (06/18/19)
     
  2320. Activation and Senescence Markers in HIV Patients with Chronic Kidney Disease - (06/17/19)
     
  2321. NEW DATA RELEASED BY THERATECHNOLOGIES DEMONSTRATE POSITIVE IMPACT OF TESAMORELIN IN PATIENTS WITH LIVER FIBROSIS - (06/17/19)
     
  2322. Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity - (06/14/19)
     
  2323. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in HIV-Infected Adults - (06/14/19)
     
  2324. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation A Randomized Clinical Trial - (06/14/19)
     
  2325. Cancer Risk in Older Persons Living With Human Immunodeficiency Virus Infection in the United States - (06/14/19)
     
  2326. Aging Grant - NIH Grant Funds $23 Million Study of Diseases Affecting People Living with HIV - (06/12/19)
     
  2327. PrEP Recommended - "Preexposure Prophylaxis for the Prevention of HIV Infection - US Preventive Services Task Force Recommendation Statement" - (06/12/19)
     
  2328. New USPSTF Guidelines for HIV Screening and Preexposure Prophylaxis (PrEP)Straight A's - Editorial - (06/12/19)
     
  2329. HIV Screening Recommended - Screening for HIV Infection - US Preventive Services Task Force Recommendation Statement - (06/12/19)
     
  2330. Preexposure Prophylaxis for the Prevention of HIV Infection Evidence Report and Systematic Review for the US Preventive Services Task Force - (06/12/19)
     
  2331. The Changing Face of HIV-Associated Malignancies: Advances, Opportunities, and Future Directions / Treatment Access Denied to HIV+ - (06/10/19)
     
  2332. HIV/Safe PD-1 Cancer Treatment / Studies Should Include HIV+ - (06/10/19)
     
  2333. New PrEP Long-Acting MK-8591, for HIV Treatment Too - (06/10/19)
     
  2334. Excess Vitamin D Linked to Kidney Damage - (06/10/19)
     
  2335. Interferon Stops Parkinson Disease: Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection - (06/07/19)
     
  2336. Short-term outcomes for lung cancer resection surgery in HIV infection - (06/05/19)
     
  2337. Cardiac ageing: extrinsic and intrinsic factors in cellular renewal and senescence - (06/05/19)
     
  2338. ACTG Long-Acting (LA) ART (Rilpivirine/Cabotegravir to Standard of Care (SOC) in persons living with HIV (PLWH) who have had barriers for adherence / LATITUDE Study Health Care Provider Fact Sheet - (06/05/19)
     
  2339. CROI: Lower bone strength by peripheral quantitative CT (pQCT) in children living with HIV - (06/05/19)
     
  2340. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association - (06/05/19)
     
  2341. Congestive Heart Failure and Chronic Kidney Disease The CardioRenal/NephroCardiology Connection - EDITORIAL COMMENT - (06/05/19)
     
  2342. Heart Disease Risk Factors in HIV+ This study just published: "Factors Associated With Excess Myocardial Infarction Risk in HIV-Infected Adults" But there are key crucial points NOT covered in this meta-analysis study...... - (06/05/19)
     
  2343. Arterial Stiffness in the Heart Disease of CKD - Kidney/Cardio Connection - (06/05/19)
     
  2344. Metabolic Bone Disease in Chronic Kidney Disease - Kidney-Bone-Cardio Connection - (06/03/19)
     
  2345. Impact of HIV/simian immunodeficiency virus infection and viral proteins on adipose tissue fibrosis and adipogenesis - (06/03/19)
     
  2346. Intranasal Insulin for Cognition / New study in HIV+ - (06/03/19)
     
  2347. Energy Drinks: Another Cause of QT Prolongation? - (06/03/19)
     
  2348. CROI: HIV Infection and the Risk of Fracture among Fallers - (06/03/19)
     
  2349. CROI: Senescence & Exhaustion of T Cell Memory Subsets Increased in Aging Persons with HIV - (06/03/19)
     
  2350. CROI: Mood Disorders & Increased Risk of Non-communicable Diseases in Adults Aging with HIV.....more HIV+ females had mood disorders 27% vs 22% - (05/31/19)
     
  2351. CROI: Bone, Frailty, and Aging at CROI 2019 - Todd Brown, MD, PhD Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University - (05/31/19)
     
  2352. Ageing with HIV: Emerging importance of chronic comorbidities in patients over 75: 2-3 times the numbers of Comorbidities vs 50-74 - (05/28/19)
     
  2353. Ageing with HIV: Emerging importance of chronic comorbidities in patients over 75: 2-3 times the numbers of Comorbidities vs 50-74 - (05/28/19)
     
  2354. Type 2 diabetes prevalence [doubled] and its risk factors in HIV: A cross-sectional study - (05/28/19)
     
  2355. "The absurdly high cost of insulin" - as high as $350 a bottle, often 2 bottles per month needed by diabetics - (05/28/19)
     
  2356. Diabetes Risk 39% Higher: BMI, Obesity, Old PIs and NRTIs Associated; Insulin Cost Tripled; Competition Limited - (05/28/19)
     
  2357. 20th Intnl Wrkshp Clin Pharm: Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir - (05/26/19)
     
  2358. Clinical significance of elevated liver transaminases in HIV-infected patients: clinicians practicing HIV care should promptly approach the finding of elevated liver transaminases for its diagnostic and prognostic implications. - (05/24/19)
     
  2359. Ageing with HIV: Emerging importance of chronic comorbidities in patients over 75 - (05/24/19)
     
  2360. Chronic kidney disease is associated with < low BMD at the hip but not at the spine - (05/24/19)
     
  2361. Long-Acting Once A Month Injection of Cabotegravi/rilpivirine in PLWH with History of Sub-Optimal Adherence Enrolling - (05/24/19)
     
  2362. Positive Action Southern Initiative Funding Announcement: Grants for Direct Linkage & Adherence Services in AR, FL, KY, NC, SC, TN, TX, VA - (05/24/19)
     
  2363. 20th Intnl Wrkshp Clin Pharm: Short-term intravenous proton pump inhibitors and histamine H2 antagonists do not negatively affect sustained virologic response in hepatitis C cirrhotic patients treated with ledipasvir or velpatasvir containing antiviral regimens: a case series (05/23/19)
     
  2364. 20th Intnl Wrkshp Clin Pharm: PLASMA AND INTRACELLULAR PHARMACOKINETICS OF COBICISTAT IN THE CLINICAL SETTING (05/23/19)
     
  2365. SWITCHING FROM ATAZANAVIR/RITONAVIR (ATV/RTV) TO ATV/COBICISTAT (COBI) IS ASSOCIATED WITH DECREASE OF PLASMA LIPIDS AND LIVER FIBROSIS - (05/21/19)
     
  2366. Beneficial associations of low and large doses of leisure time physical activity with all-cause, cardiovascular disease and cancer mortality: a national cohort study of 88,140 US adults - (05/21/19)
     
  2367. Recommendations [listed just below] for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting - (05/21/19)
     
  2368. 20th Intnl Wrkshp Clin Pharm: DRUGS ABUSE AND CHEMSEX: A NEW CHALLENGE FOR ANTIRETROVIRAL DRUG-DRUG INTERACTION - (05/20/19)
     
  2369. 20th Intnl Wrkshp Clin Pharm: An exploration of adherence measures to detect recent changes in Truvada® dosing patterns - (05/20/19)
     
  2370. 20th Intnl Wrkshp Clin Pharm: Population Pharmacokinetics of VRC01 in Infants and Adults - (05/20/19)
     
  2371. 20th Intnl Wrkshp Clin Pharm: Pharmacokinetics of Tenofovir Alafenamide 25mg with PK Boosters During Pregnancy & Postpartum - (05/20/19)
     
  2372. 20th Intnl Wrkshp Clin Pharm: Sofosbuvir and 007 Pharmacokinetics Among Persons with HCV and Active Drug Use - (05/20/19)
     
  2373. 20th Intnl Wrkshp Clin Pharm: Comparison of Relative Bioavailability of Pediatric Triumeq and Pediatric Dolutegravir/Lamivudine Dispersible Tablets to Conventional Film Coated Tablets in Healthy Adults - (05/20/19)
     
  2374. 20th Intnl Wrkshp Clin Pharm: Predose concentrations of DTG and RPV steady through 100 weeks in SWORD trials - "Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Characterization of the Two-drug Anti-Retroviral Regimen (2DR) Dolutegravir/Rilpivirine Following Switch From Current Anti-Retroviral Therapy in the SWORD-1 and SWORD-2 Phase 3 Studies" - Mark Mascolini (05/20/19)
     
  2375. 20th Intnl Wrkshp Clin Pharm: The Initial Phase I Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK3640254, a Next-Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects - (05/20/19)
     
  2376. 20th Intnl Wrkshp Clin Pharm: PHARMACOKINETICS OF ATAZANAVIR BOOSTED WITH COBICISTAT DURING PREGNANCY AND POSTPARTUM - (05/20/19)
     
  2377. 20th Intnl Wrkshp Clin Pharm: Two thirds of Montreal in-hospital HCV group have interactions with DAAs - Mark Mascolini (05/20/19)
     
  2378. 20th Intnl Wrkshp Clin Pharm: Proportion of serious drug interactions dropping on Liverpool antiretroviral website - Mark Mascolini (05/20/19)
     
  2379. 20th Intnl Wrkshp Clin Pharm: Lower cobicistat and atazanavir troughs in smokers with HIV - Mark Mascolini (05/20/19)
     
  2380. 20th Intnl Wrkshp Clin Pharm: Reported dolutegravir-valproic acid interaction probably not clinically relevant - Mark Mascolini (05/20/19)
     
  2381. 20th Intnl Wrkshp Clin Pharm: Model suggests physiologic changes with aging underlie ritonavir PK shifts - Mark Mascolini (05/20/19)
     
  2382. 20th Intnl Wrkshp Clin Pharm: Other than dolutegravir, no antiretroviral interactions with valproic acid in 134 people - Mark Mascolini (05/16/19)
     
  2383. Gilead Donating 2.4 Million Bottles of Truvada to CDC for PrEP - (05/17/19)
     
  2384. Osteoarthritis in HIV May Be Accelerated - new study - (05/17/19)
     
  2385. Mediterranean/Low Carb Diet Superior in Reducing Hepatic Fat for Fatty Liver/NAFLD & Non-NAFLD too - (05/17/19)
     
  2386. 20th Intnl Wrkshp Clin Pharm: Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV - (05/16/19)
     
  2387. 20th Intnl Wrkshp Clin Pharm: Management of antiretrovirals in Seniors - The importance of assisted treatment for adherence to treatment - (05/16/19)
     
  2388. 20th Intnl Wrkshp Clin Pharm: One third of French HIV group uses illicit drugs, often risking antiretroviral interactions - Mark Mascolini - (05/16/19)
     
  2389. 20th Intnl Wrkshp Clin Pharm: IV PPIs and H2 antagonists did not thwart response to ledipasvir or velpatasvir - Mark Mascolini - (05/16/19)
     
  2390. 20th Intnl Wrkshp Clin Pharm: Two thirds of Montreal in-hospital HCV group have interactions with DAAs - Mark Mascolini - (05/16/19)
     
  2391. 20th Intnl Wrkshp Clin Pharm: Lower cobicistat and atazanavir troughs in smokers with HIV - Mark Mascolini - (05/16/19)
     
  2392. 20th Intnl Wrkshp Clin Pharm: Sofosbuvir exposure higher in opioid users, lower with darunavir - Mark Mascolini - (05/16/19)
     
  2393. 20th Intnl Wrkshp Clin Pharm: Predose concentrations of DTG and RPV steady through 100 weeks in SWORD trials - Mark Mascolini - (05/16/19)
     
  2394. 20th Intnl Wrkshp Clin Pharm: Phase 1 results show safety and once-daily potential of new HIV maturation inhibitor - Mark Mascolini - (05/16/19)
     
  2395. EASL: CANCER RISK AMONG PEOPLE WITH HIV, HBV AND/OR HCV INFECTIONS - (05/16/19)
     
  2396. Mediterranean/Low Carb Diet Superior in Reducing Hepatic Fat for Fatty Liver/NAFLD & Non-NAFLD too - (05/17/19)
     
  2397. MECHANISMS OF WHITE-MATTER LOSS DUE TO HIV INFECTION AND ANTIRETROVIRAL THERAPY - (05/13/19)
     
  2398. RELAPSE OF SYMPTOMATIC CSF HIV ESCAPE UPON PREVIOUSLY OPTIMIZED cART REGIMEN CHANGES / CNS Eradication Reservoir - (05/13/19)
     
  2399. EASL: Is it possible to successfully link migrants to HBV, HCV and HIV services upon arrival in the European Union? - (05/13/19)
     
  2400. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication - (05/13/19)
     
  2401. NAFLD in lipodystrophy - (05/10/19)
     
  2402. Increasing Cognitive Aging in HIV+ WIHS Women Despite Viral Suppression, MACS Men - (05/10/19)
     
  2403. HIV+ Women & Aging: worse for women with HIV - (05/10/19)
     
  2404. NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens - (05/10/19)
     
  2405. Increasing Cognitive Aging in HIV+ WIHS Women Despite Viral Suppression, MACS Men - (05/09/19)
     
  2406. Increasing Cognitive Aging in HIV+ WIHS Women Despite Viral Suppression, MACS Men - (05/09/19)
     
  2407. HIV+ Women & Aging: worse for women with HIV - (05/09/19)
     
  2408. NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens - (05/09/19)
     
  2409. Bictegravir and dolutegravir: head to head at 96 weeks, Comment + study - (05/08/19)
     
  2410. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial - (05/08/19)
     
  2411. AdverseReactComor: MSM Associated with Lower CD4/CD8 Ratio - (05/01/19)
     
  2412. New HIV Cure Approach - Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1 - (05/01/19)
     
  2413. 35% of HIV+ Taking > 10 Comedications at Northwestern ID Clinic - (05/01/19)
     
  2414. 50% Polypharmacy Rates in HIV MACS >5 Comoedications / Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016 - (05/01/19)
     
  2415. Frailty phenotype in older people living with HIV: concepts, prevention and issues - (04/29/19)
     
  2416. ViiV HEALTHCARE ANNOUNCES CHMP POSITIVE OPINION FOR DOVATO® (DOLUTEGRAVIR/LAMIVUDINE) AS A ONCE-DAILY, SINGLE-PILL, TWO-DRUG REGIMEN FOR THE TREATMENT OF HIV INFECTION - (04/29/19)
     
  2417. ViiV HEALTHCARE SUBMITS NEW DRUG APPLICATION TO US FDA FOR THE FIRST MONTHLY, INJECTABLE, TWO-DRUG REGIMEN OF CABOTEGRAVIR AND RILPIVIRINE FOR TREATMENT OF HIV - (04/29/19)
     
  2418. Complicated Complications at CROI - David Alain Wohl, MD - The University of North Carolina Institute of Global Health and Infectious Diseases - (04/26/19)
     
  2419. HIV is Associated with Lung Function Impairment in the Multicenter AIDS Cohort Study - (04/23/19)
     
  2420. 2 Studies on Sudden Cardiac Death in HIV+ at CROI 2019 with surprising findings regarding causes of deaths - (04/23/19)
     
  2421. PSYCHOLOGICAL BURDEN AND THE IMPACT ON ENGAGEMENT WITH CARE AMONG ETHNICALLY DIVERSE OLDER WOMEN WITH HIV - (04/23/19)
     
  2422. People living with HIV in the UK have a higher risk of progression to CNS disorders and other comorbidities than matched counterparts - (04/23/19)
     
  2423. FATTY LIVER in HIV+, alcohol, 50% have NAFLD, 27% Liver Fibrosis - The prevalence of liver fibrosis in HIV infected patients with abnormal liver function tests - (04/23/19)
     
  2424. Multimorbidity burden in an HIV population aged over 50 in South-East England - (04/23/19)
     
  2425. "I'm 51 but living in the body of a 65-year old":Exploring the experiences and needs of those living with HIV and multiple comorbidities - (04/23/19)
     
  2426. Comorbidities Prevalence & Clustering Together in 2 European Aging/HIV Cohorts - POPPY & AGEHIV - (04/18/19)
     
  2427. Expanded Access - Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection - (04/18/19)
     
  2428. Study Finds No Benefit for Dietary Supplements - (04/18/19)
     
  2429. Aging & HIV: Gilead Funds 30 Organizations with $17 Million; ViiV Project - "Aging/HIV has become the #1 issue from at least a clinical perspective" - (04/17/19)
     
  2430. HIV and aging: time to bridge the gap between clinical research and clinical care - Editorial "PLWH seem to be biologically older than their chronological age..... something has to be done to bridge the gap between clinical research and clinical care." - (04/17/19)
     
  2431. Why are people with HIV considered "older adults" in their fifties? "immunosenescence" - (04/17/19)
     
  2432. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Rapid Initiation for HIV-1 Infection: Primary Analysis of the DIAMOND Study at ACTHIV - (04/15/19)
     
  2433. Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA® through 48 Weeks - (04/15/19)
     
  2434. EASL: HIV-infected individuals at high risk of non-alcoholic fatty liver disease (NAFLD) and progressive liver disease- ILC 2019: Latest studies confirm increasing burden of NAFLD in people with HIV infection as viral hepatitis prevalence and associated mortality decline - (04/12/19)
     
  2435. American Heart Association Recommends Depression Screening for Cardiovascular Disease Patients Cardiovascular Disease / 'Double the Concern in Older HIV+' - (04/10/19)
     
  2436. ViiV HEALTHCARE ANNOUNCES JULUCA (DOLUTEGRAVIR/RILPIVIRINE) MAINTAINS HIV VIRAL SUPPRESSION AT 148-WEEKS - (04/10/19)
     
  2437. Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to DTG + RPV 2-Drug Regimen: SWORD-1 and -2 Studies at BHIVA - (04/10/19)
     
  2438. US FDA APPROVES ViiV HEALTHCARE'S DOVATO (DOLUTEGRAVIR/LAMIVUDINE), THE FIRST, ONCE-DAILY, SINGLE-TABLET, TWO-DRUG REGIMEN FOR TREATMENT-NAïVE HIV-1 ADULTS (dolutegravir/3TC) - (04/10/19)
     
  2439. Clinical Pharmacology at CROI 2019 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE (04/09/19)
     
  2440. Updates New ARTs/ New ART Data - CROI including Bictegravir, Dolutegravir+Rilpivirine, Dolutegravir+3TC, Doravirine; Fostemsavir & MK-8591 - (04/10/19)
     
  2441. US FDA APPROVES ViiV HEALTHCARE'S DOVATO (DOLUTEGRAVIR/LAMIVUDINE), THE FIRST, ONCE-DAILY, SINGLE-TABLET, TWO-DRUG REGIMEN FOR TREATMENT-NAïVE HIV-1 ADULTS (dolutegravir/3TC) - (04/10/19)
     
  2442. How all-type dementia risk factors and modifiable risk interventions may be relevant to the first-generation aging with HIV infection? Dementia Risk in HIV+ is Higher - (04/09/19)
     
  2443. Working memory revived in older adults by synchronizing rhythmic brain circuits - (04/09/19)
     
  2444. CROI: GS-6207, A POTENT AND SELECTIVE FIRST-IN-CLASS LONG-ACTING HIV-1 CAPSID INHIBITOR - (04/08/19)
     
  2445. CROI: Weight Gain in HIV - Integrase - (04/08/19)
     
  2446. New VIDEO - Staying Golden: Aging With HIV - (04/05/19)
     
  2447. Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies - (04/05/19)
     
  2448. Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy for HIV Pre-Exposure Prophylaxis - (04/05/19)
     
  2449. Letter from the OAR Director - (04/05/19)
     
  2450. CROI: HIGH RATES OF VIROLOGIC SUPPRESSION AFTER RAPID ART START IN A SAFETY-NET CLINIC - (04/05/19)
     
  2451. AMCP - Long-Term Benefits of Rapid Antiretroviral Therapy Initiation Among Medicaid-Covered Patients With Human Immunodeficiency Virus - (04/04/19)
     
  2452. AMCP - Rapid Initiation of Antiretroviral Treatment Following Diagnosis of Human Immunodeficiency Virus Among Commercially-Insured Patients in the United States - (04/04/19)
     
  2453. AMCP - Estimating Costs of Health Resource Utilization for Patients Living With Human Immunodeficiency Virus - (04/04/19)
     
  2454. CROI: Aging At CROI 2019 - (04/02/19)
     
  2455. Weight gain, blood pressure rise seen with JAK inhibitor therapy - (04/02/19)
     
  2456. Study Confirms Tesamorelin Significantly Reduces Liver Fat in HIV Patients With NAFLD - press announcement - (04/02/19)
     
  2457. CROI: EFFECT ON PLASMA NFL, A MARKER OF NEURONAL INJURY, AFTER SWITCHING FROM TDF TO TAF - (04/01/19)
     
  2458. CROI: EFFECTS OF PROBIOTIC VISBIOME ES ON COLONIC MUCOSAL CD4 CELLS: RESULTS FROM A5352S - (04/01/19)
     
  2459. CROI: BENEFICIAL EFFECT OF 6 MONTHS OF PROBIOTICS ON ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT - (04/01/19)
     
  2460. CROI: 26th Conference on Retroviruses and Opportunistic Infections (CROI) Seattle, WA - Eric S. Daar, M.D. - (03/29/19)
     
  2461. CROI: HIV Prevention at CROI 2019 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/29/19)
     
  2462. CROI: Changes in Kidney Function Among MSM Initiating On-Demand TDF/FTC for HIV Pre-Exposure Prophylaxis - (03/29/19)
     
  2463. CROI: I Keep Forgetting HIV, Aging, and Cognitive Disorders - (03/29/19)
     
  2464. CROI: THE PROJECTED AGE DISTRIBUTION OF WHITE, BLACK, AND HISPANIC MSM ON ART, 2009-2030 / 20% White MSM Projected to be over 70 by 2030 - (03/28/19)
     
  2465. CROI: THE PROJECTED AGE DISTRIBUTION OF WHITE, BLACK, AND HISPANIC MSM ON ART, 2009-2030 - (03/28/19)
     
  2466. CROI: Earlier Age of Onset and Higher Prevalence of Comorbidities in People Living with HIV: A Population-Based Cohort Study in British Columbia, Canada - (03/28/19)
     
  2467. CROI: PROJECTED GROWTH AND NEEDS OF AGING PLWH IN HRSA'S RYAN WHITE HIV/AIDS PROGRAM .....from 2010 through 2030 % > 50 years old doubles with curve sharply increasing-see graph below - (03/28/19)
     
  2468. CROI: Suicide rates among adults living with HIV, 2000-2015 - (03/28/19)
     
  2469. NHPC: Trends in HIV Testing, Diagnosis, and Linkage to Care among Transgender Women Tested in Tested in CDC-Funded Sites, 2012-2017 - (03/27/19)
     
  2470. NHPC: CDC Reports 57% Viral Suppression Rates - (03/27/19)
     
  2471. NHPC: CDC Viral Load Suppression Reporting - (03/27/19)
     
  2472. NHPC: Dental Care for HIV Difficult To Secure / Is Very Important - (03/27/19)
     
  2473. NHPC: CDC Prevention Conference: 9 Highlights - 50% Tested for HIV / Transmission Rate 0 if Undetectable / Florida: 73% in care - (03/27/19)
     
  2474. NHPC: HIV care engagement and sustained viral suppression among persons with diagnosed HIV Infection in Medicaid expansion and non-expansion states, United States, 2015 - (03/27/19)
     
  2475. NHPC: HIV care engagement and sustained viral suppression among persons with diagnosed HIV Infection in Medicaid expansion and non-expansion states, United States, 2015 - (03/27/19)
     
  2476. CROI: Delayed HCC Diagnosis in HIV/HCV Coinfected: HIV not linked to worse liver cancer survival in people with HCV - (03/26/19)
     
  2477. CROI: AIDS illness, living in US South, lower CD4s linked to longer hospital stay with HIV - (03/26/19)
     
  2478. CROI: Factors associated with therapeutic failure of 2-drug regimens, DAT'AIDS cohort: Two-antiretroviral maintenance failure--raltegravir regimens seem most vulnerable - Mark Mascolini (03/26/19)
     
  2479. Neurocognitive SuperAging (SA) in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates (CHARTER) - (03/25/19)
     
  2480. CROI: Integrase Strand Transfer Inhibitors are Associated With Weight Gain in Women - (03/25/19)
     
  2481. CROI: Can HBV Be Cured? - "Single hepatocyte analysis in HIV-HBV co-infection shows transcriptional silencing" - (03/22/19)
     
  2482. CROI: Integrase Inhibitor Exposure and Central Nervous System & Neural Tube Defects - Data from the Antiretroviral Pregnancy Registry - (03/20/19)
     
  2483. NHPC: HIV risk in MSM, transgender people, high-school students, new mothers - Mark Mascolini (03/25/19)
     
  2484. NHPC: PrEP prescribers multiply as adherence and persistence get high marks - Mark Mascolini (03/22/19)
     
  2485. NHPC: US trends in HIV testing, linkage to care, and transmission - Mark Mascolini (03/22/19)
     
  2486. CROI: High maternal HBV with HIV tied to low infant weight and HIV transmission - Mark Mascolini (03/22/19)
     
  2487. NY Times article: This is Not A Cure for My H.I.V. - (03/22/19)
     
  2488. Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors - (03/22/19)
     
  2489. Aspirin Use Discourged / 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease - (03/22/19)
     
  2490. Ten Things I Learned About Aspirin at ESC 2018, 3 studies on aspirin use COMMENTARY - BOTH STUDIES ARE BELOW - (03/22/19)
     
  2491. CROI: Real-life efficacy and safety of Glecaprevir/Pibrentasvir in a large cohort of HCV-infected patients: the MISTRAL study - (03/20/19)
     
  2492. CROI: Liver stiffness at SVR predicts hepatic complications in HCV-infected patients - (03/20/19)
     
  2493. CROI: Integrase Inhibitor Exposure and Central Nervous System & Neural Tube Defects - Data from the Antiretroviral Pregnancy Registry - (03/20/19)
     
  2494. CROI: Inflammation, Arterial Stiffness and Directly-Acting ntivirals in HCV and HIV/HCV, no beneft observed in this study - (03/20/19)
     
  2495. CROI: Successful HCV treatment does not affect rate of heart disease or non-AIDS cancer - Mark Mascolini (03/20/19)
     
  2496. CROI: DAA therapy for HCV lowers risk of cardiovascular disease at all fibrosis stages - (03/20/19)
     
  2497. CROI: Maternal HBV Viremia Is Associated With Adverse Infant Outcomes In HIV/HBV Women: Post-Hoc Analysis of HPTN 046 - (03/20/19)
     
  2498. CROI: HCV treatment with DAAs halves risk of new diabetes diagnosis - Mark Mascolini (03/20/19)
     
  2499. CROI: High maternal HBV with HIV tied to low infant weight and HIV transmission - Mark Mascolini (03/20/19)
     
  2500. CROI: High endothelial dysfunction rate with recent HIV in young adults with low cardiovascular risk - Mark Mascolini (03/19/19)
     
  2501. CROI: ART IN EARLY INFECTION IMPROVES NEUROCOGNITION REGARDLESS OF INFECTION DURATION - (03/19/19)
     
  2502. CROI: GENOTYPIC AND PHENOTYPIC SUSCEPTIBILITY TO FOSTEMSAVIR IN MULTIDRUG-RESISTANT HIV-1 - (03/19/19)
     
  2503. CROI: DOLUTEGRAVIR: ABSENCE OF DEVELOPMENTAL TOXICITY INCLUDING NTDs IN ANIMAL STUDIES - (03/19/19)
     
  2504. CROI: NO INCREASE IN BIRTH DEFECTS IN INFANTS EXPOSED TO INTEGRASE INHIBITORS AT CONCEPTION - (03/19/19)
     
  2505. CROI: Integrase Inhibitor Exposure and CNS and Neural Tube Defects: Data from the Antiretroviral Pregnancy Registry (APR) - (03/19/19)
     
  2506. CROI: Reports of Neural Tube Defects for 8 ARVs in FDA, WHO, EMA and UK Pharmacovigilance Safety Databases - (03/19/19)
     
  2507. CROI: Antiretroviral Adherence and HIV-1 Drug Resistance in the US - (03/19/19)
     
  2508. CROI: RELAPSE OF SYMPTOMATIC CSF HIV ESCAPE UPON PREVIOUSLY OPTIMIZED C-ART REGIMEN CHANGES - (03/18/19)
     
  2509. CROI: Combination of CRISPR and LASER ART Eliminates Replication Competent Rebound in Humanized Mice - (03/18/19)
     
  2510. CROI: Lymphoid Tissue Pharmacokinetics of Tenofovir-alafenamide vs. disoproxil fumarate - (03/18/19)
     
  2511. CROI: MODERATE EFFICACY OF ORAL SINGLE-AGENT TAF AGAINST VAGINAL SHIV INFECTION IN MACAQUES - (03/18/19)
     
  2512. CROI: USING EHR DATA TO IDENTIFY POTENTIAL PREP CANDIDATES IN A LARGE HEALTH CARE SYSTEM - (03/18/19)
     
  2513. CROI: Prediction of Renal OAT1 and OAT3 Inhibition by Cabotegravir Using PBPK Modelling - (03/18/19)
     
  2514. CROI: Hormonal Contraceptives Do Not Alter Cabotegravir PK in HIV Uninfected Women: HPTN 077 - (03/18/19)
     
  2515. CROI: Immediate PrEP Initiation at New York City Sexual Health Clinics - (03/18/19)
     
  2516. CROI: One in 50 in NYC with recently diagnosed HIV used PrEP in preceding months..... PrEP Use in Persons With Undetected HIV Infections Contributes to Resistance - Mark Mascolini (03/18/19)
     
  2517. CROI: Sex-specific Patterns in HIV-associated Cardiovascular Mortality in New York City - (03/18/19)
     
  2518. CROI: New HIV/ART Drugs at CROI 2019 - (03/18/19)
     
  2519. CROI: THERAPEUTIC ACTIVITY OF PGT121 MONOCLONAL ANTIBODY IN HIV-INFECTED ADULTS - (03/18/19)
     
  2520. CROI: THERAPEUTIC ACTIVITY OF PGT121 MONOCLONAL ANTIBODY IN HIV-INFECTED ADULTS - (03/15/19)
     
  2521. CROI: GS-9722: First-in-Class, Effector-Enhanced, Broadly Neutralizing Antibody for HIV Cure - and PGT121 in HIV+ / PGT121 bNAb in HIV+ - (03/15/19)
     
  2522. CROI: CHARACTERIZING THE HIV DNA RESERVOIRS IN WHOLE-BODY TISSUES IN THE "LAST GIFT" COHORT - (03/15/19)
     
  2523. CROI: A Phase IIa Study of a Novel Maturation Inhibitor GSK2838232 in HIV patients - (03/15/19)
     
  2524. CROI: Long-Term B/F/TAF Switch Efficacy in Patients with Archived Pre-Existing Resistance - (04/08/19)
     
  2525. CROI: Susceptibility to Bictegravir in Highly ARV Experienced Patients After INSTI Failure - (03/15/19)
     
  2526. CROI: High Level of Preexisting NRTI Resistance Prior to Switching to B/F/TAF: Study 4030 - (03/15/19)
     
  2527. CROI: Sharp drop in acute HCV among London MSM with HIV after DAAs arrived - Mark Mascolini (03/15/19)
     
  2528. CROI: BICTEGRAVIR/FTC/TAF SINGLE-TABLET REGIMEN IN ADOLESCENTS & CHILDREN: WEEK 48 RESULTS - (03/15/19)
     
  2529. CROI: Half with HIV in US have virus over 3 years before diagnosis--some groups lag overall trends - "Duration of infectiousness among persons with HIV diagnosed during 2012-2016" - Mark Mascolini (03/15/19)
     
  2530. CROI: Frequent PSA screening, lower prostate cancer incidence, in veterans with HIV - Mark Mascolini (03/15/19)
     
  2531. CROI: In utero HIV exposure tied to obesity, reactive airway disease in adolescence - Mark Mascolini (03/15/19)
     
  2532. CROI: HIV Resistance Associated Mutations Observed in Cell-Associated DNA Sequencing Assay - (03/14/19)
     
  2533. CROI: Oral TAF alone offers modest protection against vaginal SHIV in monkeys - Mark Mascolini (03/14/19)
     
  2534. CROI: New fracture independently boosts death risk in big US HIV cohort - Mark Mascolini (03/14/19)
     
  2535. CROI: BICTEGRAVIR CONCENTRATIONS AND VIRAL SUPPRESSION IN CSF of HIV-INFECTED PATIENTS - (03/14/19)
     
  2536. CROI: PRO 140 (leronlimab) SC: Long-Acting Single-Agent Maintenance Therapy (SAMT) for HIV-1 Infection - (03/14/19)
     
  2537. CROI: FAVOURABLE OUTCOME of IN VITRO SELECTIONS WITH NOVEL NRTI PRODRUG GS-9131 - (03/14/19)
     
  2538. CROI: PML-IRIS ensuing CNS and subsequent peripheral viral escape of ARV-resistant variants - (03/14/19)
     
  2539. CROI: Rebound Of HIV-1 In Cerebrospinal Fluid (CSF) After Treatment Interruption (TI) - (03/14/19)
     
  2540. CROI: Changes in HIV PrEP awareness and use among men who have sex with men, 2014 vs 2017 - (03/14/19)
     
  2541. CROI: Neurosymptomatic HIV-1 CSF Escape can Occur with Replication in CD4+ T Cells in the CNS - (03/13/19)
     
  2542. CROI: Estimated PrEP Eligibility in a National Sexual Network Study of US MSM - (03/13/19)
     
  2543. CROI: Neurosymptomatic HIV-1 CSF Escape can Occur with Replication in CD4+ T Cells in the CNS - (03/13/19)
     
  2544. CROI: Up to 95% virologic response rate with rapid ART in safety-net clinic - Mark Mascolini (03/13/19)
     
  2545. CROI: Estimate of US MSM eligible for PrEP jumps from 25% in 2015 to 45% today - Mark Mascolini (03/13/19)
     
  2546. TENOFOVIR ALAFENAMIDE VS TENOFOVIR DF IN WOMEN: POOLED ANALYSIS OF 7 CLINICAL TRIALS - (03/13/19)
     
  2547. CROI: DIFFERENTIAL BMI CHANGES FOLLOWING PI- AND INSTI- BASED ART INITIATION BY SEX AND RACE - (03/13/19)
     
  2548. CROI: Viral Suppression Among People Initiating HIV Care: Outcomes from iENGAGE Trial - (03/13/19)
     
  2549. CROI: Injecting drugs, HCV, race are syphilis risk factors in US women with HIV - Mark Mascolini (03/13/19)
     
  2550. CROI: More than 1 year to HIV control raises failure risk almost 10-fold - Mark Mascolini (03/13/19)
     
  2551. CROI: Single monoclonal antibody infusion controls HIV for over 5 months in 2 people - - Mark Mascolini (03/13/19)
     
  2552. CROI: ACTIVITY OF ECD4-IG AGAINST CCR5 ANTAGONIST-RESISTANT HIV-1 - (03/13/19)
     
  2553. CROI: IBALIZUMAB: 96-WEEK DATA AND EFFICACY IN PATIENTS RESISTANT TO COMMON ANTIRETROVIRALS - (03/13/19)
     
  2554. CROI: Rebound of HIV-1 in Cerebrospinal Fluid (CSF) after Treatment Interruption (TI). Themed discussion webcast - (03/13/19)
     
  2555. CROI: DTG vs LPV/r (DAWNING): Efficacy by Baseline NRTI Resistance and Second-Line NRTI Use - (03/13/19)
     
  2556. CROI: Efficacy and Safety of the Once-daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Single-tablet Regimen in Antiretroviral Treatment (ART)-experienced and ART-naïve Women Living with HIV-1: EMERALD and AMBER Week 96 Results - (03/13/19)
     
  2557. CROI: Efficacy and Safety of the Once-daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Single-tablet Regimen in Antiretroviral Treatment (ART)-experienced and ART-naïve Women Living with HIV-1: EMERALD and AMBER Week 96 Results - (03/13/19)
     
  2558. CROI: LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV MAINTENANCE: FLAIR WEEK 48 RESULTS - (03/11/19)
     
  2559. CROI: Obesity & Weight Gain on Antiretroviral Therapy - (03/11/19)
     
  2560. CROI: RISK FACTORS FOR EXCESS WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITOR-BASED ART - (03/11/19)
     
  2561. CROI: Dolutegravir and Insulin Resistance - (03/11/19)
     
  2562. CROI: MIDLIFE ADIPOSITY PREDICTS COGNITIVE DECLINE IN THE MULTICENTER AIDS COHORT STUDY (MACS) - (03/11/19)
     
  2563. CROI: Pharmacogenetics of Weight Gain after Switch from Efavirenz to Integrase Inhibitors - (03/11/19)
     
  2564. CROI: LONG-LASTING ALTERATIONS IN FAT DISTRIBUTION IN PLWH EXPOSED TO THYMIDINE ANALOGUES - (03/11/19)
     
  2565. CROI: Weight Gain During Treatment Among 3,468 Treatment-Experienced Adults with HIV - (03/11/19)
     
  2566. CROI: GREATER WEIGHT GAIN AMONG TREATMENT-NAIVE PERSONS STARTING INTEGRASE INHIBITORS - (03/11/19)
     
  2567. CROI: Weight Gain among Virally Suppressed Persons who Switch to INSTI-Based ART, The HIV Outpatient Study - (03/11/19)
     
  2568. CROI: Two thirds of HIV group report pain and 14% endure "widespread" pain [50% to 80% report pain, average age only 53] - Mark Mascolini (03/11/19)
     
  2569. CROI: The Impact of Weight Gain and Sex on Immune Activation Following Initiation of ART - (03/11/19)
     
  2570. CROI: INTEGRASE STRAND TRANSFER INHIBITORS ARE ASSOCIATED WITH WEIGHT GAIN IN WOMEN - (03/11/19)
     
  2571. CROI: Higher cardiovascular risk in older HIV group tied to worse cognitive function - Mark Mascolini (03/08/19)
     
  2572. CROI: One in 50 in NYC with recently diagnosed HIV used PrEP in preceding months - Mark Mascolini (03/08/19)
     
  2573. CROI: One third of elderly HIV group takes complex regimens and risks drug interactions - Mark Mascolini (03/08/19)
     
  2574. CROI: HIV-Cognitive Impairment/Obesity-Overweight-Exercise-Efavirenz-Age "OBESITY IS INDEPENDENTLY ASSOCIATED WITH NEUROCOGNITIVE DECLINE IN HIV".....16% had neurocognitive impairment (NCI) & 6% frailty at baseline (03/08/19)
     
  2575. CROI: Changes in Lipids After a Direct Switch from TDF to TAF (03/08/19)
     
  2576. CROI: Memory and Learning Dysfunction with Integrase Strand Transfer Inhibitor Use (03/08/19)
     
  2577. CROI: MK-8591 Potency and PK Provide High Inhibitory Quotients at Low Doses QD and QW (03/08/19)
     
  2578. CROI: Once-Daily Doravirine in HIV-1-Infected, Antiretroviral-Naive Adults: An Integrated Efficacy Analysis (03/08/19)
     
  2579. CROI: Obesity--but not frailty--predicts neurocognitive impairment with HIV - Mark Mascolini (03/08/19)
     
  2580. CROI: SAFETY AND PK OF SUBCUTANEOUS GS-6207, A NOVEL HIV-1 CAPSID INHIBITOR (03/08/19)
     
  2581. CROI: Efficacy of the Two-Drug Regimen of Dolutegravir Plus Lamivudine (DTG+3TC) vs Dolutegravir Plus Tenofovir/Emtricitabine (DTG+TDF/FTC) at W48 in Antiretroviral Naive Women: GEMINI Studies Subgroup Analysis (03/08/19)
     
  2582. CROI: Week 48 Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Women in the BRIGHTE Study (03/08/19)
     
  2583. CROI: ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily, Three-Drug Oral Treatment in Adults Living with HIV-1 Infection (03/08/19)
     
  2584. CROI: Monthly injected cabotegravir/rilpivirine noninferior to oral DTG at 48 weeks - Mark Mascolini (03/08/19)
     
  2585. CROI: Janssen Announces Results Of Two Phase 3 Studies Which Showed Long-Acting Injectable HIV Treatment Regimen Of Rilpivirine And Cabotegravir Demonstrated Comparable Safety And Efficacy To Daily Oral HIV Therapy (03/08/19)
     
  2586. CROI: ANALYTIC TREATMENT INTERRUPTION (ATI) AFTER ALLOGENEIC CCR5-D32 HSCT FOR AML IN 2013 (03/08/19)
     
  2587. CROI: Lymphoid Tissue Pharmacokinetics of Tenofovir-alafenamide vs. disoproxil fumarate (03/08/19)
     
  2588. CROI: Lymphoid tissue PKs of tenofovir-alafenamide vs. -disoproxil fumarate / Tenofovir levels in human PBMCs and lymph nodes higher with TAF than TDF - Mark Mascolini (03/08/19)
     
  2589. CROI: Yearly suicide rate in white men with HIV usually far exceeds rate in US population - Mark Mascolini (03/08/19)
     
  2590. CROI: LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR MAINTENANCE THERAPY: ATLAS WEEK 48 RESULTS (03/07/19)
     
  2591. CROI: SUSTAINED HIV-1 REMISSION FOLLOWING HOMOZYGOUS CCR5 DELTA32 ALLOGENIC HSCT (03/07/19)
     
  2592. CROI: Edoxaban lowers coagulation but not inflammation in people on ART - Mark Mascolini (03/07/19)
     
  2593. CROI: Cognitive impairment tied to doubled death risk in US and African HIV groups - Mark Mascolini (03/07/19)
     
  2594. CROI: Higher risk of recurrent venous thromboembolism with HIV in Dutch national study - Mark Mascolini (03/07/19)
     
  2595. CROI: THE PHASE 3 DISCOVER STUDY: DAILY F/TAF OR F/TDF FOR HIV PREEXPOSURE PROPHYLAXIS - (03/06/19)
     
  2596. CROI: EFFECTS OF PROBIOTIC VISBIOME ES ON COLONIC MUCOSAL CD4 CELLS: RESULTS FROM A5352S - (03/06/19)
     
  2597. CROI: BENEFICIAL EFFECT OF 6 MONTHS OF PROBIOTICS ON ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT - (03/06/19)
     
  2598. CROI: CABOTEGRAVIR IS NOT ASSOCIATED WITH WEIGHT GAIN IN HIV-NEGATIVE INDIVIDUALS - (03/06/19)
     
  2599. CROI: Evaluation of Neural Tube Defects After Exposure to Raltegravir During Pregnancy - (03/06/19)
     
  2600. CROI: BREAKING BONES IS BAD: INCIDENT FRACTURE AND MORTALITY IN THE HIV OUTPATIENT STUDY - 45% Increased Mortality Associated with Fracture - (03/06/19)
     
  2601. CROI: Antiactivation activity with kinase inhibitor - JAK Inhbitor - added to suppressive ART / "Safety, tolerability and immunologic activity of ruxolitinib added to suppressive ART" - Mark Mascolini (03/05/19)
     
  2602. CROI: Longer sustained use of levonorgestrel IUD than copper IUD by women with HIV / "Randomized controlled trial of intrauterine device safety in women living with HIV" - Mark Mascolini (03/05/19)
     
  2603. CROI: Better HIV control with dolutegravir than efavirenz started late in pregnancy / "RCT of dolutegravir vs efavirenz-based therapy initiated in late pregnancy: DOLPHIN-2" - Mark Mascolini (03/05/19)
     
  2604. CROI: COPD doubles heart attack risk with HIV regardless of smoking / "COPD and the risk of MI by type in people living with HIV" - Mark Mascolini (03/05/19)
     
  2605. CROI: Sudden cardiac death risk higher with HIV--but not with sustained HIV control / "Sudden cardiac death among HIV-infected and -uninfected veterans" - Mark Mascolini (03/05/19)
     
  2606. CROI: Probiotic does not alter inflammation/activation markers in group on stable ART / "Assessing the probiotic effect in treated HIV: results of ACTG A5350" - Mark Mascolini (03/05/19)
     
  2607. CROI: HIV tied to almost 2-fold lower breast cancer survival - Mark Mascolini (03/05/19)
     
  2608. CROI: Has a second person with HIV been cured? - (03/05/19)
     
  2609. CROI: UPDATE ON HIV PREVENTION CROI 2019 - (03/05/19)
     
  2610. CROI: UPDATE ON HIV CURE - CROI 2019 - (03/05/19)
     
  2611. CROI: NASH IN HIV - CROI 2019 - (03/05/19)
     
  2612. SHIVER: 1ST INTERNATIONAL WORKSHOP OF THE STEATOHEPATITIS IN HIV EMERGING RESEARCH (SHIVER) NETWORK - (03/01/19)
     
  2613. HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy - (03/01/19)
     
  2614. ViiV ADHOC - Aging with Dignity, Health, Optimism, & Community Study /Registry - (03/01/19)
     
  2615. ViiV ADHOC Aging/HIV Study Registry / Database - "Loneliness Among Older Adults HIV+" - (03/01/19)
     
  2616. Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV - (03/01/19)
     
  2617. 2 Very Recent Studies Linking Inflammation to Causing Cognitive Impairment / inflammation-telomerase connection - (02/27/19)
     
  2618. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials - (02/27/19)
     
  2619. Primary prevention with statins for older adults - Editorial / Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study - (02/27/19)
     
  2620. Primary prevention with statins for older adults - Editorial / Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study - (02/26/19)
     
  2621. ART - Lipodystrophy/Diabetes/Fat Tissue/Mitochondrial damage/Heart Disease: Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy - (02/26/19)
     
  2622. High-Fat Diets Linked With Changes in Gut - (02/26/19)
     
  2623. 2 Studies: Frailty Associated with 4 Times Increased Death Rates in HIV+, Associated with Comorbidities Onset, 2- Frailty and NCI (neurocognitive impairment) in study 2 Led to Increased disability, falls, in inability to Function Measuring by IADLs, independent living - (02/26/19)
     
  2624. OAR Advisory Council Meeting - Aging/HIV Discussion Slide Presentation by NIA HIV-Brain Researcher - Nov 15 2018 - (02/26/19)
     
  2625. Diagnosis and Treatment of Cognitive Impairment in HIV Patients - (02/25/19)
     
  2626. Clinical outcomes of young black men receiving HIV medical care in the United States, 2009-2014 - (02/25/19)
     
  2627. Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate - (02/25/19)
     
  2628. Fanconi Syndrome and Tenofovir Alafenamide: A Case Report - (02/25/19)
     
  2629. Statin Toxicity in HIV+ & Elderly - (02/25/19)
     
  2630. Systemic inflammation during midlife and cognitive change over 20 years - (02/15/19)
     
  2631. New Frailty HIV-Specific Index- see table below listing 37-item frailty list index used in this study / What is Frailty in HIV ??? / 52% Pre-Frail at 48 in this study - (02/15/19)
     
  2632. Fanconi Syndrome and Tenofovir Alafenamide: A Case Report - (02/13/19)
     
  2633. TAT Vaccine Study......decays HIV DNA, immune restoration: increased CD4, improved CD4/CD8 ratio, slowed disease progression - (02/13/19)
     
  2634. New Full Text AHA Heart Disease Guidelines & Recommendations - cholesterol, LDL, statins, PCSK inhibitors, ezetimibe therapy / Statin Safety published by AHA - (02/11/19)
     
  2635. HIV Viral Load and Transmissibility of HIV InfectionUndetectable Equals Untransmittable - Viewpoint - (02/11/19)
     
  2636. Ending the HIV Epidemic-A Plan for the United States - Editorial - (02/11/19)
     
  2637. Ultra-long-acting removable drug delivery system for HIV treatment and prevention/Dolutegravir Implant - (02/11/19)
     
  2638. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial Clinical Infectious Diseases, Volume 68, Issue 4, 1 February 2019 supplementary material - (02/11/19)
     
  2639. Cardiac dysfunction prevalent in patients with HIV. - Editorial - Myocardial Dysfunction With Contemporary Management of HIV Prevalence, Pathophysiology, and Opportunities for Prevention - Belly Fat-Lipodystrophy Connection - (01/30/19)
     
  2640. GLASGOW: Week 48 Resistance Analyses of the Once-daily, Single-tablet Regimen Darunavir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the AMBER and EMERALD Phase 3 Trials - (02/6/19)
     
  2641. Cardiac dysfunction prevalent in patients with HIV. - Editorial - Myocardial Dysfunction With Contemporary Management of HIV Prevalence, Pathophysiology, and Opportunities for Prevention - Belly Fat-Lipodystrophy Connection - (01/30/19)
     
  2642. Do people living with HIV experience greater age advancement than their HIV-negative counterparts? - (01/30/19)
     
  2643. Prevalence and 1-year incidence of frailty among women with and without HIV in the Women's Interagency HIV Study - (01/30/19)
     
  2644. MACS Frailty - HIV-1 Infection Is Associated With an Earlier Occurrence of a Phenotype Related to Frailty - (01/30/19)
     
  2645. Myocardial Dysfunction With Contemporary Management of HIV Prevalence, Pathophysiology, and Opportunities for Prevention / Belly Fat-VAT-Lipodystrophy - (01/29/19)
     
  2646. Myocardial Dysfunction With Contemporary Management of HIV Prevalence, Pathophysiology, and Opportunities for Prevention / Belly Fat-VAT-Lipodystrophy - (01/29/19)
     
  2647. A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction - (01/29/19)
     
  2648. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia - (01/28/19)
     
  2649. GLASGOW: Comorbidities, Comedication, and Polypharmacy Burden in Patients With HIV: Retrospective Claims Data in Germany - (01/28/19)
     
  2650. U.S. FDA Accepts sNDAs for PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) - (01/23/19)
     
  2651. High Rates of Virologic Suppression Achieved in MSM or Black/African American Individuals Using a Rapid Initiation Model of Care for Patients Newly Diagnosed With HIV-1 Infection: A Week 24 Interim Analysis of the DIAMOND Study - (01/22/19)
     
  2652. Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm - (01/16/19)
     
  2653. Dolutegravir+3TC 2-Drug ART Awaiting FDA Approval - (01/14/19)
     
  2654. ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine (1) - (01/14/19)
     
  2655. HIV Viral Load and Transmissibility of HIV InfectionUndetectable Equals Untransmittable - (01/14/19)
     
  2656. Mild renal impairment is associated with calcified plaque parameters assessed by computed tomography angiography in people living with HIV - (01/14/19)
     
  2657. Fat redistribution phenotypes, characterized by SAT loss and/or VAT accumulation, may be linked to arterial injury and inflammation in HIV - (01/14/19)
     
  2658. Do people living with HIV experience greater age advancement than their HIV-negative counterparts? Yes-Biological Age greater by 13 Years in HIV+ - (01/14/19)
     
  2659. Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (01/14/19)
     
  2660. Merck Exercises Option for NGM Bio's Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes - (01/08/19)
     
  2661. Aging & the Brain - Hyperactive Innate Immunity Causes Degeneration of Dopamine Neurons upon Altering Activity of Cdk5 - (01/04/19)
     
  2662. Weight Gain TAF vs TDF - A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017 - (01/04/19)
     
  2663. Cognitive Impairment and 1-Year Outcome in Elderly Patients with Hip Fracture.....hip fracture death rates are 11% to 34% - (01/04/19)
     
  2664. Unintended Harm Associated With the Hospital Readmissions Reduction Program - Editorial - (01/03/19)
     
  2665. CMS Incentivizes Bad Health Care - Hospital Readmissions Reduction Program Associated With Higher Mortality - (01/03/19)
     
  2666. Brain Atrophy in HIV+ > 60 is Progressive Despite Viral Suppression / ART Neurotoxicity /LIMC / Aging/ Mental & Substance Abuse Disorders - (01/02/19)
     
  2667. HIV-positive participants had worse complex motor performance than HIV-negative participants - (01/02/19)
     
  2668. HIV infection [slows brain activity] results in ventral-striatal reward system hypo-activation during cue processing - (01/02/19)
     
  2669. How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 randomised controlled trials assessing exercise and medication effects on systolic blood pressure - (01/02/19)
     
  2670. The Challenges of Improving Treatments for Depression - (01/02/19)
     
  2671. EVALUATING THE LINK BETWEEN MITOCHONDRIAL STATE & HIV-SPECIFIC CD8+ T CELL EXHAUSTION - (01/02/19)
     
  2672. Updated HHS ART Guidelines/Oct 25 2018 - (12/21/18)
     
  2673. HIV-Related Stigma Affects - impairs - Cognition, Physical Function & the Brain in Older Men Living with HIV - (12/19/18)
     
  2674. De novo NAD+ synthesis enhances mitochondrial function and improves health - (12/19/18)
     
  2675. ART Promise is Gone For Older Aging HIV+ - (12/19/18)
     
  2676. HIV Death Rates Will Increase Due To Aging/Comorbidities & Healthcare Costs Will Double Housing, This Must Get Close Attention - (12/19/18)
     
  2677. Beating Aging/HIV - How to Be More Resilient - (12/19/18)
     
  2678. Preclinical Biomarkers for Functional Decline in HIV and Aging - (12/19/18)
     
  2679. Cure: Little Progress & Disappointing thus far, Researchers say - (12/19/18)
     
  2680. The Demographic Shift in HIV: The Aging HIV Patient - (12/19/18)
     
  2681. Effect of Testosterone Use on Bone Mineral Density in HIV-Infected Men - (12/12/18)
     
  2682. Antiretroviral treatment interruptions in HIV clinical trials: A systematic review - (12/12/18)
     
  2683. Fracture Prevention with Zoledronate in Older Women with Osteopenia + Editorial - (12/11/18)
     
  2684. Cardiovascular Risk Reduction with Icosapent Ethyl (Vascepa) for Hypertriglyceridemia - (12/11/18)
     
  2685. NYC DOH Released New 2017 HIV Surveillance Report....23.9% over 60 years old, 77% over 40....55% over 50 - (12/05/18)
     
  2686. Differential Detection of M184V/I Between Plasma Historical HIV Genotypes and Proviral DNA from PBMCs - (12/05/18)
     
  2687. Initial Viral Load Decline and Response Rates by Baseline Viral Load Strata With Dolutegravir Plus Lamivudine Versus Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Results From the GEMINI Studies - (12/05/18)
     
  2688. Prevalence of Neuropsychiatric Conditions among HIV Positive Compared to HIV Negative Commercially Insured Individuals - (12/05/18)
     
  2689. Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients - modest TG reduction - (11/30/18)
     
  2690. HIV & Liver Disease Research Grants up to $130,000 - (11/28/18)
     
  2691. European Commission Approves Merck's DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients - (11/28/18)
     
  2692. 79 Year old HIV+ Alzheimers Case Reported - (11/28/18)
     
  2693. VITAL Signs for Dietary Supplementation to Prevent Cancer and Heart Disease - Editorial - (11/28/18)
     
  2694. CVD & Vascepa EPA Fish Oil 4000 mg Daily - "Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial" REDUCE-It Trial - (11/28/18)
     
  2695. The VITamin D and OmegA-3 TriaL (VITAL): Principal Results for Cardiovascular Disease and Cancer - (11/28/18)
     
  2696. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer - (11/28/18)
     
  2697. Reduction of Cardiovascular Events With Icosapent Ethyl (Vascepa) -Intervention Trial - REDUCE-IT / 20% to 28% improved CVD outcomes "highly impressive" ! - (11/27/18)
     
  2698. New Valsarten Recall by FDA / Mylan - (11/27/18)
     
  2699. Mylan Recalls 15 Lots of Valsartan Products in US - (11/27/18)
     
  2700. Vitamin D and Omega-3 Trial - VITAL - (11/27/18)
     
  2701. REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides - (11/27/18)
     
  2702. Icosapent Ethyl Reduces Ischemic Event Risk in Patients With Hypertriglyceridemia Despite Statin Use - (11/27/18)
     
  2703. REDUCE-IT: Cardiovascular Risk Reduction With Icosapent Ethyl for Hypertriglyceridemia - (11/27/18)
     
  2704. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials - (11/20/18)
     
  2705. AASLD: VITAMIN E IS AN EFFECTIVE TREATMENT FOR NASH IN HIV MONO-INFECTED PATIENTS: THE CTN-PT 024 TRIAL - (11/20/18)
     
  2706. HIVR4P: Anal Sex Frequent--and Often Condom-Free--in Global Female Sex Worker Study - Mark Mascolini (11/09/18)
     
  2707. HIVR4P: New HIV Rate Remains "Alarmingly High" in MSM and TGW of Sub-Saharan Africa - Mark Mascolini (11/09/18)
     
  2708. AGE: Comprehensive Geriatric Assessment (CGA) - (11/09/18)
     
  2709. GLASGOW: HIV and Cancer Curative Approaches Cross-disciplinary research - (11/09/18)
     
  2710. GLASGOW: Pharmacokinetics of MK-8591, Dolutegravir and Tenofovir Disoproxil Fumarate Are Not Altered After Coadministration When Compared to Single Agent Administration - (11/09/18)
     
  2711. GLASGOW: Factors associated with HIV associated neurocognitive disorder in an unselected cohort in East and South London-The HAND study - (11/08/18)
     
  2712. GLASGOW: Long-term survivors in a cohort of HIV+ patients diagnosed between 1985 and 1992: predictive factors associated with more than 25 years of survival - (11/08/18)
     
  2713. GLASGOW: HIV and Ageing Challenges and Goals - Plenary Talk at Glasgow 2018 - (11/08/18)
     
  2714. GLASGOW: Cumulative Safety Review of Elvitegravir and Bictegravir use During Pregnancy and Risk of Neural Tube Defects - (11/08/18)
     
  2715. GLASGOW: High Prevalence of Previously Undocumented Baseline M184V/I Does Not Affect Virologic Outcome in Virologically-Suppressed Patients Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from a Boosted Protease Inhibitor-based Regimen - (11/08/18)
     
  2716. GLASGOW: ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV - (11/08/18)
     
  2717. GLASGOW: Analysis of Patients Completing the Ibalizumab Phase 3 Trial and Expanded Access Program - (11/07/18)
     
  2718. GLASGOW: E-Vaccine Registry Helps HIV Group Improve Poor Vaccination Record - Mark Mascolini (11/07/18)
     
  2719. GLASGOW: SVR With DAAs--and Darunavir--Tied to Lipid Jumps in Big HCV/HIV Group - Mark Mascolini (11/07/18)
     
  2720. GLASGOW: Viral Load and Genotypic Resistance Score Predict Response to 2-Drug ART Switch - Mark Mascolini (11/07/18)
     
  2721. GLASGOW: Two Thirds Reach Sub-50 Viral Load Through 48 Weeks With Ibalizumab - Mark Mascolini (11/07/18)
     
  2722. GLASGOW: HIV Linked to Higher Odds of Anemia, Neutropenia, and Thrombocytopenia - Mark Mascolini (11/07/18)
     
  2723. GLASGOW: Waist-to-Hip Ratio Predicts Hepatic Steatosis in People With HIV - Mark Mascolini (11/07/18)
     
  2724. GLASGOW: Viral Load and Genotypic Resistance Score Predict Response to 2-Drug ART Switch - Mark Mascolini (11/07/18)
     
  2725. Non-Smokers Are At Risk for COPD & Marijuana May Add to Risk, Smokers Are At Greater Risk. Lung Cancer in HIV+ is one of the more frequent cancers among men - (11/06/18)
     
  2726. Survey on Cure Research Among HIV+ presented at NIH Strategies for an HIV Cure Meeting - (11/06/18)
     
  2727. PrEP New in Development & Current at HIVR4P - (11/06/18)
     
  2728. HIVR4P: One Year Retention in PrEPCare Outcomes in a Three-site Implementation Science Program in the United States - (11/06/18)
     
  2729. HIVR4P: Tenofovir Rectal Douche Provides Protective Drug Levels in MSM Colon Tissue - on-demand, behaviorally-congruent - Mark Mascolini - (11/06/18)
     
  2730. HIVR4P: Safety and pharmacokinetics of dapivirine and levonorgestrel vaginal rings for multipurpose prevention of HIV and pregnancy - Mark Mascolini - (11/06/18)
     
  2731. HIVR4P: Subcutaneous TAF Implants Pass 63-Day Test in Rabbits for Long-Acting PrEP - Mark Mascolini (11/06/18)
     
  2732. HIVR4P: Development of an End-user Informed Tenofovir Alafenamide (TAF) Implant for Long-acting (LA)-HIV Pre-exposure Prophylaxis (PrEP) - (11/06/18)
     
  2733. HIVR4P: PrEP New in Development & Current at HIVR4P - (11/06/18)
     
  2734. Characterizing the HIV DNA Reservoirs in Whole-Body Tissues in the "Last Gift" Cohort - (11/05/18)
     
  2735. GLASGOW: Approaches towards a cure for HIV - (11/05/18)
     
  2736. GLASGOW: Meta-analysis of the risk of Grade 3/4 or serious clinical adverse events in 12 randomised trials of PrEP - Mark Mascolini - (11/05/18)
     
  2737. GLASGOW: How safe is PrEP? An analysis of the safety of TDF(/FTC) as PrEP - (11/05/18)
     
  2738. GLASGOW: Prevalence of mental health problems among people living with HIV: - (11/05/18)
     
  2739. GLASGOW: Dolutegravir- versus an efavirenz 400mg-based regimen for the initial treatment of HIV-infected patients in Cameroon: 48-week efficacy results of the NAMSAL ANRS 12313 trial - (11/05/18)
     
  2740. GLASGOW: Dolutegravir- versus an efavirenz 400mg-based regimen for the initial treatment of HIV-infected patients in Cameroon: 48-week efficacy results of the NAMSAL ANRS 12313 trial - (11/02/18)
     
  2741. GLASGOW: Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 100 Results From the SWORD-1 and SWORD-2 Studies - (11/02/18)
     
  2742. GLASGOW: Two-Drug Regimen of Dolutegravir Plus Lamivudine (DTG + 3TC) Is Non-Inferior to Dolutegravir Plus Tenofovir/Emtricitabine (DTG + TDF/FTC) at 48 Weeks in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: Subgroup Analyses in the GEMINI Studies - (11/02/18)
     
  2743. GLASGOW: Comparison of Viral Replication Below 50 c/mL for Two-Drug (DTG + RPV) Versus Three-Drug Current Antiretroviral Regimen (CAR) Therapy in the SWORD-1 and SWORD-2 Studies - (11/02/18)
     
  2744. GLASGOW: Phase 3 Study of Fostemsavir in Heavily Treatment-Experienced HIV-1-Infected Participants: BRIGHTE Week 48 Subgroup Analysis in Randomised Cohort Participants - (11/02/18)
     
  2745. GLASGOW: Distribution in Cerebrospinal Fluid (CSF) of Cabotegravir (CAB) and Rilpivirine (RPV) After Intramuscular Administration of Long-Acting (LA) Injectable Suspensions in HIV-1-Infected Patients - (11/02/18)
     
  2746. GLASGOW: Safety, Efficacy and Durability of Long-acting Cabotegravir (CAB) and Rilpivirine (RPV) as Two-Drug IM Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 160 Results - (11/02/18)
     
  2747. GLASGOW: B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naïve adults with high baseline viral load or low baseline CD4 count in two phase III randomized, controlled clinical trials: week 96 results - Mark Mascolini (11/02/18)
     
  2748. AdverseReactComor: Switching tenofovir disoproxil fumarate to tenofovir alafenamide - not only bone and kidney - (11/01/18)
     
  2749. AdverseReactComor: HIV-negative men who have sex with men have lower CD4/CD8 ratios driven by higher absolute CD8 T-lymphocyte counts compared to HIV-negative heterosexual men - (11/01/18)
     
  2750. GLASGOW: Distribution in Cerebrospinal Fluid (CSF) of Cabotegravir (CAB) and Rilpivirine (RPV) After Intramuscular Administration of Long-Acting (LA) Injectable Suspensions in HIV-1-Infected Patients - oral talk has extra data - (11/02/18)
     
  2751. GLASGOW: Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study - (11/02/18)
     
  2752. GLASGOW: Impact of HIV on quality of life: Preliminary data exploring differences by sex and country (UK and US) using the HIV Dependent Quality of Life questionnaire (HIVDQoL) - (11/02/18)
     
  2753. GLASGOW: New Drugs and Strategies for the Treatment of HIV - (11/02/18)
     
  2754. GLASGOW: Safety and Efficacy of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1 Infected Adults With Transmitted Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations - (11/02/18)
     
  2755. GLASGOW: The impact of M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir regimens prescribed in treatment-experienced patients - (11/02/18)
     
  2756. GLASGOW: Comparison of HIV-1 Intermittent Viremia for Two Drug (DTG+RPV) vs Three Drug Current Antiretroviral Therapy in the SWORD-1 and SWORD-2 Studies - (11/02/18)
     
  2757. GLASGOW: Week 48 Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Participants (BRIGHTE Study) - (11/02/18)
     
  2758. GLASGOW: Patient Proportion With Above-Target LDL Rises 70% With TDF-to-TAF Switch - Mark Mascolini - (11/01/18)
     
  2759. GLASGOW: OUTCOMES OF PATIENTS NOT ACHIEVING PRIMARY ENDPOINT FROM AN IBALIZUMAB PHASE 3 TRIAL - Mark Mascolini - (11/01/18)
     
  2760. GLASGOW: Phase III Randomized, Controlled Clinical Trial of Bictegravir Coformulated with FTC/TAF in a Fixed-dose Combination (B/F/TAF) versus Dolutegravir (DTG) + F/TAF in Treatment-naïve HIV-1 Positive Adults: Week 96 - Mark Mascolini - (11/01/18)
     
  2761. GLASGOW: Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA® in Treatment-Naïve Adults with HIV-1 - Mark Mascolini - (11/01/18)
     
  2762. GLASGOW: Good HIV Response Rate, Sustained Safety Through 96 Weeks With D/C/F/TAF - Mark Mascolini - (11/01/18)
     
  2763. GLASGOW: Efficacy of MK-8591 against diverse HIV-1 subtypes and NRTI-resistant clinical isolates - (11/01/18)
     
  2764. GLASGOW: Efficacy of MK-8591 Against Diverse HIV-1 Subtypes and NRTI-Resistant Clinical Isolates - (10/31/18)
     
  2765. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study - (10/31/18)
     
  2766. GLASGOW: Viral Decay Similar With 2- and 3-Drug Dolutegravir Regimens - Mark Mascolini - (10/30/18)
     
  2767. GLASGOW: Good Later Responses in Some People Whose Ibalizumab "Failed" After 7 Days - Mark Mascolini - (10/30/18)
     
  2768. GLASGOW: Higher Hospital Rate With HIV in Women and Straight Men Than in MSM - Mark Mascolini - (10/30/18)
     
  2769. HIVR4P: Global Update: State of Oral PrEP Implementation and Scale-up - (10/30/18)
     
  2770. HIVR4P: Pharmacokinetic and Pharmacodynamic Evaluation of the Antiretroviral Compound MK-2048 Released From an Intravaginal Ring in Rhesus Macaques - (10/30/18)
     
  2771. HIVR4P: Cabotegravir (CAB) Long-Acting (LA) Phase 3 (Ph3) PrEP Dose Selection Based on Population Pharmacokinetics (PPK) in Healthy and HIV-Infected Adults - (10/30/18)
     
  2772. GLASGOW: No Uptick in HIV Replication After Switch to DTG/3TC in Randomized Trial - Mark Mascolini - (10/29/18)
     
  2773. GLASGOW: Mixed Signals With Cardiovascular Markers in Dolutegravir Switch Study - Mark Mascolini - (10/29/18)
     
  2774. GLASGOW: Neuro Impairment in Over One Third of London HIV Group--Anxiety Doubles Risk - Mark Mascolini - (10/29/18)
     
  2775. GLASGOW: TDF/FTC PrEP as Safe as Placebo in Meta-analysis of 13 Trials Across Globe - Mark Mascolini - (10/29/18)
     
  2776. GLASGOW: Higher Hospital Rate With HIV in Women and Straight Men Than in MSM - Mark Mascolini (10/29/18)
     
  2777. GLASGOW: Annual Comorbidity Cost Averages $8674 in German Analysis of People With HIV - Mark Mascolini (10/29/18)
     
  2778. GLASGOW: The economic burden of comorbidities among people living with HIV in Germany; A cohort analysis using health insurance claims data - (10/29/18)
     
  2779. GLASGOW: Multimorbidity and risk of death differs by gender in people living with HIV in the Netherlands - the ATHENA cohort study - (10/29/18)
     
  2780. GLASGOW: Non-HIV Comorbidity Predicts Mortality: Impact Greater in Women - Mark Mascolini - (10/29/18)
     
  2781. GLASGOW: Integrase Inhibitors, Once-Daily Dosing Boost First-ART Response in 77,999-Person Analysis - Mark Mascolini (10/29/18)
     
  2782. GLASGOW: Integrase Inhibitor Use Doubles in Big Elderly Cohort--No Jump in 2-Drug Regimens / Use of 2-Drug ART - Mark Mascolini (10/29/18)
     
  2783. GLASGOW: Polypharmacy in One Third of Big HIV Cohort vs One Fifth of Non-HIV Group - Mark Mascolini (10/29/18)
     
  2784. GLASGOW: ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen - (10/29/18)
     
  2785. HIVR4P: Beyond TDF/FTC: The Future of Systemic Pre-exposure Prophylaxis - (10/29/18)
     
  2786. HIVR4P: Examining PrEP Interruptions in a Safety-net Primary Care Network: Missed Opportunities to Re-engage PrEP Users Accessing non-PrEP Services - (10/29/18)
     
  2787. HIVR4P: Decreased HIV Incidence Among PrEP Users Compared to Non-users in a Boston Community Health Center, 2012-2017 - (10/29/18)
     
  2788. HIVR4P: Cabotegravir (CAB) Long-Acting (LA) Phase 3 (Ph3) PrEP Dose Selection Based on Population Pharmacokinetics (PPK) in Healthy and HIV-Infected Adults - (10/29/18)
     
  2789. HIVR4P: "AMP" PREP Broadly Neutralizing Antibody Studies / Next Generation PrEP / Tracking Global PrEP Use - (10/29/18)
     
  2790. HIVR4P: Pharmacokinetics of PrEP Agents: Where Do Drugs Go? How Long Do They Last? - (10/26/18)
     
  2791. HIVR4P: HIV Incidence in Persons Using Truvada (FTC/TDF) for HIV Pre-exposure Prophylaxis (PrEP): Worldwide Experience From 46 Studies - (10/26/18)
     
  2792. HIVR4P: Long-term Delivery of Anti-HIV Monoclonal Antibodies with Gene Therapy Approach in Monkeys - (10/26/18)
     
  2793. HIVR4P: Acceptability of long-acting injectable cabotegravir (CAB LA) in HIV-uninfected individuals: HPTN 077 - Mark Mascolini (10/25/18)
     
  2794. HIVR4P: PER ACT HIV TRANSMISSION RISK THROUGH ANAL INTERCOURSE: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS1 - (10/25/18)
     
  2795. HIVR4P: Tail-phase safety, tolerability and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected individuals: HPTN 077 final results - Mark Mascolini - (10/25/18)
     
  2796. HIVR4P: CDC- New HIV Infections / Ending AIDS by Tony Fauci at HIVR4P 2018 - (10/24/18)
     
  2797. HIVR4P: Dapivirine Vaginal Ring Next Steps: Study Results Review, Planning for Introduction & Access, Regulatory Overview - (10/24/18)
     
  2798. HIVR4P: HIV Transmission Rate 10 Times Higher With Anal vs Vaginal Sex: Meta-Analysis - Mark Mascolini (10/24/18)
     
  2799. HIVR4P: Some Men With Urethritis Have HIV in Semen While Suppressed in Blood - Mark Mascolini (10/24/18)
     
  2800. HIVR4P: Low-Dose Aspirin Cuts Inflammation in Blood and HIV Target Cells in Female Genital Tract - Mark Mascolini (10/24/18)
     
  2801. HIVR4P: CD4s in "Normal" Anal Mucosa Are Activated in HIV+ Men With Anal Cancer Precursor - Mark Mascolini (10/24/18)
     
  2802. IDWeek: IMMEDIATE ACCESS TO POST-EXPOSURE PROPHYLAXIS (PEP) THROUGH A 24/7 NYC PEP HOTLINE - (10/22/18)
     
  2803. AdverseReactComor: High Levels of Impaired Physical Function in HIV+ 54 Years Old: Physical functioning among patients aging with HIV vs. HIV-uninfected: feasibility of using the Short Performance Physical Battery in clinical care of people living with HIV aged 50 or older, in the CNICS Cohort. - (10/22/18)
     
  2804. AdverseReactComor: Predictive performance of cardiovascular disease risk equations in people living with HIV - (10/22/18)
     
  2805. SF Aging Survey: Lack of Service; older aging-loneliness-depression, feeling abandoned - (10/22/18)
     
  2806. Low CD4 Measures Predict Virus-Related Cancers in HIV-Negative Gay/Bisexual Men - (10/19/18)
     
  2807. ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV - (10/19/18)
     
  2808. AdverseReactComor: Inflammatory biomarkers, adipokines and longitudinal changes in gait speed and fatigue in men with or at risk for HIV infection - (10/19/18)
     
  2809. AdverseReactComor: Coronary artery calcium scores (CAC) among long-term virologically suppressed non-diabetic HIV-infected elderly - (10/19/18)
     
  2810. Opioid Pain Medication in HIV+: affects brain, cognitive impairment; retention & viral suppression affects - (10/17/18)
     
  2811. Association of antiretroviral therapy with brain aging changes among HIV-infected adults - (10/17/18)
     
  2812. Combination HIV Antibody Infusions Safely Maintain Viral Suppression in Select Individuals: "phase 1b clinical trial in which a combination of 3BNC117 and 10-1074, two potent monoclonal anti-HIV-1 broadly neutralizing antibodies that target independent sites on the HIV-1 envelope spike, was administered during analytical treatment interruption" - (10/17/18)
     
  2813. IAC: Tony Fauci Dismisses Cure/Eradication - Slides at IAC on Vedolizumab Study Imbedded in his talk, where Fauci said...in quotations marks just below - (10/17/18)
     
  2814. AdverseReactComor: Lung disease in HIV: Causes and consequences - (10/16/18)
     
  2815. AdverseReactComor: Alterations in oral microbiota in HIV-infected individuals related to pulmonary function - (10/16/18)
     
  2816. AdverseReactComor: Plasma desmosine/isodesmosine and lung function among people with or at risk of HIV infection - (10/16/18)
     
  2817. AdverseReactComor: ART Initiation with Integrase Inhibitors is Associated with Greater Weight Gain than with PI- or NNRTI-Based ART in the US and Canada - (10/15/18)
     
  2818. AdverseReactComor: HIV-infected individuals using integrase inhibitors are at high risk of weight gain - (10/15/18)
     
  2819. AdverseReactComor: Valganciclovir Reduces an Immune Activation Pathway that Strongly Predicts Morbidity and Mortality in Treated HIV Infection - (10/15/18)
     
  2820. AGE: Aging and Falls & Fractures in HIV+ - (10/15/18)
     
  2821. 50% Have Pain, Neuropathy in HIV+: its implications & psychological affects- distress opioid abuse, depression, adherence - (10/15/18)
     
  2822. IDWeek: With HIV, Does U=U (Undetectable = Untransmittable)? Uh, well, maybe not...... - (10/13/18)
     
  2823. IDWeek: U=U Pro.... - (10/15/18)
     
  2824. IDWeek: PHARMACOKINETIC PROFILE OF IBALIZUMAB FROM A PHASE 3 TRIAL - (10/13/18)
     
  2825. IDWeek: Investigating the Mechanism of a Unique Human Immunodeficiency Virus-1 (HIV-1) Entry Inhibitor, MF275 - (10/13/18)
     
  2826. IDWeek: No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-administration - (10/13/18)
     
  2827. IDWeek: MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol - (10/13/18)
     
  2828. IDWeek: Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States - good picture of the aging generation - (10/13/18)
     
  2829. IDWeek: Retrospective Analysis of Clinical Characteristics and Treatment Patterns among HIV Patients with Commercial and Medicare Advantage Health Insurance in the US: high comorbidities & polypharmacy rates increasing with age - (10/13/18)
     
  2830. IDWeek: Adherence and Persistency with Modern Single vs Multi-Tablet Antiretroviral (ARV) Regimens in 1st treatment of HIV in Clinical Practice - (10/13/18)
     
  2831. IDWeek: Evaluation of Relationships Between UGT1A1Genotypes and Cabotegravir Long-Acting Injection Pharmacokinetics Among HIV-Infected Subjects in the LATTE-2 Study - (10/13/18)
     
  2832. IDWeek: An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults - (10/13/18)
     
  2833. IDWeek: The aging epidemic: virologic control, immunologic recovery, treatment regimens, and clinical outcomes among older adults living with HIV in Washington, DC: Long-Term CD4 and Viral Rebound Trends Worse Over Age 59 Than at 18 to 35 - Mark Mascolini (10/12/18)
     
  2834. IDWeek: Hospitalization rates among persons with HIV who gained Medicaid or private insurance in 2014: Moving From Ryan White to Medicaid or Private Insurance Did Not Boost Hospital Use; BUT Older HIV+ 55-64 Had Double the Hospitalization Rate; Low CD4 & Detectable Viral load also had Higher Hospitalization Rates (10/12/18)
     
  2835. IDWeek: Immune recovery of acute HIV treated patients is characterized by an increase in immune senescence. (10/12/18)
     
  2836. IDWeek: Rational Design of Doravirine (DOR): A Review of Development From Bench to Patients (10/12/18)
     
  2837. IDWeek: The Hepatitis C Virus Cascade of Care at Stony Brook University Hospital: Risk Factors for Linkage to Care (20% linkage to care) (10/12/18)
     
  2838. IDWeek: Real-World Data on Safety and Effectiveness of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection on Opioid Substitution Therapy: Latest Results From the German Hepatitis C-Registry (10/12/18)
     
  2839. IDWeek: Time to Viral Suppression Does not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir (10/12/18)
     
  2840. IDWeek: Hospital Rates Rise With Age for Cancer, Cardio, Other Diseases in US HIV Group - Mark Mascolini (10/10/18)
     
  2841. IDWeek: HCV Testing Among Adolescents and Young Adults in a National Sample of Federally Qualified Health Centers - (10/10/18)
     
  2842. IDWeek: Key factors for treatment changes within one year after starting ART in the German ClinSurv Cohort; between 2005 and 2017: Higher Pretreatment Load, More Pills Predict Faster ART Stop or Switch - Mark Mascolini (10/10/18)
     
  2843. IDWeek: Improving HIV outcomes among HIV-infected patients diagnosed with cancer and followed in an integrated, multidisciplinary, infectious disease/cancer clinic: Better CD4 and Viral Load Outcomes After Meshing HIV and Cancer Care - Mark Mascolini - (10/10/18)
     
  2844. IDWeek: Serum Albumin is Associated with Higher Inflammation and Carotid Atherosclerosis in Treated HIV Infection - (10/10/18)
     
  2845. IDWeek: Acquisition of TDF-Susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis - (10/10/18)
     
  2846. IDWeek: A RETROSPECTIVE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A NUCLEOSIDE-SPARING REGIMEN OF DARUNAVIR, RITONAVIR AND DOLUTEGRAVIR - (10/10/18)
     
  2847. IDWeek: Week 96 results of the phase 3, randomized, non-inferiority EMERALD trial: Efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed adults living with HIV-1 - (10/10/18)
     
  2848. IDWeek: Time to Viral Suppression Does not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir - (10/09/18)
     
  2849. IDWeek: Only 30% With HCV/HIV in Safety-Net System Get HCV Therapy in DAA Era - Hepatitis C eradication: who is being left behind in the HIV population? - Mark Mascolini (10/09/18)
     
  2850. IDWeek: Week 96 results of the phase 3, randomized, non-inferiority EMERALD trial: Efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed adults living with HIV-1 - (10/09/18)
     
  2851. IDWeek: Sustained viral suppression with dolutegravir and boosted darunavir dual therapy among highly treatment-experienced individuals. Sustained Viral Suppression After Switch to Darunavir/Dolutegravir - Mark Mascolini(10/09/18)
     
  2852. IDWeek: Antiretrovirals Perturb Cholesterol Biosynthesis in PBMCs of HIV-Infected Individuals - (10/09/18)
     
  2853. IDWeek: Lung Cancer Chemotherapy Less Frequent With HIV, But Toxicity No Greater - Mark Mascolini (10/09/18)
     
  2854. IDWeek: Primary CNS Lymphoma Treatment Less Aggressive With HIV, But Survival Similar - Mark Mascolini (10/09/18)
     
  2855. IDWeek: Mail-Order Pharmacy, Travel Time to Pharmacy Do Not Affect HIV Control - Mark Mascolini (10/09/18)
     
  2856. IDWeek: Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions following initiation of commonly prescribed antiretrovirals - (10/09/18)
     
  2857. IDWeek: Delayed ART, Smoking, Sleep Apnea, PI, (CVD) Tied to Erectile Dysfunction With HIV - Mark Mascolini (10/09/18)
     
  2858. IDWeek: Mental Health Medications (Non-ARV meds) in Older HIV+ Appear to Cause Cognitive Impairment & Slow Gait Speed - Ethnicity, Insurance Differ in Older HIV Group Taking Mental Health Meds - Mark Mascolini - (10/09/18)
     
  2859. IDWeek: Virally Suppressed PLH Switching From Abacavir To Tenofovir Alafenamide Did Not Have Changes in Immune Activation or Inflammation - (10/06/18)
     
  2860. AGE: Hospital Rates Rise With Age for Cancer, Cardio, Other Diseases in US HIV Group - Mark Mascolini (10/06/18)
     
  2861. AGE: Cumulative Affects of Aging & HIV: mental & physical affects Reported at 2018 aging Workshop - 'mental & physical functional Disabilities' - (10/06/18)
     
  2862. Combination HIV Antibody Infusions Safely Maintain Viral Suppression in Select Individuals: "phase 1b clinical trial in which a combination of 3BNC117 and 10-1074, two potent monoclonal anti-HIV-1 broadly neutralizing antibodies that target independent sites on the HIV-1 envelope spike, was administered during analytical treatment interruption" - (10/06/18)
     
  2863. IDWeek: Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Naïve Patients - (10/06/18)
     
  2864. IDWeek: Doravirine/Lamivudine/Tenofovir DF continues to be Non-Inferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-naïve Adults with HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial - (10/06/18)
     
  2865. IDWeek: Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial - (10/06/18)
     
  2866. IDWeek: A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs DTG/ABC/3TC in Treatment-Naïve Adults at Week 96 - (10/05/18)
     
  2867. IDWeek: Safety of in utero antiretroviral (ARV) exposure: neurologic outcomes in HIV-exposed, uninfected children - (10/05/18)
     
  2868. IDWeek: Results of Patient-Reported Outcome Data from the Phase III BRIGHTE Study of Fostemsavir - (10/05/18)
     
  2869. IDWeek: Half of 50-Plus HIV Group Lonely, But Loneliness Declines in the 60s - Mark Mascolini - (10/05/18)
     
  2870. IDWeek: In 60-Year-Plus HIV Group With Viral Suppression, 70% Have Low CD4:CD8 Ratio - Mark Mascolini - (10/05/18)
     
  2871. IDWeek: Predictors of cardiovascular outcomes in older HIV-infected patients: CORE50 Cohort 10-year follow-up / Framingham Score, Depression, Aspirin Predict Cardiovascular Events in Older People With HIV - Mark Mascolini - (10/05/18)
     
  2872. IDWeek: Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed Adults with HIV-1 - (10/03/18)
     
  2873. IDWeek: Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy - (10/03/18)
     
  2874. IDWeek: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4+ Count, and WHO Clinical Staging - (10/03/18)
     
  2875. IDWeek: Virologic Failure Rate No Higher in Blacks Than Whites in US Military - Mark Mascolini - (10/03/18)
     
  2876. IDWeek: GS-6207: A Novel, Potent and Selective First-In-Class Inhibitor of HIV 1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long Acting Potential in Humans - (10/03/18)
     
  2877. IDWeek: Integrase Inhibitors-based HAART is Associated with Greater BMI Gains in Blacks and Hispanics. - (10/03/18)
     
  2878. IDWeek: HIV More Advanced at Diagnosis in Older People, ART Response Slower - Mark Mascolini - (10/03/18)
     
  2879. IAC: Digital Pre-Exposure Prophylaxis (PrEP): near real-time remote capture of medication ingestion for clinical use in trials and adherence support (09/28/18)
     
  2880. AGE: CD4 effector memory T cells connected to death in veterans living with HIV..... "suggest an accelerated aging of the immune system, and an increase in this particular risk factor for death" - (09/26/18)
     
  2881. AGE: Association between cognitive reserve and cognitive performance in people with HIV: a systematic review and meta-analysis - (09/26/18)
     
  2882. AGE: The Impact of Structured Exercise on Brain Health in Individuals with HIV: A Pilot Study from the Brain Positive Health Now Cohort (BHN).....Improved Physical Function - (09/26/18)
     
  2883. AGE: Falls Among Older Men With or at Risk for HIV Infection - (09/25/18)
     
  2884. AGE: Detectable viral load quadruples odds of recurrent falls in older men with HIV - Mark Mascolini (09/25/18)
     
  2885. Probiotic Safety-No Guarantees - (09/25/18)
     
  2886. Aspirin in Elderly "Healthy" Men Over 65 - Not Effective, Caused Excessive Bleeding, Increased Cancer Rates - (09/25/18)
     
  2887. AGE: 75% Projected to Be Over 50. 85% of HIV+ projected to Have Cadiovascular Disease in USA, 30% malignancy, 23% diabetes. Care Costs Increase by 40% due to Comorbidities. - (09/25/18)
     
  2888. AGE: Frailty Phenotype in Canadian Men and Women with HIV. from Jules: Fried Frailty test is too simple in HIV - (09/25/18)
     
  2889. AGE: How Different Are Invisible and Visible Disabilities in HIV? Over 60 functioning Very Limited - Important Report: mental & physical limitations in Aging HIV+ - (09/25/18)
     
  2890. AGE: Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Treatment-experienced, Virologically Suppressed (EMERALD) and Treatment-naïve (AMBER) Patients: Week 48 Subgroup Analysis by Age - (09/25/18)
     
  2891. AGE: Acute Exercise-Induced Inflammatory Response among Older Adults with and without HIV - (09/25/18)
     
  2892. AGE: Exercise-Induced Inflammatory Changes among Older Adults with and without HIV.... from Jules: look at slides at end showing improved functioning due to exercise with high intensity exercise appearing to show more benefits, and decreased CRP with high intensity. - (09/25/18)
     
  2893. AGE: HIV and the "Geri-ome": Linking Gut Dysbiosis to Inflammation - (09/25/18)
     
  2894. AGE: 'Premature Muscle Aging In Middle-Aged HIV+ men & women' - (09/25/18)
     
  2895. AGE: Aging with HIV? I'm fine, thanks for asking! - 14% Age Well in Canada Cohort - (09/21/18)
     
  2896. Viagra & Melanoma / Hearing-Vision Risk - Role of Sildenafil in Melanoma Incidence and Mortality - (09/20/18)
     
  2897. AGE: Associations of loneliness with cognitive function and quality of life (QoL) among older adults living with HIV - (09/19/18)
     
  2898. AGE: Considerations for The HIV Positive Woman during menopause - (09/19/18)
     
  2899. AGE: Frailty and the Risk of Falls in HIV-Infected Older Adults in the ACTG A5322 Study - (09/19/18)
     
  2900. AGE: Advance Directives and Medical Power of Attorney Assignment in Individuals with HIV - low rates: only 30%-50% or less leave advance directives or power of attorney before death - (09/19/18)
     
  2901. AGE: Cognitive aging in the era of effective antiretrovirals - (09/19/18)
     
  2902. AGE: More than 40% of HIV group has hepatic steatosis, regardless of age - Mark Mascolini (09/19/18)
     
  2903. AGE: Associations of loneliness with cognitive function and quality of life (QoL) among older adults living with HIV - 18% lonely quite often - Mark Mascolini (09/19/18)
     
  2904. AGE: Aging HIV+ Brain - The relationship between synaptodendritic neuropathology and HIV-associated neurocognitive disorders is moderated by age - (09/19/18)
     
  2905. AGE: Muscle mitochondrial function and contemporary anti-retroviral therapy - (09/19/18)
     
  2906. AGE: Physical function worse in older women than men with HIV, despite better CD4 recovery - Mark Mascolini (09/19/18)
     
  2907. AGE: Metabolic syndrome tied to neurocognitive deficit with (but not without) HIV - Mark Mascolini (09/19/18)
     
  2908. AGE: Older age raises odds of amnestic mild cognitive impairment (but not HAND) with HIV - by 5% per year of aging - Mark Mascolini (09/19/18)
     
  2909. AGE: 63% Frail at 65 Years Old-Itlalian Study/NEW HIV Index+Protective Index / HIV-related and social frailty predictors and protectors in 1612-person Italian cohort - (09/19/18)
     
  2910. AGE: HIV and frailty predict first fracture in middle-aged US women's cohort - doubled fracture rates - Mark Mascolini (09/19/18)
     
  2911. ASCEND: Aspirin Not Needed for Primary Prevention in Diabetes - (09/19/18)
     
  2912. ASCEND study results: Definitive data on the use of aspirin and omega-3 fatty acids in diabetic patients - (09/19/18)
     
  2913. AGE: Frailty Phenotype: A Clinical Marker of Age Acceleration in the older HIV-Infected Population - (09/18/18)
     
  2914. AGE: Exhausted & Depleted T Cells in HIV+ Cause Premature Aging & Comorbidities & Frailty Memory loss: T cell subsets associated with mortality in HIV+ and HIV- veterans - (09/18/18)
     
  2915. AGE: Effects of Comorbidity Burden and Age on Brain Integrity in HIV - (09/17/18)
     
  2916. AGE: The Impact of Number of Medications on Falls in Aging Persons Living with HIV - every increase in 1 medication increased risk by 10% for a fall - "50, the new 65?" - (09/17/18)
     
  2917. AGE: Frailty Predicts Fractures Among HIV-infected and Uninfected Women: Results from the Women's Interagency HIV Study - (09/17/18)
     
  2918. AGE: People taking more medications and women have higher fall risk in older HIV group - written by Mark Mascolini - (09/17/18)
     
  2919. AGE: Exercise-induced inflammatory changes among older adults with and without HIV Inflammation does not drop more with HIV after 24 weeks of exercise - written by Mark Mascolini - (09/17/18)
     
  2920. AGE: Only 42% in HIV group have an advance directive immediately before death - written by Mark Mascolini - (09/17/18)
     
  2921. AGE: "Aging well" more frequent than frailty in Canadian HIV group - written by Mark Mascolini - (09/17/18)
     
  2922. AGE: People taking more medications and women have higher fall risk in older HIV group - written by Mark Mascolini - (09/14/18)
     
  2923. AGE: Big HIV clinic sees more than 1000% jump in patients 65 and older - written by Mark Mascolini - (09/14/18)
     
  2924. AGE: Depression, bipolar disorder tied to noncommunicable disease risk with HIV - written by Mark Mascolini - (09/14/18)
     
  2925. Caffeine consumption and mortality in chronic kidney disease: a nationally representative analysis - new study reports caffeine can reduce mortality in chronic kidney disease - (09/14/18)
     
  2926. in NYC - Club drug users had higher odds of reporting a bacterial STI compared with non-club drug users: results from a cross-sectional analysis of gay and bisexual men on HIV pre-exposure prophylaxis - (09/14/18)
     
  2927. HIV testing and pre-exposure prophylaxis (PrEP) use, familiarity, and attitudes among gay and bisexual men in the United States: A national probability sample of three birth cohorts - (09/14/18)
     
  2928. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV - Time to Recognize HIV Infection as a Major Cardiovascular Risk Factor - (09/11/18)
     
  2929. The Aging HIV Brain - HIV Accelerates Brain Aging by 3 to 15 Years in Various Studies over the Past 9 years - (09/11/18)
     
  2930. Caring for Older Adults Living with HIV Infection: policy needed - (09/11/18)
     
  2931. What is Cognitive impairment ? - (09/11/18)
     
  2932. Cognitive Burden of Common Non-antiretroviral Medications in HIV-Infected Women (WIHS) - (09/11/18)
     
  2933. Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials - (09/10/18)
     
  2934. Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy - (09/10/18)
     
  2935. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration - (09/10/18)
     
  2936. FDA Approves Merck's DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients - (09/10/18)
     
  2937. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus [75% were on statin]..,.also is study looking at n-3 fatty acids in sub study, also in diabetics with 75% using a statin, adherence was 77% - (09/10/18)
     
  2938. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial - (09/07/18)
     
  2939. Marijuana Impairs Brain Function - (09/07/18)
     
  2940. Swapping daily pills for monthly shots could transform HIV treatment and prevention - (09/07/18)
     
  2941. Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials - (09/05/18)
     
  2942. Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients - 'fatty liver & NASH in HIV mono-infected called non-viral hepatitis is a new aging comorbidty' - (09/05/18)
     
  2943. Met and unmet health, welfare and social needs of people living with HIV social isolation - (09/05/18)
     
  2944. Health-related quality of life of adults living with HIV in England and Wales: a utility analysis of EQ-5D-5L compared to the general population - (09/05/18)
     
  2945. The cost of comorbidities in treatment for HIV/AIDS in California - (09/05/18)
     
  2946. Does Social Isolation Predict Hospitalization and Mortality Among HIV+ and Uninfected Older Veterans? YES - (09/05/18)
     
  2947. HIV disease and diabetes interact to affect brain white matter hyperintensities and cognition - (09/05/18)
     
  2948. Impact of glycemic status on longitudinal cognitive performance in men with and without HIV infection - (09/05/18)
     
  2949. IAC: French Cohort / Integrase inhibitors and neuropsychiatric adverse events in a large prospective cohort - (09/05/18)
     
  2950. HCV & HCV/HIV Coinfection Micro-Elimination Grants: funding for 30+ projects - - (09/04/18)
     
  2951. Eliminating Excess CVD Risk for Diabetic Type2 - Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes - (08/17/18)
     
  2952. IAC: Higher Prevalence NCI In Aging HIV-Infected Women Despite Lower Comorbidities Than Men (08/17/18)
     
  2953. IAC: Eliminating Excess CVD Risk for Diabetic Type2 - Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes (08/17/18)
     
  2954. IAC: Select Key IAC 2018 Highlight Reports / Coverage: ART drugs, PrEP, Aging/Comorbidities/Mortality/Fatty Liver/Heart & Kidney diseases (08/17/18)
     
  2955. IAC: PrEP & Prevention - HIV & HCV (08/17/18)
     
  2956. Accelerated and Premature Aging Characterizing Regional Cortical Volume Loss in Human Immunodeficiency Virus Infection: Contributions From Alcohol, Substance Use, and Hepatitis C Coinfection - (08/15/18)
     
  2957. Viral suppression and HIV transmission in serodiscordant male couples (Opposites Attract study): an international, prospective, observational, cohort study, Editorial - (08/15/18)
     
  2958. ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen - (08/15/18)
     
  2959. Elevated HIV Prevalence and Correlates of PrEP Use Among a Community Sample of Black Men who Have Sex with Men...more STIs, more drug use, more sex partners, less likely to use condoms...... - (08/15/18)
     
  2960. HIV Aging New Funding Grants RFPs from Gilead - (08/15/18)
     
  2961. IAC: HIV Prevention at AIDS 2018 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (08/15/18)
     
  2962. HIV Aging New Funding Grants RFPs from Gilead - (08/15/18)
     
  2963. IAC: Partners of people living with HIV (PLHIV): Findings from the positive perspectives survey (08/14/18)
     
  2964. IAC: Incidence and Prevalence of Diarrhea in HIV Clinical Trials in the Recent Post-cART Era: Analysis of Data From 38 Clinical Trials From 2008-2017 in Over 21,000 Patients (08/14/18)
     
  2965. Targeting HPV16 DNA using CRISPR/Cas inhibits anal cancer growth in vivo - (08/13/18)
     
  2966. New CDC HIV Surveillance Report/USA Statistics Overview - (08/13/18)
     
  2967. CDC - HIV in the United States: At A Glance - (08/13/18)
     
  2968. New CDC HIV Surveillance Report/USA Statistics Overview - (08/13/18)
     
  2969. IAC: Prevalence and immuno-metabolic associations of frailty in older Australian men living with HIV: a crosssectional analysis (08/08/18)
     
  2970. IAC: Antiretroviral Treatment Maintenance Strategies and Blood Telomere Length Change (08/08/18)
     
  2971. IAC: Weight Gain After ARV Initiation Correlates with Increased Inflammatory Biomarkers (08/08/18)
     
  2972. IAC: Severe menopausal symptoms double odds of poor ART adherence in UK women - Mark Mascolini (08/08/18)
     
  2973. Weight Gain & Integrase Inhibitors - (08/07/18)
     
  2974. IAC: CD4 count and viral load tied to atherogenic cholesterol in people with HIV - Mark Mascolini (08/07/18)
     
  2975. IAC: Vitamin D does not modulate immune-mediated bone loss during ART initiation: A5280 (08/07/18)
     
  2976. IAC: Liver enzyme spikes--then normalizes--when elderly start dolutegravir - Mark Mascolini (08/07/18)
     
  2977. High incidence of HCV (re-)infections among PrEP users in the Netherlands: implications for prevention, monitoring and treatment - (08/07/18)
     
  2978. IAC: Will hepatitis C transmission be eliminated by 2025 among HIV-positive men who have sex with men in Australia? - Mark Mascolini (08/06/18)
     
  2979. IAC: Shared HCV transmission networks among HIV-1 positive and HIV-1 negative men having sex with men in Paris (08/06/18)
     
  2980. IAC: Statins not linked to lower HIV persistence, inflammation, or immune activation - Mark Mascolini (08/06/18)
     
  2981. IAC: Partner Violence: A Significant Part of a Syndemic Among Black Men Who Have Sex With Men (08/06/18)
     
  2982. IAC: High uptake of yearly digital rectal exam for anal cancer in Australian MSM with HIV - Mark Mascolini (08/06/18)
     
  2983. IAC: COMPLACENCY IS THE NEW PROBLEM: COMPARATIVE ANALYSIS OF RECENT OUTBREAKS OF HIV AMONG PERSONS WHO INJECT DRUGS IN EUROPE AND NORTH AMERICA (08/06/18)
     
  2984. IAC: Steep virologic failure drop in Netherlands: initial VL and CD4 strong predictors - Mark Mascolini (08/06/18)
     
  2985. IAC: Alcohol screening less likely in blacks, people with AIDS, in big HIV group - Mark Mascolini (08/06/18)
     
  2986. IAC: HIV incidence drops in Melbourne MSM, reflecting changing HIV testing and control - Mark Mascolini (08/06/18)
     
  2987. IAC: DETERMINANTS OF POST-DISCLOSURE VIOLENCE AGAINST HIV POSITIVE WOMEN IN SERODISCORDANT UNIONS: A CROSSSECTIONAL STUDY IN KUMASI, GHANA (08/06/18)
     
  2988. IAC: One third of black MSM in NYC group experience partner violence - Mark Mascolini (08/06/18)
     
  2989. IAC: Treatment failure in 20% on ART in Australian group: toxicity main culprit - Mark Mascolini (08/06/18)
     
  2990. IAC: A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single-Tablet Regimen in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V and/or M184I (GS-US-292-1824): Week 24 Results (08/06/18)
     
  2991. IAC: Eight recent HIV outbreaks in drug injectors point to prevention complacency - Mark Mascolini (08/06/18)
     
  2992. IAC: Editorial - Cardiovascular Outcomes in Persons With HIV and Heart Failure Medication Class or Suboptimal Viral Suppression? - Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure (08/03/18)
     
  2993. IAC: HIV DNA reservoir size and make-up "remarkably" stable through 20 years of ART - Mark Mascolini (08/03/18)
     
  2994. IAC: Possible link between HIV and vestibular impairment in men and women - Mark Mascolini (08/03/18)
     
  2995. IAC: Half of adults in HIV group have insomnia--fewer than half of them treated (08/02/18)
     
  2996. IAC: Comparison of depression and anxiety between HIV-positive and HIV-negative people.... 3-7 Times Higher Rates for HIV+/Aging Increases Rates (08/02/18)
     
  2997. IAC: Population Pharmacokinetics of Cabotegravir in Healthy Adult Subjects and HIV-1 Infected Patients Following Administration of Oral Tablet and Long-Acting Intramuscular Injection (08/02/18)
     
  2998. IAC: Half of adults in HIV group have insomnia--fewer than half of them treated - Mark Mascolini (08/02/18)
     
  2999. IAC: Quantifying the Relationship Between HIV Patient and Treatment Characteristics, ART Adherence and Viral Suppression Using Contemporary Data (08/02/18)
     
  3000. IAC: Kick-and-kill with vaccines plus vorinostat has no impact on CD4 reservoir - Mark Mascolini (08/01/18)
     
  3001. IAC: Uptake and Effectiveness of Two-drug Compared to Three-drug Antiretroviral Regimens among HIV-positive Individuals in Europe (08/01/18)
     
  3002. IAC: Clinical Effectiveness of Guideline-Recommended Antiretroviral Therapy Core Agents in HIV/HCV Co-infected Patients in the OPERA Observational Database (08/01/18)
     
  3003. IAC: Virologic Outcomes Among Treatment Naive HIV+ Patients Initiating Common First Antiretroviral Therapy Core Agents in the OPERA Observational Database (08/01/18)
     
  3004. IAC: A Comprehensive Assessment of Hepatobiliary Disorders in HIV-Infected Patients Treated With Dolutegravir, Elvitegravir, Raltegravir or Darunavir in the OPERA Database - Liver Chemistry Elevations/DILI (08/01/18)
     
  3005. IAC: Medication errors with Retrovir oral solution in neonates and infants ≤ 23 months (08/01/18)
     
  3006. IAC: Comparison of depression and anxiety between HIV-positive and HIV-negative people....3-7 Times Higher Rates for HIV+/Aging Increases Rates (08/01/18)
     
  3007. IAC: Healthcare Utilization and STI Incidence in Young Men on Pre-exposure Prophylaxis (PrEP) Compared to Young Men Who Are Not on PrEP: The PrEPARE Study (08/01/18)
     
  3008. IAC: Changes, Patterns and Predictors of Sexually Transmitted Infections in Gay and Bisexual Men Using PrEP - Interim Analysis from the PrEPX Study (08/01/18)
     
  3009. IAC: PrEP use rising in US MSM, but rectal STI rate remains stable - Mark Mascolini (08/01/18)
     
  3010. IAC: Cardiovascular Disease Risk Assessments and Fasting Lipid Changes in Virologically Suppressed Patients Randomized to Switch to Tenofovir Alafenamide versus Continuing Tenofovir Disoproxil Fumarate (08/01/18)
     
  3011. IAC: Changes in Cardiovascular Risk Estimation and Fasting Lipids in Virologically Suppressed Patients Randomized to Switch to Tenofovir Alafenamide versus Continuing Abacavir (07/31/18)
     
  3012. IAC: Switching from an Abacavir (ABC)/Lamivudine (3TC)-Based Regimen to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF): Cardiovascular Disease Risk Profile Analysis from a Randomized Controlled Study in Virologically-Suppressed Adults (07/31/18)
     
  3013. IAC: Noncommunicable disease rates with HIV lower in England than in 4 other countries - Mark Mascolini (07/31/18)
     
  3014. IAC: Adherence to Long-Acting CAB and RPV Injections Through 96 Weeks of Maintenance Therapy in LATTE-2 / Good adherence to injected cabotegravir and rilpivirine in 230 LATTE-2 participants - Mark Mascolini (07/31/18)
     
  3015. IAC: Virologic Outcomes Among Treatment Naive HIV+ Patients Initiating Common First Antiretroviral Therapy Core Agents in the OPERA Observational Database (07/31/18)
     
  3016. IAC: Resistance Through Week 48 in the DAWNING Study Comparing Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/r) Plus 2 NRTIs in Second-line Treatment (07/31/18)
     
  3017. IAC: ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018 (07/31/18)
     
  3018. IAC: Two-fold higher chance of liver steatosis with HIV in big Brazilian study - Mark Mascolini (07/31/18)
     
  3019. IAC: Two-fold higher chance of liver steatosis with HIV in big Brazilian study - Mark Mascolini (07/31/18)
     
  3020. IAC: Trends in mortality among HIV-infected subjects; differences by HCV coinfection - 70% of Deaths Non-AIDS: liver-HCV, psychiatric, malignancies, cardiovascular & pulmonary diseases common causes of death (07/31/18)
     
  3021. IAC: "Increased risk of both mortality and incident comorbidity among frail HIV-positive and HIV-negative participants and increased risk of frailty progression in those with HIV." (07/31/18)
     
  3022. IAC: HIV infection independently increases the risk of developing heart failure: The HIV HEART study - Mark Mascolini (07/30/18)
     
  3023. IAC: Very high levels of inflammation marker CRP in young MSM with or without HIV - Mark Mascolini (07/30/18)
     
  3024. IAC: Higher depression and anxiety rates with HIV across ART and viral load categories - Mark Mascolini (07/30/18)
     
  3025. IAC: Janssen Presents Switch Data for New HIV-1 Treatment SYMTUZA™ (D/C/F/TAF) and Second Study Supporting its Use in a Rapid Initiation Scenario (07/30/18)
     
  3026. IAC: Characterization of Doravirine-Selected Resistance Patterns From Participants in Treatment-Naïve Phase 3 Clinical Trials (07/30/18)
     
  3027. IAC: Surveillance for Neural Tube Defects following Antiretroviral Exposure from Conception (07/30/18)
     
  3028. IAC: Surveillance for Neural Tube Defects following Antiretroviral Exposure from Conception (07/30/18)
     
  3029. IAC: HIV-1 subtype (B or non-B) had no impact on the efficacy of B/F/TAF or resistance development in five phase 3 treatment-naïve or switch studies (07/30/18)
     
  3030. IAC: IL-10 contributes to and predicts viral persistence in ART-treated, SIV-infected rhesus macaques (07/30/18)
     
  3031. IAC: FDA-Approved Chemotherapeutic Drugs that Inhibit VEGF, RAF-1, B-RAF and the Proteosome Reverse HIV-1 Latency Without Global T cell Activation (07/30/18)
     
  3032. IAC: Understanding the Resistance Profile of the HIV-1 NNRTI Doravirine in Combination With the Novel NRTTI MK-8591 (07/30/18)
     
  3033. IAC: Phase 3 Study of Fostemsavir in Heavily Treatment-Experienced HIV-1-Infected Participants: BRIGHTE Week 24 Subgroup Analysis in Randomized Cohort Participants (07/27/18)
     
  3034. IAC: Durable Suppression 2 Years After Switch to DTG + RPV 2-Drug Regimen: SWORD-1 and SWORD-2 Studies (07/27/18)
     
  3035. IAC: Mortality and cause of death among HIV patients in London in 2016: 77% Die of Non-AIDS Conditions/Comorbidities/majority virally suppressed - Ending AIDS? Only applies to stopping new transmissions? (07/27/18)
     
  3036. IAC: Pharmacokinetic and 4-week safety/efficacy of dolutegravir (S/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to <6 years: results from IMPAACT P1093 (07/27/18)
     
  3037. IAC: Mortality 4.5 times higher in Canadian women with HIV than in general population - Mark Mascolini (07/27/18)
     
  3038. IAC: Patient Satisfaction, Tolerability and Acceptability of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting Therapy in HIV-1-Infected Adults: LATTE-2 Week 96 Results (07/27/18)
     
  3039. IAC: Emergence of resistance in HIV-1 Integrase following dolutegravir (DTG) treatment in 6 to <18 year old participants enrolled in the P1093 study (07/27/18)
     
  3040. IAC: Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/r) plus 2 NRTIs in second-line treatment - 48-week data from the DAWNING Study (07/27/18)
     
  3041. IAC: Pharmacokinetics, Safety, And Efficacy Of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Single-tablet Regimen In Children (6 To <12 Years) Living With HIV-1 (07/27/18)
     
  3042. IAC: B/F/TAF vs DTG/ABC/3TC or DTG + F/TAF in Treatment-Naïve Adults With High Baseline Viral Load or Low Baseline CD4 Count in 2 Phase 3 Randomized, Controlled Clinical Trials (07/27/18)
     
  3043. IAC: Efficacy and Safety of Switching From Boosted Protease Inhibitor-based Regimens to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide for Treatment of HIV-1 Infection: Subgroups Analysis by Baseline Regimen (07/27/18)
     
  3044. IAC: The Impact of Pre-exposure Prophylaxis with FTC/TDF on HIV Diagnoses, 2012-2016, United States (07/27/18)
     
  3045. IAC: Among 2590 US adolescents using PrEP, 83.5% are girls, 59% on Medicaid - Mark Mascolini (07/27/18)
     
  3046. IAC: Kaposi sarcoma incidence flat among black men in southern US (07/27/18)
     
  3047. IAC: Kaposi sarcoma incidence flat among black men in southern US - Mark Mascolini (07/27/18)
     
  3048. IAC: Incidence of HIV-infection in the ANRS Prevenir Study in the Paris Region with Daily or On Demand PrEP with TDF/FTC - (07/26/18)
     
  3049. IAC: Kaposi disease in HIV-infected patients with suppressed HIV viremia: the experience of the French national multidisciplinary committee ONCOVIH - New Kaposi disease in 21 people with 3 years of HIV control in France - Mark Mascolini (07/26/18)
     
  3050. IAC: DolPHIN-1: Randomised controlled trial of dolutegravir(DTG)-versus efavirenz(EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy - (07/26/18)
     
  3051. IAC: INSPIRING: SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED ART IN TB/HIV CO-INFECTED ADULTS AT WEEK 48 - (07/26/18)
     
  3052. IAC: Universal test-and-treat improves population viral suppression in rural South Africa - Mark Mascolini -(07/26/18)
     
  3053. IAC: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in a Test-and-Treat Model of Care for HIV-1 Infection: Interim Analysis of the DIAMOND Study - (07/26/18)
     
  3054. IAC: Adolescent Use of Truvada (FTC/TDF) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States: (2012-2017) - (07/26/18)
     
  3055. IAC: Adolescent Use of Truvada (FTC/TDF) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States: (2012-2017) - (07/26/18)
     
  3056. IAC: Global Partners Pledge over $1.2 billion to Launch the MenStar Coalition (HIV in men) - (07/26/18)
     
  3057. IAC: ViiV Healthcare's commitments to accelerate the availability of dolutegravir for the treatment of HIV in children - (07/26/18)
     
  3058. IAC: Mortality after ART starts remains higher in women in Americas and Africa than in Europe - Mark Mascolini - (07/25/18)
     
  3059. IAC: Global Partners Pledge over $1.2 billion to & Launch the MenStar Coalition (HIV in men) - (07/25/18)
     
  3060. IAC: Beyond the 60s: Changing co-morbidities in people living with HIV aged over 60 attending clinic in 2010 and 2017 - (07/25/18)
     
  3061. IAC: HIV transmission risk through condomless sex in gay couples with suppressive ART: The PARTNER2 Study extended results in gay men - (07/25/18)
     
  3062. IAC: The Impact of Pre-exposure Prophylaxis With FTC/TDF on HIV Diagnoses, 2012-2016, United States - (07/25/18)
     
  3063. IAC: Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine - (07/25/18)
     
  3064. IAC: ViiV Healthcare presents phase III data showing two drug regimen has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no resistance - (07/25/18)
     
  3065. IAC: GILEAD SCIENCES PROVIDES GRANT TO AID FOR AIDS INTERNATIONAL TO EXPAND ACCESS TO HIV TREATMENT IN VENEZUELA - (07/25/18)
     
  3066. IAC: Gilead Announces New Data on the Impact of Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States - (07/25/18)
     
  3067. IAC: Dolutegravir/3TC noninferior to DTG/TDF/FTC at 48 weeks in big ART-naive group - Mark Mascolini (07/25/18)
     
  3068. IAC: Antiretroviral therapy (ART) interruption is associated with reduced cortical structures at age 5 years compared to uninterrupted. - (07/25/18)
     
  3069. IAC: Doravirine (DOR) Versus Ritonavir-Boosted Darunavir (DRV+r): 96-Week Results of the Randomized, Double-Blind, Phase 3 DRIVE-FORWARD Noninferiority Trial - (07/25/18)
     
  3070. IAC: the PARTNER Study: new results from PARTNER 2 - PDF - Q and A - (07/25/18)
     
  3071. IAC: Long-term data from APPROACH study - (07/25/18)
     
  3072. IAC: Variables Associated With Neuropsychiatric Symptoms in PLWH Receiving Dolutegravir-Based Therapy in Phase III Clinical Trials - (07/25/18)
     
  3073. IAC: PARTNER-2 Study No HIV transmissions in 8 years when gay HIV+ partner has undetectable load - Mark Mascolini (07/25/18)
     
  3074. IAC: Non-Inferior Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) vs DTG Plus Tenofovir/Emtricitabine (TDF/FTC) Fixed-Dose Combination in Antiretroviral Treatment-Naive Adults With HIV-1 Infection-Week 48 Results From the GEMINI Studies - (07/25/18)
     
  3075. IAC: Kick-and-kill with vaccines plus vorinostat has no impact on CD4 reservoir - Written by Mark Mascolini (07/24/18)
     
  3076. IAC: ViiV Healthcare presents phase III data showing two drug regimen has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no resistance - (07/24/18)
     
  3077. IAC: Rates of kidney and bone disease--and multiple comorbidities--rising in elderly HIV group - Written by Mark Mascolini (07/24/18)
     
  3078. CROI: Trends in Unsuppressed HIV RNA After Linkage to Care Among Key Populations - (07/24/18)
     
  3079. CROI: HIV Viral Suppression Assessed by Two Metrics in North Carolina during 2016 - (07/24/18)
     
  3080. CROI: Depression (24%) is Associated with Missed Visits, Emergency Room Utilization, and Drug Use - (07/24/18)
     
  3081. CROI: CLINIC-LEVEL FACTORS ASSOCIATED WITH TIME TO VIRAL SUPPRESSION IN WASHINGTON DC - (07/24/18)
     
  3082. IAC: Viral suppression for HIV treatment success and prevention of sexual transmission of HIV - (07/23/18)
     
  3083. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial - (07/23/18)
     
  3084. [low] HIV Viral Suppression, 37 States and the District of Columbia, 2014 - (07/23/18)
     
  3085. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine - (07/23/18)
     
  3086. What did we learn from the bictegravir switch studies? Comment - (07/23/18)
     
  3087. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial - (07/23/18)
     
  3088. Mortality in HIV - study Estimates Increased Death Risk of 1.6 vs General Population in HIV+ Over 50 Without Comorbidities, Higher in 65-70 Year Olds (2.5)....75% Over 45 Years Old in NY, SF, Boston, Florida - (07/23/18)
     
  3089. HIV+ Women's Issues - (07/23/18)
     
  3090. GILEAD SCIENCES AT THE 22ND INTERNATIONAL AIDS CONFERENCE (AIDS 2018) - For Immediate Release - (07/20/18)
     
  3091. FDA Approves Darunavir STR: DRV+Cobi+FTC+TAF - (07/19/18)
     
  3092. ViiV at IAS 2018 - ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018 - fostemsavir, DTG+3TC, DTG+RPV, Cabotegrvir - (07/19/18)
     
  3093. EATG Aging / HIV Project - Europe Addressing HIV & Aging - there is no such project in the USA. - (07/19/18)
     
  3094. Janssen Announces U.S. FDA Approval of SYMTUZA™ (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection - (07/19/18)
     
  3095. Statins for the Elderly - efficacy ?? - (07/12/18)
     
  3096. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection - (07/12/18)
     
  3097. HPV Vaccine Anti-Cancer Treatments / HPV vaccine to treat patient with skin cancer - (07/10/18)
     
  3098. Managing blood pressure in older adults - Editorial - (07/10/18)
     
  3099. Aging/HIV - Gilead RFPs - (07/10/18)
     
  3100. Blood Telomere Length Changes after Ritonavir-boosted Darunavir Combined with Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected with HIV-1 - (07/06/18)
     
  3101. Factors associated with deaths from suicide in a French nationwide HIV-infected cohort: mental health, substance abuse history, "Suicide prevention measures should target PLHIV with the psychological morbidities identified in our cohort." - (07/06/18)
     
  3102. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17 - (07/05/18)
     
  3103. PREP STIGMA AS A BARRIER TO UPTAKE - Women - Planned Parenthood Study - (07/05/18)
     
  3104. Factors associated with deaths from suicide in a French nationwide HIV-infected cohort - (07/05/18)
     
  3105. Blood Telomere Length Changes after Ritonavir-boosted Darunavir Combined with Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected with HIV-1 - (07/05/18)
     
  3106. CROI: Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity - (07/05/18)
     
  3107. CROI: FAT QUALITY IS INDEPENDENTLY ASSOCIATED WITH CARDIOMETABOLIC RISK IN HIV INFECTION - (07/05/18)
     
  3108. CROI: HIV Immune Dysregulation Predicts Lean Tissue & Fat Changes During Chronic Disease - (07/05/18)
     
  3109. CROI: Lower Pretreatment Gut Integrity Associated With Fat Gains on Antiretrovirals - (07/05/18)
     
  3110. Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018 - (07/02/18)
     
  3111. Associations between antiretroviral use and subclinical coronary atherosclerosis..... - (06/28/18)
     
  3112. Cancer risk among the HIV-infected elderly in the United States - (06/22/18)
     
  3113. NIH: Is marijuana addictive? - Yes, You Can Become Addicted to Marijuana. And the Problem is Growing. - (06/15/18)
     
  3114. ViiV Healthcare reports positive results for landmark phase III studies for dolutegravir and lamivudine - (06/15/18)
     
  3115. Association of Viral Suppression With Lower AIDS-Defining and Non-AIDS-Defining Cancer Incidence in HIV-Infected Veterans: A Prospective Cohort Study - (06/13/18)
     
  3116. Older MACS Men - Abdominal obesity, sarcopenia, and osteoporosis are associated with frailty in men living with and without HIV - (06/12/18)
     
  3117. (MACS) Long-term kidney function, proteinuria, and associated risks among HIV-infected and uninfected men - (06/12/18)
     
  3118. Travel Scholarships Available for the 2018 HIV Co-morbidity Workshop - NYC Oct 13-14 - (06/12/18)
     
  3119. ASM - Primary Efficacy Results of PRO 140 SC in a Pivotal Phase 2b/3 Study in Heavily Treatment-Experienced HIV-1 Patients - Mark Mascolini - (06/11/18)
     
  3120. HIV-1 resistance rarely observed in subjects using darunavir once-daily regimens across clinical studies - (06/11/18)
     
  3121. Loneliness in Older Adults Living with HIV (58%) - (06/7/18)
     
  3122. TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy - (06/4/18)
     
  3123. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer - TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy - (06/4/18)
     
  3124. Pharm: Population pharmacokinetic analysis for darunavir and tenofovir alafenamide in HIV-1-infected patients on the darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (AMBER and EMERALD studies) - (06/4/18)
     
  3125. Pharm: SIMULATED PHARMACOKINETIC INTERACTIONS OF RIFAMPICIN WITH RITONAVIR-BOOSTED DARUNAVIR - (06/4/18)
     
  3126. Pharm: Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202 - (06/4/18)
     
  3127. Pharm: Age, Inflammation, Blood Brain Barrier Permeability and Single Nucleotide Polymorphisms in Transporters May Influence Cerebrospinal Fluid Antiretrovirals' Concentrations - (05/31/18)
     
  3128. Pharm: Defining total-body AIDS-virus burden with implications for curative strategies - (05/31/18)
     
  3129. Recommendations Regarding the Use of Dolutegravir in Adults and Adolescents with HIV who are Pregnant or of Child-Bearing Potential - (05/30/18)
     
  3130. CROI: SWITCHING TO TAF IN EVG-BASED REGIMENS: CSF PHARMACOKINETICS AND ANTIVIRAL ACTIVITY - (05/30/18)
     
  3131. CROI: Seminal Tenofovir concentrations, viral suppression and semen quality with TAF vs TDF - (05/30/18)
     
  3132. Pharm: Differential brain tissue penetration of antiretrovirals and fluconazole - (05/30/18)
     
  3133. Pharm: Effects of Low and High Mineral Water Content on the Relative Bioavailability of a Co-Formulated TRIUMEQ (Abacavir/Dolutegravir/Lamivudine) Dispersible Tablet in Healthy Adults - (05/28/18)
     
  3134. Pharm: More than half of 75-and-older Swiss HIV group takes 5 or more non-ART drugs - Mark Mascolini (05/28/18)
     
  3135. Pharm: CSF is not on-target marker of antiretroviral and fluconazole levels in brain - Mark Mascolini (05/28/18)
     
  3136. Pharm: No oral cabotegravir dose adjustment expected with rifabutin - Mark Mascolini (05/28/18)
     
  3137. Pharm: Comparison of Relative Bioavailability of TIVICAY Immediate Release and Dispersible Pediatric Tablets to Immediate Release TIVICAY Adult Tablets - (05/28/18)
     
  3138. Pharm: Pharmacokinetics, Metabolism and Excretion of Radiolabeled Fostemsavir Administered With or Without Ritonavir in Healthy Male Subjects - (05/28/18)
     
  3139. Pharm: Rifabutin (RBT) Decreases Cabotegravir (CAB) Exposure Following Oral Co-administration - (05/28/18)
     
  3140. Pharm: Assessment of maternal and fetal dolutegravir exposure by integrating ex vivoplacental perfusion data and physiologically-based pharmacokinetic modeling - (05/28/18)
     
  3141. Pharm: Pharmacokinetic and virological efficacy of dolutegravir (50 mg BID) containing regimen in association with rifampin in HIV-infected patients using Dried Blood Spot: ANRS-12313 NAMSAL sub-study in Cameroon - (05/28/18)
     
  3142. Pharm: Bictegravir/Emtricitabine/Tenofovir Alafenamide Phase 3 Exposure-Response Analysis of Safety and Efficacy in the Treatment of HIV Infection - (05/28/18)
     
  3143. Pharm: PHARMACOKINETICS OF DOLUTEGRAVIR 100 MG ONCE-DAILY WITH RIFAMPICIN - (05/26/18)
     
  3144. Pharm: Elvitegravir pharmacokinetics during Pregnancy and Postpartum - (05/26/18)
     
  3145. Pharm: First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women - (05/26/18)
     
  3146. Pharm: Elvitegravir pharmacokinetics during pregnancy and postpartum Low elvitegravir troughs in third trimester confirm caution in pregnancy - Mark Mascolini - (05/25/18)
     
  3147. Pharm: First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women - Unbound dolutegravir trough similar in third trimester and postpartum - Mark Mascolini - (05/25/18)
     
  3148. Pharm: Elvitegravir pharmacokinetics during pregnancy and postpartum Low elvitegravir troughs in third trimester confirm caution in pregnancy - Mark Mascolini - (05/25/18)
     
  3149. Pharm: Does hepatic impairment affect the exposure of monoclonal antibodies? - Mark Mascolini - (05/25/18)
     
  3150. Pharm: Intracellular 007-TP Concentrations are Associated with Gradients of Adherence to Ledipasvir/Sofosbuvir - (05/25/18)
     
  3151. Pharm: Differing drug distribution in penis and rectum of men taking TDF/FTC PrEP - Mark Mascolini - (05/25/18)
     
  3152. Pharm: Adherence gradient strongly tied to sofosbuvir triphosphate level in HCV/HIV group - Mark Mascolini - (05/25/18)
     
  3153. Risk of skin cancer in HIV-infected patients: a Danish nationwide cohort study - (05/23/18)
     
  3154. CROI: Carotid IMT Progression is Most Striking in First 48 Weeks of Antiretroviral Therapy - (05/23/18)
     
  3155. CROI: Effects of Antiretroviral Therapy on Allele-Associated Lipoprotein(a) Levels in HIV - (05/23/18)
     
  3156. Risk of skin cancer in HIV-infected patients: a Danish nationwide cohort study - (05/22/18)
     
  3157. CROI: HIV+ Men Matched By Age And FRS With Controls Have More Cardiovascular Events - (05/22/18)
     
  3158. CROI: CARDIAC VENTRICULAR DISFUNCTION IN YOUNG VERTICALLY INFECTED HIV PATIENTS - (05/22/18)
     
  3159. CROI: Myocardial Steatosis in Relation to Cardiac Dysfunction Among Women Living with HIV - (05/22/18)
     
  3160. CROI: Coronary Arterial Wall Thickening and Association with Myocardial Diastolic Function in HIV - (05/22/18)
     
  3161. HHS - Statement on Potential Safety Signal in Infants Born to Women Taking Dolutegravir from the HHS Antiretroviral Guideline Panels - (05/21/18)
     
  3162. FDA Drug Safety Communication: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq) - (05/21/18)
     
  3163. Cutaneous Melanoma Risk among People with HIV in the United States and Canada - "These results suggest that HIV-induced immune dysfunction does not influence melanoma development." - (05/21/18)
     
  3164. Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV Following Dual CCR2 and CCR5 Antagonism - (05/21/18)
     
  3165. Janssen Announces European Commission Approval of JULUCA®∇ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1 - (05/21/18)
     
  3166. ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV - (05/21/18)
     
  3167. Increased dolutegravir peak concentrations in people living with HIV aged 60 and over and analysis of sleep quality and cognition - (05/17/18)
     
  3168. U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents - (05/17/18)
     
  3169. U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents - (05/16/18)
     
  3170. ATI and the Central Nervous System (CNS): Introduction - (05/16/18)
     
  3171. Impact of aging and HIV infection on serologic response to seasonal influenza vaccination - (05/15/18)
     
  3172. TMC120 displayed potent cytotoxic effect on human cervical carcinoma through enhancing the polymerization of microtubules - (05/15/18)
     
  3173. CROI: Mental Disability in HIV- Misunderstood & Unmet Need - (05/15/18)
     
  3174. CROI: The Mediterranean Portfolio diet in HIV dyslipidaemia: a pilot randomised controlled trial - (05/14/18)
     
  3175. Perinatally acquired HIV infection accelerates epigenetic aging in South African adolescents - (05/14/18)
     
  3176. Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia - (05/14/18)
     
  3177. CROI: Insurer Denial of DAA Prescription Requests Rising Across United States - Mark Mascolini (05/14/18)
     
  3178. CROI: Cardiovascular Update CROI 2018 - by Priscilla Hsue MD Professor of Medicine, UCSF - (05/11/18)
     
  3179. BHIVA - Muscle mitochondrial function and contemporary anti-retroviral therapy - (05/09/18)
     
  3180. HIV-Infected Women Gain More Weight than HIV-Infected Men Following the Initiation of Antiretroviral Therapy - (05/09/18)
     
  3181. Clinical Use of Brain Magnetic Resonance Imaging (MRI) for neurological symptoms in people with HIV - (05/08/18)
     
  3182. CROI: Predictors of Severe Weight/Body Mass Index Gain Following Antiretroviral Initiation - (05/8/18)
     
  3183. Dolutegravir and weight gain: an unexpected bothering side effect? - (05/07/18)
     
  3184. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens - (05/07/18)
     
  3185. Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals - (05/07/18)
     
  3186. Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors - (05/04/18)
     
  3187. BHIVA - Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate -is there a true difference in efficacy and safety? - (05/04/18)
     
  3188. BHIVA - HIV as a risk factor in the initial presentation of a range of cardiovascular, coronary, cerebrovascular, and peripheral arterial diseases: a linked electronic health records study of 8 million adults in the UK - (05/04/18)
     
  3189. CROI: Longitudinal trajectory of brain volume and cortical thickness in primary infection - (05/04/18)
     
  3190. BHIVA - Supporting self-management of metabolic comorbidities in HIV: a multi-disciplinary model - (05/02/18)
     
  3191. EACS: Meta-analysis of safety for DTG versus other ARVs in randomized trials: Analysis of cardiovascular, CNS and IRIS endpoints - (01/04/18)
     
  3192. CROI: IMPACT OF PREVIOUS M184V ON VIROLOGICAL OUTCOME OF SWITCH TO 3TC-BASED DUAL THERAPIES - (05/01/18)
     
  3193. THERATECHNOLOGIES TO SEEK REGULATORY APPROVAL OF TROGARZO™ (IBALIZUMAB) IN EUROPE BASED ON EFFICACY AND SAFETY DATA USED FOR FDA APPROVAL - (05/01/18)
     
  3194. THERATECHNOLOGIES ANNOUNCES THAT TROGARZOTM (IBALIZUMAB-UIYK) INJECTION IS NOW AVAILABLE IN THE U.S. - (05/01/18)
     
  3195. BHIVA - Meta-analysis of dolutegravir for 7340 patients in 13 randomised trials: effects of current HIV RNA suppression on efficacy and safety - (05/01/18)
     
  3196. Disparities and determinants of cancer treatment in elderly Americans living with HIV/AIDS - (04/30/18)
     
  3197. Claims of sexual harassment and assault threaten UN agency - (04/30/18)
     
  3198. Editorial - UNAIDS - Sexual harassment and abuse-the sinister underbelly - (04/30/18)
     
  3199. HIV-infected people are living for years, but age-related diseases set in early - (04/23/18)
     
  3200. EASL: Safety And Efficacy At 1 Year After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide In Chronic HBV Patients With Risk Factors For TDF Use - (04/23/18)
     
  3201. CROI: Rapid reduction in HIV diagnoses after targeted PrEP implementation in New South Wales, Australia - (04/13/18)
     
  3202. A tale of two diseases: Aging HIV patients inspire a closer look at Alzheimer's disease - (04/11/18)
     
  3203. Bictegravir Phase 3 - (04/11/18)
     
  3204. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? - (04/11/18)
     
  3205. Grindr defends HIV-related data sharing - (04/11/18)
     
  3206. CROI: HIV Prevention at CROI 2018 and PrEP Updates on PrEP - Disparities; Current & Future; Delivery/Use/Barriers; Women. Transmission Clusters - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (04/9/18)
     
  3207. CROI: Clinical Pharmacology at CROI 2018 - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (04/9/18)
     
  3208. CROI: CROI 2018 Summary Report, Eric Daar M.D. - Boston, MA Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (04/4/18)
     
  3209. CROI: PrEP at CROI 2018 Report 2: uptake, HIV incidence; barriers/challenges - (04/10/18)
     
  3210. CROI: Geographic Access to PrEP Clinics among US MSM: Documenting PrEP Deserts - (04/10/18)
     
  3211. CROI: "RAPID REDUCTION IN HIV DIAGNOSES AFTER TARGETED PrEP IMPLEMENTATION IN NSW, AUSTRALIA" - PrEP NATAP Report 3 - (04/10/18)
     
  3212. CROI: Female HIV acquisition per sex act is elevated in late pregnancy and postpartum - (04/10/18)
     
  3213. CROI: Vaginal Contraceptive Hormone Exposure Profoundly Altered by EFV- And ATV/r-based ART AIDS Clinical Trials Group A5316 - (04/10/18)
     
  3214. CROI: RIFAMPIN EFFECT ON TENOFOVIR ALAFENAMIDE ONCE DAILY PLASMA AND INTRACELLULAR PHARMACOKINETICS - (04/10/18)
     
  3215. CROI: PrEP at CROI 2018 - (04/10/18)
     
  3216. CROI: Factors Impacting Appropriate HIV/STI Screening and PrEP Persistence in Primary Care in SF - (04/10/18)
     
  3217. CROI: STIMULANT USE AND CONDOMLESS SEX WITH MULTIPLE PARTNERS: EFFECT ON PREP ADHERENCE - (04/9/18)
     
  3218. CROI: High Discontinuation of Pre-Exposure Prophylaxis Within Six Months of Initiation - (04/9/18)
     
  3219. CROI: Predictors of Willingness to Take PrEP Among Black and Latina Transgender Women - (04/9/18)
     
  3220. CROI: Reported PrEP use among HIV-negative partners of US MSM receiving HIV medical care - (04/6/18)
     
  3221. CROI: HIV Risk Perception Among Men who have Sex with Men (MSM): A Randomized Controlled Trial - (04/6/18)
     
  3222. CROI: NEW DIAGNOSES OF HIV AMONG INJECTING DRUG USERS, NEW YORK CITY 2006-2016 - (04/6/18)
     
  3223. CROI: DRUG OVERDOSE DEATHS AMONG PERSONS WITH HIV IN NEW YORK CITY, 2007-2015 - (04/6/18)
     
  3224. CROI: Durability of Financial Incentives Effect on Viral Suppression and Continuity in Care - (04/6/18)
     
  3225. CROI: ART Reduces T Cell Activation and Immune Exhaustion Markers in HIV Controllers - (04/6/18)
     
  3226. CROI: In Silico Drug Interaction of Long-acting Rilpivirine and Cabotegravir With Rifampin - (04/6/18)
     
  3227. CROI: Female HIV acquisition per sex act is elevated in late pregnancy and postpartum - (04/6/18)
     
  3228. CROI: Reported PrEP use among HIV-negative partners of US MSM receiving HIV medical care - (04/5/18)
     
  3229. CROI: Assessing PrEP Needs Among Heterosexuals and People Who Inject Drugs, Washington, DC - (04/5/18)
     
  3230. CROI: Monitoring PrEP Use Among Washington State MSM: Results of an Internet Survey - (04/5/18)
     
  3231. CROI: HIGH SEROCONVERSION RATES FOLLOWING PrEP DISCONTINUANCE IN A MONTREAL CLINIC - (04/5/18)
     
  3232. CROI: DECREASES IN HIV INCIDENCE IN A MONTREAL CLINIC COINCIDE WITH EXPANDING PREP USE - (04/5/18)
     
  3233. CROI: PrEP USE HISTORY OF PERSONS NEWLY DIAGNOSED WITH HIV: NEW YORK CITY, 2015-2017 - (04/5/18)
     
  3234. CROI: Trends in PrEP Uptake, Adherence, and Discontinuation Among YMSM in Chicago - (04/5/18)
     
  3235. CROI: Patterns and Correlates of Participant Retention in the U.S. PrEP Demonstration Project - (04/5/18)
     
  3236. CROI: High Discontinuation of Pre-Exposure Prophylaxis Within Six Months of Initiation- Los Amgeles - (04/5/18)
     
  3237. CROI: INCREASING PREP UPTAKE, PERSISTENT DISPARITIES, IN AT-RISK PATIENTS IN A BOSTON COMMUNITY HEALTH CENTER - (04/5/18)
     
  3238. CROI: Seroconversion on PrEP [4th case]: A Protocol for Untangling Adherence vs. Resistance Failure - (04/4/18)
     
  3239. CROI: A Public Health Approach to Viremic Individuals With PrEP-resistant Virus - (04/4/18)
     
  3240. CROI: HIV Diagnoses Among People Who Inject Drugs -United States, 2010-2016 - (04/4/18)
     
  3241. CROI: Geographic Access to PrEP Clinics among US MSM: Documenting PrEP Deserts - (04/4/18)
     
  3242. Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial - (03/29/18)
     
  3243. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial - (03/29/18)
     
  3244. CROI: PREDICTORS OF PrEP ELIGIBILITY AMONG AT-RISK WOMEN IN THE SOUTHERN UNITED STATES - (03/29/18)
     
  3245. CROI: HIV BIOMEDICAL PREVENTION AMONG U.S. WOMEN: KNOWLEDGE, BELIEFS, AND PRACTICES - (03/29/18)
     
  3246. CROI: The PREP Cascade at NYC Sexual Health Clinics: Navigation is the Key to Uptake - (03/29/18)
     
  3247. CROI: PrEP Implementation and Persistence in a County Health Department in Atlanta, GA - (03/29/18)
     
  3248. CROI: Summary from CROI 2018 for viral Hepatitis HCV micro-elimination in HIV/HCV coinfection: successes and challenges - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (03/29/18)
     
  3249. CROI: A Multicenter Registry in HIV/HCV Co-infected Patients Initiating Ledipasvir/Sofosbuvir - (03/29/18)
     
  3250. CROI: HCV RNA and Antigen Detection for Diagnosis of Acute Hepatitis C Among MSM on PreP..... In the ANRS IPERGAY PrEP trial among high risk MSM - (03/29/18)
     
  3251. CROI: Nine of 100 MSM in German Cohort Get HCV Reinfection Every Year in DAA Era - Mark Mascolini (03/29/18)
     
  3252. Bictegravir Added to HHS Guidelines 1st-Line/Changes to Guidelines - (03/28/18)
     
  3253. CROI: Disparities in PrEP Uptake Among Primary Care Patients (03/28/18)
     
  3254. CROI: Getting to Zero New Diagnoses in San Francisco: The Potential Role of PrEP (03/28/18)
     
  3255. CROI: The PrEP Care Continuum and HIV Racial Disparities among Men Who Have Sex with Men (03/28/18)
     
  3256. CROI: By Race/ethnicity, Blacks Have Highest Number Needing PrEP in the United States, 2015 (03/28/18)
     
  3257. CROI: CVD Factors Tied to Cognitive Impairment Differ in Women and Men With HIV - Mark Mascolini (03/28/18)
     
  3258. CROI: The association of pain and long-term opioid therapy with HIV treatment outcomes - Chronic Pain Tied to Virologic Failure, While Long-Term Opioids Lower Odds of Failure - Mark Mascolini (03/28/18)
     
  3259. CROI: HCV incidence in HIV-infected and in PrEP-using MSM - New HCV Rate Similar in HIV+ MSM and HIV- MSM on PrEP in France - Mark Mascolini (03/27/18)
     
  3260. Bictegravir FDA Product Insert - BIKTARVY® (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use Initial U.S. Approval: 2018 - (03/27/18)
     
  3261. CROI: Olfactory Mucosa HIV RNA Correlates With CSF RNA in People On/Off ART - Mark Mascolini (03/26/18)
     
  3262. CROI: QUANTIFICATION OF REPLICATION COMPETENT LATENT HIV-1 IN GALT AND SEMEN - Mark Mascolini (03/26/18)
     
  3263. CROI: High Level Resistance to Dolutegravir (DTG) after Emergence of T97A Mutation - Mark Mascolini (03/26/18)
     
  3264. CROI: Pharmacokinetcs of dolutegravir with and without darunavir/cobicistat in healthy volunteers (03/26/18)
     
  3265. CROI: Low Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations Across Botswana (03/26/18)
     
  3266. CROI: High Level Resistance to Dolutegravir (DTG) after Emergence of T97A Mutation (03/26/18)
     
  3267. CROI: Resistance Analyses of Bictegravir/Emtricitabine/Tenofovir Alafenamide Switch Studies (03/26/18)
     
  3268. CROI: [Bictegravir] Integrase Inhibitor Resistance Selections Initiated with Drug Resistant HIV-1 (03/26/18)
     
  3269. CROI: PROGRESSIVE LYMPH NODE DYSFUNCTION DURING SIV INFECTION IS NOT REVERSED WITH ART (03/26/18)
     
  3270. CROI: Combined Effects of Bisphosphonates and TDF→TAF Switch in HIV+ Adults With Low BMD - Mark Mascolini (03/26/18)
     
  3271. CROI: Life Extectancy, Mental Comorbidities, Inflammation, /Anti-Inflammatories Drug Research - Life Expectancy Lags in Some HIV Groups: Black MSM, Drug Injectors, HCV+ (03/26/18)
     
  3272. CROI: Fat and Lean Mass Changes Similar With and Without HIV in Ireland Cohort - Mark Mascolini (03/23/18)
     
  3273. CROI: Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women - Cervical Outcomes Similar With Immediate Cryotherapy and Standard Cytology in HIV+ Women - Mark Mascolini (03/23/18)
     
  3274. CROI: CDC: Clinical outcomes of US young black men with HIV receiving medical care, 2009-2014 - More ART for Young Black Men in US, But Adherence and Suppression Flat - Mark Mascolini (03/23/18)
     
  3275. CROI: HIV Transmission Risk Higher With HIV+ Opioid Misusers, Especially Injectors - less adherence, viral suppression/more condomless sex - Mark Mascolini (03/23/18)
     
  3276. CROI: Comparing Strategies for Reducing Myocardial Infarction Rates in HIV Patients - Mark Mascolini (03/23/18)
     
  3277. CROI: HIV Diagnosis After Age 50 Often Delayed Despite Clear Clues - Should age-associated, Non-AIDS conditions Invite HIV Testing, YES - Mark Mascolini (03/23/18)
     
  3278. CROI: Prognosis Prediction in START Similar with IL-6, D-dimer, CD8s, and CD4:CD8 Ratio - Mark Mascolini (03/23/18)
     
  3279. CROI: New HCV Infections Still Rising Among MSM With HIV in France - Mark Mascolini (03/22/18)
     
  3280. CROI: Ablation Outcomes for HIV Infected and Uninfected Patients with High-Grade Anal Dysplasia (03/21/18)
     
  3281. CROI: CHANGES IN BRAIN VOLUME AND COGNITION IN MICE EXPOSED IN UTERO TO ABC/ 3TC-ATV/ RTV (03/21/18)
     
  3282. CROI: Safety, Pharmacokinetics, and Efficacy of FTC/TAF in HIV-Infected Adolescents (12-18 years) (03/21/18)
     
  3283. CROI: Comparative Impact of Antiretrovirals on Human Platelet Activation (03/21/18)
     
  3284. CROI: LEUKOCYTES ARE KEY TO THE PRO-THROMBOTIC EFFECTS OF ABACAVIR (03/21/18)
     
  3285. CROI: Antiretroviral Drugs Associated with Subclinical Coronary Artery Disease. (03/21/18)
     
  3286. CROI: HIV-1 VIRAL REBOUND AND SAFETY OUTCOMES OF POSTPARTUM TREATMENT INTERRUPTION IN WOMEN (03/21/18)
     
  3287. CROI: SHORT-TERM ART INTERRUPTION HAS LITTLE EFFECT ON LEVELS OF INTEGRATED PROVIRAL DNA (03/20/18)
     
  3288. CROI: A5340: BRIEF ATI DOES NOT ALTER THE SIZE OR COMPOSITION OF THE LATENT HIV-1 RESERVOIR (03/20/18)
     
  3289. CROI: Impact of Treatment Interruption on HIV Reservoirs and Immunologic Parameters (03/20/18)
     
  3290. CROI: QUANTIFICATION OF REPLICATION COMPETENT LATENT HIV-1 IN GALT AND SEMEN Replication Competent HIV-1 in Reservoir-GALT/Rectal/Semen/Blood - Mark Mascolini (03/20/18)
     
  3291. CROI: DETERMINANTS OF HIV-1 RESERVOIR SIZE AND LONG-TERM DYNAMICS UNDER SUPPRESSIVE ART - Mark Mascolini (03/20/18)
     
  3292. CROI: No Evidence for Ongoing HIV-1 Replication in Lymph Nodes During Suppressive ART - Mark Mascolini (03/20/18)
     
  3293. CROI: The Kidney at CROI 2018 -Christina Wyatt MD - Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY - (03/20/18)
     
  3294. CNS Monitoring of cART Interruption in Individuals Treated during Fiebig I Acute HIV - (03/18/18)
     
  3295. CROI: P38 MAPK in vivo inhibition impacts SIV-mediated immune activation & CD4 T-cell loss (03/16/18)
     
  3296. CROI: Prevalence of Active Hepatitis B Among New York City MSM Initiating PrEP and PEP, 2016-2017 (03/16/18)
     
  3297. CROI: IMPACT OF METHOTREXATE ON ARTERIAL INFLAMMATION IN PERSONS WITH TREATED HIV (03/16/18)
     
  3298. CROI: LONGITUDINAL COGNITIVE OUTCOMES AFTER TREATMENT IN ACUTE HIV INFECTION (03/16/18)
     
  3299. CROI: Results of ACTG A5288: A Strategy Study in RLS [resource limited setting] for 3rd Line ART Candidates (03/16/18)
     
  3300. CROI: METHAMPHETAMINE USE INDEPENDENTLY PREDICTS PREMATURE AGING IN HIV+ INDIVIDUALS (03/16/18)
     
  3301. CROI: Low Prevalence of Hepatitis C Virus Among New York City MSM Initiating PrEP and PEP, 2016-2017 at NYC Sexual Health Clinics (03/15/18)
     
  3302. CROI: A treatment as prevention trial to eliminate HCV in HIV positive men who have sex with men: The Swiss HCVree Trial - e-health assisted behavioral intervention to reduce risk in HCV re-infection in MSM - Mark Mascolini (03/15/18)
     
  3303. CROI: FUELING THE EPIDEMIC: Low Spontaneous HCV Clearance in Big European HCV/HIV Cohort - Mark Mascolini (03/15/18)
     
  3304. CROI: MITOCHONDRIAL DYSFUNCTION IN WELL-SUPPRESSED PERINATALLY HIV-INFECTED CHILDREN ON ANTIRETROVIRAL THERAPY (03/14/18)
     
  3305. CROI: ViiV Healthcare Announces Positive Action Southern Initiative Expansion and Request for Proposals (03/14/18)
     
  3306. CROI: Lopinavir/ritonavir Induces Mitochondrial Toxicity in HIV-exposed Uninfected Children (03/14/18)
     
  3307. CROI: Metabolic Shut Down of CD4 T Cells Activity Induced by HAART (03/14/18)
     
  3308. CROI: Statin exposure is associated with decreased risk of cancer - Mark Mascolini (03/14/18)
     
  3309. CROI: Change in Soluble Glycoprotein VI When Switching From ABC/3TC to TAF/FTC (03/14/18)
     
  3310. CROI: PLATELET FUNCTION UPON SWITCHING TO TAF VS CONTINUING ABC: A RANDOMIZED SUBSTUDY - Mark Mascolini (03/14/18)
     
  3311. CROI: Protection against repeated vaginal SHIV challenges by bNAb 3BNC117 and 10-1074 - Mark Mascolini (03/14/18)
     
  3312. CROI: Antiretroviral Therapy CROI 2018 New Agents/Combinations - Joseph J. Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/13/18)
     
  3313. CROI: CROI 2018: Comorbidities and Inflammation - David H Shepp, MD Associate Professor of Medicine Zucker School of Medicine at Hofstra-Northwell Manhasset, NY - (03/13/18)
     
  3314. CROI: INCREASED RISK OF PERIPHERAL ARTERY DISEASE IN PERSONS WITH HIV COMPARED TO CONTROLS (03/13/18)
     
  3315. Recent abacavir use increases risk for Types 1 and 2 myocardial infarctions among adults with HIV (03/13/18)
     
  3316. CROI: Bictegravir at CROI (03/13/18)
     
  3317. Major features of immunesenescence, including reduced thymic output, are ameliorated by high levels of physical activity in adulthood - (03/12/18)
     
  3318. How Exercise May Help Protect Your Brain From Cognitive Decline and Dementia - (03/12/18)
     
  3319. CROI: HIV Incidence and Adherence in DREAM -An Open-Label Trial of Dapivirine Vaginal Ring (03/12/18)
     
  3320. CROI: 8 weeks of grazoprevir plus elbasvir for acute hepatitis C virus genotype 1 or 4 infection - the DAHHS 2 study - a single-arm, prospective, open-label, multicenter phase 3b trial (03/12/18)
     
  3321. CROI: BRAIN VOLUMES CHANGES AFTER ABC/3TC + EFV OR TDF/FTC + ATV/r AS FIRST LINE ART (03/12/18)
     
  3322. CROI: Amyloid uptake by PET imaging in older HIV+ individuals with cognitive impairment (03/12/18)
     
  3323. CROI: Asymptomatic Neurocognitive Impairment With HIV Marked by Brain Atrophy - Mark Mascolini (03/12/18)
     
  3324. CROI: Reversing Accelerated Aging in HIV patients: Metabolic and Mitochondrial Mechanisms (03/12/18)
     
  3325. CROI: LOWER MITOCHONDRIAL DNA COPY NUMBER IS ASSOCIATED WITH HIV & PREDICTIVE OF MORTALITY (03/12/18)
     
  3326. CROI: Cabotegravir long-acting protects macaques against repeated penile SHIV exposures (03/12/18)
     
  3327. CROI: IMPACT OF ART REGIMENS ON CSF VIRAL ESCAPE IN HIV-1 INFECTED ADULTS - Mark Mascolini (03/12/18)
     
  3328. CROI: Methotrexate Reins in CD8 Cells But Does Not Improve Endothelial Function - Mark Mascolini (03/12/18)
     
  3329. CROI: CROI - Non-AIDS Complications / Inflammation Markers-Kidney Disease-Plaque Predict Outcomes (03/12/18)
     
  3330. CROI: High HBV and HIV Suppression With Treatment of HIV/HBV Coinfection in B/F/TAF Studies (03/10/18)
     
  3331. CROI: NEUROIMAGING CORRELATES OF FRAILTY, COGNITION, AND HIV (03/09/18)
     
  3332. CROI: Virologic Response To 2-Drug ART Regimens Among Treatment-Experienced HIV+ Patients (03/09/18)
     
  3333. CROI: DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO-Recommended NRTI Backbone (03/09/18)
     
  3334. CROI: BRAIN 18F-FDG PET OF SIV-INFECTED MACAQUES AFTER TREATMENT INTERRUPTION OR INITIATION - s(03/09/18)
     
  3335. CROI: Oral TAF/FTC PrEP Prevents Vaginal SHIV Infection in Monkeys - Mark Mascolini (03/09/18)
     
  3336. CROI: IBALIZUMAB FDA Product Insert (03/09/18)
     
  3337. CROI: POORER NEUROCOGNITIVE PERFORMANCE ASSOCIATED WITH CSF HIV DNA DESPITE LONG-TERM ART ACTG HIV Reservoirs Cohort study A5321 (03/09/18)
     
  3338. CROI: HIV-1 persists in CSF cells in half of individuals on long-term ART - Mark Mascolini (03/09/18)
     
  3339. CROI: New Positive Data on Trogarzo™ (ibalizumab-uiyk) Injection and EGRIFTA® (tesamorelin for injection) Presented at 25th Conference on Retroviruses and Opportunistic Infections (03/09/18)
     
  3340. CROI: SIV REBOUND IN THE SPINAL CORD AFTER STOPPING ART: A NOVEL CNS RESERVOIR (03/09/18)
     
  3341. CROI: Pharmacokinetics of Total and Unbound Darunavir in HIV-1-infected Pregnant Women Receiving a Darunavir/Cobicistat-based Regimen (03/09/18)
     
  3342. CROI: HIV Treatment-experienced Patients Switched to D/C/F/TAF: Age, Gender, and Race Analyses (03/09/18)
     
  3343. CROI: Analysis of HIV Patients Switching to D/C/F/TAF by Prior ARV Treatment Experience (03/09/18)
     
  3344. CROI: Retreatment of Hepatitis C Infection in Patients Who Failed Glecaprevir/Pibrentasvir (03/09/18)
     
  3345. CROI: Age, Gender, and Race Analyses of D/C/F/TAF in HIV-1 Treatment-naïve Patients (03/08/18)
     
  3346. CROI: IBALIZUMAB SUSCEPTIBILITY & Potency vs ART Resistance - New HIV Drug for Multi-Drug Resistant Patients (03/08/18)
     
  3347. CROI: Antiviral Activity of Tenofovir Alafenamide Against HIV-1 with Thymidine Analog Mutation(s) and M184V (03/08/18)
     
  3348. CROI: Efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in virologically-suppressed, treatment-experienced and treatment-naïve women with human immunodeficiency virus type 1 (03/08/18)
     
  3349. CROI: High uptake and reduced HIV-1 incidence in an open-label trial of the dapivirine ring (03/08/18)
     
  3350. CROI: The Rapid ART Program Initiative for HIV Diagnoses (RAPID) in San Francisco (03/08/18)
     
  3351. CROI: IBALIZUMAB SUSCEPTIBILITY IN PATIENT HIV ISOLATES RESISTANT TO ANTIRETROVIRALS (03/08/18)
     
  3352. CROI: EFV and ATV/r "Profoundly Alter" Levels of Vaginal Ring Hormonal Contraceptives - Mark Mascolini (03/07/18)
     
  3353. CROI: IBALIZUMAB SUSCEPTIBILITY IN PATIENT HIV ISOLATES RESISTANT TO ANTIRETROVIRALS - (03/07/18)
     
  3354. CROI: San Francisco RAPID ART Program Halves Span From HIV Diagnosis to Suppression - Mark Mascolini (03/07/18)
     
  3355. CROI: Starting ART on Day of Home HIV Test Improves Linkage, Viral Suppression - Mark Mascolini (03/07/18)
     
  3356. CROI: Hyperkyphosis and Aging in the Women's Interagency HIV Study - Mark Mascolini (03/07/18)
     
  3357. CROI: Impact of Low Dose Methotrexate on Immune Activation and Endothelial Function in Treated HIV - Mark Mascolini (03/07/18)
     
  3358. CROI: Statin Use Linked to Lower Cancer Risk With or Without HIV - Mark Mascolini (03/07/18)
     
  3359. CROI: No Evidence of Residual Virus Replication in a Randomised Controlled Trial of Dolutegravir Intensification - (03/07/18)
     
  3360. CROI: PGT121 Combined with GS-9620 Delays Viral Rebound in SHIV-Infected Rhesus Monkeys - (03/07/18)
     
  3361. CROI: Persistent Detection of HIV RNA+ Cells With ART Started in Fiebig 1 & 2 vs Fiebig 3-5 - (03/07/18)
     
  3362. CROI: ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis - (03/07/18)
     
  3363. CROI: Safety and Efficacy of E/C/F/TAF in HIV-Infected Adults on Chronic Hemodialysis - (03/07/18)
     
  3364. CROI: Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1 - (03/07/18)
     
  3365. CROI: FDA approves new HIV treatment (Long-Acting Ibalizumab) for patients who have limited treatment options - (03/07/18)
     
  3366. CROI: SERIOUS CLINICAL EVENTS IN HIV-POSITIVE PERSONS WITH CHRONIC KIDNEY DISEASE (CKD) - D:A:D - (03/07/18)
     
  3367. CROI: IL-6, D-dimer or T-cells: which best predict events or explain benefits of early ART? - (03/07/18)
     
  3368. CROI: Progression of Coronary Plaque: The MACS Longitudinal Coronary CT Angiography Study" - Mark Mascolini (03/07/18)
     
  3369. CROI: Carotid Plaque Predicts All-Cause Mortality in Women and Men With HIV: "Association of carotid artery atherosclerosis with mortality in HIV+ women and men" - Mark Mascolini (03/07/18)
     
  3370. CROI: INSTI-based initial ART in the HIV Outpatient Study [Integrase s Non-Integrase Viral Suppression/Duration of ART] - (03/07/18)
     
  3371. CROI: Switching to RPV/FTC/TAF From RPV/FTC/TDF or EFV/FTC/TDF: Week 96 Results - (03/07/18)
     
  3372. CROI: Distribution of Active PrEP Prescriptions and the PrEP-to-Need Ratio, US Q2 2017 - (03/07/18)
     
  3373. CROI: Low-Dose Oral MK-8591 Protects Monkeys From Rectal SHIV Infection - Mark Mascolini (03/07/18)
     
  3374. CROI: Low-Dose Hydrocortisone Improves Learning and Memory in Women With HIV - Mark Mascolini (03/07/18)
     
  3375. CROI: High-Intensity Exercise Has Edge Over Moderate Intensity in Older Group With HIV - Mark Mascolini (03/06/18)
     
  3376. CROI: Integrase Inhibitor Penetration Generally Worse in Lymphoid Tissue Than Blood Cells - Mark Mascolini (03/06/18)
     
  3377. CROI: Antiretroviral Hair Levels Predict Failure in ACTG PI-Raltegravir Trial ACTG5257 - Mark Mascolini (03/06/18)
     
  3378. CROI: Multiple Low Doses of Nucleoside MK-8591 Strong in Healthy Volunteers - Long-Acting MK-8591 /Treatment / PrEP-vaginal/rectal tissue - Mark Mascolini (03/06/18)
     
  3379. CROI: Mortality Plateaued in 2001 in Large Baltimore Drug Injector Cohort / Mortality Steeply Increased due to Comorbidities - (03/06/18)
     
  3380. CROI: Pharmacokinetics of Bictegravir Administered Twice Daily In Combination With Rifampin - (03/06/18)
     
  3381. CROI: Similar Efficacy and Safety By Subgroup in DRIVE-AHEAD: DOR/3TC/TDF vs EFV/FTC/TDF - (03/06/18)
     
  3382. CROI: Bictegravir/FTC/TAF Single-Tablet Regimen in Adolescents: Week-24 Results - (03/06/18)
     
  3383. CROI: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Women - (03/06/18)
     
  3384. CROI: POORER NEUROCOGNITIVE PERFORMANCE ASSOCIATED WITH CSF HIV DNA DESPITE LONG-TERM ART ACTG HIV Reservoirs Cohort study A5321 - (03/06/18)
     
  3385. CROI: Tenofovir Diphosphate in Dried Blood Spots is a Strong Predictor of Viral Suppression - (03/06/18)
     
  3386. CROI: Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen - (03/06/18)
     
  3387. CROI: DolPHIN-1: Dolutegravir vs Efavirenz when Initiating Treatment in Late Pregnancy - (03/06/18)
     
  3388. CROI: Impact of Raltegravir Intensification of first-line ART on IRIS in the REALITY trial (Reduction of EArly mortaLITY in HIV-infected adults and children starting ART) - (03/05/18)
     
  3389. CROI: MULTIPLE DAILY DOSES OF MK-8591 AS LOW AS 0.25 MG ARE EXPECTED TO SUPPRESS HIV - (03/05/18)
     
  3390. CROI: Hair antiretroviral (ARV) levels strongly predict virologic outcomes in ACTG A5257 - (03/05/18)
     
  3391. CROI: Switch to Bictegravir/F/TAF Noninferior to Staying with DTG/ABC/3TC - written by Mark Mascolini (03/05/18)
     
  3392. CROI: Antiretroviral Hair Levels Predict Failure in ACTG PI-Raltegravir Trial - written by Mark Mascolini (03/05/18)
     
  3393. CROI: INSPIRING: SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED ART IN TB/HIV COINFECTED ADULTS AT WEEK 24 - (03/05/18)
     
  3394. CROI: Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy®(Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine - (03/05/18)
     
  3395. CROI: Switch to Bictegravir/F/TAF From DTG and ABC/3TC - (03/05/18)
     
  3396. LOW DOSE MK-8591 PROTECTS RHESUS MACAQUES AGAINST RECTAL SHIV INFECTION - (03/05/18)
     
  3397. CROI: NIH bNAB+PGT121 Keeps Viral Suppression in 45% of Monkeys After ART Stop - (03/05/18)
     
  3398. CROI: Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys - (03/05/18)
     
  3399. CROI: Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018 - (03/05/18)
     
  3400. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir with Once-Weekly Isoniazid and Rifapentine - (03/02/18)
     
  3401. New Cancer Guidelines Say HIV+ with Cancer Should get Appropriate Care - HIV+ are 2-3 times more likely to receive no cancer treatment - "Disparities in cancer treatment among patients infected with the human immunodeficiency virus" - (03/02/18)
     
  3402. HIV+ Women - Frailty / Falls / Fracture / Mortality - (03/02/18)
     
  3403. Aging in HIV-Infected Subjects: A New Scenario and a New View - (03/05/18)
     
  3404. New Cancer Guidelines: HIV+ 2-3 Times More Likely Not To receive Cancer Treatment. Cancer is 2nd Leading Cause of Death in HIV - (02/28/18)
     
  3405. Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: Implications for HIV-associated neurocognitive disorders (alzheimers in HIV+) - (02/28/18)
     
  3406. Statins Affect Skeletal Muscle Performance: Evidence for Disturbances in Energy Metabolism - (02/28/18)
     
  3407. Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women - (02/28/18)
     
  3408. Bone Mineral Density and Parathyroid Hormone as Independent Risk Factors for Mortality in Community-Dwelling Older Adults: A Population-Based Prospective Cohort Study in Brazil. The Sao Paulo Ageing & Health (SPAH) Study - (02/28/18)
     
  3409. Gait Speed/Mitochondria/ Functional Decline in HIV+ - The Role of Mitochondrial DNA Variation in Age-Related Decline in Gait Speed Among Older Men Living with HIV - (02/28/18)
     
  3410. Bone Mineral Density and Parathyroid Hormone as Independent Risk Factors for Mortality in Community-Dwelling Older Adults: A Population-Based Prospective Cohort Study in Brazil. The Sao Paulo Ageing & Health (SPAH) Study - (02/26/18)
     
  3411. Find drugs that delay many diseases of old age: class of drugs called geroprotectors / European Aging Researchers Unite for Aging Drug Development - (02/26/18)
     
  3412. Experienced HIV-Related Stigma in Health Care and Community Settings: Mediated Associations With Psychosocial and Health Outcomes - (02/23/18)
     
  3413. Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines - (02/23/18)
     
  3414. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial - (02/23/18)
     
  3415. Doxycycline post-exposure prophylaxis: let the debate begin - Comment - (02/23/18)
     
  3416. CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection - (02/23/18)
     
  3417. HIV-positive women have higher risk of HPV infection, precancerous lesions, and cervical cancer: a systematic review and meta-analysis - (02/23/18)
     
  3418. How Exercise May Help Protect Your Brain From Cognitive Decline and Dementia - (02/23/18)
     
  3419. Risks of HPV Infection in Men, Heterosexual Men, Screening - (02/23/18)
     
  3420. Nano-Formulated Long-Acting Dolutegravir - cell/tissue/reservoir penetration - (02/23/18)
     
  3421. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health - (02/23/18)
     
  3422. HIV: ageing, cognition and neuroimaging at 4-year follow-up - 'Accelerated Brain Aging' - (02/15/18)
     
  3423. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study - (02/14/18)
     
  3424. Vaginal microbes, inflammation, and HIV risk in African women - Comment - (02/12/18)
     
  3425. Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women - (02/12/18)
     
  3426. ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment (Dolutegravir+3TC) - (02/09/18)
     
  3427. 3TC - Epivir FDA Label, Prescribing Information, Product insert - (02/09/18)
     
  3428. Redefining Hypertension - Assessing the New Blood-Pressure Guidelines - Perspective - (02/09/18)
     
  3429. U.S. Food and Drug Administration Approves Gilead's Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection - (02/07/18)
     
  3430. (dolutegravir Generic) Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modeling study - (02/07/18)
     
  3431. Biohackers Disregard FDA Warning on DIY Gene Therapy - (02/07/18)
     
  3432. 'Block & Lock' Cure Approach - Exploiting immune cell metabolic machinery for functional HIV cure and the prevention of inflammaging - (02/07/18)
     
  3433. Gene Therapy Do-It-Yourself FDA WARNS of Dangers / Price Tag for Gene Therapy - (02/07/18)
     
  3434. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV - (02/07/18)
     
  3435. HIV Accelerates Brain Damage ; "Neurological Complications of HIV Infection" Review - (02/06/18)
     
  3436. FDA: Prezcobix Label Revised - (02/05/18)
     
  3437. FDA: Prezista Label Revised - (02/05/18)
     
  3438. Hypertension among persons living with HIV in medical care in the United States- Medical Monitoring Project, 2013-2014 - "We found that about 1 in 8 patients had undiagnosed and untreated hypertension." - (02/05/18)
     
  3439. Doctors Spend 30% of Their Time With Patient - (02/05/18)
     
  3440. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks (no benefit) - Meta-analysis of 10 Trials Involving 77 917 Individuals - (02/05/18)
     
  3441. CROI: HIV Cancer at CROI 2017 - (02/02/18)
     
  3442. CDC: Racial and Ethnic Disparities in Sustained Viral Suppression and Transmission Risk Potential Among Persons Receiving HIV Care - United States, 2014 - (02/02/18)
     
  3443. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study (HACM) - (02/02/18)
     
  3444. Cancers in HIV in Elderly - CD4 / Viral Load, Smoking, Lifestyle - (02/02/18)
     
  3445. MitoQ - An antioxidant to attenuate aortic aging / Mitochondria Treatment - (01/31/18)
     
  3446. Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes - (01/31/18)
     
  3447. Changes in viral suppression status among US HIV-infected patients receiving care - (01/31/18)
     
  3448. Single Viral Load Measurements Overestimate Stable Viral Suppression Among HIV Patients in Care: Clinical and Public Health Implications - (01/31/18)
     
  3449. Viral Suppression Patterns Among Persons in the United States With Diagnosed HIV Infection in 2014 - CDC - (01/31/18)
     
  3450. Long Term Outcomes: Mortality and Causes of Death in NAFLD - (01/30/18)
     
  3451. HIV & PTSD, Lifetime Trauma/Mental Health, Adherence - Aged HIV+ Deserve Better - (01/29/18)
     
  3452. WIHS HIV+ Women - More falls, comorbidities, cognitive impairment, isolation/loneliness, self-stigma, detectable viral load; CDC Viral Suppression is Over Estimated in the USA - (01/29/18)
     
  3453. Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression - (01/29/18)
     
  3454. Forgotten Aging HIV+ - An Explosive Devastating Problem Being Ignored - its scandalous - (01/24/18)
     
  3455. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer - (01/24/18)
     
  3456. PrEP - (01/24/18)
     
  3457. Marijuana / Cardiovascular Disease - (01/24/18)
     
  3458. Midlife Cardiorespiratory Fitness, Incident Cancer, and Survival After Cancer in MenThe Cooper Center Longitudinal Study - (01/24/18)
     
  3459. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade - (01/24/18)
     
  3460. Coronary CT Angiography- Should We Use It? - (01/24/18)
     
  3461. Variable HIV Life Expectancy - (01/24/18)
     
  3462. Ten Take-Home Lessons From Top HIV-Aging Articles in 2017 - (01/22/18)
     
  3463. ViiV - Research study gathers real world insights from people living with HIV through mobile devices - (01/19/18)
     
  3464. Ageing-related receptors resolved - (01/19/18)
     
  3465. 'Liquid biopsy' for cancer promises early detection - (01/17/18)
     
  3466. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain - (01/17/18)
     
  3467. SVR in HIV/HCV Coinfected / DDIs - (01/17/18)
     
  3468. Brief Report: The Right People, Right Places, and Right Practices Disparities in PrEP Access Among African American Men, Women, and MSM in the Deep South - (01/17/18)
     
  3469. Partnerships Between a University-Affiliated Clinic and Community-Based Organizations to Reach Black Men Who Have Sex With Men for PrEP Care - (01/17/18)
     
  3470. Evolving Models and Ongoing Challenges for HIV Preexposure Prophylaxis Implementation in the United States - (01/17/18)
     
  3471. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project - (01/17/18)
     
  3472. Combination ART: are two drugs as good as three? Comment - (01/13/18)
     
  3473. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies - (01/13/18)
     
  3474. Barriers & Challenges to Care - Gynecologic cancer in HIV-infected women: treatment and outcomes in a multi-institutional cohort - (01/11/18)
     
  3475. Psychiatric symptom burden in older people living with HIV with and without cognitive impairment: the UCSF HIV over 60 cohort study - (01/11/18)
     
  3476. Incidence of diabetes mellitus and factors associated with its development in HIV-positive patients over the age of 50 - at the clinic between 1997 and 2015 - (01/08/18)
     
  3477. HIV & Diabetes - risk factors/ARTs - (01/08/18)
     
  3478. FDA Accepts New Drug Applications for Merck's Doravirine, the Company's Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection - (01/08/18)
     
  3479. Doravirine Studies - efficacy, safety / FDA NDA Accepted - (01/08/18)
     
  3480. Accelerated Brain Aging: WHICH IS IT - No evidence for accelerated ageing-related brain pathology in treated HIV: longitudinal neuroimaging results from the Comorbidity in Relation to AIDS (COBRA) project - OR - Progressive Brain Atrophy Despite Persistent Viral Suppression in HIV Over Age 60 - (01/05/18)
     
  3481. HIV Cure: New Way to Find Hidden Cells Brings Scientists One Step Closer - (01/05/18)
     
  3482. A Cure for HIV? Cancer-Killing Immunotherapy Could Also Fight the Virus - (01/05/18)
     
  3483. EACS: HCV Reinfection Intervention in HCV/HIV MSM - Swiss Cohort - (01/04/18)
     
  3484. Inflammation-Related Morbidity and Mortality Among HIV-Positive Adults: How Extensive Is It? - (01/03/18)
     
  3485. Suicide in Aging Older HIV+ / Causes of Death in HIV-Infected Individuals with Immunovirologic Success in a National Prospective Survey - France - (01/03/18)
     
  3486. Selective suppression of inflammation could deplete HIV and control HIV activation - Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors - (01/03/18)
     
  3487. PrEP for IDUs - WHO, CDC, Study - (01/03/18)
     
  3488. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report - (01/03/18)
     
  3489. Gene therapy using CAR T-cells could provide long-term protection against HIV Public Release: 28-Dec-2017 - (01/03/18)
     
  3490. New HIV Drugs - Heavily Treated with Multi-Drug Resistance - (01/03/18)
     
  3491. Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men - (01/03/18)
     
  3492. Excess Clinical Comorbidity Among HIV-Infected Patients Accessing Primary Care in US Community Health Centers....[20% diabetes, 44% hypertension, 56% dyslipidemia, HPV, lymphoma & cancers were more prevalent in HIV+, so was stroke] - (12/22/17)
     
  3493. Institutionalizing HIV Healthcare - VALUE BASED CARE (VBC) is & will be a disaster - (12/21/17)
     
  3494. Eleven-year incident glucose disorders [45%] in treated HIV-infection. The St Vincent's HIV and Diabetes Study - (12/20/17)
     
  3495. Marijuana Reduced Neuro-Inflammation in vitro/new study/POT good or bad for you????? - (12/20/17)
     
  3496. Primary Prevention of Atherosclerosis Time to Take a Selfie? Editorial - Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors - (12/20/17)
     
  3497. Cure Research - Strategies to target HIV-1 in the central nervous system - (12/20/17)
     
  3498. Long-Term Outcomes of Diabetic Patients with Non-alcoholic Fatty Liver Disease (NAFLD) / HIV & the Liver, Fatty Liver/NALFD - (12/20/17)
     
  3499. HIV cure strategies [interruptions/viral rebound brain/immune affects]: response to ignore the central nervous system at your patients' peril - (12/20/17)
     
  3500. New Cure research studies, ART interruptions: biomarkers for viral rebound after interruptions, search for reservoirs where HIV rebounds from; intensified monitoring, safety concerns; patient consent - (12/20/17)
     
  3501. HIV cure strategies [interruptions/viral rebound brain/immune affects]: response to ignore the central nervous system at your patients' peril - (12/20/17)
     
  3502. Aging / HIV -USA - Time For Integrated Care / Beyond Viral Suppression / Payer Analysis - (12/15/17)
     
  3503. Social stress induces neurovascular pathology promoting depression - (12/14/17)
     
  3504. EACS: Characterization of the Aging Population Living with HIV in Portugal: a multicentre, observational study to evaluate comorbidities in patients above 50 years of age - AGING POSITIVE - (12/14/17)
     
  3505. apoB vs LDL/cholesterol - To help save the heart, is it time to retire cholesterol tests? - (12/13/17)
     
  3506. The role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue - (12/13/17)
     
  3507. EACS: BESIDE - FIRST NATIONWIDE ANALYSIS OF RECREATIONAL/ILLICIT DRUG USE IN HIV-INFECTED INDIVIDUALS IN GERMANY SHOWS HIGH PREVALENCE OF SUBSTANCE ABUSE WITH A POTENTIAL FOR DRUG-DRUG INTERACTIONS WITH ANTIRETROVIRAL THERAPY - (12/13/17)
     
  3508. EACS: BESIDE - HIGH PREVALENCE OF COMORBIDITIES AND CONCOMITANT MEDICATION IN HIV-INFECTED PATIENTS IN GERMANY CARRIES A HIGH POTENTIAL FOR DRUG-DRUG INTERACTIONS WITH ANTIRETROVIRAL THERAPY - (12/13/17)
     
  3509. EACS: Safety and Efficacy of DTG+RPV in the Phase III SWORD-1 and SWORD-2 Studies: 48 Week Subgroup Analysis by Baseline Third Agent Class and Geographic Location - (12/13/17)
     
  3510. EACS: Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Results From the SWORD-1 and SWORD-2 Studies - (12/12/17)
     
  3511. ViiV Healthcare announces start of phase III study of long-acting cabotegravir for HIV prevention in women - (12/12/17)
     
  3512. ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine - (12/12/17)
     
  3513. HIV alters neuronal mitochondrial fission/fusion in the brain during HIV-associated neurocognitive disorders - (12/11/17)
     
  3514. FDA Ibalizumab Expected Approval Date / 2 New HIV Drugs for Heavily Treated with Multi-Drug resistance - (12/08/17)
     
  3515. Cancer rates Higher in HIV+ vs HIV- for many but not for all cancers - (12/08/17)
     
  3516. HIV New Cases among IDUs Alert / Mass Dept of Health - (12/11/17)
     
  3517. County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States - (12/08/17)
     
  3518. HIV New Cases among IDUs Alert / Mass Dept of Health - Massachusetts Department of Public Health raises level of concern about increased HIV transmission through injection drug use, in light of the current epidemic of opiate/opioid misuse and recent observations. - (12/08/17)
     
  3519. Ixolaris Reduced Inflammation/Immune Activation, Prevented HIV Rapid Progression - (12/08/17)
     
  3520. EACS: Analysis of the performance of non-invasive markers of steatosis and fibrosis in HIV-monoinfected patients at-risk of NAFLD: Results from the ERANET-HIVERA ECHAM study - (11/15/17)
     
  3521. EACS: How many HIV mono-infected or HBV or HCV co-infected patients with undetectable viremia should be monitored for liver disease severity in the presence of suspect NAFLD? - (12/08/17)
     
  3522. EACS: Non-viral Liver Disease Burden in HIV Mono-infected Individuals: A Prospective Cohort Study - (12/07/17)
     
  3523. JULUCA (dolutegravir and rilpivirine)FDA Prescribing Information - (12/07/17)
     
  3524. EACS: Aging in Portugal: The number of PLHIV aged 50+ will double in the next 20 years, representing 80% of the estimated overall prevalence in 2037. The proportion over 70 will increase 4.3 times going from 6% to 26%. - (12/06/17)
     
  3525. EACS: SAFETY ANALYSIS OF GERMAN REAL-LIFE COHORT WIP SHOWS LOW RATES OF NEUROPSYCHIATRIC EVENTS LEADING TO DISCONTINUATION OF RALTEGRAVIR THERAPY - (12/06/17)
     
  3526. ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV - (12/05/17)
     
  3527. HIV Cure Drugs Safety Issues - ART Interruption Brain Affects. HDAC Gene Changes Long Term Affects / Immune Checkpoint Cancer Drugs: cardiac toxicity - (12/05/17)
     
  3528. HIV Stigma / Women /Aging / Relationships / Isolation / Depression-Mental Health / CVD - (12/02/17)
     
  3529. - (12/05/17)
     
  3530. Does Social Isolation Predict Hospitalization and Mortality Among HIV+ and Uninfected Older Veterans? [yes] - (12/02/17)
     
  3531. European Researchers/Advocates Present HIV/Aging Recommendations/EATG to European Parliament - (12/02/17)
     
  3532. US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials - (11/29/17)
     
  3533. Ongoing HIV Replication During ART Reconsidered - (11/29/17)
     
  3534. Re-evaluating evolution in the HIV reservoir - (11/28/17)
     
  3535. FDA approves first two-drug regimen for certain patients with HIV - Fixed Dose dolutegravir and rilpivirine - FDA News Release - (11/28/17)
     
  3536. Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for themaintenance treatment of virologically suppressed HIV-1 infection - PRESS RELEASE - (11/28/17)
     
  3537. Stigma in HIV: 53% Report Social Stigma & 60% Report Self-Stigma.....high levels of depression, anxiety particularly for >50 Years Old - 63% Report 3 or more Comorbidities - (11/20/17)
     
  3538. Cardiovascular Disease & Risk Assessment in HIV - Editorial & New Study: "Presence, Characteristics, and Prognostic Associations of Carotid Plaque Among People Living With HIV" - (11/20/17)
     
  3539. New Hypertension Guidelines say systolic BP 120-129 & diastolic less than 80 are ELEVATED ! - (11/16/17)
     
  3540. EACS: Dynamics of viral rebound and development of resistance associated mutations in the DOlutegravir maintenance MONOtherapy (DOMONO) study. - (11/16/17)
     
  3541. EACS: Changes outside integrase in a patient failing on dolutegravir maintenance monotherapy points to a new resistance mechanism - (11/16/17)
     
  3542. Theratechnologies Announces Decision by the FDA to Extend the Ibalizumab Review Period to April 3, 2018 - (11/16/17)
     
  3543. EACS: Analysis of the performance of non-invasive markers of steatosis and fibrosis in HIV-monoinfected patients at-risk of NAFLD: Results from the ERANET-HIVERA ECHAM study - (11/15/17)
     
  3544. IWCADRH: Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on Telomere Length Attrition in a Prospective Cohort of Aviremic HIV-Infected Participants - (11/10/17)
     
  3545. IWCADRH: RETROSPECTIVE OBSERVATIONAL STUDY TO DEFINE THE PREVALENCE OF SARCOPENIA IN HIV-INFECTED PATIENTS - (11/10/17)
     
  3546. IWCADRH: Intrahepatic triglyceride is more strongly associated with insulin-resistant glucose metabolism than visceral adiposity in HIV, and is improved with tauroursodeoxycholic acid (TUDCA) treatment - (11/10/17)
     
  3547. IWCADRH: Bone Mineral Density in a Cohort of Young Adult Women using Depo-provera and Tenofovir, Kampala, Uganda - (11/10/17)
     
  3548. IWCADRH: Bone density, microarchitecture and tissue quality after 48-weeks and 96-weeks of treatment with Tenofovir Disoproxil Fumarate. - (11/10/17)
     
  3549. IWCADRH: Analysis of serum metabolomics parameters associated with carotid intima-media thickness (c-IMT) and inflammation in HIV-infected, never-smoker men, naïve of ART or ART-controlled, compared to matched HIV-negative controls. - (11/10/17)
     
  3550. IWCADRH: A Randomized, Double-Blinded, Placebo-Controlled Trial of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed HIV Infection ACTG 5346 - (11/10/17)
     
  3551. IWCADRH: Patterns of Co-occurring Comorbidities in People Living with HIV - (11/10/17)
     
  3552. EACS: Weight Gain & Affects of Different cART Regimens: PIs, NNRTIs, Integrase - Mark Mascolini (11/08/17)
     
  3553. EACS: Higher Pre-ART Viral Load Predicts Death in 12,000-Person Italian Analysis - Mark Mascolini (11/08/17)
     
  3554. EACS: Treated people living with HIV show poorer cognitive performance at baseline but similar longitudinal changes over two years compared to appropriately chosen controls - (11/08/17)
     
  3555. Reducing Blood Pressure / Hypertension Targets - Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and MortalityA Systematic Review and Network Meta-analysis - (11/08/17)
     
  3556. CVD / Hypertension Targets in USA - "Maximizing Cardiovascular Event Reduction by Expanding and Intensifying the Targets" - (11/08/17)
     
  3557. EACS: Dolutegravir plus lamivudine maintains HIV-1 suppression through week 48 in a pilot randomized trial (ASPIRE) - (11/08/17)
     
  3558. EACS: Evolution of renal function during treatment with direct antiviral agents (DAA-t) in HIV/HCV infected patients in ICONA/HepaIcona cohorts - (11/08/17)
     
  3559. EACS: HIGH PREVALENCE AND BURDEN OF PAIN IN PEOPLE LIVING WITH HIV: THE POPPY STUDY - (11/08/17)
     
  3560. EACS: Associations Between Subcutaneous Fat Density and Metabolic and Inflammatory Biomarkers Differ by HIV Serostatus and Are Independent of Fat Quantity - (11/08/17)
     
  3561. IWCADRH: Utility of chronic kidney disease (CKD) risk prediction scores and the changing - prevalence of CKD has doubled from '09 to '15; risk scores are predictive - (11/06/17)
     
  3562. IWCADRH: Effect of Vitamin D Supplementation on Bone Turnover Markers (BTMs) During HIV Pre-Exposure Prophylaxis (PrEP) Using Tenofovir Disoproxil Fumarate-Emtricitabine (TDF-FTC) in Men who Have Sex with Men (MSM) A Matched Case-Control Substudy of CCTG 595 - (11/06/17)
     
  3563. IWCADRH: Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on Telomere Length Attrition in a Prospective Cohort of Aviremic HIV-Infected Participants - (11/06/17)
     
  3564. IWCADRH: Associations Between Subcutaneous Fat Density and Metabolic and Inflammatory Biomarkers Differ by HIV Serostatus and Are Independent of Fat Quantity - (11/06/17)
     
  3565. EACS: "Use of integrase inhibitors is an independent risk factor for immune reconstitution inflammatory syndrome (IRIS) in HIV-1 late presenters: an ATHENA cohort study" - Mark Mascolini (11/06/17)
     
  3566. EACS: Bigger Weight Gains With Contemporary PI Regimens Than With NNRTIs or INIs - Mark Mascolini (11/06/17)
     
  3567. EACS: Predictors of Stopping Dolutegravir or Elvitegravir in Large Netherlands Group - ATHENA Cohort - Mark Mascolini (11/06/17)
     
  3568. EACS: Impacts of HIV Duration (Under 10 vs Over 20 Years) in People 50 or Older - Mark Mascolini (11/06/17)
     
  3569. EACS: "Switching boosters: are they equal? An analysis of patients switching from ritonavir to cobicistat in a large London cohort" - Mark Mascolini (11/06/17)
     
  3570. EACS: Successful Attempt to Counter Hep A Outbreak in Paris MSM With HAV Vaccine - Mark Mascolini (11/06/17)
     
  3571. EACS: In Over-60 Group, Longer Known HIV Duration Tied to Kidney Disease - Mark Mascolini (11/06/17)
     
  3572. EACS: More HIV/STI Testing, Fewer Risk Habits With Chemsex Program for London MSM - Mark Mascolini (11/06/17)
     
  3573. EACS: Clinical outcomes among persons living with HIV (PLWH) initiating dolutegravir-based vs. other recommended regimens in clinical care from the Centers for AIDS Research Network of Integrated Systems (CNICS) - Mark Mascolini (11/06/17)
     
  3574. EACS: Twice-Daily TAF May Be Option With Rifampin for TB and HIV - Mark Mascolini (11/06/17)
     
  3575. EACS: Phase 3 randomized controlled trial of switching to emtricitabine/tenofovir alafenamide (F/TAF) from abacavir/lamivudine (ABC/3TC) in virologically suppressed adults: week 48 results - Mark Mascolini (11/06/17)
     
  3576. EACS: Switching from boosted protease inhibitors (PI/r) to dolutegravir (DTG) in virologically suppressed HIV-infected patients with high cardiovascular risk: 48-week effects on subclinical cardiovascular disease (CVD) - Mark Mascolini (11/06/17)
     
  3577. IWCADRH: Alterations of adipose tissue induced by HIV or SIV infection: Tat and Nef-induced senescence and fibrosis - (11/04/17)
     
  3578. IWCADRH: Frailty Predicts Recurrent but Not Single Falls 10 Years Later in HIV+ and HIV- Women - (11/04/17)
     
  3579. IWCADRH: Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV within the UCD ID Cohort - (11/04/17)
     
  3580. EACS: EU Patient Experience and Views on Antiretroviral Treatment: Findings From the Positive Perspectives Study - (11/02/17)
     
  3581. EACS: UNDERSTANDING PLWH AWARENESS AND WORRIES CONCERNING COMORBIDITIES AND OPTIMIZATION THERAPY: RESULTS FROM AN ITALIAN WEB SURVEY - (11/02/17)
     
  3582. EACS: Tolerability and persistence of dolutegravir-based regimens: Second interim analysis of the prospective multicenter DOL-ART cohort - (11/02/17)
     
  3583. EACS: Socio-structural Factors Surrounding Long Acting Injectable ART: A Qualitative Study Among PLHIV Participating in a Phase II Study of Cabotegravir + Rilpivirine (LATTE-2) in the US and Spain - (11/02/17)
     
  3584. EACS: Abacavir Hypersensitivity Reaction Reporting Rates in a Decade of HLA-B*5701 Screening as a Risk Mitigation Measure - (11/02/17)
     
  3585. EACS: Abacavir Usage Patterns and Hypersensitivity Reactions (HSR) in the EuroSIDA cohort - (11/02/17)
     
  3586. EACS: Rate of Progression to Osteoporosis in a Large Cohort of HIV-Infected Subjects. - (11/02/17)
     
  3587. EACS: Occurrence of Hypersensitivity Reaction and Hepatotoxicity in Patients Receiving Integrase inhibitors Results from the EuroSIDA study. - (11/02/17)
     
  3588. EACS: Effectiveness and tolerability of Triumeq(DTG/ABC/3TC) in routine clinical care in Germany: First interim analysis of the TRIUMPH cohort - (11/02/17)
     
  3589. EACS: Predictors of Changes in Bone Mineral Density and Proteinuria From 5 Randomized TDF-to-TAF Switch Studies: Pooled Analysis - full poster report - (11/02/17)
     
  3590. EACS: Predictors of Changes in Bone Mineral Density and Proteinuria from 5 Randomized TDF-to-TAF Switch Studies: Pooled Analysis - (11/02/17)
     
  3591. EACS: Twice Daily Administration of Tenofovir Alafenamide in Combination with Rifampin: Potential for Tenofovir Alafenamide Use in HIV-TB Coinfection - (11/02/17)
     
  3592. EACS: Planned 24-week analysis of two dolutegravir (DTG)-based simplification strategies - (11/02/17)
     
  3593. EACS: Relationships between bone density, bone quality and reported fractures within the HIV UPBEAT cohort - (10/31/17)
     
  3594. EACS: The contribution of HIV to reduced bone mineral density (BMD): the POPPY Study - (10/31/17)
     
  3595. EACS: Plasma and Seminal Pharmacokinetics of Etravirine and Raltegravir in a Dual Regimen maintenance strategy: ANRS-163 ETRAL - (10/31/17)
     
  3596. EACS: Efficacy of dolutegravir-based regimens in suppressing HIV-RNA in paired blood and semen samples in ART-naïve HIV-1 infected men - (10/31/17)
     
  3597. EACS: Dolutegravir-based Simplified Maintenance Therapy in HIV-infected Patients a Systematic Review and Meta-analysis - (10/31/17)
     
  3598. EACS: Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted protease inhibitor plus lamivudine for maintenance of virological suppression Gesida study 9717 - (10/31/17)
     
  3599. EACS: Subgroup Analyses From ONCEMRK: a Phase 3 Study of Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily in HIV-1-Infected Treatment-Naïve Adults at Week 96 - (10/31/17)
     
  3600. EACS: Subgroup Analyses From DRIVE-FORWARD, a Phase 3 Trial of Doravirine Versus Ritonavir-Boosted Darunavir in Treatment-Naïve HIV-1-Infected Participants at Week 48 - (10/31/17)
     
  3601. EACS: Week 48 results of AMBER: A Phase 3, randomised, double-blind trial in antiretroviral treatment-naïve HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofoviralafenamide(D/C/F/TAF) versus darunavir/cobicistatplus emtricitabine/tenofovirdisoproxilfumarate - (10/30/17)
     
  3602. EACS: ABX464 Decreases Total HIV DNA and Integrated HIV DNA in PBMCs When Administered During 28 Days to HIV-infected Virologically Suppressed Patients - (10/30/17)
     
  3603. EACS: Phase 3 Study of Fostemsavir in Heavily Treatment-Experienced HIV-1-Infected Participants: Day 8 and Week 24 Primary Efficacy and Safety Results (BRIGHTE Study, Formerly 205888/AI438-047) - (10/30/17)
     
  3604. Bone and renal safety week 48 subgroup analysis of EMERALD: A Phase 3, randomised study evaluating switching from boosted protease inhibitors plus FTC/TDF to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults - 2/slides - (10/30/17)
     
  3605. EACS: Bone and renal safety Week 48 subgroup analysis of EMERALD:A Phase III, randomised study evaluating switching from boosted protease inhibitors plus FTC/TDF to darunavir/cobicistat/emtricitabine/tenofovir alafenamide(D/C/F/TAF) in virologicallysuppressed, HIV-1-infected adults - (10/30/17)
     
  3606. EACS: Relative Bioavailability of Darunavir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Single-Tablet Regimen When Administered as a Whole, Split, or Crushed Tablet - (10/30/17)
     
  3607. EACS: Week 48 results of AMBER: A Phase 3, randomised, double-blind trial in antiretroviral treatment-naïve HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat plus emtricitabine/tenofovir disoproxil fumarate - (10/30/17)
     
  3608. EACS: High incidence of HCV reinfection in HIV-positive MSM in the DAA era - (10/30/17)
     
  3609. EACS: Big Gaps in HCV/HIV Care Continuum Across Europe at Start of 2015 - written by Mark Mascolini (10/30/17)
     
  3610. EACS: HCV Prevalence in HIV Patients Falls Nearly 50% in Spain in 1 Year - written by Mark Mascolini (10/30/17)
     
  3611. EACS: Impact of Diabetes and Age on Kidneys During DAA Therapy for HCV/HIV - written by Mark Mascolini (10/30/17)
     
  3612. EACS: Global Analysis Projects World Far From Goal of Eliminating HCV - written by Mark Mascolini (10/30/17)
     
  3613. EACS: High SVR 12 rates with grazoprevir/elbasvir ± ribavirin for 12-16 weeks guided by genotypic resistance testing among HIV/HCV coinfected MSM in the Swiss HCVree Trial (10/30/17)
     
  3614. EACS: Cure Rate 99% With Grazoprevir/Elbasvir in HCV/HIV-Infected MSM in Switzerland - written by Mark Mascolini (10/29/17)
     
  3615. EACS: Single-Tablet D/C/F/TAF Strong Through 48 Weeks in Naive AMBER Group - written by Mark Mascolini (10/29/17)
     
  3616. EACS: Women 65 or Older Have Worse Virologic Control Than Men in Italian Cohort - written by Mark Mascolini (10/29/17)
     
  3617. EACS: Atorvastatin Slows Kidney Function Drop More Than Nonstatin Antilipid Agents - written by Mark Mascolini (10/29/17)
     
  3618. EACS: Current Pain Risk Higher in Older HIV+ Group vs Older HIV- and Younger HIV+ - written by Mark Mascolini (10/29/17)
     
  3619. EACS: Nonavalent HPV Vaccine May Have Protected 77% of HIV+ Men With Anal HPV - written by Mark Mascolini (10/29/17)
     
  3620. EACS: Raltegravir/Etravirine Effective Maintenance Through 48 Weeks in 45 or Older Group - written by Mark Mascolini (10/29/17)
     
  3621. EACS: HIV Resistance Prevalence Flat in Italy Over Past 5 Years - written by Mark Mascolini (10/29/17)
     
  3622. EACS: AIDS, Liver Disease Down as Death Causes in Paris HIV Group; Cancer and CVD Up - written by Mark Mascolini (10/29/17)
     
  3623. EACS: Meta-analysis Finds Little Evidence of Worse Side Effect Rates With Dolutegravir - written by Mark Mascolini (10/29/17)
     
  3624. EACS: First-Line Responses Similar With Integrase Inhibitors and NNRTIs in UK - written by Mark Mascolini (10/29/17)
     
  3625. EACS: Resistance at Failure Less Likely With Dolutegravir Than Raltegravir or Elvitegravir - written by Mark Mascolini (10/29/17)
     
  3626. EACS: Antiretrovirals Pose Highest Cost in Large Swiss HIV Care Analysis - written by Mark Mascolini (10/29/17)
     
  3627. EACS: Bone Density Lower With Than Without HIV in People 50 or Older - written by Mark Mascolini (10/29/17)
     
  3628. EACS: Novel Antiretroviral Cuts HIV DNA in PBMCs When Added to Solo Darunavir - written by Mark Mascolini (10/29/17)
     
  3629. EACS: Meta-Analysis Sees Good Results With Dolutegravir-Based Dual Maintenance - written by Mark Mascolini (10/29/17)
     
  3630. EACS: Switch to Boosted PI/3TC Noninferior to Triple Therapy in 4-Trial Analysis - written by Mark Mascolini (10/29/17)
     
  3631. EACS: Single-Tablet D/C/F/TAF Strong Through 48 Weeks in Naive AMBER Group - written by Mark Mascolini (10/29/17)
     
  3632. Tivicay® and Celsentri® now included in the Essential Drug List in Russia - (10/28/17)
     
  3633. IDWeek: Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment (10/28/17)
     
  3634. IDWeek: Pharmacokinetics of Cabotegravir in Subjects With Severe Renal Impairment (10/28/17)
     
  3635. IDWeek: Pharmacokinetics of Cabotegravir in Subjects With Moderate Hepatic Impairment (10/28/17)
     
  3636. EACS: ViiV at EACS 2017 - Tackling HIV Challenges in Europe - (10/28/17)
     
  3637. EACS: New results from the Positive Perspectives global survey provide insights into the attitudes and perceptions of people living with HIV - self-stigma, treatment, attitudes - (10/26/17)
     
  3638. EACS: Investigational Darunavir-Based Single-Tablet Regimen Shows Positive Results in Previously Untreated HIV Patients in Pivotal Phase 3 AMBER Clinical Trial - (10/26/17)
     
  3639. AASLD: No Resistance to Tenofovir Alafenamide Detected Through 96 Weeks of Treatment in Patients with Chronic Hepatitis B - (10/26/17)
     
  3640. Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1 - (10/18/17)
     
  3641. Updated - Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV - Oct 17 2017 - (10/18/17)
     
  3642. IAS: Metabolics at IAS 2017: bone, CVD, Comorbidities, Brain, Fatty Liver - (10/16/17)
     
  3643. Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research - (10/16/17)
     
  3644. Gilead Announces New License Agreement With the Medicines Patent Pool for Access to Bictegravir - (10/16/17)
     
  3645. Marijuana Use Impacts Midlife Cardiovascular Events in HIV-Infected Men in MACS - (10/16/17)
     
  3646. The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation - (10/16/17)
     
  3647. IDWeek: HIV in the Brain - MANAGING COMORBIDITIES IN PATIENTS WITH HIV (10/16/17)
     
  3648. IDWeek: Medium Grade Proteinuria Is Not a Relevant Predictor of Chronic Kidney Disease in People Living with HIV/AIDS - Or Is It? (10/16/17)
     
  3649. IDWeek: Low Rate of Routine Proteinuria Screening among Male HIV Patients in an Urban Clinic (10/16/17)
     
  3650. IDWeek: Incidence of symptomatic CSF viral escape in HIV infected adults receiving atazanavir/ritonavir (ATV/r)-containing ART: A tertiary care cohort in western India (10/16/17)
     
  3651. IDWeek: Three-Part Strategy Boosts Extragenital STI Screening 23% in HIV Clinic - Mark Mascolini (10/13/17)
     
  3652. IDWeek: High Comfort Level With STI Self-Tests in HIV Group; Results Match Provider Tests - Mark Mascolini (10/13/17)
     
  3653. IDWeek: Primary Care Providers Have Limited Knowledge About STI Screening And HIV PrEP in Men Who have Sex with Men - Training Did Not Improve Provider Knowledge of STIs and PrEP for MSM - Mark Mascolini (10/13/17)
     
  3654. IDWeek: Three Quarters of Women in HIV Group May Have ART-Hormonal Interactions - Mark Mascolini (10/13/17)
     
  3655. IDWeek: Age, Gender, Race Predict Long-Term PrEP Adherence in Large Veterans Group - Mark Mascolini (10/13/17)
     
  3656. IDWeek: Should Guidelines Shorten Virologic Failure Cutoff for Integrase Inhibitors? - Mark Mascolini (10/13/17)
     
  3657. HIV Viral Suppression in USA, and Non-Adherence - (10/13/17)
     
  3658. IDWeek: Two Thirds in South Carolina With New HIV Missed Chance to Use PrEP - "Missed Opportunities to Initiate HIV Pre-exposure Prophylaxis in South Carolina - 2013-2016"....women, Blacks, young, MSM (10/12/17)
     
  3659. IDWeek: Cancer mortality among persons with Human Immunodeficiency Virus Infection, New York City, 2001-2015 - Lung (most) & Liver Cancer, Breast Cancer, Colorectal Cancers, Non-Hodgkins Lymphoma; RISK FACTORS: low CD4, unsupressed viral load; IDU; Hispanic (10/12/17)
     
  3660. IDWeek: Risk Behavior--and Sex Partner Type--Predict PrEP Adherence in MSM - Mark Mascolini (10/12/17)
     
  3661. IDWeek: Access to Online Tools Boosts Chances of HIV Control in Large US Group - "ASSOCIATION BETWEEN PATIENT PORTAL ACCESS & VIRAL SUPPRESSION AMONG PEOPLE LIVING WITH HIV" - Mark Mascolini (10/12/17)
     
  3662. IAS: LONG-ACTING IBALIZUMAB SUSCEPTIBILITY IN MULTI-DRUG RESISTANT HIV PATIENTS - (10/12/17)
     
  3663. Brain Damage - Cannabis / Nicotine / Stimulants (Cocaine/Meth), HIV - (10/13/17)
     
  3664. Cure Studies/ART Interruption & Brain Affects, Vorinostat - (10/13/17)
     
  3665. IDWeek: Similar Frequency of New HIV in US Group 45 or Older vs Younger - (10/11/17)
     
  3666. IDWeek: Prevalence of systemic hypertension among HIV-infected and HIV-uninfected young adults - Young Adults Perinatally Infected With HIV Run Higher Hypertension Risk - Mark Mascolini (10/11/17)
     
  3667. IDWeek: Effect of a multidisciplinary intervention for early ART initiation for inpatients with newly diagnosed HIV: Inpatient Program Yields Higher Linkage and ART Rates in Atlanta Hospital - Mark Mascolini (10/11/17)
     
  3668. IDWeek: Linkage and Anti-Retroviral Therapy Initiation Within 72-hours at a Ryan White-Funded FQHC in the Deep South in New Orleans - Mark Mascolini (10/11/17)
     
  3669. IDWeek: Under One Third of ID Fellows Think They Got Enough Training on ART or PrEP - Mark Mascolini (10/11/17)
     
  3670. IDWeek: 48-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1 - (10/11/17)
     
  3671. IDWeek: Cancer mortality among persons with Human Immunodeficiency Virus Infection, New York City, 2001-2015 - Lung (most) & Liver Cancer, Breast Cancer, Colorectal Cancers, Non-Hodgkins Lymphoma; RISK FACTORS: low CD4, unsupressed viral load; IDU; Hispanic (10/12/17)
     
  3672. IDWeek: Fatty Liver Disease in HIV: Predictors and Response to Statin Therapy - (10/11/17)
     
  3673. IDWeek: Faster Fatty Liver Progression With Statin Than Placebo in SATURN HIV Trial - Mark Mascolini (10/11/17)
     
  3674. AGE: Aging and Antiretroviral Neurotoxicity - - (10/11/17)
     
  3675. IDWeek: Trends and Associations with PrEP Prescription among 602 NYC Ambulatory Care Practices, 2014-16...... "PrEP prescriptIon increased 976% between Q1 2014 to Q2 2016 among 602 ambulatory care practIces in NYC" - (10/11/17)
     
  3676. IDWeek: Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Patients Coinfected With HCV GT 1 and HIV-1 - (10/11/17)
     
  3677. IDWeek: Hepatitis C Virus Treatment Response to Ledipasvir/Sofosbuvir among patients co-infected with HIV and HCV: Real World Data in a Black Population - (10/11/17)
     
  3678. IDWeek: High Asymptomatic STI Prevalence and Incidence in French MSM Starting PrEP - Mark Mascolini - (10/10/17)
     
  3679. IDWeek: Trends and Associations with PrEP Prescription among 602 NYC Ambulatory Care Practices, 2014-16......"PrEP prescriptIon increased 976% between Q1 2014 to Q2 2016 among 602 ambulatory care practIces in NYC" - (10/10/17)
     
  3680. IDWeek: Phase 3 Randomized, Controlled Trial of Switching to Fixed-Dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-Based Regimens in Virologically Suppressed Adults: Week 48 Results - (10/10/17)
     
  3681. IDWeek: Impact of Tablet Burden and Antiretroviral Therapy (ART) Choice on Virologic Outcomes in Treatment-Naive HIV+ Individuals Attending an Inner City Clinic - (10/10/17)
     
  3682. IDWeek: Switch to Darunavir/C/FTC/TAF Noninferior to Continued PI Plus TDF/FTC - Mark Mascolini - (10/10/17)
     
  3683. IDWeek: SWORD-1 & SWORD-2: Subgroup Analysis of 48-Week Results by Age, Race and Gender - Maintenance With DTG/RPV Effective Regardless of Age, Sex, or Race - Mark Mascolini - (10/10/17)
     
  3684. IDWeek: Efficacy and Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate in HIV-Infected, Virologically Suppressed, Black and Nonblack Adults Through Week 96: Subgroup Analysis of a Randomized Switch Study - - (10/10/17)
     
  3685. IDWeek: Lack of Clinically Relevant Effect of Bictegravir on Metformin Pharmacokinetics and Pharmacodynamics - (10/10/17)
     
  3686. IDWeek: Viral Failure Among Persons Living with HIV Initiating Dolutegravir-Based vs. Other Recommended Regimens in Real-World Clinical Care Settings - (10/10/17)
     
  3687. IDWeek: Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Updated Meta-analysis of Data From Clinical Trials - (10/10/17)
     
  3688. IDWeek: Selected CNS Outcomes Among a Large Sample of Patients Treated with INSTI Antiretrovirals - (10/09/17)
     
  3689. IDWeek: Real-World Experience with Higher-Than-Recommended Doses of Lamivudine in Patients with Varying Degrees of Renal Impairment - (10/09/17)
     
  3690. IDWeek: WEIGHT GAIN AFTER SWITCH FROM EFAVIRENZ-BASED TO INTEGRASE INHIBITOR-BASED REGIMENS - Atripla-to-Integrase Inhibitor Switch Tied to Weight Gain Over 18 Months - Mark Mascolini - (10/09/17)
     
  3691. IDWeek: Three Quarters of International HIV Group Worry About Long-Term Effects of ART - "Patient Experience and Views on Antiretroviral Treatment-Findings From the Positive Perspectives Study" - Mark Mascolini - (10/09/17)
     
  3692. IDWeek: SWORD-1 & SWORD-2: Subgroup Analysis of 48-Week Results by Age, Race and Gender - (10/09/17)
     
  3693. IDWeek: A Randomized Trial of Bictegravir or Dolutegravir With Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open-label Switch to Bictegravir/F/TAF Fixed-Dose Combination - High Virologic Response Rates With Bictegravir or Dolutegravir Plus FTC/TAF - Mark Mascolini - (10/09/17)
     
  3694. IDWeek: Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial - (10/09/17)
     
  3695. IDWeek: Janssen Announces Pivotal Phase 3 Study Results for Investigational Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection in Adults Switching from Boosted Protease Inhibitors Plus Emtricitabine and Tenofovir Disoproxil Fumarate Regimens - (10/09/17)
     
  3696. IDWeek: Week 48 results of EMERALD: A Phase 3, randomized, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults - (10/09/17)
     
  3697. IDWeek: The Incidence and Risk Factors Associated with Chronic Liver Enzyme Elevation (cLEE) in HIV-Monoinfected Persons - Antiretroviral Use and Race Predict High Liver Enzymes in HIV-Monoinfected - Mark Mascolini - (10/09/17)
     
  3698. IDWeek: Echocardiography Spots Abnormalities in up to 26% of Air Force Members With Early HIV - Mark Mascolini - (10/09/17)
     
  3699. AGE: Current Reality: The San Francisco Experience / SF Aging Clinic: reality switch from 1990 to 2018 / a crisis ignored by many - written by Mark Mascolini - (10/06/17)
     
  3700. AGE: Hearing Loss and Quality of Life in Middle-Aged With or Without HIV - written by Mark Mascolini - (10/06/17)
     
  3701. AGE: NY Cornell Aging / Geriatric Clinic - Current Reality: The New York Experience - - (10/06/17)
     
  3702. AGE: Subjective and Objective Fatigue Greater in Older Group With vs Without HIV - written by Mark Mascolini - (10/06/17)
     
  3703. AGE: Adherence to Recommendations from Comprehensive Geriatric Assessment in an HIV+ Population - written by Mark Mascolini - (10/04/17)
     
  3704. IDWeek: Low Dietary Calcium Tied to Low Bone Density With HCV But Not HIV - Mark Mascolini - (10/06/17)
     
  3705. IDWeek: Incidence of Herpes Zoster in a Large Cohort of Persons Living with HIV - Herpes Zoster Incidence Falling in HIV Group But Still at 1% in 2011-2016 - Mark Mascolini - (10/06/17)
     
  3706. IDWeek: Two Thirds of HIV Group Who Need Statins Not Getting Them - Mark Mascolini - (10/06/17)
     
  3707. IDWeek: Framingham Cardio Risk Score Twice Higher in Premenopausal Women With HIV - Mark Mascolini - (10/06/17)
     
  3708. IDWeek: Multiple Missed Chances to Prevent Heart Disease in Urban HIV Clinic - Mark Mascolini - (10/06/17)
     
  3709. IDWeek: Low Screening Rates for HBV, HCV, and Diabetes in NYC HIV Cohort - Mark Mascolini - (10/06/17)
     
  3710. AGE: Adherence to Recommendations from Comprehensive Geriatric Assessment in an HIV+ Population - written by Mark Mascolini - (10/04/17)
     
  3711. AGE: Cognitive Impairment in Symptomatic HIV over age 60 - written by Mark Mascolini - (10/04/16)
     
  3712. AGE: Limited evidence of biological aging in early-treated HIV-infected children - written by Mark Mascolini - (10/04/17)
     
  3713. AGE: Lean Mass Declines Consistently Over 10 Years in HIV-Infected Adults on Antiretroviral Therapy, with Patterns Differing by Sex - written by Mark Mascolini - (10/04/17)
     
  3714. Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab Presented at IDWeek 2017™ - (10/04/17)
     
  3715. AGE: Metformin suppresses human CMV infection - written by Mark Mascolini - (09/27/17)
     
  3716. AGE: Antiretroviral Therapy Does Not Dial Back Advanced Epigenetic Age With HIV - written by Mark Mascolini - (10/03/17)
     
  3717. HIV Prematurely Ages the Brain: "Effect of ageing on neurocognitive function by stage of HIV infection: evidence from the Multicenter AIDS Cohort Study" - (10/02/17)
     
  3718. Long-Acting HIV PrEP & Treatment for Women & Men / Once A Month or 8 Weeks Injection - (10/02/17)
     
  3719. Sclerostin Inhibition for Osteoporosis [Romosozumab]- A New Approach - Editorial - (10/02/17)
     
  3720. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis - (10/02/17)
     
  3721. New Bone Drug: Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis - (10/02/17)
     
  3722. Hearing Loss and HIV....MACS & WIHS - (10/02/17)
     
  3723. ECLAIR Study of Cabotegravir (CAB) LA Injections: Characterization of Safety and PK During the "PK Tail" Phase - (10/02/17)
     
  3724. 2008-2011 / HIV 13 Year Gap Life Expectancy Projected HIV+ vs HIV-Neg: 11 years for Whites; 13 yrs for Blacks; Hispanic 16 yrs. - (09/29/17)
     
  3725. New Long Acting Potent Nuke MK-8591 + Doravirine Phase 2B Study Starts - (09/27/17)
     
  3726. GLASGOW: HIV+ Aging, Comorbidites & Mortality in Belgium - (09/26/17)
     
  3727. GLASGOW: Frailty in HIV+ in Italy....average age only 49 but 12% frail, 28% pre-frail, 33% some measure of depression, 51% cognitive impairment. - (09/26/17)
     
  3728. GLASGOW: Use of dolutegravir in combination with rifampicin based TB therapy in HIV/TB co-infected patients - (09/26/17)
     
  3729. IAS: Optimism and concern at IAS 2017 - Comment - (09/26/17)
     
  3730. IAS: Ending AIDS: myth or reality? New Infections Increase in Key Populations, UN Update - (07/23/17)
     
  3731. Reyataz Reduced CVD Risk - (09/25/17)
     
  3732. IAS 2017 Cure Workshop Report/Abstracts Published - (09/25/17)
     
  3733. Generic $75 Dolutegravir Fixed Dose - New single-day pill (dolutegravir) for HIV treatment promises more bang for less buck - (09/25/17)
     
  3734. Three-in-one antibody protects monkeys from HIV-like virus: NIH and Sanofi scientists prepare to test antibody in people - (09/25/17)
     
  3735. Reyataz Reduced CVD Risk - (09/25/17)
     
  3736. IAS 2017 Cure Workshop Report/Abstracts Published - (09/25/17)
     
  3737. New single-day pill (dolutegravir) for HIV treatment promises more bang for less buck - (09/25/17)
     
  3738. Three-in-one antibody protects monkeys from HIV-like virus: NIH and Sanofi scientists prepare to test antibody in people - (09/25/17)
     
  3739. IAS: Ending AIDS: myth or reality? New Infections Increase in Key Populations, UN Update - (07/23/17)
     
  3740. Increased brain-predicted aging in treated HIV disease - - (09/22/17)
     
  3741. HIV Broadly Neutralizing Antibodies Research; treatment/cure/interruptions - (09/22/17)
     
  3742. Three-in-One Antibody Protects Monkeys from SHIV - HIV-Like Virus - (09/20/17)
     
  3743. Impact of monotherapy on HIV-1 reservoir, immune activation, and co-infection with Epstein-Barr virus - (09/20/17)
     
  3744. IAS: 2 ART Interruption Cure Studies at IAS 2017 - (09/20/17)
     
  3745. Mitochondrial energetics in the kidney.... "Hyperglycaemia is the main factor that contributes to the development of diabetic nephropathy" - (09/19/17)
     
  3746. Outdated HIV HealthCare Models - high need, aging ignored - (09/18/17)
     
  3747. ART Interruption Associated with HIV in the Brain: "Reseeding CNS during ART Interruption Leading to Intrathecal Immune Activation" - "HIV-1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment" - (09/18/17)
     
  3748. ARTs Brain Penetration: - do we need it? risks? / Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV - (09/15/17)
     
  3749. HIV Drug Pipeline - (09/14/17)
     
  3750. Neuropsychiatric events and dolutegravir in HIV patients: a worldwide issue involving a class effect - (09/14/17)
     
  3751. Ending AIDS - What is the Real prospect: New Infections Up in Key Populations, Unsupressed Viremia High in Key Populations - (09/14/17)
     
  3752. IAS: IAS 2017 Summary Report - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (09/03/17)
     
  3753. Aging with HIV: Redesigning healthcare models - (09/13/17)
     
  3754. HIV & Sleep Disorders: 100% of HIV+ with cognitive impairment have sleep disorder study reports - (09/11/17)
     
  3755. Stigma in HIV+ : 60% experience self-stigma....going along with this is 63% of older HIV+ have 3+ comorbidities which can only worsen stigma & self-stigma - (09/11/17)
     
  3756. Aging With HIV: Expert Insights on Complications and Challenges - (09/11/17)
     
  3757. Fats/Carbohydrates PURE Study Refuted by AHA - (09/11/17)
     
  3758. Fruits, vegetables, and legumes: sound prevention tools Comment questioning PURE study results - (09/11/17)
     
  3759. Fruits, vegetables, and legumes: sound prevention tools - Comment - (09/11/17)
     
  3760. Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease and Lung Cancer- CANTOS Study - (09/11/17)
     
  3761. Long acting injectable Cabotegravir for PrEP is in Phase 3 [every 4 or 8 weeks] - (09/09/17)
     
  3762. EASL: Hepatic Fibrosis is Associated With Histological Activity in Non-alcoholic Steatohepatitis: an Analysis From a Large Database of Screening Biopsies in the CENTAUR Trial - (09/09/17)
     
  3763. IAS: IAS: Stigma, New HIV Infections Up in Key Populations, PrEP Access Disparities, Poor Adherence in Medicaid, High Comorbidities in Canada, Immunosenescence in HIV+ Kids, Health Outcomes-Women who have Sex with Women/Transgender Women-US - (09/07/17)
     
  3764. IAS: Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum - (09/07/17)
     
  3765. IAS: Dolutegravir / tenofovir / emtricitabine (DTG/TDF/FTC) started in pregnancy is as safe as efavirenz / tenofovir / emtricitabine (EFV/TDF/FTC) in nationwide birth outcomes surveillance in Botswana - (09/07/17)
     
  3766. IAS: Pharmacokinetic (PK) Modelling and Simulation to Support Weight-Based Dosing of Maraviroc (MVC) in Pediatric Subjects When Co-administered With Potent CYP3A Inhibitors - (09/07/17)
     
  3767. IAS: Maraviroc Pharmacokinetics and Dosing Recommendations in CCR5-Tropic HIV-1-Infected Children Aged 2 to <18 Years - (09/07/17)
     
  3768. IAS: Longer-Term Safety of Maraviroc in Pediatric Patients With R5 HIV: Follow-up Data From Study A4001031 - (09/07/17)
     
  3769. IAS: Uptake of HLA-B*5701 Screening and Its Impact on Clinically Suspected Hypersensitivity Reaction to Abacavir in the OPERA Observational Database - (09/07/17)
     
  3770. IAS: Inhibiting memory CD4+ T-cell self-renewal to reduce HIV persistence - (09/07/17)
     
  3771. IAS: Atypical Mutations for RAL Resistant Clinical Isolates and Associated Integrase Strand Transfer Inhibitor Susceptibility With Public Algorithms With Public Algorithms - (09/07/17)
     
  3772. IAS: The Effect of Fostemsavir on Methadone and The Effect of Fostemsavir on Methadone and Buprenorphine Pharmacokinetics - (09/07/17)
     
  3773. IAS: The Effect of Fostemsavir on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone (NE) in Healthy Female Subjects - (09/07/17)
     
  3774. IAS: Pregnancy and Neonatal Outcomes following Prenatal Exposure to Dolutegravir - (09/07/17)
     
  3775. IAS: Safety, Efficacy, and Dose-Response of GSK3532795/BMS-955176 Plus Tenofovir/Emtricitabine in Treatment-Naïve HIV-1-Infected Adults: Week 24 Primary Analysis - (09/07/17)
     
  3776. IAS: Resistance Profile of HIV-1 Maturation Inhibitor GSK3532795 / GSK28338232 - (09/07/17)
     
  3777. IAS: An Analysis of Neurologic and Psychiatric Adverse Events of Subjects Receiving the Investigational HIV-1 Maturation Inhibitor (MI) GSK3532795/BMS-955176 - (09/07/17)
     
  3778. IAS: BMD After Switch to Dolutegravir+Rilpivirine - (09/07/17)
     
  3779. IAS: IAS: How Many on PrEP in USA - Changes in Truvada® for HIV Pre-exposure Prophylaxis Utilization in the USA: 2012-2016 - Disparities - (09/07/17)
     
  3780. IAS: Generic treatments for HIV, HBV, HCV, TB could be mass produced for < $90 per patient - (09/07/17)
     
  3781. IAS: Barriers to uptake of pre-exposure prophylaxis among respondents to the Flash! - PrEP in Europe survey - (09/02/17)
     
  3782. IAS: Pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in the Netherlands: motives to choose for, switch to, or stop with daily or event-driven PrEP - (09/02/17)
     
  3783. IAS: Self-Report and Medication Possession Ratio are Accurate Measures of HIV Pre-Exposure Prophylaxis Use in a Real-World Clinical Setting - (09/02/17)
     
  3784. First CAR T-Cell 'Living Drug' Approved by FDA / Safety Concerns - (09/02/17)
     
  3785. Trends in ART Prescription and Viral Suppression Among HIV-Positive Young Adults in Care in the United States, 2009-2013 - "sustainably virally suppressed significantly increased (29%-46%)" - (09/02/17)
     
  3786. Redefining HIV Preexposure Prophylaxis Failures - PrEP at Kaiser - (09/02/17)
     
  3787. Reassessing the benefits of plant-based eating (PURE) - fruit, vegetables, legumes - CVD risk, mortality - (09/01/17)
     
  3788. Stressed brain, stressed heart?..... Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study - (09/01/17)
     
  3789. CVD-PCSK9 Repatha Outcomes Study FOURIER - (09/01/17)
     
  3790. 3 studies report Hearing Loss in HIV is Worse and Suggests that Aging Worsens Hearing - (09/01/17)
     
  3791. Aging with HIV in U.S. Trans NIH Research Themes - (09/01/17)
     
  3792. Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients - (09/01/17)
     
  3793. HIV & Value Based Healthcare? .....Incorporating Geriatric Consultation Into HIV Care / Employers Plans for Value Based healthcare' - (09/01/17)
     
  3794. From One Syndrome to Many: Incorporating Geriatric Consultation Into HIV Care - (09/01/17)
     
  3795. Geriatric-HIV Medicine Is Born - Commentary - (09/01/17)
     
  3796. Fatty Liver in HIV+ / Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease - (09/01/17)
     
  3797. Antiretroviral initiation is associated with increased skeletal muscle area and fat content - (08/14/17)
     
  3798. Senescence, Telomerase, Aging HIV - (08/14/17)
     
  3799. IAS: Bone Mineral Density at the Hip Declines Twice as Quickly Among HIV-Infected Women than Men - (08/14/17)
     
  3800. IAS: HIV Prevention at IAS 2017 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington (08/14/17)
     
  3801. Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV - (08/11/17)
     
  3802. IAS: PrEP at IAS 2017 / IAS Coverage: New HIV & HCV Drugs, Fatty Liver in HIV - (08/11/17)
     
  3803. IAS: Peripheral blood and cerebrospinal fluid viremia of 24-weeks MONOtherapy of DOlutegravir in HIV-1 virologically suppressed patients: MONODO study - (08/10/17)
     
  3804. IAS: Higher HDL, better brain? Higher HDL cholesterol is associated with better cognition in a cohort of older persons living with HIV infection - (08/10/17)
     
  3805. IAS: Fatty Acid Profiles Altered by HIV Infection Persist Despite Suppressive Antiretroviral Therapy (ART) and are Associated with Immune Activation in the ACTG 5248 Study - (08/10/17)
     
  3806. IAS: No HIV Infections With Generic TDF/FTC PrEP in Large London Group - Mark Mascolini (08/10/17)
     
  3807. IAS: Beyond viral suppression: the quality of life of people living with HIV in Sweden / EATG Aging/HIV Call To Action: 'Beyond Viral Suppression' - (08/09/17)
     
  3808. IAS: Microglial Cells That Are Latently Infected By HIV Are Activated By Inflammatory Stimuli and Induce Neuronal Damage - (08/09/17)
     
  3809. IAS: Prevalence over time and predictive factors of HIV-associated neurocognitive disorder (HAND) in HIV-positive patients - (08/09/17)
     
  3810. IAS: Assessing depression's impact on neurocognitive performance in the NAMACO study - (08/09/17)
     
  3811. IAS: New HIV & HCV Drugs at IAS / Dual ARTs / Fatty Liver in HIV+ - (08/09/17)
     
  3812. Cerebral blood flow and cognitive function in HIV-infected men with sustained suppressed viremia on combination antiretroviral therapy - (08/08/17)
     
  3813. HIV - The Brain, Exercise, Diet, Comorbidities, BBB, CNS Penetration, Cure, Interruptions - (08/08/17)
     
  3814. Diet/Brain-Heart Connection - (08/08/17)
     
  3815. IAS: Cardiovascular Disease (CVD) and Chronic Kidney Disease (CKD) Event Rates in HIV-positive Persons at high Predicted CVD and CKD Risk: Results from the D:A:D Study - Combining Heart and Kidney Risk Scores Improves Prediction in HIV Group - Mark Mascolini (08/08/17)
     
  3816. IAS: Health behaviors and outcomes in a U.S. cohort of transgender women in HIV care - (08/08/17)
     
  3817. IAS: More Depression, Worse Quality of Life in Transgender Women vs Men With HIV - Mark Mascolini (08/08/17)
     
  3818. IAS: Cerebral Small Vessel Disease Signal Similar in Older Men With vs Without HIV - Mark Mascolini (08/08/17)
     
  3819. IAS: Inflammation and Obesity Tied to Incident Diabetes in Veterans With HIV - Mark Mascolini (08/07/17)
     
  3820. IAS: Effects of Syringe Distribution Policy Change at A Syringe Services Program in Baltimore, MD: A Forecast Analysis - (08/07/17)
     
  3821. IAS: Good HIV-Related Diarrhea Control With 20 to 24 Weeks of Crofelemer - Mark Mascolini (08/07/17)
     
  3822. IAS: Only 5% DAA Failure Rate in Large French Cohort With HCV/HIV - Mark Mascolini (08/07/17)
     
  3823. IAS: HIV Risk Factors and Associated Health Outcomes Among Sexual Minority Women in the United States - Sexual Violence, Drug Injecting, Risky Sex With Men Tied to STI Risk in US Lesbians - Mark Mascolini (08/07/17)
     
  3824. IAS: Widening Needle Distribution Cuts New HIV Cases in Baltimore - Mark Mascolini (08/07/17)
     
  3825. IAS: Estimating HIV incidence and the undiagnosed HIV population in the European Union/European Economic Area - Estimated 120,000 People With Undiagnosed HIV Across Europe in 2015 - Mark Mascolini (08/07/17)
     
  3826. IAS: Safety and acceptability trial of the dapivirine vaginal ring in U.S. adolescents - Dapivirine Vaginal Ring Safe and Acceptable in US Adolescents - Mark Mascolini (08/07/17)
     
  3827. IAS: An Open Label Multiple Dose Phase 1 Assessment of Long Acting Rilpivirine - Long-Acting Rilpivirine Suppresses Replication in Rectal Explants - Mark Mascolini (08/07/17)
     
  3828. IAS: Half of HIV+ Medicaid Users Have Poor Adherence, Driving Up Costs - Mark Mascolini (08/07/17)
     
  3829. IAS: Half of HIV+ Medicaid Users Have Poor Adherence, Driving Up Costs - Mark Mascolini (08/06/17)
     
  3830. IAS: Atrial Fibrillation at an Earlier Age in People With HIV Infection - Mark Mascolini (08/06/17)
     
  3831. IAS: HIV Linked to Decreased Erectile Function in MSM 45 or Older - comorbidities, depression, frailty - Mark Mascolini (08/06/17)
     
  3832. IAS: Asians, Blacks, Young People Fall Short in US Viral Suppression Comparison - Mark Mascolini (08/06/17)
     
  3833. IAS: Fatty Liver in HIV+ at IAS - (08/05/17)
     
  3834. IAS: Mortality Benefit From DAAs Most Likely With Advanced Fibrosis in Canada - Trends in cause-specific mortality in HIV-HCV co-infected patients in Canada (2003-2016): Early impact of HCV therapy - Mark Mascolini (08/04/17)
     
  3835. IAS: HIV Disclosure Crime Convictions Differ by Race/Gender, Gay/Straight Status in US - Mark Mascolini (08/04/17)
     
  3836. IAS: PIs Plus Tenofovir Not Tied to Fracture in French Case-Control Study - Mark Mascolini (08/04/17)
     
  3837. IAS: No HIV Transmissions in Gay Couples if HIV+ Partner Has Undetectable Virus - Mark Mascolini (08/04/17)
     
  3838. IAS: Low HIV+ Cell Tally in Blood, Colon, Lymph Nodes in Earliest Infection Phase - Mark Mascolini (08/04/17)
     
  3839. IAS: TCM CD4 T cell infection extent before ART associated with immune failure and HIV persistence on ART - (08/04/17)
     
  3840. IAS: Successful switch to once-daily single-tablet regimen (STR) containing elvitegravir (EVG) or dolutegravir (DTG) in virologically suppressed HIV-1 infected patients despite archived resistant quasispecies - (08/04/17)
     
  3841. IAS: COMORBIDITIES IN PATIENTS LIVING WITH HIV (PLWHIV) COMPARED TO MATCHED NON HIV CONTROLS: AN EPIDEMIOLOGICAL ANALYSIS USING A CLAIMS DATABASE IN FRANCE - (08/04/17)
     
  3842. IAS: Switch to Dolutegravir Noninferior to Continued PI in Older Group With Heart Risk - Mark Mascolini - (08/04/17)
     
  3843. IAS: Overweight/Obesity Rate Rises After SVR in HCV/HIV-Coinfected People - Mark Mascolini - (08/04/17)
     
  3844. IAS: Depression, Brain Changes & cART in HIV+ / Role of basal ganglia in depression in HIV-infected individuals - (08/03/17)
     
  3845. IAS: One-year experience with Pre-Exposure Prophylaxis (PrEP) Implementation in France with TDF/FTC - (08/03/17)
     
  3846. IAS: Is on-demand PrEP with TDF/FTC effective among MSM with infrequent sexual intercourse? - (08/03/17)
     
  3847. IAS: More and earlier cardiovascular events (CVE) and shorter overall survival (OS) in HIV-positive patients (HIV+) compared to the general population differ by sex - (08/03/17)
     
  3848. IAS: Prevalence of Comorbidities and Impact of HIV and Comorbidities on Health Care Resource Utilization - (08/03/17)
     
  3849. IAS: Potential for HIV transmission among adolescents and young adults receiving antiretroviral therapy - 'PrEP missed opportunities' - (08/03/17)
     
  3850. IAS: Zoledronic Acid Boosts Bone Density More Than Switch From TDF - Mark Mascolini - (08/03/17)
     
  3851. IAS: Changes in Truvada® for HIV Pre-exposure Prophylaxis Utilization in the USA: 2012-2016 - Disparities - (08/02/17)
     
  3852. IAS: Limited implementation of HIV pre-exposure prophylaxis among public health departments in North Carolina, United States - (08/02/17)
     
  3853. IAS: Impact of microbiota on female genital tissue and plasma concentrations of dapivirine - (08/02/17)
     
  3854. IAS: Experience of Living With HIV: Diagnosis and Disclosure - Findings From the Positive Perspectives Study - self-stigma is high, 63% of older HIV+ have 3+ Comorbidities - (08/02/17)
     
  3855. IAS: Dolutegravir Use During Pregnancy and Birth Outcomes: Data From the Antiretroviral Pregnancy Registry (APR) - (08/02/17)
     
  3856. IAS: Efficacy and Safety of Switching From RPV/FTC/TDF or EFV/FTC/TDF to RPV/FTC/TAF in Black Adults - (08/02/17)
     
  3857. IAS: Efficacy and Safety of Tenofovir Alafenamide vs Tenofovir DF in HIV-Infected, Virologically Suppressed, Older Adults at Week 96: Subgroup Analysis of a Randomized Switch Study (Study 311-1089) - (08/02/17)
     
  3858. IAS: Adults With Renal Impairment Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety Through 144 Weeks - (08/02/17)
     
  3859. IAS: Factors associated with the occurrence of suicide among French people living with HIV in the HAART era: a nested case-control study in the Dat'AIDS cohort - (08/02/17)
     
  3860. IAS: T cell immune exhaustion in gut-associated lymphoid tissue during treated primary HIV infection: Implications for HIV persistence - (08/02/17)
     
  3861. IAS: Experiences and perceptions of PrEP among gay, MSM, and TGW in the PROUD study in England: 'Rules' of Sex, Psychological, Psychosocial Benefits - Mark Mascolini - (07/31/17)
     
  3862. IAS: Reasons for not using PrEP in a national on-line sample of U.S. men who have sex with men (MSM) - Cost, Side Effects, Access Lead Reasons for PrEP Nonuse by US MSM - Mark Mascolini - (07/31/17)
     
  3863. IAS: Maintenance Therapy With 400/100 mg of Darunavir/Ritonavir for 48 Weeks - Mark Mascolini - (07/31/17)
     
  3864. Cabotegravir-LA Safe in Women, Challenges Remain - (07/31/17)
     
  3865. ECLAIR Study of Cabotegravir (CAB) LA Injections: Characterization of Safety and PK During the "Pk Tail" Phase - (07/31/17)
     
  3866. IAS: Overweight/Obesity Rate Rises After SVR in HCV/HIV-Coinfected People - Mark Mascolini (07/31/17)
     
  3867. IAS: Early initiation of antiretroviral treatment post SIV infection does not resolve lymphoid tissue activation - (07/31/17)
     
  3868. IAS: HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual-therapy DTG+3TC in the maintenance DOLULAM pilot study - (07/31/17)
     
  3869. IAS: Adherence intentions, long-term adherence and HIV acquisition among PrEP users in the PROUD open-label randomised control trial of PrEP in England - (07/31/17)
     
  3870. IAS: Long term follow up of PROUD Evidence for high continued HIV exposure and durable effectiveness of PrEP - (07/31/17)
     
  3871. IAS: HIV mediated immunosenescence in young adults infected at birth [and HIV+ adults too despite undetectable VL] - (07/31/17)
     
  3872. IAS: Prolonged HIV-1 Remission in an Individual Treated During Hyperacute Infection - (07/31/17)
     
  3873. IAS: Evidence of production of HIV-1 proteins from "defective" HIV-1 proviruses in vivo: Implication for persistent immune activation and HIV-1 pathogenesis - (07/31/17)
     
  3874. IAS: ACTG A5353: A pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA <500,000 copies/ml - (07/31/17)
     
  3875. IAS: ABX464 decreases total HIV DNA in PBMC's when administered during 28 days to HIV-infected patients who are virologically suppressed - (07/28/17)
     
  3876. IAS: New HIV Down in US MSM in 2008-2014, But Up in Hispanics, Younger Men - Mark Mascolini (07/28/17)
     
  3877. IAS: Is on-demand PrEP a suitable tool for MSM who practice chemsex? Results from a sub-study of the ANRS-IPERGAY trial - Chemsex Users in IPERGAY Twice as Likely to Use As-Needed PrEP - Mark Mascolini (07/28/17)
     
  3878. IAS: Evaluation of the risk of birth defects among children exposed to raltegravir in utero in the ANRS-French Perinatal Cohort EPF - Raltegravir Not Tied to Birth Defects in French Study of 479 Births - Mark Mascolini (07/28/17)
     
  3879. IAS: Heightened Risk of Peripheral Arterial Disease With HIV in Veterans (07/27/17)
     
  3880. IAS: Maintenance With Raltegravir/Etravirine Strong at 48 Weeks in Older Adults - Efficacy of a Maintenance Strategy with Raltegravir/Etravirine : the ANRS 163 ETRAL trial - Mark Mascolini (07/27/17)
     
  3881. IAS: CDC Transmission Study Puts Hispanic MSM at Leading Edge of HIV Spread - Analysis of U.S. HIV sequence data indicates that recent and rapid HIV transmission is focused among young Hispanic/Latino men who have sex with men - Mark Mascolini (07/27/17)
     
  3882. IAS: No HIV Transmissions in Gay Couples if HIV+ Partner Has Undetectable Virus - Mark Mascolini (07/27/17)
     
  3883. IAS: Impact of risk perception trajectory on PrEP and condom use among Men who have Sex with Men during the Open-Label-Extension of the ANRS-IPERGAY trial - (07/27/17)
     
  3884. IAS: Slowing the premature aging process: the benefits of viral control and smoking cessation on telomere length - (07/27/17)
     
  3885. IAS: Phase 3 Randomized, Controlled, Clinical Trial of Bictegravir Coformulated With FTC/TAF in a Fixed-Dose Combination vs Dolutegravir + FTC/TAF in Treatment-Naïve HIV-1-Positive Adults: Week 48 Results - (07/27/17)
     
  3886. IAS: Impact of exposure to each antiretroviral treatment (ARV) on the risk of fracture in HIV-infected individuals - (07/27/17)
     
  3887. IAS: Sub-Study 202094 of SWORD-1 and SWORD-2: Switch From TDF-Containing Regimen to DTG + RPV Improves Bone Mineral Density and Bone Turnover Markers Over 48 Weeks - (07/26/17)
     
  3888. IAS: Single Doses as Low as 0.5 mg of the Novel NRTTI MK-8591 Suppress HIV for At Least Seven Days - (07/26/17)
     
  3889. IAS: New HIV Drugs, Aging, Life Expectancy - (07/26/17)
     
  3890. IAS: Predictor factors associated with liver fibrosis and steatosis by transient elastography in HIV mono-infected patients under long-term combined antiretroviral therapy - (07/26/17)
     
  3891. IAS: Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077 - (07/26/17)
     
  3892. IAS: New Nonnuke Doravirine Strong as Single-Tablet Regimen With TDF/3TC - Mark Mascolini - (07/26/17)
     
  3893. IAS: HIV Viral Remission in Child with Perinatal HIV - (07/25/17)
     
  3894. IAS: Single doses as low as 0.5 mg of the novel NRTTI MK-8591 suppress HIV for at least seven days - (07/25/17)
     
  3895. IAS: Merck's Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection - (07/25/17)
     
  3896. IAS: Dolutegravir-Lamivudine as initial therapy in HIV-1 infected, ARV-naïve patients: 96 week results of the PADDLE trial - (07/25/17)
     
  3897. IAS: Fixed-Dose Combination of Doravirine/Lamivudine/TDF is Non-Inferior to Efavirenz/Emtricitabine/TDF in Treatment-Naïve Adults With HIV-1 Infection: Week 48 Results of the Phase 3 DRIVE-AHEAD Study - (07/25/17)
     
  3898. IAS: Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/RTV) Plus 2 NRTIs in Second-Line Treatment: Interim Data From the DAWNING Study - (07/25/17)
     
  3899. IAS: Efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxilfumarate regimens to the single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofoviralafenamide(D/C/F/TAF) in virologicallysuppressed, HIV-1-infected adults through 24 weeks: EMERALD Study - (07/25/17)
     
  3900. IAS: Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients: results of the METAFIB study - (07/25/17)
     
  3901. IAS: Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial - (07/24/17)
     
  3902. IAS: Evaluation of lead HIV-1 vaccine regimen in APPROACH: Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein - (07/24/17)
     
  3903. IAS: Dual regimen with Dolutegravir and Lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients: 96 weeks results from maintenance DOLULAM study - (07/24/17)
     
  3904. IAS: Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, in Combination With Tenofovir Disoproxil Fumarate/Emtricitabine, in Previously Untreated HIV-1 Infection Through Week 96 - (07/24/17)
     
  3905. IAS: Safety and Efficacy of Long-Acting CAB and RPV as Two Drug IM Maintenance Therapy: LATTE-2 Week 96 Results - (07/24/17)
     
  3906. IAS: ANRS 146 - GeSIDA 7211 OPTIMAL Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defining event and/or CD4 counts > 200 cells/ mm3 - (07/24/17)
     
  3907. IAS: Darunavir/Ritonavir Plus 3TC Noninferior to Triple Therapy at 24 Weeks - ANDES Study - A Phase 4, Randomized, Open Label, Study of a Ritonavir-Boosted Darunavir in Fixed Dose Combination (FD-DRV/r) plus Lamivudine Versus FD-DRV/r plus Lamivudine/Tenofovir in Naïve HIV-1 Infected Subjects - Mark Mascolini - (07/23/17)
     
  3908. IAS: Low Failure Rate With Switch to Integrase Inhibitor STR Despite Archived Mutations - Mark Mascolini - (07/23/17)
     
  3909. IAS: Long-Acting 4/8-Week Cabotegravir/Rilpivirine Maintains Control at 96 Weeks - Mark Mascolini - (07/23/17)
     
  3910. IAS: MK-8591 Protects 8 of 8 Macaques From Rectal SHIV 6 Days After Dosing - Mark Mascolini - (07/23/17)
     
  3911. IAS: CD4 Count at ART Start Rising Across Globe, But Median Still Below 350 / 25% start at below 200 CD4 - Mark Mascolini - (07/23/17)
     
  3912. IAS: Virologic Success Rate 90% at Week 24 With First-Line DTG/3TC in ACTG A5353: ACTG A5353: A pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA <500,000 copies/ml - Mark Mascolini - (07/23/17)
     
  3913. IAS: A Phase 3 Randomized Controlled Clinical Trial of Bictegravir in a Fixed Dose Combination, B/F/TAF, vs DTG/ABC/3TC in Treatment-Naïve Adults at Week 48 - (07/23/17)
     
  3914. IAS: More and earlier cardiovascular events (CVE) and shorter overall survival (OS) in HIV-positive patients (HIV+) compared to the general population differ by sex - (07/23/17)
     
  3915. IAS: Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV - (07/23/17)
     
  3916. IAS: Weekly Oral MK-8591 Protects Male Rhesus Macaques against Repeated Low Dose Intrarectal Challenge with SHIV109CP3 - (07/23/17)
     
  3917. IAS: Ending AIDS: myth or reality? New Infections Increase in Key Populations, UN Update - (07/23/17)
     
  3918. IAS: A global survey of HIV-positive people's attitudes towards cure research - (07/23/17)
     
  3919. Pharm: HIGHER DOLUTEGRAVIR PLASMA TROUGH CONCENTRATION (Ctrough) in PATIENTS presenting SIDE EFFECTS : INTEREST of THERAPEUTIC DRUG MONITORING ? - (07/23/17)
     
  3920. Dual ART Therapy Regimens - (07/23/17)
     
  3921. A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? - (07/23/17)
     
  3922. Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy - (07/23/17)
     
  3923. Johnson & Johnson at IAS 2017: Latest Innovations from its Janssen Pharmaceutical Companies Include First In-Human Data for Investigational Preventive HIV-1 Vaccine and Phase 3 Pivotal Trial Results for Darunavir-Based, Single-Tablet Regimen - (07/23/17)
     
  3924. The effects of diet and lifestyle interventions on insulin resistance in patients with nonalcoholic fatty liver disease: a systematic review - (07/22/17)
     
  3925. Healthy Plant-Based Diet What Does it Really Mean? Editorial - Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary Heart Disease in U.S. Adults - (07/22/17)
     
  3926. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada - low CD4 at ART initiation reduced life expectancy 20 years - (07/22/17)
     
  3927. Life Expectancy in HIV / Reyataz Reduced CVD Risk vs PIs/NNRTIs/Integrase - (07/22/17)
     
  3928. CROI: CURE at CROI 2017 - (07/22/17)
     
  3929. Reyataz Reduced CVD Risk Compared with other ART Regimens - Cardiovascular outcomes among HIV-infected veterans receiving atazanavir: a US national historical cohort study - (07/21/17)
     
  3930. Prisoners - "Approximately 60% of participants had an undetectable plasma HIV RNA 24 weeks after release" - (07/21/17)
     
  3931. Undiagnosed HIV & Incidence Remain High - CDC CROI Report - (07/21/17)
     
  3932. ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017 - (07/21/17)
     
  3933. European Medicines Agency Validates Gilead's Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV - (07/21/17)
     
  3934. Pharm: The 18th International Workshop on Clinical Pharmacology of Antiviral Therapy - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center Jennifer J. Kiser, Pharm.D. Associate Professor School of Pharmacy University of Colorado at Denver - (07/20/17)
     
  3935. Toll-Like Receptor Agonists: Can They Exact a Toll on Human Immunodeficiency Virus Persistence? Editorial Commentary - (07/20/17)
     
  3936. Short-Course Toll-Like Receptor 9 Agonist [MGN1703 ] Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection - (07/20/17)
     
  3937. Beyond antiretroviral therapy: early interventions to control HIV-1 infection - Opinion - (07/20/17)
     
  3938. Toll-Like Receptor Agonists: Can They Exact a Toll on Human Immunodeficiency Virus Persistence? - EDITORIAL COMMENTARY - (07/20/17)
     
  3939. Progressive Brain Atrophy Despite Persistent Viral Suppression in HIV Over Age 60 - (07/19/17)
     
  3940. Life Expectancy reduced 20 years If ART Started at < 350 CD4s - Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada - (07/19/17)
     
  3941. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia - (07/19/17)
     
  3942. HIV prematurely ages the brain - new study & Commentary - (07/19/17)
     
  3943. Repatha Lipodystrophy - (07/19/17)
     
  3944. HIV and Obesity Comorbidity Increase Interleukin 6 but Not Soluble CD14 or D-Dimer - (07/19/17)
     
  3945. Higher Body Mass Index Is Associated With Greater Proportions of Effector CD8+ T Cells Expressing CD57 in Women Living With HIV - (07/19/17)
     
  3946. Association Between Frailty and Components of the Frailty Phenotype With Modifiable Risk Factors and Antiretroviral Therapy: socioeconomic, neurocognitive impairment, Medicaid/Medicare - exercise, diet, smoking, obesity - (07/19/17)
     
  3947. Mental Health in Aging with HIV - Suicide Ideation Will Increase in Aging Older HIV+ - Successful aging and the epidemiology of HIV - (07/19/17)
     
  3948. IL-17 Treatment, Anti-Inflammatory in Diabetes/Oral Microbiome - Diabetes Enhances IL-17 Expression and Alters the Oral Microbiome to Increase Its Pathogenicity - (07/19/17)
     
  3949. "HIV and diabetes may have an additive effect on CKD risk " - HIV & the Aging Kidney - (07/11/17)
     
  3950. 2 New HIV CVD/Heart Disease Drugs: PCSK9 inhibitor & 1st CVD Anti-Inflammatory Canakinumab - (07/10/17)
     
  3951. HIV and Cardiovascular Disease: We Need a Mechanism, and We Need a Plan - Editorial - (07/10/17)
     
  3952. HIV Infection Itself May Not Be Associated With Subclinical Coronary Artery Disease Among African Americans Without Cardiovascular Symptoms - (07/10/17)
     
  3953. HIV & Heart Disease, Cognitive/Neurologic Disease, Bone Disease - (07/10/17)
     
  3954. Cancers Now in HIV..."cancer mortality much higher in HIV+" - Cancer-Attributable Mortality Among People With Treated HIV in North America - (07/10/17)
     
  3955. Merck to Present New Data from Clinical Trials Evaluating ISENTRESS® HD (raltegravir) and Investigational HIV Therapies Doravirine and MK-8591 at IAS 2017 - (07/10/17)
     
  3956. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease / Amgen Offers Refund / 'Value-Pricing' Contract Deals for PCKS9 Cholesterol Drug - (03/22/17)
     
  3957. Evolocumab - FOURIER Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk - (05/02/17)
     
  3958. Projecting 10-yr, 20-yr and Lifetime Risks of Cardiovascular Disease in Persons Living with HIV in the US - "HIV should be considered a major risk factor for CVD....risk similar to diabetes risk for CVD" - (07/06/17)
     
  3959. CVD & Renal Disease Risk in HIV+ / Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults - (07/06/17)
     
  3960. Aging / HIV / Latinos - Report Released Illuminating The Needs Of The Forgotten - "Olvidados": A National Health Assessment Of Latinos Growing Older With HIV - (07/06/17)
     
  3961. Fatty Liver: Fatty Liver in HIV+ / HIV Research Politics, Aging - Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy - (07/03/17)
     
  3962. Fatty Liver: Fatty Liver / NASH at EASL - (07/03/17)
     
  3963. Fatty Liver, NAFLD, NASH Definitions - (06/29/17)
     
  3964. Disability Among Middle-Aged and Older Persons With Human Immunodeficiency Virus Infection / ACTG HAILO Study - (06/29/17)
     
  3965. Mitochondrial toxicity and caspase activation in HIV pregnant women - (06/29/17)
     
  3966. Placental Mitochondrial Toxicity, Oxidative Stress, Apoptosis, and Adverse Perinatal Outcomes in HIV Pregnancies Under Antiretroviral Treatment Containing Zidovudine - (06/29/17)
     
  3967. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial - (06/28/17)
     
  3968. IWCADRH: Fat in and around the muscle: metabolism and pathophysiology - (06/26/17)
     
  3969. 1st CVD Anti-Inflammatory Canakinumab with Positive Phase 3 Results Announced - Studied in HIV at CROI - (06/26/17)
     
  3970. 1st CVD Anti-Inflammatory - Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack - (06/26/17)
     
  3971. Pharm: Effect of a high fat meal on the pharmacokinetics of the HIV integrase inhibitor, cabotegravir - (06/26/17)
     
  3972. Pharm: The Effect of Food on the Pharmacokinetics of the HIV-1 Attachment Inhibitor Temsavir, the Active Moiety of the Prodrug Fostemsavir - (06/26/17)
     
  3973. Pharm: The Effect of Increased Gastric pH on the Bioavailability of Extended Release Tablet of Fostemsavir in Healthy Subjects / Combinectin-GSK3732394 / 2nd Gen Maturation Inhibitor GSK2838232 - (06/26/17)
     
  3974. Pharm: Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study - (06/26/17)
     
  3975. IWCADRH: Regulation of muscle function and mass by the bone-derived hormone osteocalcin - Brain/Bones/Muscle Exercise Connection/Mortality Too/Comorbidities Workshop-NY 9/16 - (06/23/17)
     
  3976. IWCADRH: Clinical Implications of Nonalcoholic Fatty Liver Disease in Patients with HIV Infection - (06/23/17)
     
  3977. Aging with HIV in U.S. Trans NIH Research Themes - (06/22/17)
     
  3978. Using Imaging to Understand the Role of Epicardial Adipose Tissue in HIV-Related Atherosclerosis - (06/22/17)
     
  3979. Sudden Cardiac Death in Patients With Human Immunodeficiency Virus Infection (13%) - (06/22/17)
     
  3980. Types of Myocardial Infarctions in HIV+ - Type 2 vs Type 1 MIs - (06/22/17)
     
  3981. Pharm: A Comparison of the Pharmacokinetics of Dolutegravir in Pregnancy and Postpartum - (06/21/17)
     
  3982. Pharm: Confirmation of the Drug-drug Interaction Potential Between Cobicistat-boosted Antiretroviral Regimens and Hormonal Contraceptives - (06/21/17)
     
  3983. Pharm: Lack of Clinically Relevant Effect of Bictegravir on Metformin Pharmacokinetics and Pharmacodynamics - (06/21/17)
     
  3984. Pharm: The Effect of Hepatic or Renal Impairment on Bictegravir Pharmacokinetics - (06/21/17)
     
  3985. Pharm: Lack of Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate on Glomerular Filtration Rate in HIV-Infected Patients - (06/21/17)
     
  3986. Pharm: Effect of cobicistat on tenofovir disoproxil fumarate (TDF) durability: is it time to rethink at TAF trials? - Mark Mascolini (06/21/17)
     
  3987. TAF / ATV-Cobi / FTC PK, Interaction - (06/21/17)
     
  3988. TAF 10/25mg VS TDF Plasma Exposures - (06/21/17)
     
  3989. Aging & Diabetes - Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010 - YES - (06/21/17)
     
  3990. Bone Density, Microarchitecture, and Tissue Quality After Long-Term Treatment With Tenofovir DF/Emtricitabine or Abacavir/Lamivudine - (06/21/17)
     
  3991. Pharm: Evaluation of Drug-Drug Interaction Potential Between Sofosbuvir/Velpatasvir and Atorvastatin - (06/20/17)
     
  3992. Pharm: Doravirine Does Not Have a Clinically Meaningful Pharmacokinetic Interaction with Elbasvir Plus Grazoprevir - (06/20/17)
     
  3993. Pharm: Doravirine Does Not Have a Clinically Meaningful Pharmacokinetic Interaction with Ledipasvir/Sofosbuvitr (HARVONI) - (06/20/17)
     
  3994. Pharm: Evaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilapevir and Boosted or Unboosted HIV Antiretroviral Regimens - report 2 - Mark Mascolini - (06/20/17)
     
  3995. Pharm: Bioequivalence of a Fixed Dose Combination Tablet of Dolutegravir and Rilpivirine in Healthy Subjects - (06/20/17)
     
  3996. Pharm: Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis - (06/20/17)
     
  3997. Pharm: Early Safety, Tolerability and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects - (06/20/17)
     
  3998. Pharm: Evaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilapevir and Boosted or Unboosted HIV Antiretroviral Regimens - (06/20/17)
     
  3999. DTG +TMC-278 - TMC-278 Resistance / Profile Against EFV, NNRTI Resistance - (06/19/17)
     
  4000. Pharm: Effect of cobicistat on tenofovir disoproxil fumarate (TDF) durability: is it time to rethink at TAF trials? - Mark Mascolini - (06/19/17)
     
  4001. Pharm: High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600mg daily - (06/19/17)
     
  4002. Pharm: DAAs Glecaprevir and Pibrentasvir Double Levels of Statins and Dabigatran - Mark Mascolini - (06/19/17)
     
  4003. Pharm: Safety and Concentrations of GSK Maturation Inhibitor With or Without Ritonavir - Mark Mascolini - (06/19/17)
     
  4004. Pharm: Drug-Carrying Adherence Sensor Does Not Alter Levels of TDF/FTC - Mark Mascolini - (06/19/17)
     
  4005. Pharm: Dolutegravir Plus Rilpivirine Levels High Enough After Switch From NNRTI - Mark Mascolini - (06/19/17)
     
  4006. Pharm: Similar Darunavir Levels in CSF With RTV or COBI Boost - Mark Mascolini - (06/19/17)
     
  4007. Pharm: No Bictegravir Dose Adjustment With Liver or Kidney Impairment - Mark Mascolini - (06/19/17)
     
  4008. Pharm: COBI-PI Regimens Raise Drospirenone Levels in Oral Contraceptive - Mark Mascolini - (06/19/17)
     
  4009. Pharm: Dolutegravir Levels Similar in Third Trimester and After Delivery - Mark Mascolini - (06/19/17)
     
  4010. Pharm: Does TDF Need Dose Reduction When Given With Boosting Agent? - Mark Mascolini - (06/19/17)
     
  4011. Pharm: Dolutegravir Cmax Higher in Elderly, Tied to Shorter Sleep Duration - Mark Mascolini - (06/16/17)
     
  4012. Pharm: Evaluation of the Drug-Drug Interaction (DDI) Potential Between Cobicistat-Boosted Protease Inhibitors and Statins - (06/15/17)
     
  4013. Pharm: Pharmacokinetics of darunavir/cobicistat (DRV/c) and etravirine (ETR) alone and coadministered in HIV-infected patients - (06/15/17)
     
  4014. Pharm: Clinical Data Support 30 mg Daclatasvir with ATV or ATV/r, 90 mg With Etravirine - Mark Mascolini (06/15/17)
     
  4015. Pharm: Statin Levels Much Higher With Cobicistat-Boosted Atazanavir or Darunavir - Mark Mascolini (06/15/17)
     
  4016. Pharm: Etravirine Lowers Cobicistat Exposure and Darunavir Trough - Mark Mascolini (06/15/17)
     
  4017. Aging/Healthcare Costs-Europe & USA - (06/15/17)
     
  4018. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment - (06/13/17)
     
  4019. Strokes in HIV+ - (06/09/17)
     
  4020. PrEP: State of the Science (ASM/ICAAC June 2017) - (06/09/17)
     
  4021. CROI: Types of ischemic strokes among HIV-infected individuals across the United States - (06/07/17)
     
  4022. Immunologic and Virologic Responses to Antiretroviral Regimens in Treatment-naïve, HIV-infected Elderly Patients (ASM/ICAAC June 2017) - (06/07/17)
     
  4023. Identifying Cellular Factors that Silence HIV-1 Proviral Transcription (ASM/ICAAC June 2017) - (06/07/17)
     
  4024. CD4s Rise More Slowly in HIV Patients 50 or Older Starting Antiretrovirals (ICAAC June 2017) - Mark Mascolini - (06/07/17)
     
  4025. Key Select Aging & HIV Reports 2 An entire section on the NATAP website devoted to Aging & HIV. - (06/07/17)
     
  4026. Key Aging / HIV Reports 1 of 2 NATAP website devoted to Aging & HIV - (06/07/17)
     
  4027. Aerobic Interval Training Versus Continuous Moderate Exercise as a Treatment for the Metabolic Syndrome - (06/07/17)
     
  4028. PRO 140 CCR5 Monoclonal Antibody Strong in Highly Pretreated People: Week 25 - (ICAAC 2017 June 1) - Mark Mascolini (06/07/17)
     
  4029. Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use - (06/07/17)
     
  4030. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women - (06/07/17)
     
  4031. ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines - (06/02/17)
     
  4032. Gilead's Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies - (05/30/17)
     
  4033. Merck Receives FDA Approval of ISENTRESS® HD (raltegravir), a New Once-Daily Option, in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients - (05/30/17)
     
  4034. Statins effects in Older Adults Risks/Benefits - Primary Prevention / ALLHAT-LLT Study "patients without atherosclerotic cardiovascular disease" - (05/25/17)
     
  4035. Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines - new analysis: "the evidence is lacking for older adults without major cardiovascular risk aside from age" - (05/25/17)
     
  4036. Statin (JUPITER study) in Elderly with Relatively Low Risk Factors - (05/25/17)
     
  4037. Study Casts Doubt on Need for Statins in the 'Healthy Old' - But specialists cite research flaws, limitations - (05/25/17)
     
  4038. Statins - Analysis of Efficacy and Safety in Patients Aged 65-75 Years at Randomization [from Jules: relatively low risk, with Diabetes] - (05/25/17)
     
  4039. Isentress Once Daily FDA Approval Pending - (05/22/17)
     
  4040. Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS® (raltegravir) 600 mg in the European Union - (05/22/17)
     
  4041. Long Acting HIV ARTs - is This the Future - implants, nano formulations - (05/22/17)
     
  4042. Significant health impact of accelerated aging in young HIV-infected individuals on antiretroviral therapy in Malaysia - higher mortality, health-care utilization, worse quality of life, more comorbidities/geriatric conditions matched to uninfected - (05/22/17)
     
  4043. Expanded Access Program for ibalizumab in Resistant HIV-1 - (05/17/17)
     
  4044. Marijuana use impacts midlife cardiovascular events in HIV-infected men - (05/17/17)
     
  4045. Another statin option in HIV - Comment - (05/17/17)
     
  4046. Brief Report: HIV Prevalence and the Prevalence of Unsuppressed HIV in New York City, 2010-2014 - (05/17/17)
     
  4047. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data - (05/17/17)
     
  4048. Increased brain-predicted aging in treated HIV disease / CROI 2017 Brain-Neurological Disorders Reports - (05/17/17)
     
  4049. CROI: Cardiovascular Update from CROI 2017 - by Priscilla Hsue MD Professor of Medicine, UCSF - (05/16/17)
     
  4050. LDL Debate - Role in CVD / Exercise, Diet Inflammation, Mortality - (05/12/17)
     
  4051. CROI: Peripheral endothelial function is suboptimal in HCV-untreated, HIV-suppressed adults - - (05/09/17)
     
  4052. Theratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab - (05/04/17)
     
  4053. Value-Based Pricing For Pharmaceuticals In The Trump Administration
     
  4054. Gut Microbe-Generated Trimethylamine N-Oxide From Dietary Choline Is Prothrombotic in Subjects - (05/02/17)
     
  4055. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis / CROI: Higher Carnitine Levels Almost quadrupled MI Risk in HIV+ - (05/02/17)
     
  4056. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease - A Science Advisory From the American Heart Association - (05/02/17)
     
  4057. AGING CRISIS: Comorbidities Shorten Life & HALE: Healthy Years of Life Expectancy - (05/02/17)
     
  4058. Evolocumab - FOURIER Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk - (05/02/17)
     
  4059. CROI: Higher Carnitine Tied to Almost Quintupled MI Risk in People With HIV - Mark Mascolini - (05/01/17)
     
  4060. Exercise Effects on Mitochondria & Aging - Enhanced Protein Translation Underlies Improved Metabolic and Physical Adaptations to Different Exercise Training Modes in Young and Old Humans - (04/26/17)
     
  4061. Evaluation of Cardiovascular Disease (CVD) Risk in HIV-1-infected Patients Treated With Darunavir/Ritonavir (DRV/r) - (04/26/17)
     
  4062. Exercise Effects on Mitochondria & Aging - Enhanced Protein Translation Underlies Improved Metabolic and Physical Adaptations to Different Exercise Training Modes in Young and Old Humans - (04/26/17)
     
  4063. Evaluation of Cardiovascular Disease (CVD) Risk in HIV-1-infected Patients Treated With Darunavir/Ritonavir (DRV/r) - (04/26/17)
     
  4064. Demographic and Clinical Characteristics of Patients Living With HIV Treated With Darunavir- and Atazanavir-based Regimens in the Real-world Setting - (04/24/17)
     
  4065. CROI: CROI 2017 Summary Report - A lot Going On - good Conference with Lots of New Information - New HIV Drugs, Aging/Comorbidities, Cure & PrEP, Fatty Liver/HCV-HBV - - (04/19/17)
     
  4066. CROI: PHARMACOKINETICS OF RILPIVIRINE AFTER SWITCHING FROM EFAVIRENZ IN ADOLESCENTS - - (04/18/17)
     
  4067. CROI: Predictors of Severe Weight/Body Mass Index Gain Following Antiretroviral Initiation - - (04/18/17)
     
  4068. CROI: Pharmacokinetics, Safety, and Efficacy of Atazanavir or Darunavir With Cobicistat in Adolescents (12 to <18 years of age) - - (04/18/17)
     
  4069. Women with HIV - CDC: Over- Estimated Viral Suppression ...30-40% WIHS Women with Detectable Viral Load - that Doubles the MORTALITY Rate - (04/17/17)
     
  4070. LATEST UPDATE ON HIV LIPODYSTROPHY: Interview with Dr Grace McComsey - (04/17/17)
     
  4071. GSK Discontinues BMS' Maturation Inhibitor - (04/17/17)
     
  4072. CROI: PHARMACOKINETICS OF RILPIVIRINE AFTER SWITCHING FROM EFAVIRENZ IN ADOLESCENTS - - (04/17/17)
     
  4073. CROI: Substantially Lower Rilpivirine Plasma Concentrations during Pregnancy - - (04/17/17)
     
  4074. CROI: Low HIV-1 Resistance in Subjects Using Darunavir Once-daily Regimens Across Studies - - (04/17/17)
     
  4075. CROI: EXERCISE, OXIDATIVE STRESS AND FIBRINOLYTIC FUNCTION IN HIV-1 INFECTED ADULTS - - (04/17/17)
     
  4076. CROI: Blood Brain Barrier function, ART neuroactivity and risk of CSF HIV escape / BBB Permeability & Neurocognitive Performance in HIV+ - - (04/12/17)
     
  4077. CROI: DEVELOPMENT OF A PKC AGONIST DERIVED FROM INGENOL FOR HIV LATENCY DISRUPTION IN VIVO - - (04/12/17)
     
  4078. CROI: FATTY LIVER DISEASE: A GROWING CONCERN - - (04/12/17)
     
  4079. Use of Recommended and Contraindicated Statins in HIV Patients - (04/11/17)
     
  4080. Disability among Middle-Aged and Older Persons with HIV Infection - (04/11/17)
     
  4081. An Increased Rate of Fracture Occurs a Decade Earlier in HIV+ Compared to HIV- men in the Multicenter AIDS Cohort Study (MACS) - (04/11/17)
     
  4082. Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients - (04/11/17)
     
  4083. From One Syndrome to Many: Incorporating Geriatric Consultation into HIV Care - (04/11/17)
     
  4084. Grey and white matter abnormalities in treated HIV- disease and their relationship to cognitive function - (04/11/17)
     
  4085. Cholesterol Lowering [statins] in Intermediate-Risk Persons without Cardiovascular Disease - (04/11/17)
     
  4086. Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients - (04/11/17)
     
  4087. CROI: CROI: Neurocognitive Disorders - Neurologic, Brain, Cognitive Impairment - - (04/10/17)
     
  4088. CROI: Ledipasvir/Sofosbuvir Raises Tenofovir Diphosphate Concentrations in Red Cells - - (04/10/17)
     
  4089. Decision Tools to Improve Personalized Care in Cardiovascular Disease - Value Based CVD Care
     
  4090. Value-Based Payments Likely to Survive Affordable Care Act Repeal
     
  4091. Value Based CVD Care / CMS - The Million Hearts Initiative: Preventing 1 Million Heart Attacks and Strokes
     
  4092. Value Based Personalized CVD Care - Multimodality Strategy for Cardiovascular Risk Assessment: Performance in Two Population-Based Cohorts -
     
  4093. Use of Recommended and Contraindicated Statins in HIV Patients - (04/07/17)
     
  4094. HIV Infection Is Associated With Worse Bone Material Properties, Independently of Bone Mineral Density [Microindentation measures Bone Material Strength index, new test for bone]- Brief Report - (04/07/17)
     
  4095. Clinical Application of Spine Trabecular Bone Score (TBS) - New Bone Test / CROI-2017 - (04/07/17)
     
  4096. CROI: HIV Infection and the Occurrence of Medically Significant Falls: Accelerated or Accentuated Aging? - - (04/06/17)
     
  4097. CROI: A RANDOMIZED TRIAL OF VITAMIN D3 (3000 VERSUS 1000 IU) IN HIV+ POSTMENOPAUSAL WOMEN - - (04/06/17)
     
  4098. CROI: VITAMIN D DEFICIENCY IMPAIRS THE BENEFICIAL EFFECTS OF STATIN IN TREATED HIV - - (04/06/17)
     
  4099. CROI: HIGH DOSE VITAMIN D3 INCREASES SPINE BONE DENSITY IN HIV+ YOUTH ON TENOFOVIR (TDF) - - (04/06/17)
     
  4100. CROI: Frailty, Bones, and Vitamin D: CROI 2017 - Todd T. Brown, MD, PhD Professor of Medicine and Epidemiology Johns Hopkins University - (04/06/17)
     
  4101. CROI: Switching from TDF To TAF in HIV-Infected Adults With Low BMD: A Pooled Analysis - - (04/05/17)
     
  4102. CROI: Ledipasvir/Sofosbuvir Raises Tenofovir Diphosphate Concentrations in Red Cells - - (04/04/17)
     
  4103. CROI: Acute HCV Drops Sharply in HIV-Positive Dutch MSM After DAA Rollout - Mark Mascolini - (04/04/17)
     
  4104. CROI: New HIV Drugs at CROI / CROI Antiretroviral Treatment Summary / Long Acting HIV Therapies - (03/31/17)
     
  4105. CROI: Use of Cocaine, Meth, Opioids Remains High in US MSM: 2008-2014 - Mark Mascolini - (03/30/17)
     
  4106. CROI: COPD Markers Linked to Tripled Mortality Risk in People With HIV - Mark Mascolini - (03/30/17)
     
  4107. CROI: Dapivirine Vaginal Ring Does Not Blunt Effectiveness of Hormonal Contraception - Mark Mascolini - (03/30/17)
     
  4108. CROI: Frailty Status and Risk of Falls in HIV-Infected Older Adults in the ACTG A5322 Study - - (04/05/17)
     
  4109. CROI: Antiretroviral-induced Bone Loss is Durably Suppressed by A Single Dose of Zoledronic Acid - - (04/05/17)
     
  4110. CROI: Changes in Liver Fibrosis and Steatosis in HIV Mono-Infected patients over 24 months - 50% have fatty liver at average age of 46 - (03/28/17)
     
  4111. CROI: LIVER STEATOSIS AND FIBROSIS IN AT-RISK EUROPEAN HIV-MONOINFECTED PATIENTS - 64% with steatosis among those who had elevated LFTs and/or metabolic syndrome and/or lipodystrophy - (03/28/17)
     
  4112. CROI: FATTY LIVER DISEASE: A GROWING CONCERN - highly recommended - (03/28/17)
     
  4113. CROI: Emergence of Integrase Resistance Mutations During Initial Therapy with TDF/FTC/DTG - (03/27/17)
     
  4114. CROI: Physical Function and Inflammation in Older HIV-Infected Men - (03/16/17)
     
  4115. CROI: CROI Summary 2017: Antiretroviral treatment - where we are now / New HIV Drugs & Treatments - Joseph J. Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/06/17)
     
  4116. CROI: CROI 2017: Better Living with HIV Infection - written by - David Alain Wohl, MD - The University of North Carolina at Chapel Hill (03/01/17)
     
  4117. CROI: Impressions of CROI 2017 - written by- Pablo Tebas, MD University of Pennsylvania - (03/01/17)
     
  4118. CROI: The Kidney at CROI 2017 - written by - Christina Wyatt MD - Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY (03/01/17)
     
  4119. CROI: HIV Prevention at CROI 2017 Conference on Retroviruses and Opportunistic Infections - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/23/17)
     
  4120. CROI: Summary from CROI 2017 for Viral Hepatitis HCV elimination on its way: dream or emerging reality? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany Correspondence: Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany - (03/22/17)
     
  4121. CROI: Antiretroviral-induced Bone Loss is Durably Suppressed by A Single Dose of Zoledronic Acid - - (04/05/17)
     
  4122. GLASGOW: Utilizing Phase 3 Clinical Trial Data to Assess Adverse Event (AE) Frequency of a Potentially Interacting Medication (PIM) Amlodipine with Elvitegravir/Cobicistat (EVG/COBI) - (04/04/17)
     
  4123. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease - (04/04/17)
     
  4124. Aging of HIV-Infected: a explosive and underestimated phenomena being ignored, needs attention - special support services for patients & clinics needed-lack of federal/state response - HCV too - Commentary by Jules Levin - (04/04/17)
     
  4125. CROI: "Hooked on painkillers" before first injection among PWID in 16 US cities - CDC - (03/31/17)
     
  4126. CROI: HIV Awareness/Care in US Black Men May Explain Less HIV in Black Women - Mark Mascolini - (03/31/17)
     
  4127. CROI: New HIV Drugs at CROI / CROI Antiretroviral Treatment Summary / Long Acting HIV Therapies - (03/31/17)
     
  4128. CROI: Body Mass Index and the Risk of Serious Non-AIDS Events - Mark Mascolini - (03/31/17)
     
  4129. CROI: Rilpivirine Injected Every 8 Weeks Maintains Adequate Levels in Women: HPTN 076 - Mark Mascolini - (03/31/17)
     
  4130. Lipodystrophy Not Forgotten - Proinflammatory Markers, Insulin Sensitivity, and Cardiometabolic Risk Factors in Treated HIV Infection - in causing heart disease - (03/29/17)
     
  4131. Lipoatrophy, Lipodystrophy - Let's Not Forget their Contribution to Heart Disease in HIV - (03/29/17)
     
  4132. HIV: Finding latent needles in a haystack - CD32 Commentary: CD32a is a marker for only 50% of reservoir.... - (03/29/17)
     
  4133. International Workshop on NASH Biomarkers - May 2017 Wash DC - (03/29/17)
     
  4134. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study - (03/29/17)
     
  4135. Frailty Status and Risk of Falls in HIV-Infected Older Adults in the ACTG A5322 Study - (03/29/17)
     
  4136. CROI: TREND IN MULTIMORBIDITY AMONG HIV+ ADULTS IN CLINICAL CARE IN THE US - (03/29/17)
     
  4137. CROI: MRS Measures Associate with Impaired Neuropsychological Performance in Acute HIV - (03/29/17)
     
  4138. CROI: P2X receptors as therapeutic targets of HIV-1 infection and inflammation - (03/29/17)
     
  4139. CROI: LONG-TERM EFFECTS OF IMMEDIATE VERSUS DEFERRED cART IN PRIMARY HIV INFECTION - (03/29/17)
     
  4140. CROI: Prevalence of neurocognitive disorders in a well-treated and aging Swiss HIV Cohort - (03/29/17)
     
  4141. CROI: Benefit of continuous/immediate ART on disease risk: SMART & START combined analysis - (03/29/17)
     
  4142. CROI: ART in HIV persons with pre-treatment viremia <3000c/mL: the START study - (03/29/17)
     
  4143. CROI: INTEGRASE AND PROTEASE INHIBITOR CONCENTRATIONS IN LYMPH NODE AND GUT MUCOSAL TISSUE - (03/29/17)
     
  4144. CROI: Changes In Liver Steatosis After Switching Efavirenz To Raltegravir: The STERAL Study - (03/29/17)
     
  4145. CROI: Multiple-Dose Treatment With Ritonavir Increases the Exposure of Doravirine - (03/29/17)
     
  4146. CROI: Raltegravir Switch and Biomarkers of Liver Steatosis and Metabolic Syndrome in Women - (03/29/17)
     
  4147. CROI: Cost of noninfectious comorbidities in patients with HIV - Cost of HIV CARE Increases 5 fold Due to Cost for Comorbidities from <40 to >60 - (03/23/17)
     
  4148. CROI: Comprehensive Assessment of Resistance Mutations Selected by Dolutegravir (DTG) in Subjects Failing DTG-Monotherapy after Switching from other Therapies (Redomo Study) - (03/23/17)
     
  4149. Long-Acting & Nanoparticle ARTs - Future of HIV Medication??? - (03/22/17)
     
  4150. Value Based: Sustained Participation in a Pay-for-Value Program: Impact on High-Need Patients
     
  4151. CROI: TDF TO PREVENT PERINATAL HEPATITIS B VIRUS TRANSMISSION: A RANDOMIZED TRIAL (ITAP) - (03/22/17)
     
  4152. CROI: INCREASED RATES OF HBV SEROCONVERSION UNDER LONG-TERM HBV ACTIVE THERAPY IN HBV/HIV - [16%] - (03/22/17)
     
  4153. CROI: Direct-Acting Antivirals Improve Access to Care and Cure for Patients with HIV and chronic Hepatitis C Virus from 2011-2015 - (03/20/17)
     
  4154. CROI: High rates of hepatitis C virus cure among black and non-black persons with HIV-infection receiving care in an urban center - (03/20/17)
     
  4155. CROI: Same same but different? Risk of DAA therapy failure in real-life HCV/HIV coinfection: The GECCO Cohort - (03/20/17)
     
  4156. CROI: HIV-HCV Coinfection in the DAA Era: "En Route for Eradication" ? - (03/20/17)
     
  4157. CROI: Effectiveness of All-Oral DAAs for HCV Genotype 3 In HIV/HCV-Coinfected Patients - (03/20/17)
     
  4158. CROI: Resistance emergence in macaques administered Cabotegravir long-acting (CAB LA) during acute infection - (03/20/17)
     
  4159. CROI: Concordant Population-level Increases in PrEP Found with Novel Public Health Methods - (03/20/17)
     
  4160. CROI: STD PARTNER SERVICES TO MONITOR AND PROMOTE PREP USE AMONG MEN WHO HAVE SEX WITH MEN - (03/20/17)
     
  4161. CROI: Text Messaging is Associated with Improved Retention in a Clinic-based PrEP Program - (03/20/17)
     
  4162. CROI: MIDWEST PHARMACISTS' KNOWLEDGE OF & WILLINGNESS TO PROVIDE PRE-EXPOSURE PROPHYLAXIS - (03/20/17)
     
  4163. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses - (03/16/17)
     
  4164. Early antibody therapy can induce long-lasting immunity to SHIV / Dual Antibody Therapy - (03/15/17)
     
  4165. Integrase inhibitors go head-to-head - Comment - (03/15/17)
     
  4166. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial - (03/15/17)
     
  4167. Comorbidities & Life Expectancy: the affect of comorbidities on Life Expectancy - (03/15/17)
     
  4168. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study - (03/15/17)
     
  4169. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study - (03/15/17)
     
  4170. CROI: Clinical Pharmacology at CROI 2017 - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (03/13/17)
     
  4171. Aging & HIV - an unaddressed timebomb waiting to explode - slide presentation by Jules Levin, NATAP - (03/14/17)
     
  4172. CROI: Exhausted T-cells and Inflammatory Monocytes are Linked to Brain Atrophy in HIV - (03/10/17)
     
  4173. CROI: Impact of smoking, hypertension, and cholesterol on myocardial infarction in HIV-infected adults...."hypertension, cholesterol & smoking are very strong drivers of MIs in HIV+" - (03/10/17)
     
  4174. CROI: Bacterial Vaginosis Does Not Affect Oral TDF/FTC PrEP Efficacy - Mark Mascolini (03/10/17)
     
  4175. CROI: Older Age Associated with both Adherence and Renal Decline in the PrEP Demo Project - (03/10/17)
     
  4176. CROI: Bone Changes With TDF-containing and Non-TDF-containing (maraviroc) Prep in U.S. Men and Women - (03/10/17)
     
  4177. CROI: IMPACT OF VAGINAL MICROBIOTA ON GENITAL TISSUE AND PLASMA CONCENTRATIONS OF TENOFOVIR - (03/10/17)
     
  4178. CROI: Brief Behavioral Intervention Increases PrEP Drug Levels in a Real World Setting - (03/10/17)
     
  4179. CROI: The Challenges of Translating PrEP Interest into Uptake among Young Black MSM in Atlanta, GA - (03/10/17)
     
  4180. Value-Based Care: Focusing on High-Cost Patients - The Key to Addressing High Costs? - Perspective / Short Changing Patient Care - (03/08/17)
     
  4181. WIHS Viral Load Suppression - Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the Women's Interagency HIV Study, 2006-2009 - (03/08/17)
     
  4182. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use - (03/08/17)
     
  4183. Testosterone and Male Aging - Editorial - (03/08/17)
     
  4184. Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency - 2nd study - (03/08/17)
     
  4185. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone - (03/08/17)
     
  4186. CROI: Biological-vs-Chronological Age Difference Significantly Greater With HIV - Mark Mascolini (03/08/17)
     
  4187. CROI: Novel Imaging Strategy Shows High-Level Aortic CD206+ Macrophage Infiltration in HIV ......CVD risk / inflammation - (03/08/17)
     
  4188. CROI: BONE DENSITY, MICROARCHITECTURE, AND BONE STRENGTH AFTER 1 YEAR OF TDF - (03/08/17)
     
  4189. CROI: CHANGES IN THE ORAL MICROBIOME WITH ART INITIATION / Microbiome Affects of Low Baseline CD4/High Viral Load - (03/08/17)
     
  4190. CROI: Bone density and trabecular bone score improve fracture prediction in HIV-infected women - (03/06/17)
     
  4191. CROI: Bone Micro-Architectural Changes and Fracture Risk Prediction in HIV and HCV - (03/06/17)
     
  4192. CROI: CANCER INCIDENCE AMONG PERSONS ON MODERN SUPPRESSIVE ANTIRETROVIRAL THERAPY, 2000-12 - (03/06/17)
     
  4193. CROI: Cancer risk among HIV-infected people in the U.S. during the modern treatment era - (03/06/17)
     
  4194. CROI: LOW PREVALENCE OF HIV DRUG RESISTANCE WITH MODERN AGENTS - (03/06/17)
     
  4195. CROI: INCREASED PERSISTENCE OF INITIAL ART WITH INSTI-CONTAINING REGIMENS - (03/06/17)
     
  4196. CROI: A Phase 2 Open-Label Trial of Antibody UB-421 Monotherapy as a Substitute for HAART - (03/06/17)
     
  4197. CROI: Cognitive Complaints and Development of Falls among HIV-Infected and Uninfected Women - (03/06/17)
     
  4198. CROI: A Comparison of Fracture Risk Estimates in HIV-positive and HIV-negative Subjects; Data from HIV UPBEAT (Understanding the Pathology of Bone Disease in HIV-infected Subjects) - (03/06/17)
     
  4199. CROI: The Effect of ART on Inflammation, Coagulation and Vascular Injury in START..... "Immediate ART led to reductions at 8 months of 12-21% in D-dimer, IL-6, SAA, sICAM and sVCAM levels compared with deferral of ART.".....likely reducing risk for comorbidities - (03/06/17)
     
  4200. CROI: Association of Inflammation and Coagulation with Clinical Risk in the START Trial ...... - (03/06/17)
     
  4201. CROI: CROI Summary 2017: Antiretroviral treatment - where we are now / New HIV Drugs & Treatments - Joseph J. Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/06/17)
     
  4202. CROI: The Association Between HCV And Comorbid Conditions In 2 Large Patient Cohorts - Mark Mascolini - (03/02/17)
     
  4203. CROI: High prevalence of hepatitis C virus among HIV negative MSM in the Amsterdam PrEP project - (03/02/17)
     
  4204. CROI: HCC DEVELOPMENT IN HCV PATIENTS AFTER DAA: THE EXPERIENCE OF THE SCOLTA PROJECT - (03/02/17)
     
  4205. CROI: No Evidence of Ongoing HIV Replication After 7 Years on ART.....but clonal expansion persists/HIV-Cure implications - (03/02/17)
     
  4206. CROI: Impact of antiretroviral treatment containing tenofovir difumarate on the telomere length of aviremic HIV-infected patients / NRTIs, HIV & Telomerase, Aging, Comorbidities - (03/02/17)
     
  4207. CROI: Leukocyte Telomere Attrition is Rapid Following HIV but not HCV Seroconversion - (03/02/17)
     
  4208. CROI: Telomere length: neurocognitive biomarker in HIV-1-infected subjects - (03/02/17)
     
  4209. CROI: Elsulfavirine as Compared to Efavirenz in Combination with TDF/FTC: 48-week Study - (03/02/17)
     
  4210. CROI: Factors associated with rapid eGFR decline while receiving TDF and/or ATV - (03/02/17)
     
  4211. CROI: Current Statin Use Reduces Risk of Viral Rebound on Suppressive cART - (03/02/17)
     
  4212. CROI: Effect of cobicistat on tenofovir plasma concentrations: a cross-sectional study - (03/02/17)
     
  4213. CROI: Crushing of dolutegravir combination tablets increases dolutegravir exposure - (03/02/17)
     
  4214. CROI: HUMAN CONFIRMATION OF ORAL DOSE REDUCTION POTENTIAL OF NANOPARTICLE ANTIRETROVIRAL FORMULATIONS - (03/02/17)
     
  4215. CROI: Long Acting HIV ART - is this the future? Nanoformulations - Implants - (03/02/17)
     
  4216. CROI: A Bi-Specific Approach for Targeting IMRs in HIV-1 Latency - (03/02/17)
     
  4217. CROI: IMPAACT P1110: RALTEGRAVIR PHARMACOKINETICS AND SAFETY IN HIV-1 EXPOSED NEONATES: DOSE-FINDING STUDY - (03/02/17)
     
  4218. CROI: Bictegravir Dissociation Half-life from HIV-1 G140S/Q148H Integrase-DNA Complexes - (03/02/17)
     
  4219. CROI: CEREBRAL SMALL-VESSEL DISEASE IN HIV-INFECTED PATIENTS WELL CONTROLLED ON CART - (03/02/17)
     
  4220. CROI: PRO 140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update - (03/01/17)
     
  4221. CROI: CEREBRAL SMALL VESSEL DISEASE IN CART WELL-CONTROLLED HIV-INFECTED PATIENTS ANRS EP51 MICROBREAK - (02/28/17)
     
  4222. CROI: Novel HIV PI with High Resistance Barrier and Potential for Unboosted QD Oral Dosing - (02/28/17)
     
  4223. CROI: CEREBRAL SMALL VESSEL DISEASE IN CART WELL-CONTROLLED HIV-INFECTED PATIENTS ANRS EP51 MICROBREAK - (02/28/17)
     
  4224. CROI: Bictegravir Dissociation Half-life from HIV-1 G140S/Q148H Integrase-DNA Complexes - (02/28/17)
     
  4225. CROI: CEREBRAL SMALL-VESSEL DISEASE IN HIV-INFECTED PATIENTS WELL CONTROLLED ON CART - (02/28/17)
     
  4226. CROI: PRO 140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update - (02/28/17)
     
  4227. CROI: Novel Non-Catalytic Site Integrase Inhibitor with Improved Resistance Profile - (02/28/17)
     
  4228. CROI: Efficacy and Safety of Switching to E/C/F/TAF in Virologically Suppressed Women - (02/26/17)
     
  4229. CROI: CDC - HIV Incidence, Prevalence and Undiagnosed Infections in Men Who Have Sex With Men - HIV incidence decreased among all transmission categories except MSM - (02/26/17)
     
  4230. CROI: Viral Suppression in NYC, NYS, and LA - (02/26/17)
     
  4231. Atazanavir & Creatinine - (02/26/17)
     
  4232. Darunavir Package Inserts - US & EMA - (02/26/17)
     
  4233. CROI: Frailty Stronger Than Neurocognitive Impairment in Predicting Falls-Disability-Death - Mark Mascolini - (02/26/17)
     
  4234. CROI: Non-AIDS Illness Burden Differs by Sex, Race, and Insurance Type in Aging HIV+ Adults - HOPS - Number of Comorbidities Double from 45 to 60 Years Old/Blacks Disproportionately Affected - (02/26/17)
     
  4235. CROI: LONGITUDINAL VIRAL TRAJECTORY AMONG WOMEN IN THE WOMEN'S INTERAGENCY HIV STUDY - (02/26/17)
     
  4236. CROI: Time spent with HIV viral load >1500 copies/mL among patients in HIV care, 2000-2014....viral suppression and early HAART start are top federal priority - (02/26/17)
     
  4237. CROI: Ending HIV Epidemic in NYC - Plan/Strategy IF YOU CAN MAKE IT THERE: ENDING THE HIV EPIDEMIC IN NEW YORK - (02/26/17)
     
  4238. CROI: Pharmacokinetics of Total and Unbound Rilpivirine in HIV-1-infected Pregnant Women - (02/24/17)
     
  4239. CROI: HPTN 076: TMC278 LA Safe, Tolerable and Acceptable for HIV Pre-Exposure Prophylaxis - (02/24/17)
     
  4240. CROI: LONGITUDINAL ASSESSMENT OF REGIONALLY SPECIFIC BRAIN VOLUMES IN TREATED HIV+ PATIENTS - (02/24/17)
     
  4241. CROI: IMPACT OF ADVANCING AGE ON COGNITION IN HIV+ PERSONS ON A FIRST SUPPRESSIVE REGIMEN - (02/24/17)
     
  4242. CROI: Cognitive Trajectories in Suppressed HIV Infection Indicate Evolving Disease Activity - (02/24/17)
     
  4243. CROI: Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression: HIV+ virally suppressed had worse cognitive decline in 3 domains vs HIV-neg, 4 yrs followup - (02/24/17)
     
  4244. CROI: BIOMARKERS OF AGEING IN HIV-POSITIVE INDIVIDUALS AND MATCHED CONTROLS: 8 years greater biologic age in HIV+ - (02/24/17)
     
  4245. CROI: LONGITUDINAL ANALYSIS SHOWS NO EVIDENCE FOR ACCELERATED BRAIN AGEING IN TREATED HIV - (02/24/17)
     
  4246. CROI: State-Level Estimates of HIV Incidence, Prevalence, and Undiagnosed Infections: 12.2% Undiagnosed in NYS; 15% US undiagnosed - (02/24/17)
     
  4247. CROI: Antiviral Activity of EFdA [MK-8591] Against NRTI-Sensitive and -Resistant Strains of HIV-2 - (02/24/17)
     
  4248. CROI: Dolutegravir Based cART in Vertically-HIV-1-Infected Adolescents in Real-Life Setting - (02/24/17)
     
  4249. CROI: MK-8591 Concentrations at Sites of HIV Transmission and Replication - (02/23/17)
     
  4250. CROI: A LONG-ACTING NANOFORMULATED CABOTEGRAVIR PRODRUG FOR IMPROVED ANTIRETROVIRAL THERAPY - (02/23/17)
     
  4251. CROI: DOLUTEGRAVIR PHARMACOKINETICS, SAFETY AND EFFICACY IN HIV+ CHILDREN 2 TO <6 YEARS OLD - (02/23/17)
     
  4252. CROI: Increased dolutegravir exposure in HIV patients switched from ritonavir to cobicistat - (02/23/17)
     
  4253. CROI: GS-9131 is a Novel NRTI with Activity Against NRTI-Resistant HIV-1 - (02/23/17)
     
  4254. CROI: STEADY-STATE PHARMACOKINETICS OF DOLUTEGRAVIR IN PEOPLE LIVING WITH HIV OVER THE AGE OF 60 YEARS - (02/23/17)
     
  4255. CROI: EFFECT OF DOLUTEGRAVIR PLASMA CONCENTRATION ON CENTRAL NERVOUS SYSTEM SIDE EFFECTS - (02/23/17)
     
  4256. CROI: Dolutegravir as Maintenance Monotherapy for HIV-1: a Randomized Clinical Trial - (02/23/17)
     
  4257. CROI: Promising Results of Lamivudine + Dolutegravir Maintenance Therapy in ANRS 167 Lamidol Trial - (02/23/17)
     
  4258. CROI: TLR9 AGONIST TRIGGERS POTENT INTESTINAL ANTIVIRAL RESPONSE IN HIV+ INDIVIDUALS ON ART - (02/23/17)
     
  4259. CROI: TLR7 Agonist Treatment of SIV+ Monkeys on ART Can Lead to Complete Viral Remission - (02/23/17)
     
  4260. CROI: TLR7 Agonist GS-986 Markedly Activates T & B Cells From ART-suppressed Donors - (02/23/17)
     
  4261. CROI: TLR7 Agonist GS-9620 (Vesatolimod) Increases Immune-Mediated Clearance of HIV-Infected Cells - (02/23/17)
     
  4262. CROI: HIV Integrase Genotypic Testing and Resistance in the United States-9 U.S. Jurisdictions - (02/22/17)
     
  4263. CROI: The Emerging Potential for HIV Cure for Infants, Children, and Adults - and - ADVANCES IN CELLULAR THERAPY IN CANCER AND HIV - (02/22/17)
     
  4264. CROI: Cessation of cigarette smoking and the impact on cancer incidence in the D:A:D Study - (02/22/17)
     
  4265. CROI: US HIV Incidence Falling in All Transmission Risk Groups Except MSM - Mark Mascolini - (02/22/17)
     
  4266. CROI: Frailty Stronger Than Neurocognitive Impairment in Predicting Falls-Disability-Death - Mark Mascolini - (02/22/17)
     
  4267. CROI: No HIV Evolution in CHER Children With Viral Control Through 7 Years of ART - Mark Mascolini - (02/22/17)
     
  4268. CROI: Monoclonal Antibody to IL-1beta Cuts Arterial Inflammation in 10 HIV Patients - Mark Mascolini - (02/22/17)
     
  4269. CROI: Higher Bilirubin Tied to Lower CVD Risk in Veterans With or Without HIV - Mark Mascolini - (02/22/17)
     
  4270. CROI: Age, Weight, Being a Woman Tied to Falls in Veterans With/Without HIV - Mark Mascolini - (02/22/17)
     
  4271. CROI: Nonlung Cancer Incidence Drops Quickly After Smoking Stops in HIV Group - Mark Mascolini - (02/22/17)
     
  4272. CROI: Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors - D:A:D (02/22/17)
     
  4273. CROI: Oral Session Thursday: INFLAMMATION AND AGE-RELATED COMPLICATIONS - (02/20/17)
     
  4274. CROI: Psychiatric Disorders Observed in HIV+ Patients Using 6 Common 3rd Agents in OPERA - (02/20/17)
     
  4275. CROI: Neuropsychiatric Adverse Events Associated With Integrase Strand Transfer Inhibitors - (02/20/17)
     
  4276. CROI: Discontinuation of DTG, EVG/c, and RAL due to toxicity in a prospective cohort - (02/20/17)
     
  4277. CROI: Hyperbilirubinemia prevents cardiovascular disease for HIV+ and HIV-individuals - (02/20/17)
     
  4278. CROI: Darunavir/r Use and Incident Chronic Kidney Disease in HIV-positive Persons - study found increased CKD risk with ATV but not with Darunavir - D:A:D Cohort - (02/20/17)
     
  4279. CROI: Oral Session Thursday: INFLAMMATION AND AGE-RELATED COMPLICATIONS - 4 studies (1) Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors (2) Smoking Cessation & Impact on Cancers & Lung Cancer Risks in HIV+ (3) New CVD Anti-Inflammatory in Pilot Study in HIV+ (4) Hyperbillirubinemia Prevents CVD Risk - (02/20/17)
     
  4280. CROI: Acute infection with a wild-type HIV-1 virus in a PrEP user with high TDF levels - (02/20/17)
     
  4281. CROI: GLECAPREVIR AND PIBRENTASVIR INTERACTIONS WITH COMBINATION ANTIRETROVIRAL REGIMENS - (02/20/17)
     
  4282. Dolutegravir monotherapy: when should clinical practice be clinical research? - Commentary - (02/18/17)
     
  4283. CROI: Frailty Progression and Recovery among Persons Aging with HIV and Substance Use - (02/18/17)
     
  4284. CROI: HIV RNA Rebound Post-Interruption in Persons Suppressed in Fiebig I Acute HIV - (02/18/17)
     
  4285. CROI: EPICARDIAL FAT, IMMUNE ACTIVATION, AND CORONARY PLAQUE AMONG HIV+ AND HIV- WOMEN - (02/18/17)
     
  4286. CROI: APPLES - The Australian Positive & Peers Longevity Evaluation Study - (02/18/17)
     
  4287. CROI: Identification of Latency Reversing Agents (LRAs) Active in Diverse Primary T-cell Models of HIV Latency - (02/18/17)
     
  4288. CROI: Long-term Safety and Efficacy of CAB and RPV as 2-Drug Oral Maintenance Therapy - (02/18/17)
     
  4289. CROI: Nonlung Cancer Incidence Drops Quickly After Smoking Stops in HIV Group - written by Mark Mascolini - (02/18/17)
     
  4290. CROI: Cardiovascular Risk as Great With Darunavir as With Indinavir or Lopinavir - written by Mark Mascolini - (02/18/17)
     
  4291. CROI: Less Inflammation Tied to Lower Frailty Progression, Greater Frailty Recovery - written by Mark Mascolini - (02/18/17)
     
  4292. CROI: Earlier [cd4 350-500] Versus Delayed Antiretroviral Therapy Initiation and Risk of Cancer - written by Mark Mascolini - (02/18/17)
     
  4293. CROI: The Large Gap Between Statin Eligibility and Prescription in the NA-ACCORD - written by Mark Mascolini - (02/18/17)
     
  4294. CROI: Persistent Immune Activation Despite ART: The "Die is Cast" Before ART Initiation - (02/16/17)
     
  4295. CROI: On Demand Post-Exposure Prophylaxis with Doxycycline for MSM Enrolled in a PrEP Trial - (02/16/17)
     
  4296. CROI: On Demand Post-Exposure Prophylaxis with Doxycycline for MSM Enrolled in a PrEP Trial - (02/16/17)
     
  4297. CROI: Higher Rates of Heart Disease, Diabetes, Neuropathy in Older Men With vs Without HIV - written by Mark Mascolini - (02/16/17)
     
  4298. CROI: PEP With Doxycycline Halves Bacterial STI Rate in MSM on TDF/FTC PrEP - written by Mark Mascolini - (02/16/17)
     
  4299. CROI: "Critical Barrier" Between PrEP Interest and Uptake in Young Black MSM - written by Mark Mascolini - (02/16/17)
     
  4300. CROI: HIV Compartmentalization in Central Nervous System During Acute Infection - written by Mark Mascolini - (02/16/17)
     
  4301. CROI: HIV More Than Doubles Odds of Cerebral Small-Vessel Disease in French Study - written by Mark Mascolini - (02/16/17)
     
  4302. CROI: Viral Load Undetectable 288 Days Without ART After Stem Cell Transplant - written by Mark Mascolini - (02/16/17)
     
  4303. CROI: Steady Drop in Time Spent With Viral Load Above 1500 Copies in US Group - written by Mark Mascolini - (02/16/17)
     
  4304. CROI: Significant Efficacy and Long-term Safety Difference With TAF-Based STR in NaÏve Adults - (02/16/17)
     
  4305. CROI: 288 Day Drug-Free Remission From HIV Rebound by Allogeneic PBSCT - (02/16/17)
     
  4306. CROI: Longitudinal HIV Viral Trajectories and Co-Morbidities Longitudinal in the WIHS: Viral Suppression Key to Survival - (02/16/17)
     
  4307. CROI: Long-Term Efficacy of Dolutegravir 50 mg BID in INI-Resistant Failing HIV-1 Subjects - (02/16/17)
     
  4308. CROI: HIV Attachment Inhibitor Fostemsavir / BMS-663068, GSK3684934 - (02/16/17)
     
  4309. CROI: In Vitro -In Vivo Evaluation of a Biodegradable Implant Containing TAF for HIV PrEP - (02/16/17)
     
  4310. CROI: LONG-ACTING IBALIZUMAB IN PATIENTS WITH MULTI-DRUG RESISTANT HIV-1: A 24-WEEK STUDY - (02/16/17)
     
  4311. CROI: Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab - (02/16/17)
     
  4312. CROI: DORAVIRINE IS NON-INFERIOR TO DARUNAVIR+RITONAVIR IN PHASE 3 TREATMENT-NAÏVE TRIAL AT WEEK 48 - (02/16/17)
     
  4313. CROI: Discovery of Novel Potent HIV Capsid Inhibitors with Long-Acting Potential - (02/16/17)
     
  4314. CROI: Viral Load Dynamics Among Persons with Diagnosed HIV: United States, 2014 - (02/16/17)
     
  4315. CROI: PREVALENCE AND IMPACT OF PRETREATMENT DRUG RESISTANCE IN 12249 TREATMENT AS PREVENTION TRIAL - (02/16/17)
     
  4316. CROI: Doravirine in Non-Inferior To Darunavir+Ritonavir in Phase 3 Treatment-Naive Trial at Week 48 - (02/16/17)
     
  4317. CROI: Clinical Pharmacology of the Unboosted HIV Integrase Strand Transfer Inhibitor (INSTI) Bictegravir (BIC) - (02/16/17)
     
  4318. CROI: Randomized Trial of Bictegravir or Dolutegravir with FTC/TAF for Initial HIV Therapy - (02/16/17)
     
  4319. CROI: SWORD 1 & 2: Switch to DTG + RPV Maintains Virologic Suppression Through 48 Weeks, a Phase III Study - (02/16/17)
     
  4320. CROI: Inflammation and Coagulation Markers Predict Clinical Risk in START Trial - written by Mark Mascolini - (02/15/17)
     
  4321. CROI: Excess Epicardial Fat Tied to Noncalcified Plaque in Women With HIV - written by Mark Mascolini - (02/15/17)
     
  4322. CROI: Cardiovascular Risk More Likely With Longer Viral Control in WIHS Women - written by Mark Mascolini - (02/15/17)
     
  4323. CROI: Monoclonal Antibody Suppresses HIV in Half With Multidrug-Resistant Virus - written by Mark Mascolini - (02/15/17)
     
  4324. CROI: New Integrase Inhibitor Attains 97% Viral Suppression Through 48 Weeks - written by Mark Mascolini - (02/15/17)
     
  4325. CROI: Only Half of Big US HIV Group Had Durable Viral Suppression in 2014 - written by Mark Mascolini - (02/15/17)
     
  4326. CROI: Three in 30 Infants Treated in First 48 Hours of Life Become PCR Negative - written by Mark Mascolini - (02/15/17)
     
  4327. Inflammation Explained - Research for Therapies / Review - Inflammation, metaflammation and immunometabolic disorders - (02/14/17)
     
  4328. New PrEP Cascade Methods Find 1 in 10 Benefit from PrEP - Uptake of HIV Pre-Exposure Prophylaxis (PrEP) in a National Cohort of Gay and Bisexual Men in the United States - (02/14/17)
     
  4329. Gilead Sciences, Inc. Medical Affairs HIV/HCV NoCo program: Toward Elimination of HCV in HIV-Infected Populations - $ 3 Million in Grants - (02/14/17)
     
  4330. CROI: ViiV Announces SWORD Study Results: Dolutegravir+Rilpivirine in Virologically Suppressed - (02/14/17)
     
  4331. CROI: Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors - (02/14/17)
     
  4332. CROI: Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV - (02/14/17)
     
  4333. TAF vs NRTI Resistance Mutations - Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse Transcriptase and Protease in Antiretroviral Treatment-Naïve Patients do not Affect Response to Tenofovir Disoproxil Fumarate- or Tenofovir Alafenamide-Containing Regimen - (02/13/17)
     
  4334. New SF General clinic treats older HIV patients / Aging Clinic 'Golden Compass' - (02/13/17)
     
  4335. Golden Compass Aging Clinic / program launches at SF General - "one-stop shop for HIV-positive people age 50 and older" - (02/13/17)
     
  4336. Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment - (02/09/17)
     
  4337. WHO IS MANAGING AGING PATIENTS & THEIR RISK FOR FALLS ? No ONE - Jules Levin, NATAP - (02/09/17)
     
  4338. Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis - (02/06/17)
     
  4339. Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study - (02/06/17)
     
  4340. NIH Cure Meeting - overview by Dan Kuritzkes /Cure Research direction - Concerns, questions, treatment interruptions - (02/06/17)
     
  4341. Cure Research Review at OAR NIH Meeting, The Brain, Treatment Interruptions - (02/06/17)
     
  4342. CytoDyn's Two-Year Update on Its PRO 140 Monotherapy Study in HIV Accepted at CROI 2017 - (02/06/17)
     
  4343. Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010 - (02/06/17)
     
  4344. Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques - (02/06/17)
     
  4345. Hormone Blockers Can Prolong Life if Prostate Cancer Recurs - (02/06/17)
     
  4346. Inflammation, Immune Activation, Immunosenescence, and Hormonal Biomarkers in the Frailty-Related Phenotype of Men With or at Risk for HIV Infection - lower CD4, detectable viral load, more inflammation, lower testosterone, HIV associated with senescence & immune activation.....Exercise & Diet recommended - (02/06/17)
     
  4347. Commonalities Between Vasculature and Bone - (02/03/17)
     
  4348. Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010 - (02/03/17)
     
  4349. Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis - (02/03/17)
     
  4350. Next Generation anti-HIV Agents - Capsid Inhibitors - (02/03/17)
     
  4351. CytoDyn Reports Treatment of First Several Patients With PRO 140 in Its Phase 3 Monotherapy Trial for HIV - (02/03/17)
     
  4352. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals - (02/02/17)
     
  4353. Cure Research Review at OAR NIH Meeting - (02/02/17)
     
  4354. FDA Update - EVOTAZ (atazanavir/cobicistat) label was updated to include new data - (02/01/17)
     
  4355. HIV Related Distressing Symptoms for Young & Aging HIV+ - (02/01/17)
     
  4356. New HIV Cure Research/Reports - (02/01/17)
     
  4357. CROI: A Long-Acting Biodegradable Subcutaneous Implant for Tenofovir Alafenamide Fumarate HIV PrEP - (01/31/17)
     
  4358. Aging - Death Rates of HIV+ Increase Only in those Over 60 Years Old, in Younger Groups Death Rates Decrease - (01/31/17)
     
  4359. Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors - (01/30/17)
     
  4360. Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission - (01/30/17)
     
  4361. A link between antiretrovirals and perinatal outcomes? - (01/30/17)
     
  4362. Ending HIV/AIDS - LA & NY Care Continuum - (01/27/17)
     
  4363. 80% of HIV+ Are Over 45 / 20% over 60 /50% Over 50 in NY, SF, Boston, Florida - (01/27/17)
     
  4364. Evolving epidemiology of HIV-associated malignancies - (01/27/17)
     
  4365. High Rates of Anal High-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Who Do Not Meet Screening Guidelines - Anal Cancer Screening in HIV+ Women Under-Screened / Routine Testing Recommended for All HIV+ Women - (01/27/17)
     
  4366. Psychiatric Symptoms in Patients Receiving Dolutegravir - (01/25/17)
     
  4367. IBALIZUMAB 24-WEEK PIVOTAL PHASE III STUDY RESULTS ACCEPTED AS A LATE BREAKER WILL BE PRESENTED AT CROI 2017 - (01/25/17)
     
  4368. TLR9, TLR7 HIV Cure Research - (01/24/17)
     
  4369. 2 New Cure HIV Antibodies Studies Reported, Combination 3 Antibodies, Two-Pronged Antibody - (01/24/17)
     
  4370. Aging & HIV : "A Call to Action - Uncharted Territory A report into the first generation growing older with HIV" UK Patient Survey Report - (01/24/17)
     
  4371. 2 New HIV Antibodies Studies Reported, combining 3 antibodies - (01/24/17)
     
  4372. TLR9, TLR7 HIV Cure Research - (01/24/17)
     
  4373. Darunavir + Genvoya [elvitegravir/cobi/FTC/TAF] in Treatment-Experienced Patients with HIV Drug Resistance - (01/24/17)
     
  4374. IL-15 HIV Cure Research - (01/20/17)
     
  4375. Inhibition of Telomerase Activity by Human Immunodeficiency Virus (HIV) Nucleos(t)ide Reverse Transcriptase Inhibitors: A Potential Factor Contributing to HIV-Associated Accelerated Aging - (01/20/17)
     
  4376. A microbial protein that alleviates metabolic syndrome - (01/20/17)
     
  4377. Cure Research Ethics, Risks for Participants - (01/20/17)
     
  4378. Darunavir + Genvoya [elvitegravir/cobi/FTC/TAF] in Treatment-Experienced Patients with HIV Drug Resistance - (01/18/17)
     
  4379. Brisk Walking & Strength Training Reduced Inflammation (CRP) & LDL/total Cholesterol - (01/18/17)
     
  4380. HIV Remodels Brain Function Study Suggests - also: illicit drug use history, comorbidities - (01/18/17)
     
  4381. Questioned - Statin Recommendations / Risk Calculator / American College of Cardiology/American Heart Association (ACC/AHA) guidelines on assessment of cardiovascular risk1 and on treatment of blood cholesterol - (01/13/17)
     
  4382. Statin Benefit vs Harm - OPINION - (01/04/16)
     
  4383. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults - (01/13/17)
     
  4384. CVD Prediction- Diabetes/Lipids/Hypertension - (01/11/17)
     
  4385. Diabetes / CVD in HIV+ / Inaccuracy of A1C - (01/11/17)
     
  4386. Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network - (01/11/17)
     
  4387. Predicting HIV-Life Expectancy, Comorbidities - Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population - (01/11/17)
     
  4388. Health & AIDS Spending USA - (01/11/17)
     
  4389. CVD Prediction- Diabetes/Lipids/Hypertension - (01/10/17)
     
  4390. Medical error-the third leading cause of death in the US - (01/10/17)
     
  4391. Lipid Management Guidelines for Adults with Chronic Kidney Disease - (01/10/17)
     
  4392. The Management of Dyslipidemia in CKD: New Analyses of an Expanding Dataset - (01/10/17)
     
  4393. Interpretation of the evidence for the efficacy and safety of statin therapy - (01/10/17)
     
  4394. Under Estimating HIV Cardiovascular Disease Risk / Association Between HIV and Cardiovascular Diseases - Finding a Solution to Double Jeopardy - (01/10/17)
     
  4395. Interpretation of the evidence for the efficacy and safety of statin therapy - (01/05/16)
     
  4396. An assessment by the Statin Liver Safety Task Force: 2014 update - (01/05/16)
     
  4397. 2014 Statin Safety Task Force - (01/04/16)
     
  4398. Lipid Management Guidelines for Adults with Chronic Kidney Disease - (01/04/16)
     
  4399. An assessment by the Statin Muscle Safety Task Force: 2014 update - (01/04/16)
     
  4400. Amgen Announces Positive Top-